```
=> d his

     (FILE 'HOME' ENTERED AT 13:43:30 ON 20 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 13:43:42 ON 20 SEP 2006

     FILE 'CAPLUS' ENTERED AT 13:43:51 ON 20 SEP 2006
               ACT FIONA/A
               ---------
L1             STR
L2   (     12311)SEA FILE=REGISTRY SSS FUL L1
L3   (      1515)SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L4          1452 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 AND PY<2004
               ---------

     FILE 'REGISTRY' ENTERED AT 13:44:09 ON 20 SEP 2006
L5             STRUCTURE UPLOADED
L6            41 SEARCH L5 SSS SAM
L7          6183 S L6 FULL

     FILE 'CAPLUS' ENTERED AT 13:45:47 ON 20 SEP 2006
L8           273 S L7
L9           235 S L8 AND PY<2004

=> d que l9 stat
L5             STR
```




```
G1 H,Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Ph


Structure attributes must be viewed using STN Express query preparation.
L7          6183 SEA FILE=REGISTRY SSS FUL L5
L8           273 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7
L9           235 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8 AND PY<2004


=> d 1-235 bib abs hitstr
```

L9 ANSWER 1 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:818425 CAPLUS
DN 139:337987
TI Preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases.
IN Belema, Makonen; Bunker, Amy; Nguyen, Van; Beaulieu, Francis; Ouellet, Carl; Marinier, Anne; Roy, Stephan; Yang, Xuejie; Qiu, Yuping; Zhang, Yunhui; Martel, Alain; Zusi, Christopher
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084959	A1	20031016	WO 2003-US9549	20030327 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003222106	A1	20031020	AU 2003-222106	20030327 <--
	US 2004058930	A1	20040325	US 2003-400387	20030327
	US 6933294	B2	20050823		
	EP 1490371	A1	20041229	EP 2003-718092	20030327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-369698P	P	20020403		
	WO 2003-US9549	W	20030327		

OS MARPAT 139:337987
GI



I

II

AB Title compds. [I; R1-R3 = H, halo, (perfluoro)alkyl; R4 = (CR5R6)mZ, (cycloalkyl)Z; R5, R5a, R6, R6a = H, OH, (substituted) amino, alkoxy, (cyclo)alkyl, heterocyclyl, (hetero)aryl; R7 = halo, cyano, (substituted) alkyl, alkenyl, (CR5aR6a)qOR8a, (CR5aR6a)qSR8a, (CR5aR6a)qSO2R10,

L9 ANSWER 1 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 1 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CR5aR6a)qNR8R9, (CR5aR6a)qNR8SO2, (CR5aR6a)qNR8SO2R10, (CR5aR6a)qSO2NR8R9, (CR5aR6a)qNR8aCOR9a, (CR5aR6a)qNR8aCO2R9a, (CR5aR6a)qCOR8a, (CR5aR6a)qCO2R8a, (CR5aR6a)qO2CR8a, (CR5aR6a)qCONR8aNR5R9, (CR5aR6a)qCONR8aSO2R10, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl, aralkyl, heteroaryl(alkyl), etc.; when A = heterocycle, cycloalkyl, 1 of R7 may = O, when A = bond, then R7 may = H; X = bond, O, S, NR1, (CH2)n, CH:CH, C.tplbond.C; A = bond, (hetero)aryl, heterocycle, cycloalkyl; Z = H, Me, OR14, CO2R14, NR12COR13, NR12CO2R13, NR12SO2R13, NR12CONR14R15, etc.; R8, R8a, R9, R9a = H, (substituted) alkenyl, (cyclo)alkyl, (cycloalkyl)alkyl, (heterocyclyl)alkyl, aryl, aralkyl, heteroaryl, (heteroaryl)alkyl; R8R9N, R14R15N = heterocyclyl; R10, R10a = (substituted) (cyclo)alkyl, heterocyclyl, (hetero)aryl; R11 = H, (amino)alkyl, hydroxyalkyl; R12 = H, alkyl; R13 = H, (substituted) (cyclo)alkyl, heterocyclyl, (hetero)aryl; R14, R14a, R15, R15a = H, (substituted) (cyclo)alkyl, (cycloalkyl)alkyl, (heterocyclyl)alkyl, aryl(alkyl), heteroaryl(alkyl); m, q = 0-6; n = 1, 2; p = 0-4], were prepd. Thus, tris(dibenzylideneacetone)dipalladium(0) and bis[(2-diphenylphosphino)phenyl]ether in toluene were bubbled with argon for 3 min; N-(2-bromo-8-methyl-1-thia-4,6,8a-triaza-as-indacen-5-yl)-N-methylamine was added followed by 2-mercaptopyrimidine and KOCMe3 in THF followed by refluxing for 2h to give 18% title compd. (II).
IT 615532-62-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazothienopyrazines for treatment of inflammatory and immune diseases)
RN 615532-62-2 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-[3-[5-[(2-hydroxyethyl)amino]-8-methylimidazo[1,2-a]thieno[3,2-e]pyrazin-2-yl]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH2—OH

L9 ANSWER 2 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:809341 CAPLUS
DN 139:323513
TI Preparation of sulfonamides and their use as anti-HIV agents
IN Yamamoto, Osamu; Fujii, Masahiro; Ogami, Tetsuro; Masuda, Naoyuki; Fujiyasu, Jiro; Kontani, Toru; Moritomo, Ayako; Kageyama, Toshiharu; Inoe, Hiroshi; Hatta, Toshifumi; Kodama, Eiichi; Matsuoka, Masao
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Soyaku Gijutsu Kenkyusho K. K.
SO Jpn. Kokai Tokkyo Koho, 52 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003292485	A2	20031015	JP 2002-98332	20020401 <--
PRAI	JP 2002-98332		20020401		

OS MARPAT 139:323513
GI



I

AB Sulfonamides I [the broken lines may be bond; at least one of them is bond; R1, R2 = none, H, lower (halo)alkyl, lower alkylene-OH, lower alkylene-heterocyclyl, lower alkylene-CO2H, etc.; X = O, S; ring A = (un)substituted (hetero)aryl; ring B = (un)substituted N-containing heterocyclyl] or their salts are prepared Thus, 2-amino-5-tert-butyl-4-methylthiazole HCl salt was condensed with 3-nitrobenzenesulfonyl chloride to give N-(5-tert-butyl-4-methylthiazol-2-yl)-3-nitrobenzenesulfonamide, which was treated with NaH and MeI to afford N-(5-tert-butyl-3,4-dimethyl-2,3-dihydrothiazol-2-ylidene)-3-nitrobenzenesulfonamide. The product inhibited reverse transcriptase of wild type, Y181C mutant, and K103N mutant HIV-1 with IC50 values of 0.27, 0.066, and 13 μM, resp.
IT 612538-98-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as reverse transcriptase inhibitors and anti-HIV agents)
RN 612538-98-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-bromo-2-[[[4-chloro-3-methyl-5-(1-methylethyl)-2(3H)-thiazolylidene]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 2 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 3 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:688976 CAPLUS
DN 139:230483
TI Preparation of aroyl hydrazides and related compounds as glucagon antagonists/inverse agonists
IN Ling, Anthony; Gregor, Vlad; Gonzalez, Javier; Hong, Yufeng; Kiel, Dan; Kuki, Atsuo; Shi, Shenghua; Naerum, Lars; Madsen, Peter; Sams, Christian; Lau, Jesper; Plewe, Michael Bruno; Feng, Jun; Teng, Min; Johnson, Michael David; Teston, Kimberly Ann; Sidelmann, Ulla Grove; Knudsen, Lotte Bjerre
PA Novo Nordisk A/S, Den.
SO U.S., 370 pp., Cont.-in-part of U.S. Ser. No. 107,400.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6613942	B1	20030902	US 1998-220003	19981223 <--
	ZA 9805759	A	19990125	ZA 1998-5759	19980701 <--
	WO 2000039088	A1	20000706	WO 1999-DK705	19991216 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140823	A1	20011010	EP 1999-960939	19991216 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002533439	T2	20021008	JP 2000-591000	19991216 <--
PRAI	US 1997-886785	A2	19970701		
	US 1998-32516	A2	19980227		
	US 1998-107400	A2	19980630		
	US 1998-220003	A	19981223		
	WO 1999-DK705	W	19991216		

OS MARPAT 139:230483
AB AXNR3NR1CR2R4(CH2)nBKmD [R1, R2 H, alkyl; R1R2 = bond; R3, R4 = H, alkyl; n = 0-3; m = 0, 1; X = CO, CS, CNR5, SO2; R5 = H, alkyl, aralkyl, OR6; R6 = H, alkyl, aryl, aralkyl; A = (substituted) Ph, pyridyl, pyrimidyl, naphthyl, indolyl, benzotriazolyl, benzimidazolyl, triazolyl, pyrazolyl, imidazolyl, etc.; B = (substituted) azinyl, benzazinyl, naphthyl, azolyl, etc.; D = H, (substituted) Ph, azinyl, benzazinyl, naphthyl, azolyl, etc.; K = Lc(CH2)b(CR3aR3b)p(CH2)aMf(CH2)c(CR4aR4b)q(CH2)d; R3a, R3b, R4a, R4b = H, halo, CN, CF3, OCF3, OCH2CF3, NO2, OR24, NR24aR25a, alkyl, aryl, aralkyl, SCF3, SR24a, CHF2, OCHF2, OCF2CHF2, OSO2CF3, CONR24aR25a, CH2CONR24aR25a, OCH2CONR24aR25a, CH2OR24a, CH2NR24aR25a, O2CR24a, CO2R24a; R24 = H, alkyl, aryl, aralkyl, etc.; R24a, R25a = H, COR26a, SO2R26a, alkyl, aryl, aralkyl; R26a = H, alkyl, aryl, aralkyl; R3aR3b, R4a R4b, R3aR4b = (CH2)i; i = 1-4; a, b, c, d = 0-4; e, f, p = 0-1; L, M = O, S, CH:CH, C.tplbond.C, CO, SO, SO2, etc.], were prepared as antidiabetics (no data). Thus, 3-chloro-4-hydroxybenzoic acid hydrazide, 4-(3,5-bis-trifluoromethylbenzyloxy)-1-naphthaldehyde, and catalytic HOAc were stirred together overnight in Me2SO to give 3-chloro-4-hydroxybenzoic acid [4-(3,5-bis-trifluoromethylbenzyloxy)-1-naphthylmethylene]hydrazide.

L9 ANSWER 3 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Pharmaceutical compns. contg. title compds. are claimed.
IT 219683-89-3P 219683-91-7P 219683-93-9P
219683-96-2P 280135-43-5P 280135-53-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aroyl hydrazides and related compds. as glucagon antagonists/inverse agonists)
RN 219683-89-3 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[2-methoxy-4-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-91-7 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[3-methoxy-4-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-93-9 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-96-2 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(2,4-dichlorophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 280135-43-5 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(4-cyanophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 280135-53-7 CAPLUS
CN Benzoic acid, 3-cyano-4-hydroxy-, [[4-[[(4-cyanophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:491188 CAPLUS
DN 139:69057
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders
IN Ebdrup, Soren; Hansen, Holger Claus; Vedso, Per; Cornelis De Jong, Johannes; Jacobsen, Poul
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051842	A2	20030626	WO 2002-DK853	20021213 <--
	WO 2003051842	A3	20040603		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002351732	A1	20030630	AU 2002-351732	20021213 <--
	US 2003166690	A1	20030904	US 2002-319212	20021213 <--
	US 7067517	B2	20060627		
	US 2003166644	A1	20030904	US 2002-319885	20021213 <--
	EP 1458375	A2	20040922	EP 2002-787449	20021213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1602191	A	20050330	CN 2002-828075	20021213
	JP 2005518377	T2	20050623	JP 2003-552729	20021213
	ZA 2004004324	A	20050721	ZA 2004-4324	20040602
PRAI	DK 2001-1879	A	20011214		
	DK 2002-645	A	20020430		
	DK 2002-1000	A	20020627		
	DK 2002-1562	A	20021011		
	US 2002-346909P	P	20020103		
	US 2002-384253P	P	20020510		
	US 2002-393068P	P	20020628		
	US 2002-418481P	P	20021015		
	WO 2002-DK853	W	20021213		

OS MARPAT 139:69057
GI

L9 ANSWER 4 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10 μM. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).
IT 548766-05-8P, N-Methyl-N-phenylcarbamic acid 4-(2-phenoxyacetylamino)phenyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)
RN 548766-05-8 CAPLUS
CN Carbamic acid, methylphenyl-, 4-[(phenoxyacetyl)amino]phenyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:491187 CAPLUS
DN 139:69056
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders
IN Ebdrup, Soren; Cornelis De Jong, Johannes; Jacobsen, Poul; Hansen, Holger Claus; Vedso, Per
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 519 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051841	A2	20030626	WO 2002-DK852	20021213 <--
	WO 2003051841	A3	20040624		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2468413	AA	20030626	CA 2002-2468413	20021213 <--
	AU 2002351731	A1	20030630	AU 2002-351731	20021213 <--
	US 2003166690	A1	20030904	US 2002-319212	20021213 <--
	US 7067517	B2	20060627		
	US 2003166644	A1	20030904	US 2002-319885	20021213 <--
	EP 1458374	A2	20040922	EP 2002-787448	20021213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1602191	A	20050330	CN 2002-828075	20021213
	BR 2002014967	A	20050510	BR 2002-14967	20021213
	JP 2005518376	T2	20050623	JP 2003-552728	20021213
	ZA 2004004324	A	20050721	ZA 2004-4324	20040602
	NO 2004002962	A	20040908	NO 2004-2962	20040713
PRAI	DK 2001-1879	A	20011214		
	DK 2002-645	A	20020430		
	DK 2002-1000	A	20020627		
	DK 2002-1562	A	20021011		
	US 2002-346909P	P	20020103		
	US 2002-384253P	P	20020510		
	US 2002-393068P	P	20020628		
	US 2002-418481P	P	20021015		
	WO 2002-DK852	W	20021213		

OS MARPAT 139:69056
GI

L9 ANSWER 5 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10 μM. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).
IT 548766-05-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)
RN 548766-05-8 CAPLUS
CN Carbamic acid, methylphenyl-, 4-[(phenoxyacetyl)amino]phenyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:356249 CAPLUS
DN 138:368758
TI Preparation of oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
IN Bombrun, Agnes; Gerber, Patrick; Church, Dennis
PA Applied Research Systems ARS Holding N.V., Neth.
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037328	A1	20030508	WO 2002-EP11919	20021024 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463615	AA	20030508	CA 2002-2463615	20021024 <--
	EP 1439834	A1	20040728	EP 2002-779510	20021024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005511558	T2	20050428	JP 2003-539672	20021024
	US 2005043388	A1	20050224	US 2004-493066	20041005
PRAI	EP 2001-125380	A	20011030		
	WO 2002-EP11919	W	20021024		

OS MARPAT 138:368758
GI



I



II

L9 ANSWER 6 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 521290-05-1 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, (5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)



IT 521289-79-2P, N-[4-(Hydrazinocarbonyl)phenyl]-2-phenoxyacetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxindole hydrazide modulators of protein tyrosine phosphatases)
RN 521289-79-2 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, hydrazide (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB The present invention is related to the use of oxindole hydrazide derivs. (shown as I; variables defined below; e.g. N-[4-[[2-(5-iodo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]carbonyl]phenyl]-3-phenylpropanamide (shown as II)) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of I to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel I and a method of preparing them; included are 126 example prepns. of I. For example, II was prepared in 3 steps starting from Me 4-aminobenzoate and hydrocinnamoyl chloride in pyridine followed by an aminomethyl resin to give Me 4-[(3-phenylpropanoyl)amino]benzoate (90% yield), which was reacted with hydrazine hydrate to give N-[4-(hydrazinocarbonyl)phenyl]-3-phenylpropanamide (77%), which was reacted with 5-iodo-1H-indole-2,3-dione in HOAc to give II (77%). For I: R1 is halogen or C(O)N-(C6-C18)-alkyl; d is 1 to 4; R2 is H, CONHR or (CH2)uCOOR, wherein u = 1-7 and R is H or (C1-C6)-alkyl; R3 is H or C1-C6-alkyl; R4, R5, R6 and R7 = H, halogen, NO2, OH, (C1-C6)-alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms = O, N or S, (C1-C6)-alkylheterocycloalkyl wherein said heterocyclolalkyl may contain 1-2 further heteroatoms = O, N or S, aryl, (C1-C6)-alkylaryl, heteroaryl, (C1-C6)-alkylheteroaryl. R8 = H, halogen, hydroxy, acyl, amino, carboxy, cyano, nitro, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, carbonylamino, hydrazinocarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, acylamino, C1-C6-alkyl acylamino, ureido, C1-C6-alkyl ureido, C1-C6-alkyl carbamate, C1-C6-alkyl amino, etc. A = a bond, O, S, SO, SO2, amino, urea, sulfonylamino or acylamino; B is arylene, heteroarylene, heterocycloalkylene or cycloalkylene; X is C, S or SO; m, n and p = 0-6; m is also 0, 1 or 2, while n is 0 or 1, and p is 1 or 2; addnl. details are given in the claims. Tested I displayed an inhibition (illustrated by IC50 values) with regard to PTP1B, TC-PTP, SHP and GLEPP-1 of <30 μM; some of these displayed an inhibition <10 μM; compound II exhibits IC50 for PTP1B of 340 nM, and of about 496 nM with regard to GLEPP-1. Three I were tested in an in vivo assay in db/db mice, e.g. compound N'-(5-iodo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4-nitrophenoxy)acetohydrazide caused a reduction of blood glucose level of 34% when administered at 100 mg/kg.
IT 521289-78-1P, N-[4-[[2-(5-Iodo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]carbonyl]phenyl]-2-phenoxyacetamide 521290-05-1P, N-[4-[[2-(5-Bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]carbonyl]phenyl]-2-phenoxyacetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxindole hydrazide modulators of protein tyrosine phosphatases)
RN 521289-78-1 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, (1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 7 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:5963 CAPLUS
DN 138:73267
TI Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors
IN Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran
PA Almirall Prodesfarma S.A., Spain
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000694	A1	20030103	WO 2002-EP6727	20020618 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ES 2193839	A1	20031101	ES 2001-1452	20010622 <--
	ES 2193839	B1	20050216		
	EP 1409489	A1	20040421	EP 2002-780834	20020618
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534828	T2	20041118	JP 2003-507097	20020618
	US 2005070558	A1	20050331	US 2004-481728	20041019
PRAI	ES 2001-1452	A	20010622		
	WO 2002-EP6727	W	20020618		

OS MARPAT 138:73267
GI



I

AB The title compds. [I; R1, R2 = H, (CH2)nR7, (un)substituted alkyl (wherein n = 0-4; R7 = cycloalkyl, (un)substituted Ph, 3-7 membered (non)aromatic ring containing 1-4 heteroatoms and which is optionally fused to (hetero)aromatic ring); R3 = H, halo, NO2, etc.; R4, R5 = H, halo, alkyl, etc.; L1 = a direct bond, O, S, etc.; R6 = CONR10R11, SO2NR10R11, ON:CR12R13, aryl, etc.; R10, R11 = H, alkyl, cycloalkyl, etc.; R12, R13 = defined as R10 and R11, except that either or both of R12 and R13 can be an amino, alkylamino or dialkylamino] which have therapeutic potential as A2 adenosine receptor

L9 ANSWER 7 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inhibitors (biol. data given), were prepd. and formulated. Thus, coupling {4-[2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydropyrimidin-4-yl)vinyl]phenoxy}acetic acid (prepn. given) with aniline (yield 42%) followed by reductive cyclization of the resulting intermediate mediated by triethylphosphite (46%) afforded I [R1, R2 = Pr; R3-R5 = H; L1 = OCH2; R6 = CONHPh].
IT 480991-26-2P 480991-40-0P 480991-45-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors)
RN 480991-26-2 CAPLUS
CN Benzamide, 4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 480991-40-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 480991-45-5 CAPLUS
CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-4-[[[4-(2,3,4,5-tetrahydro-2,4-dioxo-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 7 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:883966 CAPLUS
DN 138:122448
TI Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide
AU Madsen, Peter; Ling, Anthony; Plewe, Michael; Sams, Christian K.; Knudsen, Lotte B.; Sidelmann, Ulla G.; Ynddal, Lars; Brand, Christian L.; Andersen, Birgitte; Murphy, Douglas; Teng, Min; Truesdale, Larry; Kiel, Dan; May, John; Kuki, Atsuo; Shi, Shenghua; Johnson, Michael D.; Teston, Kimberly Ann; Feng, Jun; Lakis, James; Anderes, Kenna; Gregor, Vlad; Lau, Jesper
CS Department of Medicinal Chemistry, Novo Nordisk A/S, Mlov, DK-2760, Den.
SO Journal of Medicinal Chemistry (2002), 45(26), 5755-5775
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:122448
GI



I



II

AB Highly potent human glucagon receptor antagonists are prepared by structural modifications of a variety of structural elements of the lead antagonist, cyanohydroxybenzoic acid dimethoxyisopropylbenzyloxybenzylidenehydrazide I. Electron-rich aryl aldehyde hydrazones such as II containing mono- and dimethoxy benzene, naphthalene, or indole moieties are active glucagon receptor antagonists. Structure-activity relationships indicated that the terminal benzyl group in I is not necessary for obtaining high affinity glucagon receptor antagonists, although substitution there is useful in optimizing glucagon receptor antagonists. The activity of glucagon receptor antagonists related to I is not affected much by the linker

L9 ANSWER 8 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
between the aryl aldehyde hydrazone and benzyl moieties. The metab. of the glucagon receptor antagonists is evaluated. II is found to be a highly active and noncompetitive human glucagon receptor antagonist (IC50 = 2.3 nM, KB = 760 pM) with low metabolic turnover; in rats, II inhibits the glucagon-mediated release of glucose. II is also orally available in dogs (Fpo = 15%).
IT 219683-91-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of alkylidene hydrazides as human glucagon receptor antagonists
for the treatment of hyperglycemia and diabetes)
RN 219683-91-7 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[3-methoxy-4-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:695941 CAPLUS
DN 137:232453
TI Preparation of substituted benzophenones as inhibitors of reverse transcriptase
IN Chan, Joseph Howing
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070470	A2	20020912	WO 2002-US6037	20020228 <--
	WO 2002070470	A3	20030306		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439820	AA	20020912	CA 2002-2439820	20020228 <--
	EP 1363877	A2	20031126	EP 2002-723265	20020228 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007752	A	20040323	BR 2002-7752	20020228
	CN 1494528	A	20040505	CN 2002-805882	20020228
	NZ 527864	A	20040528	NZ 2002-527864	20020228
	JP 2004525914	T2	20040826	JP 2002-569791	20020228
	ZA 2003006549	A	20041122	ZA 2003-6549	20030821
	NO 2003003857	A	20031027	NO 2003-3857	20030901 <--
	US 2004122064	A1	20040624	US 2004-469104	20040205
	US 6995283	B2	20060207		
	US 2006009651	A1	20060112	US 2005-223634	20050909
PRAI	US 2001-272953P	P	20010302		
	WO 2002-US6037	W	20020228		
	US 2004-469104	A3	20040205		

OS MARPAT 137:232453
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = ≥1 substituent chosen from halo, CF3, alkyl, aminoalkyl, alkoxy, CN, NO2, NH2, thioalkoxy, etc.; R2 = H, halo, alkyl, NO2, NH2, alkylamino, CF3, alkoxy; R3 = OH, halo, CF3, NO2, alkyl; R4 = sulfonamido, sulfonylimino, etc.;] were prepared For instance, 3,5-dichlorobromobenzene was metalated (MTBE, n-BuLi, -50°) and acylated with the N,2-dimethoxy-N-methyl-5-chlorobenzamide and the resulting benzophenone converted to II. II was converted to III in 5 steps. Polymorphic forms of sodium, choline, calcium, magnesium,

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457636-22-5 CAPLUS
CN Acetamide, N-[4-[[(bromoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457636-23-6 CAPLUS
CN Acetamide, N-[4-[[(bromoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457636-28-1 CAPLUS
CN Carbamic acid, [(1S,2S)-1-[[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ethanolamine and triethylamine salts of III were prepd. and characterized. Oral bioavailability and soly. parameters were detd. for III and polymorphic salt forms thereof. Compds. of the present invention have anti-HIV activity and deliver compds. that have anti- HIV activity in the range IC50 = 1-1000 nM against wild type and mutant viruses.

IT 329936-49-4P 329939-64-2P 329940-99-0P
457636-22-5P 457636-23-6P 457636-28-1P
457636-29-2P 457636-30-5P 457636-31-6P
457636-32-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted benzophenones as inhibitors of reverse transcriptase)

RN 329936-49-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-64-2 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-99-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457636-29-2 CAPLUS
CN Carbamic acid, [1-[[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 457636-30-5 CAPLUS
CN Carbamic acid, [(1S)-1-[[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457636-31-6 CAPLUS
CN Carbamic acid, [(1R)-2-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457636-32-7 CAPLUS
CN Carbamic acid, [2-[[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 457636-12-3P 457636-14-5P 457636-15-6P
457636-16-7P 457636-17-8P 457636-18-9P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prodrug reverse-transcriptase inhibitor; preparation of substituted benzophenones as inhibitors of reverse transcriptase)

RN 457636-12-3 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 457636-14-5 CAPLUS
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]propanamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 457636-13-4
CMF C26 H20 C12 N3 O6 S

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 62-49-7
CMF C5 H14 N O

$Me_3{}^+N-CH_2-CH_2-O^-$

RN 457636-15-6 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)



●1/2 Ca

RN 457636-16-7 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, magnesium salt (2:1) (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●1/2 Mg

RN 457636-17-8 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, compd. with 2-aminoethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 457635-65-3
CMF C26 H21 C12 N3 O6 S



CM 2

CRN 141-43-5
CMF C2 H7 N O

$H_2N-CH_2-CH_2-OH$

RN 457636-18-9 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 457635-65-3
CMF C26 H21 C12 N3 O6 S



CM 2

CRN 121-44-8
CMF C6 H15 N

IT 457635-45-9P 457635-46-0P 457635-47-1P
457635-48-2P 457635-49-3P 457635-51-7P
457635-52-8P 457635-53-9P 457635-54-0P
457635-55-1P 457635-56-2P 457635-57-3P
457635-58-4P 457635-59-5P 457635-60-8P
457635-61-9P 457635-62-0P 457635-63-1P
457635-64-2P 457635-65-3P 457635-66-4P
457635-67-5P 457635-68-6P 457635-69-7P
457635-70-0P 457635-71-1P 457635-72-2P
457635-73-3P 457635-74-4P 457635-75-5P
457635-76-6P 457635-77-7P 457635-78-8P
457635-79-9P 457635-80-2P 457635-81-3P
457635-82-4P 457635-83-5P 457635-84-6P
457635-85-7P 457635-87-9P 457635-88-0P
457635-89-1P 457635-90-4P 457635-91-5P
457635-92-6P 457635-93-7P 457635-94-8P
457635-95-9P 457635-96-0P 457635-99-3P
457636-00-9P 457636-01-0P 457636-02-1P
457636-03-2P 457636-04-3P 457636-05-4P
457636-06-5P 457636-07-6P 457636-08-7P
457636-09-8P 457636-10-1P 457636-11-2P
457643-46-8P

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrug reverse-transcriptase inhibitor; prepn. of substituted benzophenones as inhibitors of reverse transcriptase)

RN 457635-45-9 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-46-0 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457635-47-1 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-48-2 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-49-3 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-51-7 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-52-8 CAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● Na

RN 457635-53-9 CAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-55-1 CAPLUS
CN 1-Piperidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-56-2 CAPLUS
CN 4-Morpholineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 457635-54-0 CAPLUS
CN 1-Piperidineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-57-3 CAPLUS
CN 4-Morpholineacetamide, N-[[4-[[[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-58-4 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-59-5 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-60-8 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-63-1 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 457635-64-2 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-61-9 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-62-0 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-65-3 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-66-4 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-67-5 CAPLUS
CN Propanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 457635-68-6 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-69-7 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 457635-70-0 CAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● Na

RN 457635-71-1 CAPLUS
CN 1-Pyrrolidineacetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 457635-72-2 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-73-3 CAPLUS
CN Butanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-74-4 CAPLUS
CN Pentanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-75-5 CAPLUS
CN Pentanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457635-76-6 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-77-7 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 457635-78-8 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-79-9 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 457635-80-2 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methoxyethyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-81-3 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 457635-82-4 CAPLUS
CN Acetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methoxy-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-83-5 CAPLUS
CN Acetamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 457635-84-6 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[(ethoxymethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457635-85-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[[2-(2-methoxyethoxy)ethoxy]methyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH2—OMe

RN 457635-87-9 CAPLUS
CN Pentanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl-, (2S,3S)- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 457635-88-0 CAPLUS
CN Butanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 457635-89-1 CAPLUS
CN Pentanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457635-90-4 CAPLUS
CN Propanamide, 2-amino-N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457635-91-5 CAPLUS
CN Acetamide, N-[4-[[(aminoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 457635-92-6 CAPLUS
CN Acetamide, N-[4-[[(aminoacetyl)amino]sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 457635-93-7 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-94-8 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 457635-95-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-1-methyl-, monosodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457635-96-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457635-99-3 CAPLUS
CN Hexanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-00-9 CAPLUS
CN Hexanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-01-0 CAPLUS
CN Heptanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-02-1 CAPLUS
CN Heptanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-03-2 CAPLUS
CN Octanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-04-3 CAPLUS
CN Octanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-05-4 CAPLUS
CN Nonanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-06-5 CAPLUS
CN Nonanamide, N-[[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 457636-07-6 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 1-methylethyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-08-7 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 457636-09-8 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, ethyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457636-10-1 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 457636-11-2 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 457643-46-8 CAPLUS
CN Carbamic acid, [[4-[[[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:516824 CAPLUS
DN 137:201626
TI One-Pot Synthesis of Dendritic Poly(amide-urea)s via Curtius Rearrangement. 1. Monomer Syntheses and Model Reactions for the Dendritic Poly(amide-urea)s Synthesis
AU Okaniwa, Motoki; Takeuchi, Kazuhiko; Asai, Michihiko; Ueda, Mitsuru
CS Joint Research Center for Precision Polymerization, Japan Chemical Innovation Institute, Tsukuba, Ibaraki, 305-8565, Japan
SO Macromolecules (2002), 35(16), 6224-6231
CODEN: MAMOEX; ISSN: 0024-9297
PB American Chemical Society
DT Journal
LA English
AB The syntheses of two AB2 monomers, aminodicarboxylic acid (I) and aminodicarbonyl azide (II), and their model reactions for the one-pot synthesis of dendritic aromatic poly(urea-amide)s using the two AB2 monomers were carried out. The model reaction of II and p-tolyl isocyanate produced the target urea with two acyl azide groups in 93% yield at 25 °C for 30 min in THF. The Curtius rearrangement from an acyl azide to an isocyanate was completed at 140 °C for 30 min in THF. The isocyanate produced via the Curtius rearrangement readily reacted with aniline to give a urea compound in 93% yield. P-Tolyl isocyanate selectively reacted with an amine group of I to give a urea with end carboxylic acid groups. The end carboxylic acid groups of the urea could be activated with a condensing agent, diphenyl(2,3-dihydro-2-thioxo-3-benzoxazolyl)phosphonate (DBOP), and the condensation of the active amide with II provided an amide with acyl azide end groups.
IT 452339-60-5P 452339-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(monomer syntheses and model reactions towards one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-60-5 CAPLUS
CN 1,3-Benzenedicarbonyl diazide, 5,5',5''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylene(1-oxo-3,1-propanediyl)imino]]tris- (9CI) (CA INDEX NAME)

L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B

RN 452339-63-8 CAPLUS
CN Benzenepropanamide, 4,4',4''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino]]tris[N-[3,5-bis[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-C



PAGE 2-B



L9 ANSWER 10 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 3-A



PAGE 3-B



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:512076 CAPLUS
DN 137:201676
TI One-Pot Synthesis of Dendritic Poly(amide-urea)s via Curtius Rearrangement. 2. Synthesis and Characterization of Dendritic Poly(amide-urea)s
AU Okaniwa, Motoki; Takeuchi, Kazuhiko; Asai, Michihiko; Ueda, Mitsuru
CS Joint Research Center for Precision Polymerization, Japan Chemical Innovation Institute, Tsukuba, Ibaraki, 305-8565, Japan
SO Macromolecules (2002), 35(16), 6232-6238
CODEN: MAMOBX; ISSN: 0024-9297
PB American Chemical Society
DT Journal
LA English
AB Dendritic poly(amide-urea)s from the first to fourth generations with a narrow mol. weight distribution were prepared from 1,1,1-tris(4-carboxymethyloxyphenyl)ethane as a core mol., using aminodicarboxylic acid and aminodicarbonyl azide as two AB2 monomers in a one-pot procedure. This procedure involves activation of end carboxyl groups with a condensing agent, diphenyl(2,3-dihydro-2-thioxo-3-benzoxazolyl)phosphonate, condensation of the active amide with aminodicarbonyl azide, the Curtius rearrangement in the presence of aminodicarboxylic acid, and, finally, capping of the end groups with p-tert-butylaniline. All dendritic polymers were obtained quant. and fully characterized by elemental anal. and IR and NMR spectroscopies. Number average mol. wts. (Mn) of dendritic poly(amide-urea)s were estimated by end group anal., and each dendritic poly(amide-urea) had Mn close to the calculated value. Degrees of branching for the second and third generation dendritic polymers were 0.93 and 0.90, resp. by 1H NMR spectroscopy.
IT 452339-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(dendritic model, G1; one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-63-8 CAPLUS
CN Benzenepropanamide, 4,4',4''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino]]tris[N-[3,5-bis[[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-C



PAGE 2-B



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 3-A



PAGE 3-B



IT 452339-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dendritic, G1; one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-60-5 CAPLUS
CN 1,3-Benzenedicarbonyl diazide, 5,5',5''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylene(1-oxo-3,1-propanediyl)imino]]tris- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B

IT 452339-61-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dendritic, G2; one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-61-6 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 4,4',4'',4''',4'''',4'''''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylene(1-oxo-3,1-propanediyl)imino-5,1,3-benzenetriylbis[iminocarbonyli

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
mino-4,1-phenylene(1-oxo-3,1-propanediyl)imino]]]hexakis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-C



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



PAGE 2-C



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-D



PAGE 3-A



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 3-B



PAGE 3-C



IT 452339-60-5DP, reaction products with p-tert-butylaniline and dihexylamine
RL: SPN (Synthetic preparation); PREP (Preparation)
(linear model, Gl; one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-60-5 CAPLUS
CN 1,3-Benzenedicarbonyl diazide, 5,5',5''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylene(1-oxo-3,1-propanediyl)imino]]tris- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B

IT 452339-64-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(terminal model, G1; one-pot synthesis of dendritic poly(amide-urea)s via Curtius rearrangement)
RN 452339-64-9 CAPLUS

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzenepropanamide, 4,4',4''-[ethylidynetris[4,1-phenyleneoxy(1-oxo-2,1-ethanediyl)imino]]tris[N-[3,5-bis[[(dihexylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-C



PAGE 2-A

L9 ANSWER 11 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-B



PAGE 3-B

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:440873 CAPLUS
DN 138:170104
TI Synthesis and antimicrobial evaluation of new phenoxyacetamide derivatives
AU Raffa, D.; Migliara, O.; Daidone, G.; Maggio, B.; Schillaci, D.
CS Dipartimento di Chimica e Tecnologie Farmaceutiche, Univ. degli Studi di Palermo, Palermo, 90123, Italy
SO Bollettino Chimico Farmaceutico (2002), 141(1), 3-7
CODEN: BCFAAI; ISSN: 0006-6648
PB Societa Editoriale Farmaceutica
DT Journal
LA English
OS CASREACT 138:170104
GI



I

AB New N-(5-methylisoxazol-3-yl)-2- or -3- or -4-(phenoxyacetamido)benzamides (I; R1, R3 = H, Cl, Me; R2 = H, Cl; side chain attached at 2-, 3-, or 4-position) were synthesized and tested for their in vitro antimicrobial activity against gram pos. (Staphylococcus aureus ATCC 25923) and gram neg. (Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853) bacteria as well as fungi (Candida albicans ATCC 10231, Candida tropicalis ATCC 13803 and Cryptococcus neoformans ATCC 90112). I were devoid of antibacterial and antifungal activities at the maximum tested concns. of 50 μg/mL for bacteria and 100 μg/mL for yeast.
IT 496844-02-1P 496844-03-2P 496844-04-3P
496844-05-4P 496844-06-5P 496844-07-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antimicrobial evaluation of new (phenoxyacetamido)-N-(methylisoxazolyl)benzamides)
RN 496844-02-1 CAPLUS
CN Benzamide, N-(5-methyl-3-isoxazolyl)-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 12 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 496844-07-6 CAPLUS
CN Benzamide, N-(5-methyl-3-isoxazolyl)-4-[[(4-methylphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 496844-03-2 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-(5-methyl-3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 496844-04-3 CAPLUS
CN Benzamide, 4-[[(2,3-dichlorophenoxy)acetyl]amino]-N-(5-methyl-3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 496844-05-4 CAPLUS
CN Benzamide, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-N-(5-methyl-3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 496844-06-5 CAPLUS
CN Benzamide, N-(5-methyl-3-isoxazolyl)-4-[[(2-methylphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 13 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:234508 CAPLUS
DN 137:109242
TI Synthesis and evaluation of the analgesic and antiinflammatory activities of O-substituted salicylamides
AU Fahmy, H. H.; El-Eraky, W.
CS Department of Therapeutical Chemistry, National Research Centre, Cairo, Egypt
SO Archives of Pharmacal Research (2001), 24(3), 171-179
CODEN: APHRDQ; ISSN: 0253-6269
PB Pharmaceutical Society of Korea
DT Journal
LA English
OS CASREACT 137:109242
AB The present investigation deals with the synthesis of some new salicylamidoacetyl sulfonamides, [2-(aminocarbonyl)phenoxy]acetic acid Et ester and [2-(aminocarbonyl)phenoxy]acetic acid hydrazide, which is considered as the key intermediate for the synthesis of several series of new compds. N-imido derivs., thiadiazole and oxadiazole-derived Schiff bases were prepared Cyclocondensation of Schiff bases with thioglycolic acid gave thiazolidinones, while the reaction with acetyl chloride afforded azetidinones and with acetic anhydride gave 1,4-benzoxazepine-3,5-dione. Some of the compds. were tested for their analgesic and antiinflammatory activities as well as ulcerogenic effects. Some derivs. were more effective than salicylamide and ulcerogenic activity was variably lowered.
IT 442908-87-4P 442908-89-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic and antiinflammatory activities of O-substituted salicylamides)
RN 442908-87-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(2-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 442908-89-6 CAPLUS
CN Benzamide, 2-[2-[[4-(aminosulfonyl)phenyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



IT 442908-91-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L9 ANSWER 13 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 442908-91-0 CAPLUS
CN Benzamide, 2-[2-[[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:10434 CAPLUS
DN 136:85670
TI Preparation of aralkylguanidines related compounds for treatment of viral infection.
IN Drysdale, Martin James; Starkey, Ian David; Swarbrick, Terry Mark; Potter, Andrew John; Bower, Justin Fairfield
PA Ribotargets Limited, UK
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000614	A1	20020103	WO 2001-GB2816	20010622 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2000-15676	A	20000626		
US 2000-214690P	P	20000627		
US 2000-256120P	P	20001215		

OS MARPAT 136:85670
GI



AB Title compds. [I; X = O, S, SO, SO2, NR, CR2, C(OH)R, CO; R1 = H, alkyl, aryl; R2 = H, alkyl, aryl; R3 = alkyl, alkoxy, alkanoyl, aryl, aryloxy, aroyl; Y1, Y2 = alkylene, arylene, aralkylene, carbonylalkylene, carbonylarylene, carbonylaralkylene; A, B = NR2, CONR2, C(:NR)NR2, CSNR2, NOR, NHOR, CONROR, NRNR2, :NNR2, SO2NR2, SONR2, SO(:NR), NRCONR2, NRC(:NR)NR2, aromatic and non-aromatic N-heterocyclyl; R = H, alkyl, aryl; any 2 R may together comprise a C1-6 alkylene chain], were prepared Thus, 5-methoxysalicylaldehyde, BrCH2CH2NHBOC, and Cs2CO3 were stirred overnight in DMF to give 2-(N-tert-butoxycarbonylaminoethoxy)-5-methoxybenzaldehyde. This was stirred 15 min. with BOCNHCH2CH2NH2 in ClCH2CH2Cl followed by addition of NaBH(OAc)3 stirring for 16 h to give the diprotected triamine, which was stirred with CF3CO2H in CH2Cl2 to give the TFA salt of the deprotected triamine. This in MeCN was stirred overnight with (Me2CH)2NEt

L9 ANSWER 14 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
and N,N'-bis-tert-butoxycarbonylpyrazolecarboxamidine to give the fully protected bis-guanidine, which was stirred with CF3CO2H in CH2Cl2 to give title compd. (II). The latter inhibited binding of Tat to Tar with Ki<50 μM.
IT 385800-73-7P 385800-77-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aralkylguanidines related compds. for treatment of viral infection)
RN 385800-73-7 CAPLUS
CN Benzoic acid, 4-[[[3-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-4-(3-aminopropoxy)phenoxy]acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 385800-77-1 CAPLUS
CN Benzoic acid, 4-[[[3-[[[4-[(aminoiminomethyl)amino]butyl]amino]methyl]-4-[2-[(aminoiminomethyl)amino]ethoxy]phenoxy]acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 14 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:932464 CAPLUS
DN 136:58529
TI Skin-whitening compositions containing phenoxyacetate derivatives
IN Kobayashi, Koji; Ifuku, Oji; Ota, Naomi; Shishido, Tadao; Mikoshiba, Takashi
PA Shiseido Co., Ltd., Japan; Fuji Photo Film Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001354511	A2	20011225	JP 2000-174851	20000612 <--
PRAI JP 2000-174851		20000612		

OS MARPAT 136:58529
AB The invention provides a skin-whitening composition containing a phenoxyacetate derivative as an active ingredient. A skin-whitening cream containing N'-acetyl-2-[2,4-di(tert-pentyl)phenoxy]acetohydrazide 10, stearic acid 6, stearyl alc. 3, iso-Pr myristate 18, glycerin monostearate 3, propylene glycol 10, and other ingredients q.s. to 100 % was formulated.
IT 381718-73-6
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(skin-whitening compns. containing phenoxyacetate derivs.)
RN 381718-73-6 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(trimethylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:597806 CAPLUS
DN 135:162520
TI Compounds useful for the treatment or prevention of a disease mediated by the α2B-adrenoceptor
IN Wurster, Siegfried; Engstroem, Mia; Huovinen, Liisa; Kalliokoski, Sari; Kelanne, Leila; Savola, Eeva-Liisa
PA Oy Juvantia Pharma Ltd., Finland
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001058454	A1	20010816	WO 2001-FI105	20010207 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002058618	A1	20020516	US 2001-773512	20010202 <--
US 6521632	B2	20030218		
CA 2399421	AA	20010816	CA 2001-2399421	20010207 <--
EP 1253926	A1	20021106	EP 2001-907585	20010207 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008221	A	20030305	BR 2001-8221	20010207 <--
JP 2003522148	T2	20030722	JP 2001-557564	20010207 <--
EE 200200435	A	20031215	EE 2002-435	20010207 <--
NZ 520500	A	20050128	NZ 2001-520500	20010207
AU 780802	B2	20050421	AU 2001-35510	20010207
ZA 2002005835	A	20030722	ZA 2002-5835	20020722 <--
NO 2002003773	A	20020809	NO 2002-3773	20020809 <--
PRAI US 2000-182021P	P	20000211		
FI 2000-303	A	20000214		
WO 2001-FI105	W	20010207		

GI

L9 ANSWER 16 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I, R = Et
II, R = Me



III

AB A composition (e.g., oral, parenteral, transdermal or rectal) useful for the treatment or prevention of a disease mediated by the α2B-adrenoceptor, such as a coronary heart disease, essential hypertension, and a vascular disease, in a mammal comprises a selective α2B-adrenoceptor antagonist (5 μg-100 mg/kg daily) selected from example (I-III) or their pharmaceutically acceptable salts. The α2B-adrenoceptor antagonists are also used for potentiating the clin. efficacy of an anesthetic and/or analgesic α2-adrenoceptor agonist not selective for α2B-adrenoceptor subtype.
IT 312743-82-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment or prevention of diseases mediated by α2B-adrenoceptor)
RN 312743-82-1 CAPLUS
CN Acetamide, N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:207547 CAPLUS
DN 135:73613
TI [3H]MRS 1754, a selective antagonist radioligand for A2B adenosine receptors
AU Ji, X.-d.; Kim, Y.-C.; Ahern, D. G.; Linden, J.; Jacobson, K. A.
CS Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, Room B1A-19, Bldg. 8A, National Institutes of Health, Bethesda, MD, 20892, USA
SO Biochemical Pharmacology (2001), 61(6), 657-663
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
AB MRS 1754 [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide] is a selective antagonist ligand of A2B adenosine receptors. This is the least well-defined adenosine receptor subtype, and A2B antagonists have potential as antiasthmatic drugs. For use as a radioligand, MRS 1754, a p-cyanoanilide xanthine derivative, was tritiated on the Pr groups in a two-step reaction using a p-carboxamido precursor, which was dehydrated to the cyano species using trifluoroacetic anhydride. [3H]MRS 1754 (150 Ci/mmol) bound to recombinant human A2B adenosine receptors in membranes of stably transfected HEK-293 cells. Specific binding was saturable, competitive, and followed a one-site model, with a KD value of 1.13±0.12 nM and a Bmax value of 10.9±0.6 pmol/mg protein. Specific binding utilizing 0.7 nM [3H]MRS 1754 was > 70% of total binding. The affinity calculated from association and dissociation binding consts. was 1.22 nM (N = 4). Binding to membranes expressing rat and human A1 and A3 adenosine receptors was not significant, and binding in membranes of HEK-293 cells expressing human A2A receptors was of low affinity (KD > 50 nM). The effects of cations and chelators were explored. Specific binding was constant over a pH range of 4.5 to 6.5, with reduced binding at higher pH. The pharmacol. profile in competition expts. with [3H]MRS 1754 was consistent with the structure-activity relationship for agonists and antagonists at A2B receptors. The Ki values of XAC (xanthine amine congener) and CPX (8-cyclopentyl-1,3-dipropylxanthine) were 16 and 55 nM, resp. NECA (5'-N-ethylcarboxamidoadenosine) competed for [3H]MRS 1754 binding with a Ki of 570 nM, similar to its potency in functional assays. Thus, [3H]MRS 1754 is suitable as a selective, high-affinity radioligand for A2B receptors.
IT 347394-51-8P 347394-53-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
([3H]MRS 1754 selective antagonist radioligand for A2B adenosine receptors)
RN 347394-51-8 CAPLUS
CN Benzamide, 4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-di-2-propenyl-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 17 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347394-53-0 CAPLUS
CN Benzamide, 4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetyl]amino]-, labeled with tritium (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:185739 CAPLUS
DN 134:237301
TI Preparation of benzophenones and phenyl heteroaryl ketones as inhibitors of reverse transcriptase
IN Andrews, Clarence Webster; Chan, Joseph Howing; Freeman, George Andrew; Romines, Karen Rene; Tidwell, Jeffrey H.
PA Glaxo Group Limited, UK; Pianetti, Pascal Maurice Charles
SO PCT Int. Appl., 436 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017982	A1	20010315	WO 2000-EP8487	20000831 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383782	AA	20010315	CA 2000-2383782	20000831 <--
	BR 2000013771	A	20020514	BR 2000-13771	20000831 <--
	EP 1208091	A1	20020529	EP 2000-967637	20000831 <--
	EP 1208091	B1	20060503		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200201187	T2	20020821	TR 2002-1187	20000831 <--
	JP 2003510252	T2	20030318	JP 2001-521729	20000831 <--
	JP 3739704	B2	20060125		
	NZ 517451	A	20040130	NZ 2000-517451	20000831
	AU 770302	B2	20040219	AU 2000-77743	20000831
	CN 1636984	A	20050713	CN 2004-10095621	20000831
	CN 1636985	A	20050713	CN 2004-10095622	20000831
	CN 1636986	A	20050713	CN 2004-10097470	20000831
	AT 325106	E	20060615	AT 2000-967637	20000831
	ZA 2002001664	A	20030527	ZA 2002-1664	20020227 <--
	NO 2002001042	A	20020430	NO 2002-1042	20020301 <--
	JP 2006077019	A2	20060323	JP 2005-272533	20050920
PRAI	GB 1999-20872	A	19990904		
	JP 2001-521729	A3	20000831		
	WO 2000-EP8487	W	20000831		

OS MARPAT 134:237301
GI

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. [I; X = C, O, N; R1 = alkyl, cycloalkyl, (un)substituted aryl, etc.; R2 = H, halo, alkyl; R3, R4 = H, OH, (un)substituted heterocyclyl, etc.; R5 = H, halo, alkyl, etc.], useful in the treatment of HIV infections, were prepared E.g., a 4-step synthesis of the ketone II which showed IC50 of between 101 nM and 1,000 nM against HIV-1 in MT4 cell assay, was described.

IT 329936-15-4P 329936-19-8P 329936-29-0P
329936-31-4P 329936-37-0P 329936-49-4P
329936-51-8P 329936-77-8P 329936-83-6P
329937-01-1P 329937-03-3P 329937-31-7P
329937-35-1P 329937-44-2P 329937-45-3P
329937-61-3P 329937-65-7P 329937-71-5P
329937-73-7P 329937-76-0P 329937-80-6P
329937-83-9P 329938-00-3P 329938-02-5P
329938-04-7P 329938-06-9P 329938-08-1P
329938-28-5P 329938-38-7P 329938-45-6P
329938-54-7P 329938-58-1P 329938-60-5P
329938-63-8P 329938-96-7P 329938-98-9P
329939-08-4P 329939-12-0P 329939-16-4P
329939-44-8P 329939-61-9P 329939-63-1P
329939-64-2P 329939-66-4P 329939-68-6P
329939-72-2P 329939-76-6P 329939-83-5P
329939-85-7P 329939-87-9P 329939-91-5P
329939-93-7P 329939-95-9P 329939-97-1P
329940-03-6P 329940-05-8P 329940-06-9P
329940-08-1P 329940-10-5P 329940-13-8P
329940-15-0P 329940-17-2P 329940-21-8P
329940-22-9P 329940-26-3P 329940-28-5P
329940-30-9P 329940-32-1P 329940-35-4P
329940-38-7P 329940-40-1P 329940-42-3P
329940-44-5P 329940-46-7P 329940-55-8P
329940-59-2P 329940-61-6P 329940-69-4P
329940-71-8P 329940-73-0P 329940-75-2P
329940-77-4P 329940-79-6P 329940-81-0P
329940-83-2P 329940-85-4P 329940-99-0P
329941-16-4P 329941-25-5P 329941-27-7P
329966-53-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzophenones and Ph heteroaryl ketones as inhibitors of reverse transcriptase)

RN 329936-15-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329936-19-8 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329936-29-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(1-methyl-1H-imidazol-2-yl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329936-31-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-thiazolylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329936-37-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329936-49-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329936-51-8 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 329937-03-3 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(2-thienylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329937-31-7 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[3-(dimethylamino)propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329937-35-1 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[[3-(dimethylamino)propyl]thio]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dichlorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329936-77-8 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(ethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329936-83-6 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 329937-01-1 CAPLUS

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329937-44-2 CAPLUS
CN Benzamide, 4-[[(2-benzoyl-4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 329937-45-3 CAPLUS
CN Benzamide, 4-[[(2-benzoyl-4-chlorophenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 329937-61-3 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(4-cyano-2-thienyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 329937-65-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[(5-bromo-3-pyridinyl)carbonyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 329937-71-5 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-[(trifluoromethyl)thio]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329937-73-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-[(trifluoromethyl)sulfonyl]benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329937-76-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-ethynylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329937-80-6 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-(cyclopentylethynyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329937-83-9 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-(phenylethynyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329938-00-3 CAPLUS
CN Acetamide, N-[4-[3-(aminosulfonyl)propoxy]-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329938-02-5 CAPLUS
CN Acetamide, N-[4-[3-(aminosulfonyl)propoxy]-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329938-04-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[3-[[(1,1-dimethylethyl)amino]sulfonyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329938-06-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[3-[(dimethylamino)sulfonyl]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329938-08-1 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[3-[(methylamino)sulfonyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329938-28-5 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329938-38-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[[3-(diethylamino)propyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329938-45-6 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(cyclopropylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329938-63-8 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(methylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329938-96-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2,6-dichlorophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 329938-98-9 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methoxyphenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329938-54-7 CAPLUS
CN Benzoic acid, 4-[[(2-benzoyl-4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 329938-58-1 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-[2-(4-chlorobenzoyl)-4-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 329938-60-5 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329939-08-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-nitrophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 329939-12-0 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[2-chloro-4-[3-(dimethylamino)propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329939-16-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-(2-benzoyl-4-chlorophenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329939-44-8 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 329939-61-9 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethoxybenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-63-1 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromo-5-chlorobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-72-2 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-fluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-76-6 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-ethylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-83-5 CAPLUS

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329939-64-2 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-66-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dimethylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329939-68-6 CAPLUS

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 329939-85-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[(cyclopropylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329939-87-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[[(cyclopropylmethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329939-91-5 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[(diethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329939-93-7 CAPLUS

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-05-8 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[(4-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-06-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[[(2-hydroxyethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-08-1 CAPLUS
CN Acetamide, N-[4-[(1H-benzotriazol-5-ylamino)sulfonyl]-2-methylphenyl]-2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[4-[(ethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329939-95-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329939-97-1 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[[3-(4-morpholinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-03-6 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3,5-difluorobenzoyl)phenoxy]-N-[2-methyl-4-[[(3-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-10-5 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(diethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-13-8 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[(cyclopropylmethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-15-0 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[(3-methoxyphenyl)methyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-17-2 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[(2-methoxyethyl)amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-21-8 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[2-(2-thienyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-22-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 329940-30-9 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[[[(4-methoxyphenyl)methyl]amino]sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-32-1 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-35-4 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-38-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[(3-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[2-methyl-4-[[(1-phenylpropyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-26-3 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-28-5 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-bromo-5-methylbenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-40-1 CAPLUS
CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 329940-42-3 CAPLUS
CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-44-5 CAPLUS
CN Acetamide, 2-[2-[3,5-bis(trifluoromethyl)benzoyl]-4-chlorophenoxy]-N-[2-methyl-4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-46-7 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[[(4-pyridinylmethyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-55-8 CAPLUS
CN Acetamide, 2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-[2-methyl-4-[(4-morpholinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-59-2 CAPLUS
CN Acetamide, N-[4-[3-[(aminocarbonyl)amino]propoxy]-2-methylphenyl]-2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-61-6 CAPLUS
CN Acetamide, N-[4-[3-[(aminocarbonyl)amino]propoxy]-2-methylphenyl]-2-[4-chloro-2-(3-cyanobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-69-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(5-cyano-3-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-71-8 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(2-chloro-6-methyl-4-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-73-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3,5-dibromobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-75-2 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[2-methyl-4-[(methylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329940-77-4 CAPLUS
CN Acetamide, 2-[4-chloro-2-[3-fluoro-5-(trifluoromethyl)benzoyl]phenoxy]-N-[4-[(dimethylamino)sulfonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 329940-79-6 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[(6-bromo-2-pyridinyl)carbonyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329940-81-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[(6-cyano-2-pyridinyl)carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 329940-83-2 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-[4-bromo-2-(trifluoromethyl)benzoyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 329940-85-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[4-cyano-2-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 329940-99-0 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-[3-cyano-5-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 329941-16-4 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 329941-25-5 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(2-bromobenzoyl)-4-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 329941-27-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[4-chloro-2-(3-pyridinylcarbonyl)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 18 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 329966-53-2 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)-2-methylphenyl]-2-[2-(3-cyanobenzoyl)-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:861682 CAPLUS
DN 134:29253
TI Preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors
IN Linden, Joel M.; Jocobson, Kenneth A.; Kim, Yong-Chul
PA University of Virginia Patent Foundation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000073307	A2	20001207	WO 2000-US15233	20000601 <--
	WO 2000073307	A3	20010531		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6545002	B1	20030408	US 2000-505504	20000217 <--
	CA 2370598	AA	20001207	CA 2000-2370598	20000601 <--
	EP 1192158	A2	20020403	EP 2000-938072	20000601 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-136898P	P	19990601		
	US 1999-136900P	P	19990601		
	US 1999-505504	A	19990601		
	US 1999-151875P	P	19990831		
	US 2000-505504	A	20000217		
	WO 2000-US15233	W	20000601		

OS MARPAT 134:29253
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R, R1 = H, alkyl, alkenyl, etc.; Z = phenylene, cyclohexylene, cyclopentylene; X = alkylene, alkenylene, alkynylene, etc.; R2 = H, alkyl, alkenyl, etc.; R8 = H, cycloalkyl, aralkyl, etc.; R9 = cycloalkyl, aryl, alkyl, etc.] which are selective antagonists of A2B adenosine receptors (ARs), were prepared (general procedures for their preparation were given). Thus, hydrolysis of the ester II with 1N NaOH afforded the title compound III which showed Ki of 3.34 ± 0.51 nM against hA2B receptor binding.
IT 264622-55-1P 264622-56-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 8-phenylxanthines as antagonists of A2B

L9 ANSWER 19 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L9 ANSWER 19 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
adenosine receptors)
RN 264622-55-1 CAPLUS
CN Benzamide, 4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 264622-56-2 CAPLUS
CN Benzamide, N-methyl-4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



IT 104576-54-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted 8-phenylxanthines as antagonists of A2B adenosine receptors)
RN 104576-54-7 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(1,3-diethyl-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 20 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:457029 CAPLUS
DN 133:73951
TI Hydroxybenzoylhydrazones of aromatic and heterocyclic aldehydes as glucagon antagonists/inverse agonists
IN Ling, Anthony; Kuki, Atsuo; Shi, Shenghua; Plewe, Michael Bruno; Feng, Jun; Truesdale, Larry Kenneth; May, John; Kiel, Dan; Madsen, Peter; Sams, Christian; Lau, Jesper
PA Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc; et al.
SO PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039088	A1	20000706	WO 1999-DK705	19991216 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6613942	B1	20030902	US 1998-220003	19981223 <--
	EP 1140823	A1	20011010	EP 1999-960939	19991216 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002533439	T2	20021008	JP 2000-591000	19991216 <--
PRAI	US 1998-220003	A	19981223		
	US 1997-886785	A2	19970701		
	US 1998-32516	A2	19980227		
	US 1998-107400	A2	19980630		
	WO 1999-DK705	W	19991216		

OS MARPAT 133:73951
GI



I



II

AB Hydroxybenzoylhydrazones I [R1 = Cl, F, NO2, CN; R2 = substituted 4-, 5-indolyl, 1-naphthyl, 4-quinolyl] were prepared for use as glucagon

L9 ANSWER 20 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antagonists in the treatment of hyperglycemia (no data). Thus, the hydrazone II was obtained by treating 4-formylindole with 2-chloromethyl-4-methylpyridine and 3-cyano-4-hydroxybenzoic acid hydrazide.
IT 280135-43-5P 280135-53-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxybenzoylhydrazones of aromatic and heterocyclic aldehydes as glucagon antagonists/inverse agonists)
RN 280135-43-5 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(4-cyanophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 280135-53-7 CAPLUS
CN Benzoic acid, 3-cyano-4-hydroxy-, [[4-[[(4-cyanophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:456786 CAPLUS
DN 133:96720
TI Photographic element containing pyrazolone photographic useful group (PUG) releasing coupler and imaging process employing same
IN Slusarek, Wojciech Kazimierz; Poslusny, Jerrold Neal; Wu, Zheng Zhi; Yang, Xiqiang
PA Eastman Kodak Company, USA
SO Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1016915	A1	20000705	EP 1999-204424	19991220 <--
	EP 1016915	B1	20020306		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6150078	A	20001121	US 1998-223215	19981230 <--
	JP 2000199942	A2	20000718	JP 2000-5017	20000104 <--
PRAI	US 1998-223215	A	19981230		

AB The invention provides a photog. element comprising a light-sensitive silver halide emulsion layer having associated therewith an 1-arylpyrazol-5-one coupler bearing a 4-aryloxy coupling-off group containing a group capable of releasing a photog. useful group (PUG) wherein: (1) the 1-arylpyrazol-5-one ring contains a 3-aryl substituent which in turn contains substituents for which the sum of the Hammett's <r constant values is at least 0, provide that two or more such substituents may join to form one or more addnl. rings; and (2) the 4-aryloxy coupling-off group: (a) contains ring substituents selected so that the sum of the Hammett's sigma constant values for all substituents on the aryloxy ring is at least 0.4 but does not contain a nitro substituent in the ortho position, and: (b) contains in at least one position ortho or para to the oxygen atom bonding the aryloxy group to the pyrazolone ring a substituent comprising a tetrahedral carbon atom bonded to a photog. useful group (PUG) or to another timing group which timing group is in turn bonded to a PUG directly or through a further timing group; provided substituents may join to form one or more addnl. rings.
IT 280757-49-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(silver halide photog. emulsion layer)
RN 280757-49-5 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-(4-hydrazinophenyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 22 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:398996 CAPLUS
DN 133:51271
TI Photothermographic material useful for printing platemaking
IN Suzuki, Hiroyuki; Ezoe, Toshihide; Yamada, Kozaburo
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000162733	A2	20000616	JP 1998-353852	19981127 <--
PRAI	JP 1998-353852		19981127		
OS	MARPAT 133:51271				
GI					



AB The material, possessing ≥1 image-forming layer, contains an organic Ag salt, a reducing agent, and a compound I, II, or III [Z1-3 = nonmetal atoms required to form a 5- to 7-membered ring; X1-3 = OH (or its salt), alkoxy, aryloxy, heterocyclic oxy, SH (or its salt), alkylthio, arylthio, heterocyclic thio, acyloxy, amino, acylamino, sulfonamide, heterocyclic group; Y1 = CO, C:S, SO, SO2, C(:NR7), O, S, NR8, N:, :CR9; R1-9 = H, substituent]. The material shows high sensitivity, Dmax, and contrast and low fog.
IT 275380-17-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photothermog. material containing cyclic alkene compound and hydrazine compound)
RN 275380-17-1 CAPLUS
CN Acetamide, 2-[4-(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 23 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:323843 CAPLUS
DN 133:43162
TI FT-IR and laser Raman spectra of the derivatives of analogues of sulfanilamide
AU Zhang, Wei-hong; Chen, Jian; Zhang, Yu-hui; Xie, Mei-qi; Zhang, Zhuo-liang
CS Instrumentation Analysis and Research Center, Zhongshan University, Canton, 510275, Peop. Rep. China
SO Zhongshan Daxue Xuebao, Ziran Kexueban (2000), 39(1), 114-117
CODEN: CHTHAJ; ISSN: 0529-6579
PB Zhongshan Daxue Xuebao Bianjibu
DT Journal
LA Chinese
AB The FT-TR and laser Raman spectra of the new compds., namely amino-group-substituted p-(4-chlorophenoxyacetyl)sulfamethazine, p-(2,3,5-trichlorobenzoyl)sulfamethazine and p-(2,4-dichlorophenoxyacetyl)sulfamethoxazole were measured. The vibration modes were assigned. The inhibitory action of the compds. on the growth of the human cervical cancer Hela cell was discussed .
IT 154820-80-1P 154820-82-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(FT-IR and laser Raman spectra of sulfamethazine and sulfamethoxazole amide derivs.)
RN 154820-80-1 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 154820-82-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 24 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2003-662183 A3 20030912
OS MARPAT 132:251067
GI



I



II

AB The invention concerns novel amidine derivs., including compds. I [R = H, alkyl, alkoxy; A = certain substituted aryl or (un)substituted heteroaryl groups; B = alkyl, (un)substituted aryl or heteroaryl, (un)substituted or heterocyclic amino; X = bond, (CH2)m, O(CH2)m, (CH2)mO, S(CH2)m, O(CH2)mCO, CH:CH, etc.; Y = bond, (CH2)n, (CH2)rQ(CH2)s; Q = piperazine, homopiperazine, piperidine, pyrrolidine, azetidine, thiazolidine, saturated C3-7 carbocycles, etc; Z = bond, (CH2)pO(CH2)q, (CH2)pS(CH2)q, (CH2)pNH(CH2)q, etc; m, n, p, q, r, s = 0-6}, as well as addnl. specific compds. In particular, 2-hydroxy-5-methoxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide (II) and 2,5-dihydroxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide are disclosed. Also disclosed are the use of I as medicines, and pharmaceutical compns. containing them. For instance, amidation of 5-methoxysalicylic acid with 4-nitrophenethylamine-HCl, followed by hydrogenation of the nitro group to amino, condensation of the amine with S-methyl-2-thiophenethiocarboximide-HI, and acidification in acetone, gave II.HCl. The IC50 of selected I, including II.HCl, against rat neuronal NO synthase in vitro, was < 3.5 μM.
IT 262613-33-2P 262614-20-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of amidine derivs. as inhibitors of NO synthase and/or lipid peroxidn.)
RN 262613-33-2 CAPLUS
CN Acetamide, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]-N-[2-[4-[(imino-2-thienylmethyl)amino]phenyl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

L9 ANSWER 24 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:210150 CAPLUS
DN 132:251067
TI Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them
IN Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000017190	A2	20000330	WO 1999-FR2250	19990922 <--
WO 2000017190	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2783519	A1	20000324	FR 1998-11868	19980923 <--
FR 2783519	B1	20030124		
CA 2344224	AA	20000330	CA 1999-2344224	19990922 <--
AU 9956314	A1	20000410	AU 1999-56314	19990922 <--
AU 766373	B2	20031016		
BR 9913904	A	20010703	BR 1999-13904	19990922 <--
EP 1115719	A2	20010718	EP 1999-943024	19990922 <--
EP 1115719	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526493	T2	20020820	JP 2000-574099	19990922 <--
AT 233750	E	20030315	AT 1999-943024	19990922 <--
EP 1318149	A1	20030611	EP 2002-26170	19990922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1115719	T	20030731	PT 1999-943024	19990922 <--
NZ 511189	A	20030926	NZ 1999-511189	19990922 <--
ES 2194501	T3	20031116	ES 1999-943024	19990922 <--
RU 2238939	C2	20041027	RU 2001-111022	19990922
IL 141998	A1	20050925	IL 1999-141998	19990922
US 6653312	B1	20031125	US 2001-787467	20010316 <--
NO 2001001479	A	20010518	NO 2001-1479	20010322 <--
ZA 2001003204	A	20020919	ZA 2001-3204	20010419 <--
HK 1042486	A1	20050225	HK 2002-103892	20020524
US 2005261269	A1	20051124	US 2003-662183	20030912
US 2006084667	A1	20060420	US 2005-250783	20051014
PRAI FR 1998-11868	A	19980923		
EP 1999-943024	A3	19990922		
WO 1999-FR2250	W	19990922		
US 2001-787467	A3	20010316		

L9 ANSWER 24 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HI

RN 262614-20-0 CAPLUS
CN Acetamide, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenoxy]-N-[2-[4-[(imino-2-thienylmethyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 25 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:135995 CAPLUS
DN 132:293729
TI Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors
AU Kim, Yong-Chul; Ji, Xiao-duo; Melman, Neli; Linden, Joel; Jacobson, Kenneth A.
CS Molecular Recognition Section Laboratory of Bioorganic Chemistry National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892-0810, USA
SO Journal of Medicinal Chemistry (2000), 43(6), 1165-1172
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I

AB No highly selective antagonists of the A2B adenosine receptor (AR) have been reported; however such antagonists have therapeutic potential as antiasthmatic agents. Here the synthesis of potent and selective A2B receptor Antagonists is reported. The structure-activity relationships (SAR) of 8-phenyl-1,3-di-(n-propyl)xanthine derivs. in binding to recombinant human A2B ARs in HEK-293 cells (HEK-A2B) and at other AR subtypes were explored. Various amide derivs. of 8-{4-[[carboxymethyl]oxy]phenyl]-1,3-di(n-propyl)xanthine, I (R1 = n-Pr, X = OCH2, R2 = OH) (II), were synthesized. A comparison of aryl, alkyl, and aralkyl amides demonstrated that simple anilides, particularly those substituted in the para-position with electron-withdrawing groups, such as nitro, cyano, and acetyl, bind selectively to human A2B receptors in the range of 1-3 nM. The unsubstituted anilide I (R1 = n-Pr, X = OCH2, R2 = NHPh) had a Ki value at A2B receptors of 1.48 nM but was only moderately selective vs. human A1/A2A receptors and nonselective vs. rat A1 receptors. Highly potent and selective A2B antagonists were a p-aminoacetophenone derivative I (R1 = n-Pr, X = OCH2, R2 = 4-MeOC6H4NH) (Ki value 1.39 nM) and a p-cyanoanilide I (R1 = n-Pr, X = OCH2, R2 = NHC6H4CN-4) (III) (Ki value 1.97 nM). Compound III was 400-, 245-, and 123-fold selective for human A2B receptors vs. human A1/A2A/A3 receptors, resp., and 8.5- and 310-fold selective vs. rat A1/A2A receptors, resp. Substitution of the 1,3-di-Pr groups with 1,3-di-Et offered no disadvantage for selectivity, and high affinities at A2B receptors were maintained. Substitution of the p-carboxymethyloxy group of II and its amides with acrylic acid decreased affinity at A2B receptors while increasing affinity at A1 receptors. 1,3-Di(cyclohexylmethyl) groups greatly reduced affinity at ARs, although the p-carboxymethyloxy derivative I

(R1 = cyclohexylmethyl, X = CH:CH, R2 = OH) was moderately selective for A2B receptors. Several selective A2B antagonists inhibited

L9 ANSWER 25 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 25 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NECA-stimulated calcium mobilization in HEK-A2B cells.
IT 104576-54-7P 264622-55-1P 264622-56-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, human A2B adenosine receptor antagonist activity, and structure-activity relationship of phenylxanthine anilide derivs.)
RN 104576-54-7 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(1,3-diethyl-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2—NH_2

RN 264622-55-1 CAPLUS
CN Benzamide, 4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 264622-56-2 CAPLUS
CN Benzamide, N-methyl-4-[[[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 26 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:98505 CAPLUS
DN 132:137119
TI Preparation of N-substituted sulfonamide derivatives for potentiating glutamate receptor function
IN Arnold, Macklin Brian; Jones, Winton Dennis; Ornstein, Paul Leslie; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 206 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006537	A1	20000210	WO 1999-US17017	19990728 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952355	A1	20000221	AU 1999-52355	19990728 <--
US 6525099	B1	20030225	US 2001-744419	20010123 <--
PRAI US 1998-94921P	P	19980731		
WO 1999-US17017	W	19990728		

OS MARPAT 132:137119
GI



I II

AB Title compds. (I) [wherein Ra = alkyl, acyl, CO2(aryl)alkyl, CO2(alkyl)aryl, C(O)CH2OH, or N-substituted aminoacyl; R1 = (un)substituted naphthyl, Ph, furyl, thienyl, or pyridyl; R2 = (cyclo)alkyl, haloalkyl, alkenyl, alkoxyalkyl, heteroarom., (un)substituted Ph, etc.; R5-R8 = independently H, (aryl)alkyl, (aryl)alkenyl, aryl, or 2 of R5-R8 together with the C atom(s) to which they are attached form a carbocyclic ring and the remaining R5-R8 = H] were prepared as ampakines (no data) for the treatment of a wide variety of psychiatric conditions and neurol. disorders. Examples include prepns. of over 100 intermediates and 281 invention compds. For instance, reaction of 2-(4-bromophenyl)propylamine.HCl (2-step preparation given) with MeSO2Cl in

L9 ANSWER 26 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
toluene and 10% aq. NaOH gave N-2-(4-bromophenylpropyl) methanesulfonamide (81%). Arylation of the sulfonamide with 3-formylbenzeneboronic acid in the presence of K2CO3 and Pd(PPh3)4 in toluene gave II in 41% yield.
IT 211313-95-0P 211314-58-8P 211314-77-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(product; preparation of N-substituted sulfonamide derivs. as glutamate receptor potentiators for the treatment of psychiatric conditions and neurol. disorders)
RN 211313-95-0 CAPLUS
CN Acetamide, N-[4-[1-methyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 211314-58-8 CAPLUS
CN Acetamide, N-[4-[1,1-dimethyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 211314-77-1 CAPLUS
CN Acetamide, N-[4-[2-[[(dimethylamino)sulfonyl]amino]-1-methylethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:98309 CAPLUS
DN 132:137176
TI Preparation of sulfonamides for potentiating of glutamate receptor function
IN Arnold, Macklin Brian; Bender, David Michael; Cantrell, Buddy Eugene; Jones, Winton Dennis; Ornstein, Paul Leslie; Simon, Richard Lee; Smith, Edward C. R.; Tromiczak, Eric George; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006148	A1	20000210	WO 1999-US16962	19990728 <--
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339091	AA	20000210	CA 1999-2339091	19990728 <--
AU 9952334	A1	20000221	AU 1999-52334	19990728 <--
EP 994110	A1	20000419	EP 1999-305989	19990728 <--
EP 994110	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521438	T2	20020716	JP 2000-562003	19990728 <--
AT 240308	E	20030515	AT 1999-305989	19990728 <--
ES 2199525	T3	20040216	ES 1999-305989	19990728
US 6693137	B1	20040217	US 2001-744418	20010123
PRAI US 1998-94973P	P	19980731		
WO 1999-US16962	W	19990728		

OS MARPAT 132:137176
GI



I



II

L9 ANSWER 27 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. [I; L1-L3 = alkylene; r, m, n = 0-1; q = 1-2; X1-X3 = O, S, CO, etc.; R1 = H, alkyl, cycloalkyl, etc.; R2 = alkyl, cycloalkyl, fluoroalkyl, etc.; either one of R5-R8 = H, alkyl, arylalkyl, etc., or two of R5-R8 together with the carbon atom or carbon atoms to which they are attached form a carbocyclic ring, and the remainder of R5-R8 = H], useful for treating cognitive disorder, neurodegenerative disorder, age-related dementia, movement disorder, depression, attention deficit disorder, attention deficit hyperactivity disorder, and psychosis, were prepared and formulated. Thus, treatment of 4-(N,N-dimethylamino)butyric acid with (COCl)2 in the presence of one drop of DMF in CH2Cl2 followed by reaction of the intermediate with N-2-(4-aminophenyl)propyl 2-propanesulfonamide (preparation given) in the presence of Et3N in CH2Cl2 afforded the title compound
II. Compds. I are effective at 0.1-100 mg/kg/day.
IT 257279-68-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides for potentiating of glutamate receptor function)
RN 257279-68-8 CAPLUS
CN Acetamide, 2-(4-chloro-3-fluorophenoxy)-N-[4-[1-methyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 28 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:736370 CAPLUS
DN 131:344290
TI Photothermographic recording element
IN Yamada, Kohzaburoh; Suzuki, Hiroyuki; Ezoe, Toshihide
PA Fuji Photo Film Co., Ltd., Japan
SO Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 957398	A1	19991117	EP 1999-108626	19990511 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11327077	A2	19991126	JP 1998-145055	19980511 <--
US 6277554	B1	20010821	US 1999-309305	19990511 <--
PRAI JP 1998-145055	A	19980511		

OS MARPAT 131:344290
AB A photothermog. recording element exhibiting high contrast and minimized dependency of photog. properties on developing temperature comprises an organic
silver salt, a photosensitive silver halide, a reducing agent, a hydrazine derivative, and a heterocyclic compound
IT 250250-71-6 250250-73-8
RL: TEM (Technical or engineered material use); USES (Uses)
(photothermog. recording elements for photomech. processes containing organic
silver salts, silver halides, heterocyclic compds. and)
RN 250250-71-6 CAPLUS
CN Glycine, N-(phenylsulfonyl)-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 250250-73-8 CAPLUS
CN Glycine, N-(trifluoroacetyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 28 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 29 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:511151 CAPLUS
DN 131:144614
TI Preparation of pyridinedicarboxylic acid bisacylpiperazides and related compounds as tryptase inhibitors.
IN Bode, Wolfram; Moroder, Luis; Pereira, Pedro Jose Barbosa; Bergner, Andreas; Huber, Robert; Sommerhoff, Christian; Schaschke, Norbert; Bar, Thomas; Martin, Thomas; Stadlwieser, Josef; Ulrich, Wolf-rudiger; Dominik, Andreas; Thibaut, Ulrich; Bundschuh, Daniela; Beume, Rolf; Goebel, Karl-josef
PA Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Germany; Byk Gulden Lomberg Chemische Fabrik Gmbh; et al.
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940083	A2	19990812	WO 1999-EP726	19990204 <--
	WO 9940083	A3	19991111		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19851299	A1	19990812	DE 1998-19851299	19981106 <--
	AU 9929246	A1	19990823	AU 1999-29246	19990204 <--
	EP 1060175	A2	20001220	EP 1999-910192	19990204 <--
	EP 1060175	B1	20041117		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002502850	T2	20020129	JP 2000-530512	19990204 <--
	AT 282607	E	20041215	AT 1999-910192	19990204
	PT 1060175	T	20050331	PT 1999-910192	19990204
	ES 2233025	T3	20050601	ES 1999-910192	19990204
	US 6489327	B1	20021203	US 2000-601317	20001020 <--
PRAI	DE 1998-19804761	A	19980206		
	DE 1998-19851299	A	19981106		
	WO 1999-EP726	W	19990204		

OS MARPAT 131:144614
GI

L9 ANSWER 29 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB K1A5B5A3B3A1B1MB2A2B4A4B6A6K2 [I; A1, A2 = CO, NH, O, S, SO2, SO2NH, CONH, CO2, bond; A3, A4 = CO, CS, O, S, NH, CO2, CONH, bond, Q1, Q2, etc.; W = bond, CO; A5, A6 = CO, NH, O, S, CONH, CO2, bond; M = Q3, Q4, etc.; R1, R2 = H, alkyl, fluoroalkyl, OH; R1R2 = O, atoms to form a 5-6 membered (substituted) carbocyclic ring; R3, R4 = H, alkyl; R5, R6 = H, alkyl; R7 = H, alkyl, Ph, pyridyl; B1-B6 = bond, alkylene; K1 = B7(CO)mB9X1, B7(CO)mB9Y1, B7(CO)mB9Z1B11X1; X2 = B8(CO)pB10X2, B8(CO)pB10Y2, B8(CO)pB10Z2B12X2; B7-B12 = bond, alkylene; m, p = 0, 1; X1, X2 = NH2, C(:NH)NH2, C(:NH)NHOH, etc.; Y1, Y2 = heteroaryl, heterocycloalkyl; Z1, Z2 = (substituted) arylene, heteroarylene, cycloalkylene, heterocycloalkylene], were prepared Thus, pyridine-2,6-dicarboxylic acid bispiperazide trihydrochloride (preparation given), 3-tert-butoxycarbonylaminomethylbenzoic acid, Et3N, 1-hydroxybenzotriazole, and EDC were stirred in DMF to give 75% pyridine-2,6-dicarboxylic acid bis[4-(3-tert-butoxycarbonylaminomethylbenzoyl)-1-piperazide]. This was stirred with HCl in dioxane/MeOH to give pyridine-2,6-dicarboxylic acid bis[4-(3-aminomethylbenzoyl)-1-piperazide]. Tested I showed dissociation consts. with human tryptase Kiapp = 0.028-3 μM.

IT 236113-65-8P 236113-66-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinedicarboxylic acid bisacylpiperazides and related compds. as tryptase inhibitors)

RN 236113-65-8 CAPLUS
CN Acetamide, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[N-[[4-[(aminoiminomethyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 29 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 236113-66-9 CAPLUS
CN Acetamide, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[N-[[4-[(aminoiminomethyl)amino]phenyl]methyl]-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 236113-65-8
CMF C35 H40 N8 O4

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2

L9 ANSWER 30 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:511141 CAPLUS

DN 131:157757

TI Preparation of pyridinedicarboxylic acid bisacylpiperazides and related compounds as tryptase inhibitors.

IN Bode, Wolfram; Moroder, Luis; Pereira, Pedro Jose Barbosa; Bergner, Andreas; Huber, Robert; Sommerhoff, Christian; Schaschke, Norbert; Bar, Thomas; Martin, Thomas; Stadlwieser, Josef; Ulrich, Wolf-rudiger; Dominik, Andreas; Thibaut, Ulrich; Bundschuh, Daniela; Beume, Rolf; Goebel, Karl-josef

PA Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Germany; Byk Gulden Lomberg Chemische Fabrik Gmbh; et al.

SO PCT Int. Appl., 265 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940073	A2	19990812	WO 1999-EP727	19990204 <--
	WO 9940073	A3	19991111		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19851300	A1	19991216	DE 1998-19851300	19981106 <--
	AU 9927230	A1	19990823	AU 1999-27230	19990204 <--
	EP 1060171	A2	20001220	EP 1999-907497	19990204 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002502845	T2	20020129	JP 2000-530503	19990204 <--
	US 6613769	B1	20030902	US 2001-601318	20010122 <--
PRAI	DE 1998-19804761	A	19980206		
	DE 1998-19851300	A	19981106		
	WO 1999-EP727	W	19990204		

OS MARPAT 131:157757

GI

L9 ANSWER 30 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB K1LK2 [K1, K2 = head groups capable of interacting with a carboxylate group; L = linker which can assume a conformation such that the head groups are situated at a distance of 20-45 Å, such that the inhibitor can penetrate into a cavity of dimensions 52 Å X 32 Å X 40 Å, where L = A5B5A3B3A1B1MB2A2B4A4B6A6K2; A1, A2 = CO, NH, O, S, SO2, SO2NH, CONH, CO2, bond; A3, A4 = CO, CS, O, S, NH, CO2, CONH, bond, Q1, Q2, etc.; W = bond, CO; A5, A6 = CO, NH, O, S, CONH, CO2, bond; M = Q3, Q4, etc.; R1, R2 = H, alkyl, fluoroalkyl, OH; R1R2 = O, atoms to form a 5-6 membered (substituted) carbocyclic ring; R3, R4 = H, alkyl; R5, R6 = H, alkyl; R7 = H, alkyl, Ph, pyridyl; B1-B6 = bond, alkylene; X1 = B7(CO)mB9X1, B7(CO)mB9Y1, B7(CO)mB9Z1B11X1; X2 = B8(CO)pB10X2, B8(CO)pB10Y2, B8(CO)pB10Z2B12X2; B7-B12 = bond, alkylene; m, p = 0, 1; X1, X2 = NH2, C(:NH)NH2, C(:NH)NHOH, etc.; Y1, Y2 = heteroaryl, heterocycloalkyl; Z1, Z2 = (substituted) arylene, heteroarylene, cycloalkylene, heterocycloalkylene], were prepared Thus, pyridine-2,6-dicarboxylic acid bispiperazide trihydrochloride (preparation given) was stirred with Et3N, trans-4-tert-butyloxycarbonylaminomethylcyclohexanecarboxylic acid, 1-hydroxybenzotriazole, and EDC in DMF to give 65% pyridine-2,6-dicarboxylic acid bis[4-(trans-4-tert-butyloxycarbonylaminomethylcyclohexylcarbonyl)-1-piperazide]. The latter was stirred with HCl in dioxane/MeOH/H2O to give pyridine-2,6-dicarboxylic acid bis[4-(trans-4-aminomethylcyclohexanoyl)-1-piperazide] dihydrochloride. Title compds. complexed with human tryptase showed dissociation consts. Kiapp = 0.028-22 μM. X-ray diffraction data for human β-tryptase is given.

IT 236113-65-8P 236113-66-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinedicarboxylic acid bisacylpiperazides and related compds. as tryptase inhibitors)

RN 236113-65-8 CAPLUS

CN Acetamide, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[N-[[4-[(aminoiminomethyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 30 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 236113-66-9 CAPLUS

CN Acetamide, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxy)]bis[N-[[4-[(aminoiminomethyl)amino]phenyl]methyl]-, diacetate (9CI) (CA INDEX NAME)

CM 1

CRN 236113-65-8
CMF C35 H40 N8 O4

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2

L9 ANSWER 30 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 31 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:504257 CAPLUS
DN 131:272147
TI Design and synthesis of amidino-tyrosine derivatives as non-peptide fibrinogen receptor antagonists
AU Xu, Tian-Lin; Jiang, Xun-Tian; Hua, Wei-Yi; Ni, Pei-Zhou; Pei, Yong-Mei
CS Institute of Radiation Medicine, Beijing, 100850, Peop. Rep. China
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(14), 1933-1936
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB The design, synthesis and anti-aggregation activity of amidino-tyrosine derivs., e.g. I, based on Arg-Gly-Asp (RGD) tripeptide sequence as non-peptide fibrinogen receptor antagonists is described. Optimization of the spacer and the substituent at the C-terminal is reported.
IT 245428-48-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of amidino-tyrosine derivs. as non-peptide platelet aggregation inhibitors)
RN 245428-48-2 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-benzoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 31 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



IT 245428-33-5P 245428-37-9P 245428-38-0P
245428-39-1P 245428-40-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of amidino-tyrosine derivs. as non-peptide platelet aggregation inhibitors)
RN 245428-33-5 CAPLUS
CN L-Tyrosine, O-[2-[(4-cyanophenyl)amino]-2-oxoethyl]-N-[(2-methylphenoxy)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-37-9 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-[(2-methylphenoxy)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 31 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 245428-47-1P 245428-49-3P 245428-50-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of amidino-tyrosine derivs. as non-peptide platelet aggregation inhibitors)
RN 245428-47-1 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-[(2-methylphenoxy)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-49-3 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-50-6 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 31 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 245428-38-0 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-benzoyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-39-1 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(4-methylbenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 31 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 245428-40-4 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-naphthalenylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:449605 CAPLUS
DN 132:87913
TI Synthesis and biological activity of non-peptide fibrinogen receptor antagonists N-substituted-O-(4- aminoiminomethylphenylamino)carbonylmethyl-L-tyrosine methyl ester
AU Xu, Tianlin; Hua, Weiyi; Ni, Peizhou; Jiang, Xuntian; Bi, Mengyu; Pei, Yongmei; Yan, Bing
CS Research Centre of New Drug, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China
SO Yaoxue Xuebao (1999), 34(6), 428-433
CODEN: YHHPAL; ISSN: 0513-4870
PB Yaoxue Xuebao Bianjibu
DT Journal
LA Chinese
AB Eighteen compds. with inhibitory action on ADP-induced platelet aggregation were designed and synthesized according to the Arg-Glu-Asp (RGD) sequence and the non-peptide fibrinogen receptor antagonists reported, and their inhibitory effects were studied with Turbidimetric technique. Most of compds. showed antiaggregation action on platelet-rich plasma.
IT 245428-37-9P 245428-38-0P 245428-39-1P
245428-40-4P 254899-55-3P 254899-56-4P
254899-57-5P 254899-58-6P 254899-59-7P
254899-60-0P 254899-61-1P 254899-62-2P
254899-63-3P 254899-64-4P 254899-65-5P
254899-66-6P 254899-67-7P 254899-68-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of non-peptide fibrinogen receptor antagonists N-substituted-O-(4- aminoiminomethylphenylamino)carbonylmethyl-L-tyrosine Me ester as antiplatelet agents)
RN 245428-37-9 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-[(2-methylphenoxy)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-38-0 CAPLUS

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-benzoyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-39-1 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(4-methylbenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245428-40-4 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-naphthalenylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 254899-55-3 CAPLUS
CN L-Tyrosine, N-acetyl-O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-56-4 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-57-5 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(ethoxyacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-58-6 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-59-7 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(phenoxyacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 254899-60-0 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-[(2,4-dichlorophenoxy)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-61-1 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(1-oxo-3-phenyl-2-propenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 254899-62-2 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-63-3 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(4-chlorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 254899-64-4 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(3-chlorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-65-5 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(3-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-66-6 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-furanylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 254899-67-7 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(2-thienylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254899-68-8 CAPLUS
CN L-Tyrosine, O-[2-[[4-(aminoiminomethyl)phenyl]amino]-2-oxoethyl]-N-(phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 32 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 33 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:48696 CAPLUS
DN 130:110061
TI Preparation of acylhydrazones as glucagon antagonists/inverse agonists.
IN Gonzales, Javier; Sams, Christian; Teng, Min; Ling, Anthony; Gregor, Vlad; Hong, Yufeng; Kiel, Dan; Kuki, Atsuo; Shi, Shenghua; Naerum, Lars; Madsen, Peter; Lau, Jesper; Plewe, Michael Bruno; Feng, Jun; Johnson, Michael David; Teston, Kimberly Ann; Sidelmann, Ulla Grove; Knudsen, Lotte Bjerre
PA Novo Nordisk A/S, Den.; Alanex Corporation; et al.
SO PCT Int. Appl., 551 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901423	A1	19990114	WO 1998-DK287	19980701 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	JP 2003514508	T2	20030415	JP 1999-506160	19980630 <--
	CA 2294046	AA	19990114	CA 1998-2294046	19980701 <--
	AU 9879083	A1	19990125	AU 1998-79083	19980701 <--
	AU 749271	B2	20020620		
	ZA 9805759	A	19990125	ZA 1998-5759	19980701 <--
	EP 994848	A1	20000426	EP 1998-929244	19980701 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, FI, RO				
	BR 9810378	A	20000829	BR 1998-10378	19980701 <--
	MX 9911896	A	20000630	MX 1999-11896	19991216 <--
	NO 9906550	A	20000229	NO 1999-6550	19991229 <--
PRAI	US 1997-886785	A	19970701		
	US 1998-32516	A	19980227		
	WO 1998-DK287	W	19980701		

OS MARPAT 130:110061
GI



I

AB AXNR3NR1CR3R4(CH2)nBKmD [R1, R2= H, alkyl; R1R2 = bond; R3, R4 = H, alkyl; n = 0-3; m = 0, 1; X = CO, CS, C:NR5, SO2; R5 = H, alkyl, aralkyl, OR6; R6 = H, alkyl, aryl, aralkyl; A = (substituted) Ph, pyridyl, pyrimidinyl, naphthyl, indolyl, benzotriazolyl, imidazolyl, triazolyl, benzothiazolyl, pyrazolyl, isoxazolyl, oxazolyl, thienyl, furyl, etc.; B = bond, specified

L9 ANSWER 33 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(substituted) (hetero)arylene, benzo(hetero)arylene, etc.; X = Le(CH2)b(CR3aR3b)p(CH2)aMf(CH2)c(CR4aCR4b)q(CH2)d; R3a, R3b, R4a, R4b = H, halo, cyano, CF3, OCF3, OCH2CF3, NO2, alkyl, aryl, aryalkyl, SCF3, CHF2, OSO2CF3, etc.; R3aR3b, R4aR4b, or R3aR4b = (CH2)i; i = 1-4; a, b, c, d = 0-4; e, f, p = 0, 1; q = 0-2; D = H, specified (substituted) (hetero)aryl, benzo(hetero)aryl], were prepd. as antidiabetics (no data). Thus, 3-chloro-4-hydroxybenzoic acid hydrazide (prepn. given) and 4-hydroxy-1-naphthaldehyde were stirred overnight in Me2SO/HOAc to give title compd. (I).

IT 219683-89-3P 219683-91-7P 219683-93-9P
219683-96-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylhydrazones as glucagon antagonists/inverse agonists)

RN 219683-89-3 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[2-methoxy-4-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-91-7 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[3-methoxy-4-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-93-9 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 219683-96-2 CAPLUS
CN Benzoic acid, 3-chloro-4-hydroxy-, [[4-[[(2,4-dichlorophenoxy)acetyl]amino]-2-methoxyphenyl]methylene]hydrazide (9CI)

L9 ANSWER 33 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 34 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:542964 CAPLUS
DN 129:161416
TI Preparation of sulfonamides as glutamate receptor potentiators
IN Arnold, Macklin B.; Baker, Stephen R.; Bleakman, David; Bleisch, Thomas J.; Cantrell, Buddy E.; Escribano, Ana M.; Matsumoto, Ken; Mckennon, Tracey E.; Ornstein, Paul L.; Simon, Richard L.; Smith, Edward C. R.; Tizzano, Joseph P.; Zarrinmayeh, Hamideh; Zimmerman, Dennis M.
PA Eli Lilly and Company, USA; et al.
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9833496	A1	19980806	WO 1998-US1881	19980130 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2278790	AA	19980806	CA 1998-2278790	19980130 <--
	AU 9862595	A1	19980825	AU 1998-62595	19980130 <--
	AU 760056	B2	20030508		
	TR 9902368	T2	20000121	TR 1999-2368	19980130 <--
	BR 9807297	A	20000418	BR 1998-7297	19980130 <--
	NZ 336559	A	20010126	NZ 1998-336559	19980130 <--
	JP 2001511781	T2	20010814	JP 1998-533144	19980130 <--
	IL 130970	A1	20050619	IL 1998-130970	19980130
	ZA 9800842	A	19991102	ZA 1998-842	19980202 <--
	EP 860428	A2	19980826	EP 1998-300759	19980203 <--
	EP 860428	A3	20000719		
	EP 860428	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 284385	E	20041215	AT 1998-300759	19980203
	PT 860428	T	20050429	PT 1998-300759	19980203
	EP 1528055	A2	20050504	EP 2004-104929	19980203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, AL				
	ES 2232914	T3	20050601	ES 1998-300759	19980203
	NO 9903667	A	19990920	NO 1999-3667	19990728 <--
	MX 9907016	A	20000131	MX 1999-7016	19990728 <--
	US 6303816	B1	20011016	US 1999-355605	19991018 <--
	US 2002002158	A1	20020103	US 2001-912809	20010725 <--
	US 6596716	B2	20030722		
	US 2006030599	A1	20060209	US 2003-447619	20030529
PRAI	GB 1997-2194	A	19970204		
	WO 1997-EP3148	W	19970617		
	WO 1998-US1881	W	19980130		
	EP 1998-300759	A3	19980203		
	US 1999-355605	A3	19991018		
	US 2001-912809	A3	20010725		

L9 ANSWER 34 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OS MARPAT 129:161416
AB R1ZNHSO2R2 [I; R1 = (un)substituted (hetero)aryl; R2 = (cyclo)alkyl, alkenyl, (un)substituted Ph, NR3R4, etc.; R3,R4 = alkyl; NR3R4 = heterocyclyl; Z = (un)substituted alkylene] were prepared Thus, 4-BrC6H4CH2CN was α-methylated and the reduced product amidated by MeSO2Cl to give, after 3-FC6H4B(OH)2-arylation, 3-FC6H4C6H4(CHMeCH2NHSO2Me)-4. Data for biol. activity of I were given.
IT 211313-95-0P 211314-58-8P 211314-77-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as glutamate receptor potentiators)
RN 211313-95-0 CAPLUS
CN Acetamide, N-[4-[1-methyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 211314-58-8 CAPLUS
CN Acetamide, N-[4-[1,1-dimethyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 211314-77-1 CAPLUS
CN Acetamide, N-[4-[2-[[(dimethylamino)sulfonyl]amino]-1-methylethyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 35 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:405517 CAPLUS
DN 129:128903
TI Heat-developable photographic recording material for plate making
IN Yamada, Kozaburo; Kubo, Toshiaki; Suzuki, Hiroyuki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 71 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10161270	A2	19980619	JP 1997-240511	19970821 <--
PRAI	JP 1996-279957	A	19961001		

GI



I



II

AB In the title recording material having ≥1 image-forming layer, a specified hydrazine derivative and a compound I and/or II (R1-3 = H, monovalent substituent; EDW = electron attracting group; R4 = monovalent substituent) are incorporated. The invention recording material can be developed in dry process and is useful for photog. plate making.
IT 206860-30-2 206860-31-3
RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
(hydrazine derivative combined with specified double-bond-bearing compound for heat-developable photog. material)
RN 206860-30-2 CAPLUS
CN Acetic acid, (phenylsulfonyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 206860-31-3 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX

L9 ANSWER 35 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)



L9 ANSWER 36 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:402640 CAPLUS
DN 129:101985
TI Thermal recording material containing hydrazine and printing method using infrared laser
IN Washisu, Shintaro; Fukushige, Yuichi; Usami, Tomomasa
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10166733	A2	19980623	JP 1996-334288	19961213 <--
PRAI JP 1996-334288		19961213		

OS MARPAT 129:101985
AB The material comprises at least an organic Ag salt, its developer, a binder, and R1NHNHCONHR2 [R1 = (un)substituted aryl, (un)substituted heterocycle; R2 = (un)substituted aryl, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, alicyclic group, (un)substituted alkylaryl, (un)substituted aryloxyl, (un)substituted aralkyl, (un)substituted aryloxyalkyl, (un)substituted heterocycle]. The method using the material involves the following steps: (1) imagewise heating the material at color forming temperature by modulated IR laser beams; (2) overall heating the imagewise heated material at the temperature lower than that of color formation.
The material shows high absorbency of IR laser beam and the method provides images with less background stain.
IT 209673-36-9
RL: TEM (Technical or engineered material use); USES (Uses)
(thermal printing material containing organic silver salt, developer, and hydrazine for recording under modulated IR laser irradiation)
RN 209673-36-9 CAPLUS
CN Hydrazinecarboxamide, N-[2-chloro-4-[[(2,4-dipentylphenoxy)acetyl]amino]phenyl]-2-[4a,5,6,7,8,8a-hexahydro-2-(trifluoromethyl)-4-quinazolinyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 36 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 37 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:366902 CAPLUS
DN 129:95402
TI Preparation of benzamide derivatives as anticancer agents
IN Suzuki, Tsuneji; Ando, Tomoyuki; Tsuchiya, Katsutoshi; Nakanishi, Tadashi; Saito, Akashi; Yamashita, Satoshi; Shiraishi, Gengo; Tanaka, Eiji
PA Mitsui Toatsu Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 79 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10152462	A2	19980609	JP 1997-260277	19970925 <--
JP 3354090	B2	20021209		
JP 2002332267	A2	20021122	JP 2002-50102	19970925 <--
US 6174905	B1	20010116	US 1997-935087	19970926 <--
EP 847992	A1	19980617	EP 1997-307679	19970930 <--
EP 847992	B1	20040623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1437346	A1	20040714	EP 2004-8185	19970930
R: CH, DE, ES, FR, GB, IT, LI, NL, SE, FI				
ES 2218645	T3	20041116	ES 1997-307679	19970930
US 6794392	B1	20040921	US 1999-417216	19991013
US 2004147569	A1	20040729	US 2004-753365	20040109
PRAI JP 1996-258863	A	19960930		
JP 1997-260277	A3	19970925		
US 1997-935087	A3	19970926		
EP 1997-307679	A3	19970930		
US 1999-417216	A3	19991013		

OS MARPAT 129:95402
GI



I



II

AB The title compds. [I; A = (un)substituted Ph or heterocyclyl, etc.; X = alkylene, R4WR5, etc.; W = O, S, CO, etc.; R1, R2 = H, halo, OH, NH2, alkyl, etc.; R3 = OH, NH2; R4, R5 = alkylene; n = 0-4; Q = CONR7, NR7CO, OCONR7, etc.; R7 = H, (un)substituted alkylene, etc.] are prepared I are useful as anticancer agents. Thus, 4-aminomethyl-N-[2-(N-tert-butoxycarbonyl)aminophenyl]benzamide (preparation given) was reacted with C6H5COCl in the presence of pyridine and followed by treatment with 4N HCl to give the title compound (II), which showed differentiation induction

L9 ANSWER 37 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALPmin (alk. phosphatase) of 1 μM when tested with human A2780 cell.
IT 209784-66-7P 209784-67-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. as anticancer agents)
RN 209784-66-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[(4-nitrophenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 209784-67-8 CAPLUS
CN Benzamide, 4-[[(4-aminophenoxy)acetyl]amino]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



IT 209785-19-3P 209785-20-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzamide derivs. as anticancer agents)
RN 209785-19-3 CAPLUS
CN Carbamic acid, [2-[[4-[[(4-nitrophenoxy)acetyl]amino]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 209785-20-6 CAPLUS
CN Carbamic acid, [2-[[4-[[(4-aminophenoxy)acetyl]amino]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 37 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 38 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:335116 CAPLUS
DN 129:47430
TI Thermal development type silver halide photographic material containing a hydrazine and a hydroxylamine derivative
IN Kubo, Toshiaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10133326	A2	19980522	JP 1996-304010	19961030 <--
PRAI JP 1996-304010		19961030		

AB Claimed thermal development type Ag halide photog. material having an image-forming layer contains (1) an organic Ag salt, (2) a reducing agent, (3) a hydrazine derivative selected from 1-formal-2-phenyl-hydrazine, 1-(oxalyl)-2-aryl-hydrazine, 1-(acyl with electron-attractive substituent)-2-aryl-hydrazine, 1-sulfo-2-aryl-hydrazine, 1-phospho-2-aryl-hydrazine, 1-acyl-2-alkyl-hydrazine, etc., and (4) a compound selected from substituted hydroxylamine, substituted hydroxyalkylhydroxylamine and an ammonium 2-carbamoyl-1-benzoate. The combination improves the maximum d. and contrast of the thermally processed images. Thus, a thermal development type Ag halide black-and-white film containing a Ag behenate, phthalazine, 1-formyl-2-[4-(thioureylene-n-octyl)phenyl]hydrazine, N-(2,3-dihydroxypropyl)diethylamine, etc. had the mentioned advantages.
IT 206860-30-2 206860-31-3
RL: DEV (Device component use); USES (Uses)
(thermal development type photog. material containing hydrazine and hydroxylamine derivative to improve Dmax and contrast)
RN 206860-30-2 CAPLUS
CN Acetic acid, (phenylsulfonyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 206860-31-3 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 38 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 39 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:298193 CAPLUS
DN 129:21518
TI Heat development photographic materials providing high contrast image
IN Kubo, Toshiaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 69 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10123661	A2	19980515	JP 1996-298153	19961022 <--
PRAI JP 1996-298153		19961022		

GI



I

AB The title materials, possessing ≥1 image-forming layer, contain (a) an organic Ag salt, (b) a reducing agent, (c) ≥1 selected from hydrazine derivs. I, Ar1NA3NA4COX11, Ar2NA5NA6COCOX12, Ar3NA7NA8G3X13, X20CX21X22NA9NA10COX14, X30NA11NA12G5X15, X40NA13NA14X16, and Ar4NA15NA16COX17 [Y10 = NO2, MeO, alkyl, acetamido; X10 = monovalent substituent; m10 = 0-5; n10 = 0-4; A1, A2 = H, alkylsulfonyl, arylsulfonyl, acyl; m10 + n10 ≤ 5; Ar1-4 = aromatic hydrocarbon or heterocyclic group; A3-16 are each the same as defined for A1 and A2; X11 = ≥1 electron-attracting group-substituted alkyl or aryl, alkenyl, alkynyl, heterocyclic group, amino, alkylamino, arylamino, heterocyclic amino, hydrazino, alkoxy, aryloxy; X12-15 = H or blocking group; G3 = C(:S), SO2, SO, POX33 (X33 = substituent), iminomethylene; X20-22 are H or monovalent substituents; X30, X40 = aliphatic group; G5 = COCO or the same groups as defined for G3; X16 = aliphatic group, aromatic hydrocarbon, heterocyclic group; X17 = amino, alkylamino, heterocyclic amino, alkynyl], and (d) a compound Z1CONHNH2 (Z1 = alkyl, alkenyl, alkoxy, alkylthio, amido, aryl, aralkyl, aryloxy, arylthio, anilino, heterocyclic group). The materials provide high quality images with high Dmax and γ value.

IT 206860-30-2 206860-31-3
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(heat developable photosensitive material containing hydrazine compound and hydroxamic acid derivative)

RN 206860-30-2 CAPLUS
CN Acetic acid, (phenylsulfonyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 39 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 206860-31-3 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 40 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:251393 CAPLUS
DN 128:328801
TI Thermal development type silver halide photographic material
IN Sakai, Minoru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10104784	A2	19980424	JP 1996-279960	19961001 <--
PRAI JP 1996-279960		19961001		

AB Claimed thermal development type photog. material having ≥1 light-sensitive Ag halide layer on a support contains, in the Ag halide layer or in the adjacent layer, a reducing agent, a hydrazine derivative and a compound selected from formulas Y1[(X1)n1A1B1]m1, R1R2NR3(X2)n1SM1x, R4R5NA2(X3)n1R6, and R8R9NB2 (Y1 = Ag halide-adsorbing group; X1 = bivalent linkage consisting of the atoms selected from H, O, N, and S; A1 = bivalent linkage; B1 = amino, ammonium, N-containing heterocyclic group; m1 = 1-3; n1 = 0, 1; R1, R2 = H, aliphatic group; R3 = bivalent linkage; M1 = H, alkali metal atom, alkaline earth metal atom, ammonium; alkylamino, R4, R5, R8, R9 = H, C1-30 alkyl; R6 = C1-30 alkyl, aryl, heterocyclic group; A2 = alkylene; X3 = CONR, OCONR NR, NRCOO, COO, OCO, etc. R = H, C1-5 alkyl). It provides a high contrast image suitable for printing plate-making processes. It also has good development consistency. Suitable compds. to be incorporated with the hydrazine are 5-(diethylaminopropylaminocarbonylpropoxy)-2,5-di-tert.amylbenzene, etc.

IT 207000-02-0
RL: DEV (Device component use); USES (Uses)
(heat development type photog. material containing hydrazine and amine or silver halide-adsorbing compound for high contrast)

RN 207000-02-0 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 41 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:251392 CAPLUS
DN 128:328800
TI Thermal development type silver halide photographic material for high contrast and developability
IN Kubo, Toshiaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 71 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10104783	A2	19980424	JP 1996-279959	19961001 <--
PRAI JP 1996-279959		19961001		

GI



I

AB Claimed thermal development type photog. material having ≥1 image-forming layer contains (a) an organic Ag salt, (b) a reducing agent, (c) a hydrazine derivative selected from I, Ar1NA3NA4COX11, Ar2NA5NA6COCOX12, Ar3NA7NA8G3X13, X20CX21X22NA9NA10COX14, X30NA11NA12X15, X40NA13NA14X16, and Ar4NA15NA16COX17 (Y10 = nitro, methoxy, alkyl, acetamide; X10 = monovalent substituent other than Y10; m10 = 0-5; n10 = 0-4; A1-6, A9-12, A15-16 = H, alkylsulfonyl, arylsulfonyl, acyl; Ar1, Ar2, Ar3 = aromatic hydrocarbon or heterocyclic group; X11 = aryl, alkenyl, alkynyl, heterocyclic group, amino, alkylamino, hydrazino and alkoxy which are substituted by an electron-attracting group); X12, X13, X33, X14, X15 = H, blocking group; G3 = C:S-, SO2, SO, POX33, iminomethylene; X20, X21, X22 = H, monovalent substituent; G5 = C:S-, SO2, SO, POX33, COCO; ethylene; X16 = aliphatic group, aromatic hydrocarbon or heterocyclic group and (d) a compound having an activated vinyl group. The hydrazine and the vinyl compound provides the images with high developed d. and high contrast, and improves image quality. Suitable vinyl compds. are bis(2-vinylsulfo-1-hydroxyethane), N,N,N-tri(vinylsulfoaceto)triazine, 1,3,5-trivinylsulfobenzene, etc.

IT 206860-30-2 206860-31-3
RL: DEV (Device component use); USES (Uses)
(heat development type silver halide photog. material containing hydrazine and activated vinyl compound for high contrast and developability)

RN 206860-30-2 CAPLUS
CN Acetic acid, (phenylsulfonyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 41 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 206860-31-3 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 42 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 206860-31-3 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 42 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:251391 CAPLUS
DN 128:328799
TI Thermal development type silver halide photographic material to improve developability
IN Kubo, Toshiaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10104782	A2	19980424	JP 1996-279958	19961001 <--
PRAI	JP 1996-279958		19961001		

GI



I

AB Claimed thermal development type photog. material having ≥1 image-forming layer contains (a) an organic Ag salt, (b) a reducing agent, (c) a hydrazine derivative selected from I, Ar1NA3NA4COX11, Ar2NA5NA6COCOX12, Ar3NA7NA8G3X13, X20CX21X22NA9NA10COX14, X30NA11NA12X15, X40NA13NA14X16, and Ar4NA15NA16COX17 (Y10 = nitro, methoxy, alkyl, acetamide; X10 = monovalent substituent other than Y10; m10 = 0-5; n10 = 0-4; A1-6, A9-12, A15-16 = H, alkylsulfonyl, arylsulfonyl, acyl; Ar1, Ar2, Ar3 = aromatic hydrocarbon or heterocyclic group; X11 = aryl, alkenyl, alkynyl, heterocyclic group, amino, alkylamino, hydrazino, and alkoxy which are substituted by an electron-attracting group; X12, X13, X33, X14, X15 = H, blocking group; G3 = C:S-, SO2, SO, POX33, iminomethylene; X20, X21, X22 = H, monovalent substituent; G5 = C:S-, SO2, SO, POX33, COCO; ethylene; X16 = aliphatic group, aromatic hydrocarbon or heterocyclic group) and (d) a compound Z1C(:O)NZ2OH (II) (Z1, Z2 = H, alkyl, alkenyl, alkylthio, amido, aryl, aralkyl, aryloxy, etc). The hydrazine and compound II provides the images with high developed d. and high contrast, and improves image quality. Suitable compound II have Z1 = H and Z2 = Ph; Z1 = H, and Z2 = 4-butoxyphenyl; Z1 = Z2 = Ph, etc.

IT 206860-30-2 206860-31-3
RL: DEV (Device component use); USES (Uses)
(heat development type photog. material containing hydrazine and hydroxyamino-carbonyl compound for high contrast and developability)

RN 206860-30-2 CAPLUS
CN Acetic acid, (phenylsulfonyl)-, 2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 43 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:803779 CAPLUS
DN 128:58582
TI Preparation of N-acylsulfonamides as herbicide antidotes
IN Ziemer, Frank; Haaf, Klaus; Willms, Lothar; Bauer, Klaus; Bieringer, Hermann; Rosinger, Christopher
PA Hoechst Schering Agrevo G.m.b.H., Germany
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745016	A1	19971204	WO 1997-EP2305	19970506 <--
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	DE 19621522	A1	19971204	DE 1996-19621522	19960529 <--
	CA 2256328	AA	19971204	CA 1997-2256328	19970506 <--
	AU 9728921	A1	19980105	AU 1997-28921	19970506 <--
	AU 719424	B2	20000511		
	EP 912089	A1	19990506	EP 1997-922980	19970506 <--
	EP 912089	B1	20011128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
	CN 1219840	A	19990616	CN 1997-195033	19970506 <--
	CN 1102142	B	20030226		
	BR 9709491	A	19990810	BR 1997-9491	19970506 <--
	JP 2000511163	T2	20000829	JP 1997-541457	19970506 <--
	AT 209439	E	20011215	AT 1997-922980	19970506 <--
	ES 2167744	T3	20020516	ES 1997-922980	19970506 <--
	RU 2182423	C2	20020520	RU 1998-123949	19970506 <--
	PL 187140	B1	20040531	PL 1997-330355	19970506
	CZ 295148	B6	20050615	CZ 1998-3891	19970506
	IL 126853	A1	20050831	IL 1997-126853	19970506
	US 6235680	B1	20010522	US 1997-863476	19970527 <--
	ZA 9704663	A	19971201	ZA 1997-4663	19970528 <--
	KR 2000016108	A	20000325	KR 1998-709675	19981128 <--
PRAI	DE 1996-19621522	A	19960529		
	WO 1997-EP2305	W	19970506		

OS MARPAT 128:58582

GI



I

AB The N-acylsulfonamides I [R1 = H, alkyl, alkoxy, alkoxycarbonyl, etc.; R2,R4 = H or alkyl; R1CONR2 = ring; R3,R5 = halo, CN, NO2, etc; n = 0, 1-4; m = 0, 1-5] and I salts are prepd as herbicide safeners.

IT 200202-36-4P 200202-37-5P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological

L9 ANSWER 43 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
study); PREP (Preparation); USES (Uses)
(prepn. as herbicide antidote)
RN 200202-36-4 CAPLUS
CN Benzamide, 2-methoxy-N-[[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 200202-37-5 CAPLUS
CN Benzamide, N-[[4-[[(2,4-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 44 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:761862 CAPLUS
DN 128:55448
TI Photothermographic material
IN Yamada, Kozaburoh; Kubo, Toshiaki; Hirano, Shigeo
PA Fuji Photo Film Co., Ltd., Japan
SO Eur. Pat. Appl., 102 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 807850	A1	19971119	EP 1997-108057	19970516 <--
	EP 807850	B1	20001004		
	R: DE, FR, GB				
	JP 09304870	A2	19971128	JP 1996-148111	19960517 <--
	JP 09304871	A2	19971128	JP 1996-148115	19960517 <--
	JP 09304872	A2	19971128	JP 1996-148116	19960517 <--
	JP 10031282	A2	19980203	JP 1996-280356	19960930 <--
	US 6306574	B1	20011023	US 1997-857459	19970516 <--
PRAI	JP 1996-148111	A	19960517		
	JP 1996-148113	A	19960517		
	JP 1996-148115	A	19960517		
	JP 1996-148116	A	19960517		
	JP 1996-280356	A	19960930		

OS MARPAT 128:55448
AB In a photothermog. material comprising an organic silver salt, a silver halide, and a reducing agent, a hydrazine derivative represented by the formula R1GN(A1)N(A2)R2 (R1 = alkyl, aryl, alkoxy, aryloxy, amino, alkylamino, arylamino, heterocyclyl, heterocyclylamino, or hydrazino; R2 = an aliphatic group; G = COCO, SO2, SO, P(O)(R3), thiocarbonyl, or iminomethylene; R3 = a group similar to R1; A1, A2 = H, acyl, alkylsulfonyl, or arylsulfonyl) is used as a nucleating agent. The material has high sensitivity, high Dmax and good image quality.
IT 200073-96-7
RL: TEM (Technical or engineered material use); USES (Uses)
(nucleating agent for photothermog. materials)
RN 200073-96-7 CAPLUS
CN Acetamide, 2-(4-aminophenoxy)-N-[4-[1,2-difluoro-2-(2-formylhydrazino)ethenyl]phenyl]-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 200073-95-6
CMF C17 H16 F2 N4 O3



L9 ANSWER 44 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 45 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:594715 CAPLUS
DN 127:262560
TI Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin derived domains
IN Holt, Dennis A.; Keenan, Terence P.; Guo, Tao; Laborde, Edgardo; Yang, Wu
PA Ariad Gene Therapeutics, Inc., USA
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9731899	A1	19970904	WO 1997-US3157	19970228 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2244363	AA	19970904	CA 1997-2244363	19970228 <--
	AU 9721927	A1	19970916	AU 1997-21927	19970228 <--
	US 6133456	A	20001017	US 1997-808276	19970228 <--
	US 6150527	A	20001121	US 1997-808274	19970228 <--
	US 2002161240	A1	20021031	US 2002-86506	20020228 <--
	US 2003036654	A1	20030220	US 2002-86770	20020228 <--
	US 2004006233	A1	20040108	US 2003-461705	20030613
PRAI	US 1996-12432P	P	19960228		
	US 1996-24861P	P	19960828		
	US 1996-33035P	P	19961210		
	US 1994-292598	B2	19940818		
	US 1995-479694	A2	19950607		
	US 1995-793016	B2	19950818		
	US 1997-808274	A1	19970228		
	US 1997-808276	A1	19970228		
	WO 1997-US3157	W	19970228		
	US 1997-793016	B1	19971201		
	US 2000-690581	B1	20001017		
	US 2000-690797	B1	20001017		
	US 2002-86770	A1	20020228		

OS MARPAT 127:262560
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB New compds. M1-L-M2 [M1, M2 = M, B; L = linker moiety; B1, B2, B3 = H, alkyl, heteroalkyl, aryl, heteroaryl, and may be attached to linker; R1, R2, R3 = alkyl, heteroalkyl, aryl, heteroaryl; R1 and R2 may be linked to form a macrocycle; n = 1, 2; W = O, S, NH, NHCO, NHCO2, bond; X = O, NH, CH2; Y = O, NH, NR3, bond) are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. FK506 analog I was prepared via O-acylation of acetate II with N-Fmoc-pipecolic acid, N-deprotection, N-acylation of pipecolate III with 3-methyl-2-phenylvaleric acid and ester hydrolysis. I was active against human FKBP12 and mutants, IC50 = 20 nM (F36S/99G), 25 nM (F36V/99A) and 31 nM (F36S/F99A).

L9 ANSWER 45 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 178446-18-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of rapamycin analogs as multimerizing agents for immunophilin
containing chimeric proteins)
RN 178446-18-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 1,4-phenylenebis[methyleneimino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-phenylpropylidene)] ester, [2S-[2R*[S*[S*(R*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 46 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:594714 CAPLUS
DN 127:247960
TI Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
IN Holt, Dennis A.; Keenan, Terence P.; Guo, Tao; Laborde, Edgardo; Wu, Yang
PA Ariad Gene Therapeutics, Inc., USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9731898	A1	19970904	WO 1997-US3137	19970228 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2244363	AA	19970904	CA 1997-2244363	19970228 <--
	AU 9719809	A1	19970916	AU 1997-19809	19970228 <--
	AU 731826	B2	20010405		
	EP 888303	A1	19990107	EP 1997-907937	19970228 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000505475	T2	20000509	JP 1997-531139	19970228 <--
	US 6133456	A	20001017	US 1997-808276	19970228 <--
	US 6150527	A	20001121	US 1997-808274	19970228 <--
	US 2002161240	A1	20021031	US 2002-86506	20020228 <--
	US 2003036654	A1	20030220	US 2002-86770	20020228 <--
	US 2004006233	A1	20040108	US 2003-461705	20030613
PRAI	US 1996-12432P	P	19960228		
	US 1996-24861P	P	19960828		
	US 1996-33035P	P	19961210		
	US 1994-292598	B2	19940818		
	US 1995-479694	A2	19950607		
	US 1995-793016	B2	19950818		
	US 1997-808274	A1	19970228		
	US 1997-808276	A1	19970228		
	WO 1997-US3137	W	19970228		
	US 1997-793016	B1	19971201		
	US 2000-690581	B1	20001017		
	US 2000-690797	B1	20001017		
	US 2002-86770	A1	20020228		

OS MARPAT 127:247960
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB New compds. M-L-Q [M = immunophilin-binding group I; G = CB1B2XR2, B1NR2, OR2; Q = I, a naturally occurring macrocyclic FKBP ligand or derivative or is

L9 ANSWER 46 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
a synthetic FKBP ligand II; n = 1, 2; X = O, NH or CH2; B1, B2 = H, aliph., heteroaliph., aryl or heteroaryl; Y = O, S, NH, -NH(C=O)-, -NH(C=O)-O-, -NH(SO2)- or NR3, bond from R2 to carbon 9; R1, R2, R3 = aliph., heteroaliph., aryl or heteroaryl; L = covalent linker moiety between M and Q or M1 and M2 to either R1 or R2, not necessarily the same in each of M1 and M2] are disclosed for multimerizing immunophilins and proteins contg. immunophilin or immunophilin-related domains. Thus, AP1903 (III; X = CH2CONHCH2CH2NHCOCH2) was prepd. by reacting AP1867 (IV) with ethylenediamine in the presence of (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate and EtN(CHMe2)2. III had IC50 = 3.2 nM binding affinity for FKBPF36V and IC50 = 13 nM binding affinity for FKBPF36L.
IT 178446-18-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthetic derivs. of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains)
RN 178446-18-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 1,4-phenylenebis[methyleneimino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-phenylpropylidene)] ester, [2S-[2R*[S*[S*(R*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 46 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 47 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:528664 CAPLUS
DN 127:169011
TI Hydrazide compound for silver halide photographic materials
IN Yamada, Kohzaburoh; Suzuki, Hiroyuki; Ezoe, Toshihide; Kawato, Koji
PA Fuji Photo Film Co., Ltd., Japan
SO Eur. Pat. Appl., 99 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 782042	A2	19970702	EP 1996-120923	19961227 <--
	EP 782042	A3	19970730		
	EP 782042	B1	19991201		
	R: DE, FR, GB				
	JP 09235264	A2	19970909	JP 1996-52516	19960216 <--
	JP 09235265	A2	19970909	JP 1996-283817	19961025 <--
	JP 09235266	A2	19970909	JP 1996-299878	19961025 <--
	US 5789139	A	19980804	US 1996-774360	19961227 <--
PRAI	JP 1995-351132	A	19951227		
	JP 1995-351168	A	19951227		
	JP 1995-351269	A	19951227		
	JP 1996-52516	A	19960216		
	JP 1996-283817	A	19961025		
	JP 1996-299878	A	19961025		

OS MARPAT 127:169011
AB A hydrazide compound represented by the formula A(B)b (A = a heterocyclic group, a condensed polycyclic aromatic group, or a group formed by connecting at least two aromatic groups to each other; B = a group represented by the formula L1A2NHNHG1R1 or L2A3L3A4NHNHG2R2; b = an integer from 2 to 6; G1, G2 = a carbonyl, oxalyl, sulfonyl, or phosphoryl group; R1, R2 = H or a blocking group; A1, A2, A3 = an aromatic or heterocyclic aromatic group; and L1, L2, L3 = a linkage group) is disclosed and used in ultrahigh-contrast silver halide photog. materials.
IT 192930-29-3 192930-31-7
RL: TEM (Technical or engineered material use); USES (Uses)
(ultrahigh-contrast silver halide photog. materials containing)
RN 192930-29-3 CAPLUS
CN Acetic acid, trifluoro-, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis[oxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylenesulfonylimino-4,1-phenylene]]dihydrazide (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 47 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 192930-31-7 CAPLUS
CN Acetic acid, difluoro-, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis[oxy(1-oxo-2,1-ethanediyl)imino-4,1-phenylenesulfonylimino-4,1-phenylene]]dihydrazide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 48 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:515087 CAPLUS
DN 127:169024
TI Silver halide color photographic material with improved color reproducibility
IN Matsuda, Naoto; Saito, Naoki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09185155	A2	19970715	JP 1996-680	19960108 <--
PRAI	JP 1996-680		19960108		

OS MARPAT 127:169024
AB In the material, ≥1 photosensitive unit comprises ≥3 emulsion layers with different sensitivities and ≥1 layer contains a compound having a C6H6-n(OH)n unit (n = 2-4) and a R1R3NNR2R4 unit (R1-2 = alkyl, aryl, heterocyclic group, CHO, acyl, PO, SO2, SO; R3-4 = H, alkyl, aryl, heterocyclic group). The material showed improved color reproducibility and granularity.
IT 172284-50-3 193768-40-0
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(silver halide color photog. material containing color stain inhibitor)
RN 172284-50-3 CAPLUS
CN Benzeneacetic acid, 2,5-dihydroxy-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 193768-40-0 CAPLUS
CN Hydrazinecarboxamide, N-(2,5-dihydroxyphenyl)-2-[4-[[[3-[(tert-octadecylsulfonyl)amino]phenoxy]acetyl]amino]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 48 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

— ($C_{18}H_{37}$-tert)

L9 ANSWER 49 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:475696 CAPLUS
DN 127:169019
TI Silver halide color photographic material containing hydrazine derivative color contamination preventing agent
IN Shibahara, Yoshihiko; Saito, Naoki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09179261	A2	19970711	JP 1995-333106	19951221 <--
PRAI JP 1995-333106		19951221		

OS MARPAT 127:169019
AB The material contains tabular Ag halide emulsions with tubularity 10-1000 in all the emulsion layers and a compound having a residue of C6H6-n(OH)n (n = 2-4) and a residue of R1R3NNR2R4 (R1-2 = alkyl, aryl, heterocycle, formyl, acyl, phosphoryl, sulfonyl, sulfinyl; R3-4 = H, alkyl, aryl, heterocycle) in ≥1 of the constituting layers. In the material, ≥1 of the emulsion layer may contain reduction sensitized tabular Ag halide emulsion with tubularity 10-1000. The material shows good granularity, storage stability, and gives clear images with good color reproduction and sharpness.
IT 172284-50-3 193564-70-4
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. film containing tabular silver halide emulsion and hydrazine derivative contamination preventing agent)
RN 172284-50-3 CAPLUS
CN Benzeneacetic acid, 2,5-dihydroxy-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 193564-70-4 CAPLUS
CN Benzeneacetic acid, 2,5-dihydroxy-, 2-[4-[[[3-[(tert-octadecylsulfonyl)amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 49 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

— ($C_{18}H_{37}$-tert)

L9 ANSWER 50 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:453313 CAPLUS
DN 127:128672
TI Silver halide photographic material containing and image formation
IN Suzuki, Masao; Komiyama, Junichi; Higuchi, Tetsuya
PA Oriental Photo Industrial Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09160158	A2	19970620	JP 1995-345192	19951207 <--
PRAI JP 1995-345192		19951207		

OS MARPAT 127:128672
AB The title material, possessing ≥1 Ag halide emulsion layer and ≥1 other hydrophilic colloid layer on a support, contains, in the emulsion layer and/or other layer, ≥1 hydrazine compound (RNHNHCOCO2)nM [R = (substituted) aryl, (substituted) heterocycle; M = alkali metal, alkali earth metal; n = 1, 2]. The material is processed with aqueous alkali developing solns. to form images. The material, useful in photomech. process, shows high γ value and sensitivity.
IT 192879-92-8
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. film containing hydrazino oxalate compound)
RN 192879-92-8 CAPLUS
CN Ethanedioic acid, mono[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide], monolithium salt (9CI) (CA INDEX NAME)



● Li

L9 ANSWER 51 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:223937 CAPLUS
DN 126:212433
TI Sulfonyl amino acid derivatives as metalloproteinase inhibitors
IN Sakaki, Katsuhito; Kanazawa, Hidekazu; Sugiura, Tsuneyuki; Miyazaki, Tohru; Ohno, Hyroyuki
PA Ono Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 146 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 757037	A2	19970205	EP 1996-305554	19960729 <--
EP 757037	A3	19991222		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09309875	A2	19971202	JP 1996-213272	19960725 <--
US 6177466	B1	20010123	US 1996-688161	19960729 <--
US 6403644	B1	20020611	US 2000-709439	20001113 <--
PRAI JP 1995-212556	A	19950728		
JP 1996-90491	A	19960319		
US 1996-688161	A3	19960729		

OS MARPAT 126:212433
AB Benzenesulfonyl amino acids RSO2NHXCO2R1 [X = optionally substituted methylene or (CH2)m (m = 2, 3, 4); R = benzene ring substituted by A-J-E (A = H, alkyl, cycloalkyl, aryl; J = bond, alkylene, alkenylene; E = CO2, OCO, COCH2, NHCO, etc.) and optionally by an alkyl group; R1 = H, alkyl] were prepared for use as matrix metalloproteinase (MMP) inhibitors. Thus, N-[[4-(p-toluoylamino)phenyl]sulfonyl]glycine (I) was prepared by sulfonylation of glycine tert-Bu ester hydrochloride with 4-nitrobenzenesulfonyl chloride in pyridine, followed by nitro group reduction by H2/Pd, N-acylation with p-toluoyl chloride, and hydrolysis in aqueous trifluoroacetic acid. The inhibitory activity of I against gelatinase A was determined (IC50 = 0.11 μM).
IT 109065-78-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonyl amino acid derivs. as metalloproteinase inhibitors)
RN 109065-78-3 CAPLUS
CN Glycine, N-[[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 52 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:69455 CAPLUS
DN 126:96805
TI Silver halide photographic material with super high-contrast
IN Sakai, Minoru; Takeuchi, Hiroshi
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 84 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08278584	A2	19961022	JP 1995-104647	19950406 <--
	JP 3434082	B2	20030804		
PRAI	JP 1995-104647		19950406		

AB The title photog. material, having ≥1 photosensitive emulsion layer, contains ≥1 compound of A-NHNH-CO-R (R = difluoro Me, monofluoromethyl; A = aromatic group; the A-containing group may be a diffusion-resistant group, a Ag halide adsorbing group, an alkylthio, an arylthio, a quaternary ammonium, a quaternary N-containing heterocyclyl, an alkoxy containing ethylene oxy or propylene oxy, or a saturated heterocyclyl sulfide or disulfide) and ≥1 compound selected from amine derivs. and onium salts.
IT 185446-09-7
RL: DEV (Device component use); USES (Uses)
(contained in photog. material with super high-contrast)
RN 185446-09-7 CAPLUS
CN Acetic acid, fluoro-, 2-[4-[[[4-[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]sulfonyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 53 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:27535 CAPLUS
DN 126:89317
TI Synthesis of 4-aryl-5-[4-(substituted benzamido)- or -4-(2,4-dichlorophenoxyacetamido)phenyl]-3-mercapto-4H-1,2,4-triazoles as potential antidepressant agents
AU Amir, Mohd.; Srivastava, Jagriti
CS Dep. Pharmaceutical Chem. Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India
SO Pharmakeutike (1996), 9(2), 79-83
CODEN: PHMKE4; ISSN: 1105-4999
PB Pharmaceutical Publications
DT Journal
LA English
AB A series of 4-aryl-5-substituted phenyl-3-mercapto-4H-1,2,4-triazoles were prepared and evaluated for potential antidepressant activity. Members of the series were generally prepared by the alkaline ring closure of the corresponding arylthiosemicarbazides. The compds. have shown significant antidepressant activity when compared with reference drug imipramine hydrochloride.
IT 185547-21-1P 185547-28-8P 185547-29-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antidepressant activity of mercaptotriazoles)
RN 185547-21-1 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



RN 185547-28-8 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



RN 185547-29-9 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-[[(2-methylphenyl)amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 53 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 54 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:580024 CAPLUS
DN 125:208296
TI Photographic element containing scavenger for oxidized developing agent
IN Harder, John William; Nelson, John Victor; Singer, Stephen Paul
PA Eastman Kodak Company, USA
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 723193	A1	19960724	EP 1996-420006	19960109 <--
	EP 723193	B1	20020717		
	R: BE, DE, FR, GB				
	US 5629140	A	19970513	US 1995-373131	19950117 <--
	JP 08240892	A2	19960917	JP 1996-5107	19960116 <--
PRAI	US 1995-373131	A	19950117		

OS MARPAT 125:208296
AB An improved photog. element comprises a support bearing at least one silver halide emulsion layer having associated therewith a hydrazide compound that functions as a scavenger for oxidized developing agent. The hydrazide compound includes an electron-withdrawing and water-solubilizing group on an aromatic ring linked to the carbonyl of the hydrazide group and a ballasting group on an aromatic ring linked to a nitrogen atom of the hydrazide group. Preferably, the hydrazide compound is incorporated in a photog. element which comprises a four-equivalent 5-pyrazolone magenta-dye-forming coupler.
IT 181303-99-1 181304-00-7 181304-05-2
RL: TEM (Technical or engineered material use); USES (Uses)
(scavenger for oxidized photog. developers in silver halide photog. emulsions)
RN 181303-99-1 CAPLUS
CN Benzoic acid, 2-(aminosulfonyl)-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 181304-00-7 CAPLUS
CN Benzoic acid, 2-(aminosulfonyl)-, 2-[4-[[(3-pentadecylphenoxy)acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 54 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181304-05-2 CAPLUS
CN Benzoic acid, 3-(aminosulfonyl)-, 2-[4-[[(3-pentadecylphenoxy)acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 55 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:417799 CAPLUS
DN 125:86501
TI Preparation of linked piperidinecarboxylate moieties as immunophilin multimerizing agents
IN Holt, Dennis A.; Schreiber, Stuart; Keenan, Terence; Guo, Tao; Laborde, Edgardo
PA Ariad Gene Therapeutics, Inc., USA; Laborde, Edgardo
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606097	A1	19960229	WO 1995-US10559	19950818 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2197793	AA	19960229	CA 1995-2197793	19950818 <--
	AU 9533679	A1	19960314	AU 1995-33679	19950818 <--
	EP 776327	A1	19970604	EP 1995-930217	19950818 <--
	EP 776327	B1	20050706		
	R: AT, CH, DE, ES, FR, GB, LI, SE				
	JP 10504571	T2	19980506	JP 1995-508225	19950818 <--
	AT 299145	E	20050715	AT 1995-930217	19950818
	ES 2245781	T3	20060116	ES 1995-930217	19950818
	US 6133456	A	20001017	US 1997-808276	19970228 <--
	US 6150527	A	20001121	US 1997-808274	19970228 <--
	US 2002161240	A1	20021031	US 2002-86506	20020228 <--
	US 2003036654	A1	20030220	US 2002-86770	20020228 <--
	US 2004006233	A1	20040108	US 2003-461705	20030613
PRAI	US 1994-292598	A	19940818		
	US 1995-479694	A	19950607		
	US 1995-793016	B2	19950818		
	WO 1995-US10559	W	19950818		
	US 1996-12432P	P	19960228		
	US 1996-24861P	P	19960828		
	US 1996-33035P	P	19961210		
	US 1997-808274	A1	19970228		
	US 1997-808276	A1	19970228		
	US 1997-793016	B1	19971201		
	US 2000-690581	B1	20001017		
	US 2000-690797	B1	20001017		
	US 2002-86770	A1	20020228		

OS MARPAT 125:86501
GI

L9 ANSWER 55 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. M1LM2 {L = linker moiety; M1, M2 = piperidinecarboxylate moiety I attached through R1 or R2; one of R1, R2 = (cyclo)alk(en)yl, heterocyclyl, (hetero)aryl and the other = divalent (cyclo)alk(en)yl, heterocyclyl, (hetero)aryl; X = O, NH, CH2; Y = O, NR3; R3 = H or a monovalent (cyclo)alk(en)yl, heterocyclyl, (hetero)aryl} were prepared Thus, (S)-1-(1,2-dioxo-3,3-dimethylpentyl)piperidine-2-carboxylic acid was esterified by (R)-PhCH2CH2CH(OH)C6H4[O(CH2)3NHCO2CMe3] to give, after deprotection, piperidine Q [R4 = H.HCl] which was used to bisamidate Z(CH2COR)2 (II, Z = 3,5-pyridinediyl, R = succinimidooxy) to give II (R = Q). This compound showed multimerizing activity in a human 293 cell based system.
IT 178446-18-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of linked piperidinecarboxylate dimers as immunophilin multimerizing agents)
RN 178446-18-9 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 1,4-phenylenebis[methyleneimino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-phenylpropylidene)] ester, [2S-[2R*[S*[S*(R*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 55 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L9 ANSWER 56 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:259447 CAPLUS
DN 124:316765
TI Preparation of benzamidine derivatives as glycoprotein IIb/IIIa antagonists
IN Yoshida, Tomohiro; Ono, Shinichiro; Ashimori, Atsuyuki; Eda, Masahiro; Kosaka, Keigo; Mori, Fumio; Inoe, Yoshihisa; Imada, Mitsuaki; Ikegawa, Ruriko; Et, Al.
PA Green Cross Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07330695	A2	19951219	JP 1995-85532	19950411 <--
PRAI	JP 1995-85532	A	19950411		
	JP 1994-72330		19940411		

OS MARPAT 124:316765
GI



AB The amidinobenzene compds. [I; A = E-NHC(:NH), E-NHC(:NH)NH, E-NH(CH2)c; wherein E = H, amidino, guanidino, NH2-protecting group; c = 1,2,3; B = Q, Q1; wherein D = (Q2)p(CH2)r[CH(NH-E)]sCO2R5; wherein R5 = H, lower alkyl, cycloalkyl, aralkyl; Q2 = O, S, (un)substituted NH; R3, R4 = H, lower alkyl, halo, acyl, alkoxy; q = 1,2; p, s = 0,1; r = 0,1-3; provided that when p ≠ 0, at least one of r and s ≠ 0; J, G = CH, N; when G = N, then p = 0; f = 1-3; T = (un)branched alkylene; L, M = O, S, (un)substituted NH; R1, R2 = H, lower alkyl, halo, acyl, alkoxy; a = 0,1; b = 0, 1-3; provided that when a = 0, then b = 0 and B = Q1; when a = 1 and b = 0, B = Q or Q1 (wherein J = CH)], which inhibit the thrombus of blood platelet and are useful for the treatment and prevention of thrombotic diseases, seizure, cardiac infarction, inflammation, and

L9 ANSWER 56 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 56 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
arteriosclerosis, are prepd. Thus, 4-(benzyloxycarbonylamidino)phenoxyacetic acid was condensed with di-tert-Bu [(4-amino-o-phenylene)dioxy]diacetate using 1-hydroxy-1H-benzotriazole and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in DMF at room temp. to give 77% di-tert-Bu [[4-[[4-(benzyloxycarbonylamidino)phenoxy]acetylamino]-o-phenylene]dioxy]diacetate, which was hydrogenolyzed in the presence of 10% Pd-C in THF under H atm. and the treated with CF3CO2H in CH2Cl2 at room temp. for 1.5 h to give the title compd. (II) in 91% yield. II showed IC50 of 0.07 μM for inhibiting the ADP-induced aggregation of human blood platelet.
IT 175867-16-0P 175867-17-1P 176019-22-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamidine derivs. as glycoprotein IIb/IIIa antagonists as antithrombotics and blood platelet aggregation inhibitors)
RN 175867-16-0 CAPLUS
CN Phenylalanine, N-(butylsulfonyl)-4-[[[4-[imino[(phenylmethoxy)carbonyl]amino]methyl]phenoxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 175867-17-1 CAPLUS
CN Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(butylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 176019-22-0 CAPLUS
CN Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(butylsulfonyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 57 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:50667 CAPLUS
DN 124:215870
TI Silver halide color photographic material
IN Mihayashi, Keiji; Ichijima, Seiji; Kawagishi, Toshio; Saito, Naoki; Motoki, Masuji
PA Fuji Photo Film Co., Ltd., Japan
SO U.S., 48 pp. Cont.-in-part of U.S. Ser. No. 667, 806, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5476759	A	19951219	US 1993-103045	19930728 <--
PRAI	US 1993-103045	A	19930728		
	JP 1990-60735	B2	19900312		
	US 1991-667806		19910311		

OS MARPAT 124:215870
GI



AB A silver halide color photog. material comprises a support having thereon at least one light-sensitive silver halide emulsion layer is disclosed, wherein said light-sensitive material contains a DIR coupler represented by I (A = coupler residue; R = C1-4 alkyl group having or pyridyl group; and n = 1 when A represents a phenol type or naphthol type coupler residue, or n = 0 when A represents other coupler residues), and the emulsion layer contains chemical sensitized Ag halide grains which individually have a distinct layer comprising Ag iodobromide containing 7-45 mol % of Ag iodide and which individually have an overall Ag iodide content of ≥4 mol %. The photog. material is excellent in sensitivity, graininess, sharpness, color reproducibility, and preservability and is less liable to variation in photog. performance properties even when continuously processed under replenishment.
IT 174368-63-9
RL: DEV (Device component use); USES (Uses)
(photog. DIR coupler)
RN 174368-63-9 CAPLUS
CN 1H-Benzotriazolecarboxylic acid, 1-[(2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[[(4-cyanophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]methyl]-, 2-oxo-2-(pentyloxy)ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 57 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 58 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:995892 CAPLUS
DN 124:71498
TI Photographic elements containing scavengers for oxidized developing agent
IN Singer, Stephen Paul; Harder, John William
PA Eastman Kodak Co., USA
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 679944	A1	19951102	EP 1995-201032	19950422 <--
EP 679944	B1	20010919		
R: BE, DE, FR, GB, NL				
US 5543277	A	19960806	US 1995-397029	19950301 <--
JP 07301896	A2	19951114	JP 1995-102030	19950426 <--
PRAI US 1994-233196	A	19940426		

OS MARPAT 124:71498
AB An improved photog. element comprises a support bearing at least one silver halide emulsion layer having associated therewith a hydrazide compound that functions as a scavenger for oxidized developing agent. The hydrazide compound comprises at least one polyhydroxy aromatic nucleus or a precursor thereof and at least one moiety containing an group, N-N, which is bonded directly to a ring carbon atom of the polyhydroxy aromatic nucleus or precursor thereof through a linking group. The linking group can be an oxy, thio, sulfinyl, sulfonyl or alkylene group or it can be a carbonyl group when the polyhydroxy aromatic nucleus comprises at least three hydroxyl groups.
IT 172284-50-3 172284-51-4 172284-54-7
172284-55-8
RL: DEV (Device component use); USES (Uses)
(scavengers; photog. elements containing)
RN 172284-50-3 CAPLUS
CN Benzeneacetic acid, 2,5-dihydroxy-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 172284-51-4 CAPLUS
CN Benzenepentanoic acid, 2,5-dihydroxy-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX

L9 ANSWER 58 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)



RN 172284-54-7 CAPLUS
CN Benzenepentanoic acid, 2,5-dihydroxy-, 2-[4-[[(3-pentadecylphenoxy)acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Me

RN 172284-55-8 CAPLUS
CN Propanoic acid, 3-[(2,5-dihydroxyphenyl)thio]-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 59 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:818938 CAPLUS
DN 123:301423
TI Silver halide photographic materials showing high sharpness and color reproducibility
IN Aoyanagi, Noriko; Ishige, Osamu; Fujiwara, Hiroko
PA Konishiroku Photo Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07159949	A2	19950623	JP 1993-306762	19931207 <--
JP 3245758	B2	20020115		
PRAI JP 1993-306762		19931207		

GI



I



II

AB The title materials contain a pyrazole derivative I (R1-3 = H, substituent; Cp = coupler residue releasing bonding group upon reaction with oxidized developing agents; Time = timing group; n = 0-2). The materials show high sensitivity, sharpness, and color reproducibility. Thus, a support was coated with color photog. constitutive layers including a blue-sensitive Ag(Br, I) emulsion layer containing II.
IT 169553-29-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(pyrazole derivative photog. DIR coupler)
RN 169553-29-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-[[[1-(2-benzothiazolyl)-5-[2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[[(4-chloro-3-cyanophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-3-undecyl-1H-pyrazol-4-yl]methyl]thio]-1-(6-fluoro-2-pyridinyl)-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 59 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 60 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:796460 CAPLUS

DN 123:285896

TI Anticancer agents: synthesis of 4-chlorophenoxyacetamide derivatives

AU Li, L. M.; Xu, S. P.

CS Inst. Materia Medica, Chinese Academy Medical Sci., Beijing, 100050, Peop. Rep. China

SO Yaoxue Xuebao (1995), 30(7), 556-60
CODEN: YHHPAL; ISSN: 0513-4870

PB Chinese Academy of Medical Sciences, Institute of Materia Media

DT Journal

LA Chinese

AB Title compds. 4-ClC6H4OCH2CONHR [I; R = 4-R1NHSO2C6H4, carboxyphenyl, hydroxyphenyl, etc.; R1 = H, C(:NH)NH2, (un)substituted pyrimidinyl, thiazolyl, isoxazolyl, pyridyl] were prepared by condensation of 4-ClC6H4OCH2CO2H with amines. I (R = 4-H2NSO2C6H4) showed cytostatic activity.

IT 58590-34-4P 169697-01-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and anticancer activity of chlorophenoxyacetamide derivs.)

RN 58590-34-4 CAPLUS

CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 169697-01-2 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 58590-35-5P 154820-80-1P 154820-81-2P
169697-02-3P 169697-03-4P 169697-04-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and anticancer activity of chlorophenoxyacetamide derivs.)

RN 58590-35-5 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 60 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154820-80-1 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 154820-81-2 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 169697-02-3 CAPLUS

CN Acetamide, N-[4-[[(aminoiminomethyl)amino]sulfonyl]phenyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 169697-03-4 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(5,6-dimethoxy-4-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 60 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 169697-04-5 CAPLUS

CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[(2-pyridinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 61 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:767763 CAPLUS
DN 123:213033
TI Silver halide photographic materials
IN Nagami, Ken; Yoshida, Kazuhiro
PA Konishiroku Photo Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07128774	A2	19950519	JP 1993-274505	19931102 <--
PRAI	JP 1993-274505		19931102		

GI



I



II

AB The title materials, comprising a support coated with ≥1 Ag halide emulsion layer and ≥1 nonphotosensitive hydrophilic colloid layer, contain ≥1 hydrazine derivative and ≥1 water-soluble B compound in ≥1 of the emulsion and colloid layers. The fog formation during development is prevented, and the materials provide high contrast images without black spots and show good charging properties. Thus, a photog. film was prepared by using a Ag(Br, Cl) emulsion containing I and II.
IT 168092-62-4
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. emulsion containing hydrazine derivative and water-soluble boron compound)
RN 168092-62-4 CAPLUS
CN Acetic acid, [(methylthio)oxy]-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 61 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:729952 CAPLUS
DN 123:285545
TI Amidino compounds as glycoprotein IIb/IIIa antagonists and pharmaceutical compositions containing them
IN Takasugi, Hisashi; Kato, Masayuki; Ookubo, Mitsuru; Takahashi, Fumie
PA Fujisawa Pharmaceutical Co, Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07138221	A2	19950530	JP 1993-307422	19931111 <--
PRAI	JP 1993-307422		19931111		

OS MARPAT 123:285545
GI



I

AB Amidine compds. I [R1 = (un)protected amidino; R2 = H, lower alkyl; R3 = H, acyl, acyl-lower alkoxy, (un)substituted aryl-lower alkyl, N-(aryl-lower alkyl)-N-(lower alkanoyl)aminoalkyl; R4 = acyl, acyl-lower alkoxy, (un)substituted acyl-lower alkyl, N-(aryl-lower alkyl)-N-(lower alkanoyl)-lower alkyl; m = 1-6] and their salts and pharmaceutical compns. containing I or their salts as active ingredients are claimed. I antagonize glycoprotein IIb/IIIa and inhibit aggregation of blood platelet, and are useful for treatment of thrombotic diseases, e.g. arteriosclerosis, ischemic heart disease, ischemic brain diseases, diabetic complications, restenosis after PTCA, DIC, thrombocytopenia, inflammation, etc. I are also useful as cell adhesion inhibitors. A mixture of di-Me [4-[4-[N-(benzyloxycarbonyl)amidino]phenyloxyacetylamino]-1,2-phenylenedioxy]diacetate (1.0 g), Pd/C, HCl, H2O, and THF was autoclaved under H for 1 h to give 0.81 g di-Me [4-[(4-amidinophenyloxy)acetylamino]-1,2-phenylenedioxy]diacetate hydrochloride. IC50 value of this compound against ADP-induced platelet aggregation was 6.0 + 10-7M.
IT 169180-83-0P 169180-85-2P 169180-97-6P
169181-00-4P 169181-05-9P 169181-14-0P
169181-15-1P 169181-16-2P 169181-17-3P
169217-15-6P 169217-16-7P 169217-17-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
([(amidinophenoxy)alkanamido]benzenes as glycoprotein IIb/IIIa antagonists and blood platelet aggregation inhibitors for treatment of thrombotic diseases)
RN 169180-83-0 CAPLUS
CN L-Phenylalanine, N-acetyl-4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 169180-85-2 CAPLUS
CN L-Phenylalanine, N-acetyl-4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 169180-84-1
CMF C20 H22 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 169180-97-6 CAPLUS
CN L-Phenylalanine, N-acetyl-4-[[[4-[imino[[(phenylmethoxy)carbonyl]amino]methyl]phenoxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169181-00-4 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(3-ethoxy-1,3-dioxopropyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 169180-99-8
CMF C23 H26 N4 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 169181-15-1 CAPLUS
CN L-Phenylalanine, 4-[[[4-[imino[[(phenylmethoxy)carbonyl]amino]methyl]phenoxy]acetyl]amino]-N-(1-oxohexyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169181-16-2 CAPLUS
CN L-Phenylalanine, N-(3-ethoxy-1,3-dioxopropyl)-4-[[[4-[imino[[(phenylmethoxy)carbonyl]amino]methyl]phenoxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 169181-05-9 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(1-oxohexyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 169181-04-8
CMF C24 H30 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 169181-14-0 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(1-oxohexyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 169181-17-3 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(3-ethoxy-1,3-dioxopropyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 169217-15-6 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(butylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 169217-14-5
CMF C22 H28 N4 O6 S

Absolute stereochemistry.

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 169217-16-7 CAPLUS
CN L-Phenylalanine, 4-[[[4-(aminoiminomethyl)phenoxy]acetyl]amino]-N-(butylsulfonyl)-2-[(butylsulfonyl)amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 169217-17-8 CAPLUS
CN L-Phenylalanine, N-(butylsulfonyl)-2-[(butylsulfonyl)amino]-4-[[[4-[imino[[(phenylmethoxy)carbonyl]amino]methyl]phenoxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 63 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:538886 CAPLUS
DN 122:281444
TI Benzophenone Derivatives: A Novel Series of Potent and Selective Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase
AU Wyatt, Paul G.; Bethell, Richard C.; Cammack, Nicholas; Charon, Daniel; Dodic, Nerina; Dumaitre, Bernard; Evans, Derek N.; Green, Darren V. S.; Hopewell, Philippa L.; et al.
CS Medicinal Chemistry Virology Chemotherapy and Biomolecular Structure Departments, Glaxo Research and Development Limited, Greenford/ Middlesex, UB6 OHE, UK
SO Journal of Medicinal Chemistry (1995), 38(10), 1657-65
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I

AB A series of benzophenone derivs. has been synthesized and evaluated as inhibitors of HIV-1 reverse transcriptase (RT) and the growth of HIV-1 in MT-4 cells. Through the use of the structure-activity relationships within this series of compds. and computational chemical techniques, a binding conformation is proposed. The SAR also indicated that the major interactions of I with the RT enzyme are through hydrogen bonding of the amide and benzophenone carbonyls and π-orbital interactions with the benzophenone nucleus and an aromatic function separated from the benzophenone by a suitable spacer group. The crystal structure of compound I has been determined
A number of compds. with potent inhibitory activity against HIV-1 RT and HIV in cellular assays at levels comparable with AZT and our efforts to identify a metabolically stable analog are described.
IT 163130-64-1P 163130-66-3P 163130-67-4P 163130-68-5P 163130-69-6P 163130-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(benzophenone derivs. as selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase)
RN 163130-64-1 CAPLUS
CN Acetamide, N-[4-[2-(diethylamino)ethoxy]phenyl]-2-[2-(4-methoxybenzoyl)phenoxy]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 163130-63-0
CMF C28 H32 N2 O5

L9 ANSWER 63 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 163130-66-3 CAPLUS
CN Acetamide, N-[4-[2-(diethylamino)ethoxy]phenyl]-2-[2-(4-fluorobenzoyl)phenoxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 163130-65-2
CMF C27 H29 F N2 O4





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 163130-67-4 CAPLUS

L9 ANSWER 63 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, 2-(2-benzoylphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-(9CI) (CA INDEX NAME)



RN 163130-68-5 CAPLUS
CN Acetamide, 2-(2-benzoyl-5-methoxyphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 163130-69-6 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 163130-70-9 CAPLUS
CN Acetamide, 2-(2-benzoyl-4-chlorophenoxy)-N-[4-[3-(dimethylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 63 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 163130-92-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(benzophenone derivs. as selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase)
RN 163130-92-5 CAPLUS
CN Acetamide, 2-(2-benzoylphenoxy)-N-[4-[2-(diethylamino)ethoxy]phenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 163130-67-4
CMF C27 H30 N2 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 64 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:689553 CAPLUS
DN 121:289553
TI Silver halide photographic material using specific hydrazine derivative
IN Onodera, Akira; Usagawa, Yasushi
PA Konishiroku Photo Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 40 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06186711	A2	19940708	JP 1992-338606	19921218 <--
	JP 3208688	B2	20010917		
PRAI	JP 1992-338606		19921218		

GI



AB The title photog. material contains a hydrazine compound I (C1 and C2 represent C atoms adjacent to each other; Z = atoms required to form a aliphatic, aromatic, or heterocyclic ring together with C1 and C2; R1 = H, substituent; A = OH, primary, secondary, or tertiary amino; G = carbonyl, sulfonyl, sulfoxy, phosphoryl, iminomethylene; R2 = H, blocking group; either A1 or A2 is H and the other is H, acyl, sulfonyl, oxaryl; J = divalent linking group) in ≥1 of its photog. constituent layer(s). The materials provide high-contrast images using stable developing solns. and show stable photog. properties using low pH developing solns. when used as direct pos.-type photog. materials. Thus, a photog. film was prepared by using a Ag halide emulsion containing II.
IT 159068-60-7
RL: MOA (Modifier or additive use); USES (Uses)
(fogging agent; direct pos.-type photog. materials containing hydrazines as fogging agents)
RN 159068-60-7 CAPLUS
CN Ethanedioic acid, mono(1-ethyl-3-piperidinyl) ester, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-(2-hydroxyethoxy)phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 64 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 65 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:667690 CAPLUS
DN 121:267690
TI Silver halide photographic material containing iridium compound and hydrazine derivative to improve resistance to applied pressure
IN Ito, Katsuhiko; Sanpei, Takeshi; Ito, Hirohide; Kato, Mariko; Aritomi, Juji
PA Konishiroku Photo Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06161011	A2	19940607	JP 1992-307049	19921117 <--
PRAI JP 1992-307049		19921117		

OS MARPAT 121:267690
AB The photog. material is characterized by (1) that it contains an Ir compound and a hydrazine derivative, (2) that the Ag halide grains have laminar structures, and (3) that the grains have AgI in the core but not in the shell until the crystallization is completed. The emulsion has a high contrast and does not generate black peppers. It has also resistance to the application of pressure.
IT 134978-84-0
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(photog. fog. inhibitor, for high contrast and pressure resistance)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 66 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:469412 CAPLUS
DN 121:69412
TI Silver halide photographic material containing crystals with hydrazine-containing shell layer to improve developed density and shelf life
IN Nakagawa, Kunihiro; Sumi, Seiichi
PA Mitsubishi Paper Mills Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06035094	A2	19940210	JP 1992-189547	19920716 <--
PRAI JP 1992-189547		19920716		

AB The claimed photog. material comprises Ag halide crystals, whose shell layer consisting of ≤0.5 of the total Ag halide contains a hydrazine derivative It provides high developed d. with small added amount of hydrazine, and has good storage stability in spite of the incorporated hydrazine.
IT 77887-29-7
RL: USES (Uses)
(photog. emulsion shell crystals containing)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-(2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 67 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:435344 CAPLUS
DN 121:35344
TI Preparation of sulfonamidopyridine-2-carboxylic acid esters and N-oxides thereof as fibrosuppressants.
IN Weidmann, Klaus; Bickel, Martin; Gunzler-Pukall, Volkmar; Baringhaus, Karl Heinz
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 91 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 590520	A1	19940406	EP 1993-115361	19930923 <--
EP 590520	B1	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4233124	A1	19940407	DE 1992-4233124	19921002 <--
US 5428046	A	19950627	US 1993-124683	19930922 <--
AT 139227	E	19960615	AT 1993-115361	19930923 <--
ES 2090806	T3	19961016	ES 1993-115361	19930923 <--
CN 1089603	A	19940720	CN 1993-118248	19930929 <--
IL 107155	A1	19990922	IL 1993-107155	19930929 <--
FI 9304303	A	19940403	FI 1993-4303	19930930 <--
FI 103881	B1	19991015		
CZ 283869	B6	19980617	CZ 1993-2044	19930930 <--
CA 2107514	AA	19940403	CA 1993-2107514	19931001 <--
NO 9303521	A	19940405	NO 1993-3521	19931001 <--
NO 180085	B	19961104		
NO 180085	C	19970212		
AU 9348726	A1	19940414	AU 1993-48726	19931001 <--
AU 662448	B2	19950831		
ZA 9307298	A	19940425	ZA 1993-7298	19931001 <--
HU 67292	A2	19950328	HU 1993-2778	19931001 <--
RU 2117660	C1	19980820	RU 1993-56156	19931001 <--
PL 176772	B1	19990730	PL 1993-300561	19931001 <--
JP 06211795	A2	19940802	JP 1993-247717	19931004 <--
PRAI DE 1992-4233124	A	19921002		

OS MARPAT 121:35344
GI



AB Title compds. [I; A = R3, B = XNR5R6, or B = R3, A = XNR5R6; X = bond, CO; R1-R3 = H, alkyl, alkoxy, halo, cyano, OH, amino; R4 = (substituted) acyloxyalkyl, alkyl, alkenyl, alkynyl, alkenynyl, aryl, aralkyl, heteroaryl; R5 = H, alkyl, protecting group, physiol. acceptable cation; R6 = Y(CU)rDW; Y = SO2, CO; C = bond, (substituted) (cyclo)alkanediyl, (cyclo)alkenediyl, alkynediyl, alkenyndiyl; U = bond, H, CO, CO2, O, SO,

L9 ANSWER 67 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
SO2, CONH, etc.; D = bond, H, (substituted) alkanediyl, alkenediyl, alkynediyl, alkenyndiyl; W = bond, H, (substituted) cycloaliphatyl, aryl, heteroaryl; n = 0, 1; r = 1-4; with provisos], were prepd. Thus, a soln. of 4-methoxybenzenesulfonamide in THF at 0° was treated with KOCMe3 and then with a soln. of 2-methoxycarbonylpyridine-5-carbonyl chloride; the mixt. was stirred 3 h while warming to room temp. to give Me 5-[[(4-methoxyphenylsulfonyl)amino]carbonyl]pyridine-2-carboxylate. This was sapond. with NaOH in MeOH/H2O followed by esterification with 2-propanol/conc. H2SO4 to give title compd. II. In the CC14-induced liver fibrosis test in rats, I were active at 1-100 mg/kg orally or i.p.
IT 155881-76-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 155881-76-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 155881-54-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of fibrotic disease)
RN 155881-54-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(phenoxyacetyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 68 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:289526 CAPLUS
DN 120:289526
TI Antitumor compounds. VII. Syntheses of derivatives of analogs of sulfanilamide
AU Zheng, Yiya; Wang, Zhogao; Feng, Zangming; Lu, Haiyan; Xie, Bingfen; Shu, Xivyong; Liu, Zhongchao
CS Dep. Chem., Zhongshan Univ., Canton, Peop. Rep. China
SO Zhongshan Daxue Xuebao, Ziran Kexueban (1993), 32(2), 93-6
CODEN: CHTHAJ; ISSN: 0529-6579
DT Journal
LA Chinese
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Seven derivs. of plant growth regulators containing heterocycles were prepared
and tested for antitumor activity. Preliminary cytotoxicity tests showed that the inhibition ratios of the compds. (100μg/mL) against human cervical cancer Hela cell line in vitro were: 85.5% for I, 71.4% for II, 88.7% for III, 53.7% for IV, and 85.4% for V. Others were inactive.
IT 154820-80-1P 154820-81-2P 154820-82-3P
154820-83-4P 154820-84-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antitumor activity of)
RN 154820-80-1 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 154820-81-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 68 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154820-82-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 154820-83-4 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[[(5-methoxy-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 154820-84-5 CAPLUS
CN Acetamide, N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]-2-(2,4,5-trichlorophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 69 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:231861 CAPLUS
DN 120:231861
TI Silver halide color photographic material containing hydroquinone derivative
IN Matsuda, Naoto; Hirai, Hiroyuki
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05241306	A2	19930921	JP 1992-78749	19920302 <--
PRAI JP 1992-78749		19920302		

OS MARPAT 120:231861
GI



I

AB The claimed photog. material has a layer on the support which contains a compound I (R = OH, SH, CONR5OH, N(OH)COR5, CR5:NOH, SO2NHR5, NHSO2R5, CONR5NH2; Z = CO, CONR6, CO2, COS, SO2, SO2NR6; R5, R6 = H, alkyl, aralkyl, aryl; n = 0, 1; m = 2-6; R1, R2 = H, protective group; R3, R4 = H, halo, cyano, nitro, alkyl, aryl, alkenyl, aralkyl, alkoxy, aryl, aryloxy, alkylthio, acyl, sulfonyl, carbamoyl, sulfonylamino, aminocarbonylamino, aminosulfonylamino, heterocyclyl). The compound scavenges migrating oxidized developing agents and improve color reproduction
quality and image sharpness.
IT 153869-83-1
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing, as oxidized developer scavenger)
RN 153869-83-1 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2,5-dihydroxy-4-[4-[(methylsulfonyl)amino]-1-oxobutyl]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 69 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 70 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:106786 CAPLUS
DN 120:106786
TI Preparation of sulfonamido(carbon)pyridine-2-carboxamides as fibrosuppressives
IN Weidmann, Klaus; Bickel, Martin; Guenzler-Pukall, Volkmar
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 92 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 562512	A1	19930929	EP 1993-104658	19930322 <--
	EP 562512	B1	20010221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	FI 102895	B1	19990315	FI 1993-1250	19930322 <--
	SK 280884	B6	20000912	SK 1993-223	19930322 <--
	AT 199250	E	20010315	AT 1993-104658	19930322 <--
	ES 2154266	T3	20010401	ES 1993-104658	19930322 <--
	PT 562512	T	20010629	PT 1993-104658	19930322 <--
	CA 2092276	AA	19930925	CA 1993-2092276	19930323 <--
	NO 9301056	A	19930927	NO 1993-1056	19930323 <--
	NO 179867	B	19960923		
	NO 179867	C	19970102		
	CN 1076691	A	19930929	CN 1993-103349	19930323 <--
	AU 9335369	A1	19930930	AU 1993-35369	19930323 <--
	AU 657608	B2	19950316		
	ZA 9302047	A	19931019	ZA 1993-2047	19930323 <--
	JP 06049030	A2	19940222	JP 1993-63723	19930323 <--
	PL 173677	B1	19980430	PL 1993-298195	19930323 <--
	RU 2129545	C1	19990427	RU 1993-4764	19930323 <--
	HU 69685	A2	19950928	HU 1993-850	19930324 <--
	HU 219224	B	20010328		
	US 5607954	A	19970304	US 1994-355419	19941213 <--
	HK 1011987	A1	20010824	HK 1998-113239	19981211 <--
	GR 3035479	T3	20010531	GR 2001-400321	20010228 <--
PRAI	DE 1992-4209424	A	19920324		
	DE 1992-4238506	A	19921114		
	US 1993-28438	B1	19930309		

OS MARPAT 120:106786
GI



I



II

L9 ANSWER 70 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. [I; 1 of A, B = R3 and the other = XNR6R7; R1-R3 = H, halo, alkyl, alkoxy, etc.; R4, R5 = H, alkoxy, alkyl, aryl, etc.; R6 = H, alkyl, N-protective group, etc.; R7 = Y(ZU)rDW; X = bond or CO; Y = CO or SO2; Z = bond, H, alk(en)ylene, etc.; U = null, bond, H, CO, O, SO2, etc.; D = null, bond, H, alk(en)ylene, etc.; W = null, bond (sic), H, alk(en)yl, etc.; n = 0 or 1; r = 1-4] were prepared Thus, 2-methoxycarbonylpyridine-5-carboxylic acid was treated with SOCl2 and the product condensed with 4-(MeO)C6H4SO2NH2 to give, after amidation with HOCH2CH2NH2, title compound II. I were effective (sic) at 1-100 ng/kg orally or i.p. in the CCl4-induced liver fibrosis model employing rats.
IT 152457-74-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as fibrosuppressive agent)
RN 152457-74-4 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[2-[(phenoxyacetyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

L9 ANSWER 71 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:570409 CAPLUS
DN 119:170409
TI Silver halide photographic material prepared by using maleate polymer as flocculant and hydrazine for contrast enhancement
IN Goto, Kenji; Kobayashi, Akira; Fukawa, Junichi
PA Konishiroku Photo Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05107667	A2	19930430	JP 1991-269593	19911017 <--
	JP 3084457	B2	20000904		
PRAI	JP 1991-269593		19911017		

AB The photog. material is characterized by (1) a polymer p-[CH2CR(CH3)]x[CH(CO2M)CH(CO2M1)]y (R = lower alkyl; M and M1 = cation) is used as the flocculant to eliminate water-soluble salts in the emulsion making process and (2) that a hydrazine derivative is incorporated in the emulsion layer or the adjacent layer(s). The photog. material has high speed and provides a high contrast image without inducing black pepper spots.
IT 150163-64-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing, for hard image)
RN 150163-64-7 CAPLUS
CN Acetic acid, oxo[(phenylmethoxy)amino]-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 72 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:449075 CAPLUS
DN 119:49075
TI Preparation of 4-aminosalicylamides as chemosensitizers
IN Monkovic, Ivo; Wang, Lotte; Willner, David
PA Bristol-Myers Squibb Co., USA
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 529395	A2	19930303	EP 1992-113630	19920810 <--
	EP 529395	A3	19930512		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2074061	AA	19930227	CA 1992-2074061	19920716 <--
	JP 05221950	A2	19930831	JP 1992-241123	19920728 <--
PRAI	US 1991-749742	A	19910826		

OS MARPAT 119:49075
GI



I



II

AB Title compds. [I; R1 = H, alkanoyl, aroyl, etc.; R2 = (substituted)Ph, (CH2)kSmR6; R3 = H, (substituted)Ph; R4,R5 = alkyl; R6 = (halo)phenyl; k = 2 or 3; m = 0 or 1; p = 2-4] were prepared Thus, title compound II (R1 = H) was acylated with MeCH:CHCOCl to give II (R1 = COCH:CHMe) which reduced IC50 of actinomycin D from 10 to 2.4 ng/mL in HCT-116/VM = 46 human colon carcinoma cell culture at 0.4 μM.
IT 147805-54-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as chemosensitizer)
RN 147805-54-7 CAPLUS
CN Benzamide, 5-chloro-4-[[[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetyl]amino]-N-[2-(diethylamino)ethyl]-2-[2-(phenylthio)ethoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:179896 CAPLUS
DN 118:179896
TI Photographic coupler and silver halide color photographic material containing same
IN Kato, Eisaku; Sugita, Shuichi; Oya, Hidenobu; Ishige, Osamu; Kida, Shuji; Yamazaki, Chikamasa
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04269744	A2	19920925	JP 1991-30362	19910225 <--
PRAI JP 1991-30362		19910225		

GI



I

AB Claimed are pyrazolotriazole magenta couplers represented by general structure I. For I, R1 = substituent; R2 = H, alkyl, aryl; R3 = aryl, aralkyl; R4, R5 = H, or substituent; X = H, or group to be released upon coupling reaction. Also claimed is the title photog. material. The use of the title material gives excellent color reproduction
IT 146133-25-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)
RN 146133-25-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[(7-chloro-6-methyl-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl)(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 74 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:157654 CAPLUS
DN 118:157654
TI High-photosensitivity high-contrast photographic material
IN Ogasawara, Akira; Sanpei, Takeshi; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04070647	A2	19920305	JP 1990-179779	19900705 <--
PRAI JP 1990-179779		19900705		

AB In the title photog. material comprising ≥1 Ag halide emulsion layers on its support, ≥1 of the above emulsion layers on its support, ≥1 of the above emulsion layers contains an IR compd(s). and a hydrazine compd(s)., and the Ag halide grains have a layer structure with the I content at the core part higher than that of the shell part before grain formation is completed.
IT 129879-83-0 134978-84-0 142687-29-4
RL: USES (Uses)
(lith film containing)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 74 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 142687-29-4 CAPLUS
CN Pentanedioic acid, bis[2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 75 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:136092 CAPLUS
DN 118:136092
TI Silver halide color photographic material
IN Okawa, Atsuhiro; Motoki, Masushi; Obayashi, Keiji
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 84 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04211246	A2	19920803	JP 1991-37760	19910208 <--
	US 5286620	A	19940215	US 1991-655605	19910215 <--
PRAI	JP 1990-37070	A1	19900216		

AB The title material which comprises a support having thereon one or more silver halide emulsion layers contains a compound represented by AL1L2INHQ (A = coupler residue; L1 = WCR11R12, OCO; W = O, S, etc.; R11, R12 = H, substituent; or R11 and R12 may together form a ring; L2 = as defined above for L1; or L2 is a group releasing INHQ by electron movement along the conjugated system; INH = development inhibitor linked to L2 through a heteroatom; Q = secondary or tert-alkyl). The title material gives sharp images.
IT 145977-73-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)
RN 145977-73-7 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[4-[1-[[1-(1,1-dimethylpropyl)-1H-tetrazol-5-yl]thio]ethyl]-1H-imidazol-1-yl]methoxy]-N-(heptafluoropropyl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 76 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:112833 CAPLUS
DN 118:112833
TI High-contrast photographic material for lithography
IN Hara, Yoji; Kobayashi, Akira; Sanpei, Takeshi; Sai, Yoshiho; Ogasawara, Akira
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04051142	A2	19920219	JP 1990-160254	19900619 <--
	JP 2880255	B2	19990405		
PRAI	JP 1990-160254		19900619		

AB In the title photog. material having on its support ≥1 Ag halide photog. emulsion layer(s) which or whose adjacent layer(s) contain hydrazine derivs., the above emulsion layer contains an acidic polymer(s), and the emulsion bearing surface has a center line average roughness of 0.05-0.20 μm. This material shows good adhesion even when less matting agent is used.
IT 123852-45-9P
RL: PREP (Preparation)
(preparation of, as high-contrast photog. emulsion additive)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 77 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:90671 CAPLUS
DN 118:90671
TI High-contrast photographic material with improved pressure resistance
IN Ogasawara, Akira; Sanpei, Takeshi; Kobayashi, Akira; Sai, Yoshiho; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04077732	A2	19920311	JP 1990-191329	19900719 <--
PRAI	JP 1990-191329		19900719		

AB In the title photog. material comprising one or more Ag halide emulsion layers on a support, ≥1 of the emulsion layers contain Ag halide grains which are prepared in the presence of an In salt to have a ≥2-layer structure with AgI content at the shell part of the grains higher than that at the core part and the emulsion layers or other hydrophilic colloid layers contain ≥1 compound selected from Rn(CONHNHR1)[(CO)mNHNHR2] [R1, R2 = aryl, heterocyclyl; R = an organic group; n = 0-6; m = 0, 1], R3NP1NP2C(O)C(O)R4 [R3 = an aliphatic, aromatic, or heterocyclic group; R4 = H, alkoxy, heterocyclyloxy, amino, aryloxy; P1, P2 = H, acyl, asulfinic acid group] and ArNHNHC(O)R5 [Ar = aryl containing a diffusion-resisting group or Ag halide absorption-promoting group; R5 = alkyl].
IT 129879-83-0 134978-84-0
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 77 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:49168 CAPLUS
DN 118:49168
TI Silver halide color photographic material
IN Yokoyama, Shigeki; Tsukahara, Jiro; Sakai, Shuichi; Yamazaki, Shigeru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04199048	A2	19920720	JP 1990-332805	19901129 <--
PRAI JP 1990-332805		19901129		

GI



I

AB The title material which comprises a support having thereon one or more silver halide emulsion layers contains a cyan dye-forming coupler represented by general structure I. For I, R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl; R3 = substituent on benzene ring; R4, R5 = H, alkyl, alkenyl, cycloalkyl, etc.; R6 = aryl; L = O, S; Z = H, group to be released upon coupling; l = 0 to 4. The title material is suited for quick processing.

IT 144986-31-2
RL: USES (Uses)
(cyan coupler, for photog. material)

RN 144986-31-2 CAPLUS
CN Dodecanamide, N-[2-[2-[[4-[[[(4-cyanophenyl)amino]carbonyl]amino]-5-hydroxy-2-(4-methoxyphenoxy)phenyl]amino]-2-oxoethoxy]-4-methoxyphenyl]-(9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 79 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:581653 CAPLUS
DN 117:181653
TI High-contrast silver halide photographic material
IN Ogasawara, Akira; Sanpei, Takeshi; Kobayashi, Akira; Sai, Yoshiho; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04056843	A2	19920224	JP 1990-165283	19900623 <--
PRAI JP 1990-165283		19900623		

AB In the title photog. material, the Ag halide emulsion layer contains an Ir compd(s)., the Ag halide grains contain more iodide at the grain surface than in the interior, and the emulsion contains ≥1 compd(s). selected from Rn[CONHNHR1][(CO)mNHNHR2] [R1, R2 = aryl, heterocyclyl; R = organic linking group; n = 0-6; m = 0, 1; when n ≥ 2, each R may be the same or different], R21N(P1)N(P2)COCOR22 [R21 = aliphatic, aromatic, heterocyclic; R22 = H, alkoxy, heterocyclyloxy, NH2, aryloxy; P1,2 = H, aryl, sulfinic acid], and ArNHNHCOR31 [Ar = diffusion-resistant group, aryl group containing ≥1 Ag halide adsorption-promoting group; R31 = alkyl].

IT 123852-45-9 134978-84-0
RL: USES (Uses)
(photog. additive, for high-contrast films)

RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 79 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 80 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:581650 CAPLUS
DN 117:181650
TI High-contrast silver halide photographic material
IN Ogasawara, Akira; Sanpei, Takeshi; Kobayashi, Akira; Sai, Yoshiho; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04056842	A2	19920224	JP 1990-165279	19900622 <--
PRAI JP 1990-165279		19900622		

AB In the title Ag halide photog. material, the emulsion layer contains an Ir compd(s)., halogen exchange is carried out with a water-soluble iodine compound when grain formation has reached ≥90%, and the emulsion layer contains ≥1 compd(s). selected from Rn[CONHNHR1][(CO)mNHNHR2] [R1,2 = aryl, heterocyclyl; R = organic linking group; n = 0-6; m = 0, 1; when n ≥ 2, R groups may be identical], R21N(P1)N(P2)COCOR22 [R21 = aliphatic, aromatic, heterocyclic; R22 = H, alkoxy, heterocyclyloxy, NH2, aryloxy; P1,2 = H, aryl, sulfinic acid group], and ArNHNHCOR31 [Ar = diffusion-resistant group; Ag halide adsorption promoting group-containing aryl; R31 = alkyl].
IT 134978-84-0
RL: USES (Uses)
(photog. additive for high-contrast emulsions)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



IT 123852-45-9P
RL: PREP (Preparation)
(preparation of, as additive for photog. emulsions)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 80 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 81 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:521429 CAPLUS
DN 117:121429
TI Silver halide photographic material
IN Ogasawara, Akira; Sanpei, Takeshi; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04076533	A2	19920311	JP 1990-191907	19900718 <--
PRAI JP 1990-191907		19900718		

AB In the title material comprising a support having thereon one or more Ag halide emulsion layers, at least one of the emulsion layers contain an Ir compound and a hydrazine derivative The Ag halide emulsion layers in the title material may also contain a Rh compound The title material gives high-contrast images.
IT 134978-84-0
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 82 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:500842 CAPLUS
DN 117:100842
TI Silver halide photographic material containing hydrazine derivatives for high-contrast halftone image
IN Kobayashi, Akira; Sanpei, Takeshi; Ogasawara, Akira; Sai, Yoshiho; Hara, Yoji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03282448	A2	19911212	JP 1990-83339	19900330 <--
PRAI JP 1990-83339		19900330		

AB A Ag halide photog. material, having at least one Ag halide emulsion layer on a support, contains a hydrazine derivative in the said emulsion layer or its adjacent layer, wherein the desalting process for removing a residual soluble matter from the said emulsion is carried out by flocculation using a modified gelatin. The photog. material forms a super high-contrast halftone image with high sensitivity and little fog by using a relatively well preserved developing agent and is suitable for printing plate-making process.
IT 129879-83-0
RL: USES (Uses)
(photog. film containing, for high-contrast halftone image in printing plate-making process)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 82 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 83 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:479907 CAPLUS
DN 117:79907
TI Silver halide photographic material containing iridium compound and hydrazine derivative
IN Ogasawara, Akira; Sanpei, Takeshi; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04076531	A2	19920311	JP 1990-191905	19900718 <--
	JP 2814137	B2	19981022		
PRAI	JP 1990-191905		19900718		

AB In the title material comprising a support having thereon Ag halide emulsion layers, at least one of the emulsion layers contains an Ir compound and a hydrazine derivative The layer adjacent to the emulsion layer containing the Ir compound and the hydrazine derivative has an I or Br compound The title material gives high-contrast images.
IT 129879-83-0 134978-84-0 142687-29-4
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 83 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



RN 142687-29-4 CAPLUS
CN Pentanedioic acid, bis[2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 83 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L9 ANSWER 84 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:479905 CAPLUS
DN 117:79905
TI Silver halide photographic material
IN Ogasawara, Akira; Sanpei, Takeshi; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04076534	A2	19920311	JP 1990-191908	19900718 <--
PRAI JP 1990-191908		19900718		

AB In the title material comprising a support having thereon Ag halide emulsion layers, at least one of the emulsion layers contains an Ir compound and a hydrazine derivative and has multilayered Ag halide grains. Before completion of grain formation, the concentration of the Rh compound in the surface of the Ag halide grains is higher than that in the interior of the grains. The title material shows high sensitivity.
IT 129879-83-0 134978-84-0 142687-29-4
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 84 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



RN 142687-29-4 CAPLUS
CN Pentanedioic acid, bis[2-[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 85 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:479903 CAPLUS
DN 117:79903
TI Silver halide photographic material containing hydrazine and iridium compounds
IN Ogasawara, Akira; Sanpei, Takeshi; Hara, Yoji
PA Konica K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04076532	A2	19920311	JP 1990-191906	19900718 <--
PRAI JP 1990-191906		19900718		

AB In the title material comprising a support having thereon Ag halide emulsion layers, at least one of the emulsion layers contains an Ir compound and a hydrazine derivative During the preparation of the hydrazine derivative-containing emulsion layers and after desalting, the pAg of the emulsion layers is maintained at ≤10. The title material gives high-contrast images.
IT 134978-84-0
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 86 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:265422 CAPLUS
DN 116:265422
TI Silver halide color photographic material
IN Motoki, Masushi; Okawa, Atsuhiro; Obayashi, Keiji
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03223850	A2	19911002	JP 1990-19715	19900130 <--
PRAI JP 1990-19715		19900130		

GI For diagram(s), see printed CA Issue.
AB The title material contains at least one coupler selected from compds. having general structures I and II (A = a coupler residue; Z = R1, COR2, SO2R2, CO2R2; R = a substituent on the benzene ring; n = 1 to 4; m = 1 to 6; when n or m ≥2, substituents R may together form a ring; R1 = H, an aliphatic group, an aromatic ring residue, heterocyclyl; R2 = an aliphatic group, an aromatic ring residue, heterocyclyl, etc.). The title material gives excellent color reproduction
IT 141742-72-5
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)
RN 141742-72-5 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[[[(4-cyanophenyl)amino]carbonyl]amino]-2-[[4-(dioctylamino)-2-(octylamino)-1-naphthalenyl]azo]-5-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 87 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:224613 CAPLUS
DN 116:224613
TI Glass plate silver halide photographic material with improved layer-to-support adhesion by a silane coupling agent
IN Sanpei, Takeshi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03253844	A2	19911112	JP 1990-52432	19900302 <--
PRAI JP 1990-52432		19900302		

AB The photog. material comprising a glass support and ≥1 layer(s) of Ag halide emulsion contains a hydrazine derivative and a silane coupling agent in the emulsion layer or the adjacent layer(s). It has improved layer adhesion to the glass support, and also maintains high speed and high contrast. It is suitably used for production of photomasks and related applications.
IT 123852-45-9P
RL: PREP (Preparation)
(preparation of, photog. plate containing)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 88 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:204378 CAPLUS
DN 116:204378
TI Photographic material using cyan coupler with high coupling reactivity
IN Tsukahara, Jiro; Yamazaki, Shigeru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03217841	A2	19910925	JP 1990-14231	19900124 <--
PRAI JP 1990-14231		19900124		

OS MARPAT 116:204378
GI



I

AB The title photog. material having ≥1 Ag halide emulsion layers on its support contains ≥1 cyan couplers I [R1,2 = H, (cyclo)alkyl, alkenyl, aryl; R3 = benzene ring substituent group; R4 = aryl; X = primary alkyl, alkenyl, acyclic secondary alkyl, preferably carbocyclyl, heterocyclyl; Z= H, coupling-releasable group; l = 0-4]. This photog. material shows high coupling reactivity and color d.
IT 140838-54-6
RL: TEM (Technical or engineered material use); USES (Uses)
(cyan photog. coupler, for high coupling reactivity)
RN 140838-54-6 CAPLUS
CN Tetradecanamide, 2-[[4'-(acetylamino)[1,1'-biphenyl]-2-yl]oxy]-N-[4-[[[(3-chloro-4-cyanophenyl)amino]carbonyl]amino]-5-hydroxy-2-[2-[(4-[[(methylamino)carbonyl]oxy]phenyl]amino]-2-oxoethoxy]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 88 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 89 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:162432 CAPLUS
DN 116:162432
TI Silver halide color photographic material
IN Yokoyama, Shigeki; Tsukahara, Jiro; Yamazaki, Shigeru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03198051	A2	19910829	JP 1989-341465	19891227 <--
PRAI JP 1989-341465		19891227		

GI



I

AB In the title material comprising a support coated with at least one Ag halide emulsion layer, the said layer or another layer contains a cyan coupler represented by I (R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl; R3 = a substituent on benzene ring; R4, R5 = H, alkyl, alkenyl, cycloalkyl, aryl; R6 = aryl; L = O, S; Z = H, a group to be released upon coupling reaction; l = 0 to 4). The title material gives stable color images.
IT 139571-06-5
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 139571-06-5 CAPLUS
CN Dodecanamide, N-[2-[2-[[5-hydroxy-2-(4-methoxyphenoxy)-4-[[[(4-methylphenyl)amino]carbonyl]amino]phenyl]amino]-2-oxoethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 89 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 90 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:117084 CAPLUS
DN 116:117084
TI Silver halide color photographic materials containing cyan coupler
IN Tsukahara, Jiro; Yamazaki, Shigeru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03220553	A2	19910927	JP 1990-15790	19900125 <--
PRAI JP 1990-15790		19900125		

OS MARPAT 116:117084
GI



I



II

AB Cyan coupler I (R1-2 = H, alkyl, alkenyl, cycloalkyl, aryl; R3 = substituent; R4 = aryl; Z = H, leaving group at coupling; k = 0-3; R6, R6 = H, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl) is contained in the photog. materials . These couplers have high coupling efficiency and provide high color d. Thus, a photog. film with a cellulose triacetate base, a Ag(I,Br) emulsion layer containing 1 mM/m2 coupler II, and a protective layer, was sensitometrically exposed and normally processed, to show high γ-value and maximum d. compared with a reference film containing a noninvention coupler.

IT 138452-12-7
RL: USES (Uses)
(cyan coupler, high d.)

RN 138452-12-7 CAPLUS
CN Acetamide, 2-[2,3-bis[(1-methyltridecyl)oxy]phenoxy]-N-[4-[[[(3,4-dichloro-5-cyanophenyl)amino]carbonyl]amino]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 90 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L9 ANSWER 91 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:117049 CAPLUS
DN 116:117049
TI Silver halide color photographic material containing hydrazine derivative as color stain inhibitor
IN Kita, Hiroshi; Onda, Hiroyuki; Kato, Midori; Mizukura, Noboru
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03150562	A2	19910626	JP 1989-290849	19891108 <--
PRAI JP 1989-290849		19891108		

GI

I

AB In a Ag halide color photog. material having photog. layers consisting of at least one each of blue-, green-, and red-sensitive Ag halide emulsion layers containing a yellow, magenta, and cyan coupler, resp., on a support, at least one of the photog. layers contains a noncoloring and nondiffusing R1R2NNR3Z [R1 = (cyclo)alkyl, aryl, heterocyclyl; R2,R3 = H, acyl, sulfonyl; Z = cyano, NO2, perfluoroalkyl, CSR, CH:CR4R4, I; R = a substituent; R4,R5 = H, a substituent where at least one of R4 and R5 being an electron-withdrawing group having Hammet σp value >0.2; Z1 = atoms necessary to form a heterocyclic ring]. The color photog. material provides excellent color reproduction, little color stain, little change in photog. properties during storage, and excellent graininess and sharpness.

IT 139398-50-8
RL: USES (Uses)
(photog. color stain inhibitor)

RN 139398-50-8 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[2-(4-hydroxy-2-benzothiazolyl)hydrazino]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 92 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:72179 CAPLUS
DN 116:72179
TI Silver halide photographic material containing hydrazine compound and imidazolidinone derivative
IN Hanyu, Takeshi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03168736	A2	19910722	JP 1989-309571	19891129 <--
PRAI	JP 1989-309571		19891129		

GI

I

AB The photog. material contains a hydrazine derivative and I [R, R1 = (substituted) alkyl]. Thus, I (R = R1 = Me) and 1-formyl-2-(4-phenylacetamidophenyl)hydrazine was added to Ag(Br, I) emulsion to give a photog. film. The film had high sensitivity and gave high contrast and high quality images even at the finest dot area.
IT 77887-29-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. emulsion containing, with imidazolidinone derivative, for high contrast images)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 93 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 93 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:31284 CAPLUS
DN 116:31284
TI Silver halide color photographic material containing heterocyclic compounds to prevent color contamination
IN Kato, Midori; Kita, Hiroshi; Onda, Hiroyuki; Mizukura, Noboru
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03150560	A2	19910626	JP 1989-290847	19891108 <--
PRAI	JP 1989-290847		19891108		

GI

I



II

AB The photog. material comprising a support, a yellow coupler-containing blue-sensitive silver halide emulsion layer, a magenta coupler-containing green-sensitive silver halide emulsion layer, and a cyan coupler-containing red-sensitive silver halide emulsion layer contains in ≥1 layer(s) a non-color-developing, non-diffusible compound I [Z = C:O, C:S, S:O, SO2, P(:O)R1; R1 = H, substituent; R = H, sulfonyl, acyl; A = heterocyclic ring]. Thus, a multilayer color photog. paper containing II in the interlayer between the blue-sensitive and green-sensitive emulsion layers, showed good storage stability, color reproducibility without contamination, and gave images with good granularity and sharpness.
IT 138122-04-0P
RL: PREP (Preparation)
(preparation of, photog. paper interlayer containing, for color contamination prevention)
RN 138122-04-0 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-N-(2,3-dihydro-3-oxo-1,2,4-triazin-5-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 94 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:31245 CAPLUS
DN 116:31245
TI Light-sensitive silver halide color photographic material
IN Sugita, Shuichi; Kida, Shuji; Ohya, Hidenobu
PA Konica Co., Japan
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 430003	A1	19910605	EP 1990-122007	19901117 <--
	R: DE, GB				
	JP 03163542	A2	19910715	JP 1989-302003	19891122 <--
	JP 2829874	B2	19981202		
	US 5104780	A	19920414	US 1990-610086	19901107 <--
PRAI	JP 1989-302003	A	19891122		
OS	MARPAT 116:31245				

GI



II

AB The title material contains a compound (I) having a A(CO2)p methylene group at the 4-position of a pyrazole ring and having a residue of non-diffusion type coupler linked through an O atom, a S atom, or an imino group at the 5-position of the pyrazole ring; A = residue of 1-phenyl-3-pyrazolidone derivs.; p = 0 or 1. The title material shows high sensitivity, high gamma and high coloring d., and excellent graininess. Pyrazole derivative II is an example of I.
IT 138081-38-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)
RN 138081-38-6 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-[[4-[[(4,5-dihydro-4,4-dimethyl-1-phenyl-1H-pyrazol-3-yl)oxy]methyl]-1,3-dimethyl-1H-pyrazol-5-yl]thio]-5-hydroxy-4-[[[[4-(methylsulfonyl)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 94 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 95 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:594119 CAPLUS
DN 115:194119
TI A silver halide photographic light-sensitive material containing hydroazine derivatives for retouchable mat films
IN Sanpei, Takeshi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03039731	A2	19910220	JP 1989-176831	19890706 <--
PRAI JP 1989-176831		19890706		

AB The title photog. material comprises on a support at least one silver halide light-sensitive emulsion layer with the center line average coarseness of ≥0.15 μm on its coating surface, wherein the above silver halide emulsion layer or its adjacent layer contains hydrazine derivs. (preparation given) ((R)n(CONHNHR1)(CO)mNHNHR2 (R1,R2 = aryl, heterocyclyl; R = organic linkage group; n = 0-6; m = 0,1; when n ≥2, each R being the same or different), R3NP1NP2COCOR4(R3 = aliphatic, arom, or heterocyclyl group; R4 = H, (unsubstituted alkoxy, heterocyclocyloxy, NH2, acyloxy; P1, P2 = H, aryl, sulfinyl), and ArNHNHCOR5 (Ar = aryl containing at least one of anti-diffusion group or silver halide adsorption-promoting group; R5 = substituted alkyl). The use of the above hydrazine derivs. improves the covering power of the photog. material, while having sufficient retouchable property.
IT 123852-45-9P
RL: PREP (Preparation)
(preparation of, as additive for photog. retouchable mat films with high covering power)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 96 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:546535 CAPLUS
DN 115:146535
TI Silver halide photographic materials
IN Sanpei, Takeshi; Sai, Yoshiho; Ogasawara, Akira; Hara, Yoji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03037642	A2	19910219	JP 1989-173393	19890704 <--
PRAI JP 1989-173393		19890704		

OS MARPAT 115:146535
GI For diagram(s), see printed CA Issue.
AB In photog. materials having Ag halide emulsion layer(s), the emulsion layers, or layers adjacent to the emulsion layers, contain compds. R1(NR2)nC(:Y)NHR3NHNHC(:O)C(:O)R4 (R1-2 = H, aliphatic, aromatic or heterocyclic group; R3 = divalent aromatic group; R4 = alkoxy, amino; Y = S, O; n = 0, 1) or R1R2NNR3C(:Y)NHR4NHNHC(:O)R5 (R1-3 = H, aliphatic, aromatic, heterocyclic group, alkoxy, aryloxy; R4 = divalent aromatic group; R5 = alkyl, alkoxy, amino; Y = S, O), and I (R1 = alkyl; Z = 5-6-membered heterocyclic ring; Q = 5-membered heterocyclic ring; m = 1, 2). These materials for platemaking with exposure by laser scanners are safely handled under yellow light, have high sensitivity to Ar laser, and provide high contrast and good halftone images.
IT 123852-45-9
RL: USES (Uses)
(photog. films for laser-scanning platemaking containing)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 97 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:523757 CAPLUS
DN 115:123757
TI Silver halide photographic materials
IN Ogasawara, Akira; Sanpei, Takeshi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02291547	A2	19901203	JP 1989-109805	19890429 <--
PRAI JP 1989-109805		19890429		

OS MARPAT 115:123757
GI



AB The title materials comprise ≥1 silver halide emulsion layer on a support. Until phys. ripening time, grains which do not have twinning planes are formed. and, after desalting, the pAg value is set to ≥9.0. The said emulsion layer contains ≥1 compound selected from carboxylic acid hydrazides I (R1, R2 = aryl, heterocyclyl; R = organic linking group; n = 0-6; m = 0 or 1), R21P1NNP2COCOR22 [R21 = aliphatic group, heterocyclyl; R22 = H, (substituted) alkoxy, amino, etc.; P1, P2 = H, acyl, sulfinic acid], and ArNHNHCOR31 [Ar = aryl with ≥1 diffusion-resistant group or group promoting silver halide adsorption; R31 = substituted alkyl]. The use of the title materials provide images with high contrast. Compound II is an example of I.
IT 134978-84-0
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. material containing)
RN 134978-84-0 CAPLUS
CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 97 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 98 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:502731 CAPLUS

DN 115:102731

TI Silver halide photographic materials

IN Ogasawara, Akira; Sanpei, Takeshi

PA Konica Co., Japan

SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02287534	A2	19901127	JP 1989-109955	19890428 <--
PRAI	JP 1989-109955		19890428		

OS MARPAT 115:102731

GI



AB The title materials comprise >1 silver halide emulsion layer on a support. The size of the silver halide grains in the said emulsion layer is ≤1 μm. The silver halide in the said emulsion layer is either silver bromide or silver iodide. The said emulsion layer contains ≥1 compound selected from compds. I (R1, R2 = aryl, heterocyclyl; R = organic linking group; n = 0-6; m = 0 or 1), R21P1NNP2COCOR22 [R21 = aliphatic group; aryl, heterocyclyl; R22 = H, (substituted) alkoxy, etc.; P1, P2 = H, acyl, sulfinic acid group], and ArNHNHCOR31 (Ar = aryl containing ≥1 diffusion-resistant group or group for promoting silver halide adsorption; R31 = substituted alkyl). The title materials show high contrast. Compound II is an example of I.

IT 134978-84-0
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. material containing)

RN 134978-84-0 CAPLUS

CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 98 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 99 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:460717 CAPLUS

DN 115:60717

TI High-contrast silver halide photographic material

IN Hirabayashi, Kazuhiko; Sampei, Takeshi; Hara, Yoji; Sai, Miho

PA Konica Co., Japan

SO Eur. Pat. Appl., 67 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 382455	A1	19900816	EP 1990-301187	19900205 <--
	R: DE, GB, IT, NL				
	CA 2009401	AA	19900807	CA 1990-2009401	19900206 <--
	US 1281	H1	19940104	US 1990-475966	19900206 <--
	JP 02289843	A2	19901129	JP 1990-27849	19900207 <--
	JP 2835634	B2	19981214		
PRAI	JP 1989-29385	A	19890207		

OS MARPAT 115:60717

AB A Ag halide photog. material which is capable of rapidly and consistently producing high-contrast and low-fog images contains ≥1 compound selected from the group of compds. represented by the formulas (X)m(CONHNHR1)(CO)nNHNHR2, R3R4NN(R5)COCOR6, and R7R8NNHCOR9 (R1, R2 = aryl or a heterocyclic group; X = an organic linkage; m = 0-6; n = 0 or 1; R3 = an aliphatic, aromatic, or heterocyclic group R4, R5 = H, aryl, or a sulfinic acid group; R6 = H, alkoxy, aryloxy, amino, or heterocyclicoxy; R1 = aryl containing ≥1 nondiffusing group or Ag halide adsorption-accelerating group; R8 = alkyl, alkoxy, or amino; R9 = H or an organic group) and ≥1 compound represented by the formula R10O(CH2CH2O)pH (R10 = H or an aromatic group; p = an integer of 10-200). The photog. material thus disclosed provides characters and contrasty halftone images in photomech. fabrication.

IT 134978-84-0
RL: USES (Uses)
(high-contrasts silver halide photograph. materials containing polyoxyethylenes and, for photomech. processes)

RN 134978-84-0 CAPLUS

CN Acetic acid, trifluoro-, 1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-2-[[[2-(methylthio)ethyl]thio]acetyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 99 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 100 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:217984 CAPLUS
DN 114:217984
TI Silver halide photographic material
IN Sampei, Takeshi; Ogasawara, Akira; Sai, Miho; Hara, Yoji
PA Konica Co., Japan
SO Eur. Pat. Appl., 74 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 399847	A2	19901128	EP 1990-305757	19900525 <--
	EP 399847	A3	19930203		
	R: DE, GB, IT				
	JP 02310555	A2	19901226	JP 1989-133892	19890525 <--
	JP 2791797	B2	19980827		
	JP 03036540	A2	19910218	JP 1989-172575	19890703 <--
	JP 03036541	A2	19910218	JP 1989-172577	19890703 <--
	CA 2016774	AA	19901125	CA 1990-2016774	19900515 <--
	US 5130226	A	19920714	US 1991-758206	19910912 <--
PRAI	JP 1989-133892	A	19890525		
	JP 1989-172575	A	19890703		
	JP 1989-172577	A	19890703		
	US 1990-523390	B1	19900515		

OS MARPAT 114:217984
GI



I

AB In a Ag halide photog. material, the photog. emulsion layer or an adjacent layer contains a compound having the formula R1NHNHOCR(CO)mNHNHR2, R3NR4NR5COCOR6, or R7NHNHCoR8 and a compound having the formula I [R1, R2 = aryl or heterocyclyl; R = a divalent organic group; m = 0 or 1; R3 = an aliph, aromatic or heterocyclic group; R6 = H, alkoxy, heterocyclic oxy, amino, or aryloxy; R4, R5 = H, acyl, or a sulfinic acid group; R7 = an aryl group containing an antidiffusion group or an absorption-accelerating group; R8 = alkyl; R9, R10 = H, halogen, or alkyl; R11 = OR9 or R15; R12-15 = R9, alkoxy, carboxyl, carboxyalkyl, hydroxyalkyl, hydroxyalkoxyalkyl, sulfo, amidoalkyl, amidophenyl, imidoalkyl, or nitrilo]. The photog. emulsion is capable of producing high-contrast half-dot images.

IT 123852-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, in photog. material)

RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino

L9 ANSWER 100 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 101 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:217941 CAPLUS
DN 114:217941
TI Rapid processing of cyan stain-suppressed color photographic material
IN Kawamura, Tomonori; Koboshi, Shigeharu
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02110455	A2	19900423	JP 1988-264890	19881019 <--
PRAI	JP 1988-264890		19881019		

GI



I II



III

AB The title processing is carried out of a color photog. material containing ≥1 cyan couplers (I), (II) [R1 = alkyl, alkenyl, aryl, heterocyclyl; Y = CONR2R3, SO2R2, C(S)NR2R3, SO2NR2R3, CONHCOR2, CONHSO2R2 (R2 = alkyl, alkenyl, aryl, heterocyclyl; R3 = H, R2); Z = H, group releasable on coupling with oxidized color developing agent], and (III) [R1 = CONR4R5, NHCOR4, NHCO2R6, NHSO2R6, NHCONR4R5; R2 = univalent group; R3 = substituent; X = H, group releasable on reacting with oxidized color developing agent; l = 0, 1; m = 0-3; R4, R5 = H, aromatic, aliphatic, heterocycle; R6 = aromatic, aliphatic, heterocyclic] by using a bleach-fixing solution containing the salts of ≥1 Fe3+ complexes of compds. selected from (A1CH2)(A2CH2)NXN(CH2A3)(CH2A4) [A1-4 = CH2OH, CO2M, PO3M1M2 (M, M1, M2 = H, Na, K, NH4) X = C3-6 alkylene] and (A1CH2)(A12CH2)N(B1-O)nB2N(CH2A3)(CH2A4) [A1-4 = same as above; n = 1-8; B1, B2 = C2-5 alkylene] and a thiosulfate ≥1.0 mol/L.

IT 115127-97-4 130900-72-0
RL: USES (Uses)
(cyan coupler, stain-free photog. materials containing)

RN 115127-97-4 CAPLUS
CN Benzamide, N-dodecyl-4-[2-[[3-hydroxy-4-[[[[4-(1-oxopropyl)-2-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-2-oxoethoxy]-(9CI) (CA INDEX NAME)

L9 ANSWER 101 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 130900-72-0 CAPLUS
CN Benzamide, 4-[[[[4-[[[2,4-bis(1,1-dimethylethyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L9 ANSWER 102 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 102 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:132997 CAPLUS
DN 114:132997
TI Silver halide color photographic material
IN Kim, Kwang Tae; Kim, Young Soo; Kim, Jin Youl
PA Cheil Synthetic Textiles Co., Ltd., S. Korea
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4933465	A	19900612	US 1988-292536	19881230 <--
PRAI US 1988-292536		19881230		

OS CASREACT 114:132997; MARPAT 114:132997
GI



I

AB A Ag halide color photog. material contains, in a green-sensitive emulsion layer, a magenta coupler having the general formula I (R1 = halogen; R2 = H or halogen; R3 = C1-8 alkyl; Z1 = NH or NHCO; Z2 = Z5CONH or (Z6)dNHCO; Z3 = C1-8 alkylene; Z4 = O, S, or SO2; Z5 = C1-8 alkylene or phenylene; Z6 = C1-4 alkylene or phenylene; a = 0, 1, 2 or 3; b,d = 1, 2, or 3; c = 0, 1 or 2). The magenta coupler-containing photog. material produces no fog during storage and has high color-forming efficiency, excellent color reproduction, high sensitivity, and good weather resistance. The magenta images provided by the coupler have excellent color tone and fastness.
IT 129929-52-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as magenta photog. coupler)
RN 129929-52-8 CAPLUS
CN Benzamide, N-[4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]-3-[[4-[[[4-(1,1-dimethylpropyl)phenoxy]acetyl]amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 103 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:581264 CAPLUS
DN 113:181264
TI High-contrast photographic material
IN Takamukai, Yasuhiko; Fukawa, Junichi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02000051	A2	19900105	JP 1988-3582	19880111 <--
PRAI JP 1987-264231	A1	19871020		

AB A high-contrast photog. material, which contains a hydrazine derivative, Ag halide grains, and a compound whose maximum absorption is at least 50 nm longer than that of the grains, is exposed with a light beam having a maximum absorption at 390-430 nm. The photog. material may contain a desensitizer and/or a UV absorber.
IT 129879-83-0
RL: USES (Uses)
(photog. film containing)
RN 129879-83-0 CAPLUS
CN Ethanedioic acid, bis[2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 104 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:477848 CAPLUS
DN 113:77848
TI Antitumor compounds. III. Synthesis of derivatives of analogs of sulfanilamide
AU Zheng, Yiya; Wang, Peizi; Chen, Haiying; Pan, Qichao
CS Dep. Chem., Zhongshan Univ., Canton, Peop. Rep. China
SO Zhongshan Daxue Xuebao, Ziran Kexueban (1989), 28(4), 124-7
CODEN: CHTHAJ; ISSN: 0529-6579
DT Journal
LA Chinese
AB Four of the 8 title compds. prepared showed strong inhibiting effect on CNE2.
IT 128720-86-5P 128720-91-2P 128720-92-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antitumor activity of)
RN 128720-86-5 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[[4-[[(2,4-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 128720-91-2 CAPLUS
CN Acetamide, N-[4-[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]-2-(2,4,5-trichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 128720-92-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 104 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 128720-87-6P 128720-88-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 128720-87-6 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(2,4-dichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 128720-88-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(2,4,5-trichlorophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 105 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:468290 CAPLUS
DN 113:68290
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Ishii, Fumio; Uchida, Taku; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01253742	A2	19891011	JP 1988-81769	19880401 <--
PRAI JP 1988-81769		19880401		

OS MARPAT 113:68290
GI



I



II

AB The claimed photog. material having >1 Ag halide emulsion layer on the support contains in >1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = aryl; R1 = alkyl, aryl; R2 = H, alkyl, aryl; R3 = H, alkyl; R4 = substituent other than hydrocarbon residue). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical 3-step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128362-43-6 128362-49-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128362-43-6 CAPLUS
CN Acetic acid, [2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, 1-[(butylamino)sulfonyl]ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 105 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128362-49-2 CAPLUS
CN Benzoic acid, 4-[[[[[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-hydroxy-5-[2-(nitrophenylmethoxy)-2-oxoethoxy]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 106 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:468289 CAPLUS
DN 113:68289
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01253741	A2	19891011	JP 1988-81768	19880401 <--
PRAI JP 1988-81768		19880401		

OS MARPAT 113:68289
GI



I



II

AB The claimed photog. material having ≥1 Ag halide emulsion layer on the support contains in ≥1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = CR3R4R5; R2-5 = alkyl, aryl; R1 = aryl). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128197-77-3 128313-93-9
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128197-77-3 CAPLUS
CN Acetic acid, [5-[[[(4-chloro-3-cyanophenyl)amino]carbonyl]amino]-2-[[(2,4-di-tert-nonylphenoxy)acetyl]amino]-4-hydroxyphenoxy]-, 1-(cyanomethyl)-1-ethylpropyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 106 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128313-93-9 CAPLUS
CN Acetic acid, [5-[[[[4-(ethylsulfonyl)phenyl]amino]carbonyl]amino]-2-[[[4-(hexadecyloxy)phenoxy]acetyl]amino]-4-hydroxyphenoxy]-, 1,1-diethylpropyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Me

L9 ANSWER 107 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:468288 CAPLUS
DN 113:68288
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Ishii, Fumio; Uchida, Taku; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01253740	A2	19891011	JP 1988-81767	19880401 <--
PRAI JP 1988-81767		19880401		

OS MARPAT 113:68288
GI



I



II

AB The claimed photog. material having >1 Ag halide emulsion layer on the support contains in >1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = aryl; R1 = alkyl, aryl; R2 = H, alkyl; R3 = substituent). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128314-01-2 128314-03-4 128314-18-1
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128314-01-2 CAPLUS
CN Acetic acid, [2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-4-hydroxy-5-[[[[4-(methylsulfonyl)phenyl]amino]carbonyl]amino]phenoxy]-, 2-(methylsulfonyl)ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 107 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128314-03-4 CAPLUS
CN Acetic acid, [5-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-4-hydroxy-2-[[(3-pentadecylphenoxy)acetyl]amino]phenoxy]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 128314-18-1 CAPLUS
CN Benzoic acid, 4-[[[[5-[2-[2-[(1-carboxytridecyl)thio]ethoxy]-2-oxoethoxy]-4-[[[2-chloro-4-(1,1,3,3-tetramethylbutyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]amino]carbonyl]amino]-, 1-methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 107 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L9 ANSWER 108 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:431805 CAPLUS

DN 113:31805

TI Silver halide photographic materials containing cyan dye couplers

IN Miura, Akio; Uchida, Taku; Ishii, Fumio; Tsuruta, Mayumi

PA Konica Co., Japan

SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01253743	A2	19891011	JP 1988-81770	19880401 <--
PRAI	JP 1988-81770		19880401		

OS MARPAT 113:31805

GI



I



II

AB The title materials comprise Ag halide emulsion layers containing cyan couplers I [R1 = (substituted) alkyl, aryl; R2, R3 = (substituted) aryl; J = NH, O] for improved sensitivity and rapid processability. Thus, a Ag halide emulsion containing 0.03 mol equivalent II was prepared, exposed, and processed to show 105% relative sensitivity and 1.06 maximum image d. vs. 100% and 0.95, resp., for a control containing a conventional coupler.

IT 127828-11-9
RL: TEM (Technical or engineered material use); USES (Uses)
(cyan photog. coupler, for high-sensitivity and high-color-rendition films)

RN 127828-11-9 CAPLUS

CN Acetic acid, [2-[[[2-chloro-4-(1,1,3,3-tetramethylbutyl)phenoxy]acetyl]amino]-5-[[[[4-[[2-(dimethylamino)ethyl]thio]phenyl]amino]carbonyl]amino]-4-hydroxyphenoxy]-, 3-cyanophenyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 108 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 109 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:235954 CAPLUS

DN 112:235954

TI Studies of some newer polyamides as possible polymers for membranes. Part 1

AU Shukla, J. S.; Dixit, S. K.

CS Dep. Chem., Lucknow Univ., Lucknow, India

SO Journal of Macromolecular Science, Chemistry (1990), A27(3), 381-4
CODEN: JMCHBD; ISSN: 0022-233X

DT Journal

LA English

AB Nitrobenzoyl chlorides were condensed with nitrobenzhydrazides, and the resulting N-(nitrobenzoyl)-nitrobenzhydrazides were reduced to N-(aminobenzoyl)-aminobenzhydrazides, and then polymerized with either terephthaloyl chloride, isophthaloyl chloride, 1,4-phenylenedioxydiacetyl chloride, or 1,3-phenylenedioxydiacetyl chloride. The polymers were soluble in polar organic solvents, but were insol. in nonpolar organic solvents.

IT 127328-52-3P 127328-53-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and solubility characteristics of)

RN 127328-52-3 CAPLUS

CN Poly[oxy-1,3-phenyleneoxy(2-oxo-1,2-ethanediyl)imino-1,4-phenylenecarbonylhydrazocarbonyl-1,4-phenyleneimino(1-oxo-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 127328-53-4 CAPLUS

CN Poly[oxy-1,4-phenyleneoxy(2-oxo-1,2-ethanediyl)imino-1,4-phenylenecarbonylhydrazocarbonyl-1,4-phenyleneimino(1-oxo-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

L9 ANSWER 109 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 110 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:226690 CAPLUS
DN 112:226690
TI High-contrast silver halide photographic materials
IN Ishii, Fumio; Usagawa, Yasushi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01298345	A2	19891201	JP 1988-129885	19880526 <--
PRAI JP 1988-129885		19880526		

OS MARPAT 112:226690
GI



I



II

AB Photog. materials contain I (R1 = substituent; n = 0-4; R2 = H, alkyl, aryl, heterocyclyl; X = CO, sulfonyl, sulfoxy, -OPO(OR3)-, NH; Y = OH, NH2, CO2H, SH). These high-contrast materials have low fog and are suitable for halftone imaging. Thus, a sensitized Ag(Cl,Br) emulsion containing 0.5 mmol II/mol Ag and other usual agents was applied on PET base simultaneously with a protective layer. Normal exposure and processing gave high-quality halftone image without significant fog.

IT 126888-48-0
RL: USES (Uses)
(silver halide photog. films containing, for high contrast and low fog)

RN 126888-48-0 CAPLUS
CN Acetic acid, (phenylthio)-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 110 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 111 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:207788 CAPLUS
DN 112:207788
TI Silver halide photographic material containing cyan coupler for sensitivity and maximum color density
IN Miura, Akio; Ishii, Fumio; Uchida, Taku; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01219749	A2	19890901	JP 1988-45525	19880227 <--
PRAI JP 1988-45525		19880227		

OS MARPAT 112:207788
GI



I



II



III



IV

AB In the material having ≥1 Ag halide emulsion layer, the layer has a cyan coupler I [X = halo; R1 = (substituted) alkyl, aryl; R2, R3 = H, (substituted) alkyl, aryl; R2 ≠ R3 = H; R4 = (substituted) alkyl, alkenyl, aryl; n, m = 0-5; 1 ≤ n + m ≤ 5]. II was prepared from III and IV. A photog. emulsion layer containing cyan dye and II gave a photog. image with relative sensitivity and maximum color d. The coupler prevents decoloration of the cyan dye to a bleaching solution

IT 127024-90-2
RL: USES (Uses)
(cyan coupler, in photog. material, for high sensitivity and color d.)

RN 127024-90-2 CAPLUS

L9 ANSWER 111 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Propanoic acid, 2-[2-[[[2,4-bis(1,1,3,3-tetramethylbutyl)phenoxy]acetyl]amino]-5-[[[(3-chloro-4-cyanophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 112 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:207765 CAPLUS
DN 112:207765
TI Silver halide color photographic material containing photographic useful group-releasing compound
IN Ichijima, Yasushi; Sakagami, Megumi
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01221743	A2	19890905	JP 1988-47231	19880229 <--
	JP 2559247	B2	19961204		
PRAI	JP 1988-47231		19880229		

AB The title color photog. material contains a photog. useful group-releasing compound in which the photog. useful group is released by reacting ≥3-oxidized developers. The photog. useful group-releasing compound may be a development inhibitor-releasing coupler.
IT 126920-78-3
RL: USES (Uses)
(development inhibitor-releasing coupler)
RN 126920-78-3 CAPLUS
CN Benzoic acid, 4-[5-[[1-[[4-[2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[[(4-cyanophenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-2,5-dimethylphenoxy]methyl]-2,5-diphenyl-1H-imidazol-4-yl]thio]-1H-tetrazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 112 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L9 ANSWER 113 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:188916 CAPLUS
DN 112:188916
TI Silver halide color photographic materials with phenolic cyan couplers
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01253739	A2	19891011	JP 1988-81766	19880401 <--
PRAI	JP 1988-81766		19880401		

GI



I



II

AB Cyan couplers I are contained in the title materials [X = -CHR1R2; R1 = H, (cyclo)alkyl; R2 = (cyclo)alkyl, alkenyl, aryl, heterocyclyl; R1-2 are not substituted when both are Me; sum of number of C atoms in R1-2 is ≥2 when these are either alkyls or an alkyl and H; R1-2 may jointly form a ring with a :CH group; A = (substituted) alkyl; B = (substituted) alkyl or aryl]. These couplers provide cyan image with high sensitivity and d., with small loss of dye when exhausted bleach-fix is used in processing. Thus, polyester base was coated with a red-sensitive Ag(I,Br) emulsion mixed with coupler II and other reagents, exposed, and processed using fresh bleach-fix containing Fe EDTA ammonium salts or using that simulating exhausted condition. Cyan image d. was 1.00 and 0.95, resp., for these bleach-fix solns.
IT 126391-52-4 126391-64-8 126430-99-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler, for high sensitivity and low dye loss by exhausted bleach-fix)
RN 126391-52-4 CAPLUS
CN Pentanoic acid, 4-[[[2-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-[[[[2-[(butylamino)carbonyl]phenyl]amino]carbonyl]amino]-4-hydroxyphenoxy]acetyl]oxy]-, octyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 113 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—Me

RN 126391-64-8 CAPLUS
CN Acetic acid, [2-[[[2,4-bis(1,1,3,3-tetramethylbutyl)phenoxy]acetyl]amino]-5-[[[[4-(butylsulfonyl)phenyl]amino]carbonyl]amino]-4-hydroxyphenoxy]-, cyclohexyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 113 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—CMe3

RN 126430-99-7 CAPLUS
CN Benzoic acid, 4-[2-[[4-[[[[3-[(diethoxyphosphinyl)amino]phenyl]amino]carbonyl]amino]-5-hydroxy-2-[2-(octyloxy)-2-oxoethoxy]phenyl]amino]-2-oxoethoxy]-, hexadecyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 113 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

— $(CH_2)_{15}$—Me

L9 ANSWER 114 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:148949 CAPLUS
DN 112:148949
TI High-contrast development
IN Takamukai, Yasuhiko; Fukawa, Junichi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01179942	A2	19890718	JP 1988-3580	19880111 <--
JP 2564158	B2	19961218		
PRAI JP 1988-3580		19880111		

AB A Ag halide photog. material containing (R)n(CONHNHR1)[(CO)nNHNHR2] [R1, R2 = aryl, heterocyclyl, oxy group, amino, aryloxy; P1, P2 = H, acyl, sulfinic acid], or ArNHNHCOR31 [Ar = aryl group with an anti-diffusion group or Ag halide-adsorption promoter; R31 = substituted alkyl group], is developed in the presence of Y(SL1(J1)K(L2)l(Z)m(L3)n(J2L4)p(G)q]r [L1-L4 = divalent hydrocarbons; J1, J2 = O, CCO, CONR41, SO2NR42, NR42, CO, NR43, SO2, N:N NR42, CO; Y = H, divalent bond, etc.; Z = heterocyclyl; G = sulfonic acid, carboxyl, phosphoric acid groups; R42, R43 = H, alkyl, aryl; k, l, m, n = 0-2; when G = carboxyl, m = 1/2; when Y = divalent bond, r = 2]. High-contrast dot image can be obtained.
IT 122290-00-0
RL: USES (Uses)
(stabilizer, photog. material containing, for high-contrast development)
RN 122290-00-0 CAPLUS
CN Acetic acid, (methylthio)-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 115 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:88184 CAPLUS
DN 112:88184
TI Color photographic material containing phenolic cyan coupler
IN Tsuruta, Mayumi; Uchida, Taku; Miura, Akio; Ishii, Fumio
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01201657	A2	19890814	JP 1988-26974	19880208 <--
PRAI	JP 1988-26974		19880208		

GI



I



II

AB The title material contains a cyan coupler I [R1 = (substituted) alkyl, aryl; R2 = monovalent organic group ; R2 may be different; R3-4 = H, (substituted) alkyl, acyl, alkylsulfonyl, arylsulfonyl; R3-4 may form a ring; J = divalent linking group; m = 1-4]. The material gives an image with high sensitivity and high color d. in using a fatigued bleaching bath. Thus, a red-sensitive Ag(Br,I) emulsion containing a cyan coupler II was applied onto a polyester support to give the title material.
IT 125164-48-9 125181-20-6
RL: USES (Uses)
(cyan coupler, for silver halide photog. emulsion)
RN 125164-48-9 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[[[[3-cyano-4-(methylsulfonyl)phenyl]amino]carbonyl]amino]-2-[[2-[[2-(dimethylamino)ethyl]methylamino]ethyl]thio]-5-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 115 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 125181-20-6 CAPLUS
CN Acetamide, N-[4-[[[(3,4-dichloro-5-cyanophenyl)amino]carbonyl]amino]-2-[[3-(dihexylamino)propyl]thio]-5-hydroxyphenyl]-2-(3-pentadecylphenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 116 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:88126 CAPLUS
DN 112:88126
TI Rapid processing method for production of high-contrast images
IN Takamuki, Yasuhiko; Habu, Takeshi; Fukawa, Junichi
PA Konica Co., Japan
SO Eur. Pat. Appl., 93 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 324391	A2	19890719	EP 1989-100221	19890107 <--
	EP 324391	A3	19901227		
	R: DE, GB, IT, NL				
	JP 01179930	A2	19890718	JP 1988-3583	19880111 <--
	JP 02000052	A2	19900105	JP 1988-3576	19880111 <--
	JP 02000040	A2	19900105	JP 1988-3579	19880111 <--
	US 4988603	A	19910129	US 1988-287438	19881221 <--
PRAI	JP 1988-3576	A	19880111		
	JP 1988-3579	A	19880111		
	JP 1988-3583	A	19880111		
	JP 1987-249317	A1	19871001		
	JP 1987-261230	A1	19871015		

AB A rapid photog. processing method for providing images of high contrast and high dot quality with little degradation in sensitivity comprises developing a Ag halide photog. material having a Ag halide emulsion layer containing a 3-pyrazolidone derivative and a di- or trihydroxybenzene derivative by a developer containing a di- or trihydroxybenzene derivative, a sulfite, an amino compound in the presence of a compound having the formula (Z)n(CONHNHR1)(CO)mNHNHR2, R3NR4NR5COCOR6, or R7NHNHCOR8 [Z = a divalent organic group; n = an integer of 0-6; R1, R2 = aryl, heterocycle; m = 0, 1; R3 = an aliphatic group, an aromatic group, heterocyclyl; R4, R5 = H, acyl, a sulfinic acid group; R6 = H, alkoxy, amino, aryloxy, heterocyclyl; R7 = an aryl group containing a non-diffusible group or a Ag halide adsorption accelerating group; R8 = (substituted)alkyl]. The photog. processing method provides high-contrast images which are used for the formation of character images or color separation halftone dot images in photomech. process.
IT 123852-45-9
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing, for high-contrast image formation)
RN 123852-45-9 CAPLUS
CN Acetic acid, (methylamino)oxo-, 2-[4-[[[4-[[(ethylamino)thioxomethyl]amino]phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 116 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 117 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:66620 CAPLUS
DN 112:66620
TI Silver halide photographic light-sensitive material capable of obtaining high contrast images
IN Usagawa, Yasushi; Ishii, Fumio
PA Konica Co., Japan
SO Eur. Pat. Appl., 50 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 331096	A2	19890906	EP 1989-103459	19890228 <--
	EP 331096	A3	19910109		
	EP 331096	B1	19951004		
	R: DE, GB				
	JP 02000947	A2	19900105	JP 1988-314543	19881213 <--
	US 4977063	A	19901211	US 1989-317719	19890302 <--
PRAI	JP 1988-50214	A	19880303		
	JP 1988-314543	A	19881213		

GI



I

AB Ag halide photog. materials capable of producing high-contrast, halftone images that are free of pepper spots contain ≥1 Ag halide emulsion layer containing therein a hydrazine derivative of the formula R1R2N(CO)nNR3(ZZ1)mZ2NR4NR5R6 (R1, R2 = H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or NH2, and when n = 1 then ≥1 is an NH2 group; R3 = H or alkyl; R4, R5 = H or a substituent; R6 = CHO, acyl, sulfonyl, carbamoyl, sulfamoyl, alkoxycarbonyl, thioacyl, or COCOR7 where R7 = NR8R9 or OR10 and where R8, R9 = H, alkyl, alkenyl, alkynyl, heterocyclyl, OH, alkoxy, alkenyloxy, alkynyloxy, aryloxy, or heterocyclyloxy; R10 = H, alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; Z, Z2 = arylene or heterocyclylene; Z = a linking group; n = 1 or 2; m = 0 or 1). Thus, a high-contrast photog. material prepared with I in the gelatin-Ag(Br,Cl) emulsion layer gave images with excellent halftone dot quality and no pepper spots.
IT 125087-82-3
RL: DEV (Device component use); USES (Uses)
(lith photog. films containing, for high-contrast images)
RN 125087-82-3 CAPLUS
CN Hydrazinecarboxamide, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-N-[4-(2-formylhydrazino)phenyl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 117 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—Et

L9 ANSWER 118 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:644135 CAPLUS
DN 111:244135
TI High-contrast negative image formation with improved storage stability of silver image
IN Taguchi, Masaaki
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01063959	A2	19890309	JP 1987-221750	19870903 <--
PRAI	JP 1987-221750		19870903		

GI



I

AB A Ag halide photog. material containing a contrast-enhancing hydrazine derivative is treated with a solution containing a derivative with a Ag stability constant ≥9. I was used as an example of above hydrazine derivative
IT 77887-29-7
RL: USES (Uses)
(photog. treatment solution containing, for high-contrast neg. image formation)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 119 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:564131 CAPLUS
DN 111:164131
TI Silver halide photographic materials providing high contrast images
IN Hanyu, Takeshi; Yorozudo, Hidetoshi
PA Konica Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01086134	A2	19890330	JP 1987-170426	19870708 <--
	JP 07082220	B4	19950906		
PRAI	JP 1987-123448	A1	19870520		

AB Ag halide photog. materials providing high contrast images, having ≥1 Ag halide emulsion layer, contain a hydrazine compound RNHNHCOZm(CO)nNHNHR1 (I; R, R1 = aryl, heterocycle; Z = organic divalent group; m = 0-6; n = 0, 1). Thus, a PET film was coated with a Ag(Cl,Br) emulsion layer containing I (R = R1 = C6H4Me-p; Z = CH2; m = n = 1) and with a protective layer on the front side and then coated with a backcoat layer and with a protective layer on the back side to give a photosensitive film giving high contrast images with good dot-quality.
IT 123084-60-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. material containing, for high contrast image)
RN 123084-60-6 CAPLUS
CN 1,2,3-Propanetricarboxylic acid, tris[2-[4-[[[4-(1,1-dimethylethyl)phenoxy]acetyl]amino]phenyl]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 119 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



L9 ANSWER 120 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

—Et

RN 122809-72-7 CAPLUS
CN Acetamide, 2-[4-[[[[3-[2,4-bis(1,1-dimethylpropyl)phenoxy]propyl]amino]carbonyl]amino]phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 120 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:543955 CAPLUS
DN 111:143955
TI Silver halide photographic material containing hydrazine nucleating agent
IN Yagihara, Morio; Okada, Hisashi
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63306438	A2	19881214	JP 1987-143469	19870609 <--
JP 06100796	B4	19941212		
PRAI JP 1987-143469		19870609		

AB The title photog. material comprises ≥1 photosensitive Ag halide emulsion layer, and a hydrazine derivative of the formula ArN(A1)N(A2)GR [1 of A1 and A2 is H, and the other is a sulfinic acid moiety or acyl group; or both of A1 and A2 are H; R = H, alkyl, aryl, alkoxy, aryloxy, amino; G = carbonyl, sulfonyl, sulfoxy, phosphoryl iminomethylene; Ar = R1(OR2)nOR3C(O)NR4- or R1(OR2)nOR3SO2NR4-substituted aryl (R1 = H, aliphatic moiety, aromatic moiety, heterocyclyl; R2, R3 = linking group, and ≥1 of those is an arylene group; R4 = H, aliphatic group, aromatic group; n ≥ 1)] is contained in the photog. emulsion layer and/or ≥1 other photog. layer.
IT 122788-56-1 122809-72-7
RL: USES (Uses)
(photog. nucleating agent)
RN 122788-56-1 CAPLUS
CN Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[2-[[4-(2-formylhydrazino)phenyl]amino]-2-oxoethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 121 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:505682 CAPLUS
DN 111:105682
TI High-contrast silver halide photographic light-sensitive material
IN Habu, Takeshi; Uesawa, Yutaka; Usagawa, Yasushi; Ishii, Fumio; Kida, Shuji
PA Konica Co., Japan
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 311009	A2	19890412	EP 1988-116392	19881004 <--
EP 311009	A3	19900314		
R: DE, GB, IT, NL				
JP 02000037	A2	19900105	JP 1987-336565	19871231 <--
JP 08033604	B4	19960329		
JP 01230038	A2	19890913	JP 1988-251545	19881005 <--
PRAI JP 1987-250909	A	19871005		
JP 1987-336565	A	19871231		

AB A high-contrast photog. material contains a hydrazine derivative of the formula R1(NR2)nC(Y)NR3R4LR5NHNHCOCOX [R1, R2 = H, alkyl, Ph, naphthyl, cyclohexyl, pyridyl or pyrrolidinyl; R3 = H, PhCH2, alkoxy, alkyl; R4, R5 = divalent aromatic group; X = NR6R7, OR8; R6-R8 = H, alkyl, Ph, naphthyl; Y = S, O; L = linkage group; n = 0, 1] and/or ArNHNHCOR [Ar = aryl containing ≥1 ballast group and/or ≥1 group accelerating absorption on the Ag halide; R = alkyl]. The photog. material can be prepared by contact treatment with the above compds.
IT 122290-00-0
RL: USES (Uses)
(high-contrast photog. material containing)
RN 122290-00-0 CAPLUS
CN Acetic acid, (methylthio)-, 2-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 122 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:439195 CAPLUS
DN 111:39195
TI Preparation of [(phenoxy- and pyridyloxy)phenoxy]alkanoates as herbicides
IN Fukami, Harukazu; Higuchi, Naoki; Kawaguchi, Naoko; Hashimoto, Masaki; Ide, Kinya; Takahashi, Toshio
PA Suntory, Ltd., Japan; Shionogi and Co., Ltd.
SO Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 303415	A2	19890215	EP 1988-307276	19880805 <--
	EP 303415	A3	19891220		
	EP 303415	B1	19941130		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01042466	A2	19890214	JP 1987-199040	19870811 <--
	JP 2507461	B2	19960612		
	JP 01042464	A2	19890214	JP 1987-199041	19870811 <--
	JP 07096543	B4	19951018		
	JP 01110648	A2	19890427	JP 1987-266563	19871023 <--
	JP 2566991	B2	19961225		
	JP 01175967	A2	19890712	JP 1988-10	19880104 <--
	JP 2553122	B2	19961113		
	CA 1257598	A1	19890718	CA 1988-573866	19880804 <--
	ES 2068830	T3	19950501	ES 1988-307276	19880805 <--
	AU 8820469	A1	19890216	AU 1988-20469	19880808 <--
	AU 616676	B2	19911107		
	ZA 8805885	A	19891129	ZA 1988-5885	19880810 <--
	US 4976773	A	19901211	US 1988-230481	19880810 <--
	BR 8804062	A	19890307	BR 1988-4062	19880811 <--
PRAI	JP 1987-199040	A	19870811		
	JP 1987-199041	A	19870811		
	JP 1987-266563	A	19871023		
	JP 1988-10	A	19880104		

OS MARPAT 111:39195
GI



I

AB The title compds. [I; A = (un)substituted phenoxyphenyl, pyridyloxyphenyl, sulfamylphenyl, etc.; Q1 = CH, N; R = H, Cl-5 alkyl; X = H, halo, CF3, NO2; Y = H, halo; Z = O, NH] were prepared 4-ClC6H4Br was heated at 160-200° for 3 h with 4-(HO)C6H4OMe, KOH, and Cu powder and the product stirred 2 h with BBr3 in CH2Cl2 to give 4-(4-ClC6H4O)C6H4OH which was heated with BrCHMeCO2H in aqueous KOH to give, after SOCl2 treatment, 4-(4-ClC6H4O)C6H4OCHMeCOCl. The latter was stirred 2 h with AlOH [A1 = 4-{4-(O2N)C6H4O}C6H4] (preparation given) in THF containing Et3N to give I (A = A1, Q1 = CH, R = Me, X = Cl, Y = H, Z = O). I (A = phenoxyphenyl group Q2, Q1 = N, R = Me, X = CF3, Y = Cl, Z = O) gave complete kill of Echinochloa crus-galli, Digitaria ciliaris, Polygonum lapathifolium, and Amaranthus viridis at 20 g/a post-emergence.
IT 121332-38-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 121332-38-5 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-[4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 123 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:202763 CAPLUS
DN 110:202763
TI Silver halide photosensitive materials with improved dot growing ability for room light use
IN Hanyu, Takeshi; Nagashima, Toshiharu
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63314536	A2	19881222	JP 1987-152344	19870617 <--
PRAI	JP 1987-152344		19870617		

GI



I

AB The title photosensitive materials having main sensitivity at 300-450 nm contain a compound which is transformable into a sensitizer dye by exposure and a hydrazine derivative The materials can be handled under room light and give pin hole-free sensitive half tone images. A polyethylene terephthalate film was coated with a photosensitive emulsion containing S-sensitized Ag halide, antifoggants, organic photochromic compound I, 1-formyl-2-[4-(2,4-di-tert-pentylphenoxymethylamido)phenyl]hydrazine, and other desirable additives and then with a protective layer containing gelatin and poly(Me methacrylate) to give a photosensitive material which gave images having higher sensitivity and less pin holes than a photosensitive material without the hydrazine derivative and the compound I.
IT 77887-29-7
RL: USES (Uses)
(silver halide photog. emulsion containing sensitizer dye and, for room light use)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 124 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:165773 CAPLUS
DN 110:165773
TI The effects of metoclopramide and cloxacepride on human mast cells from adenoidal tissues
AU Schmutzler, W.; Greven, T.; Braam, U.
CS Med. Fac., RWTH Aachen, Aachen, D-5100, Fed. Rep. Ger.
SO Agents and Actions (1989), 27(1-2), 110-12
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English
AB Cloxacepride, an amide of the dopamine antagonist metoclopramide, possesses oral antiallergic properties in the rat PCA model. Both substances were tested in isolated mast cell prepns. from human adenoidal tissues to determine whether any therapeutic antiallergic potential in man could be expected. Metoclopramide at 10-5-10-3M had no inhibitory effect but instead enhanced Con A-induced histamine release at concns. >10-4M. Cloxacepride at 10-5-10-4M inhibited Con A-induced histamine release. This inhibitory effect was not diminished by increasing the preincubation time for up to 30 min. In contrast, cloxacepride concns. >4 + 10-5M caused a substantial histamine release. This effect could not be alleviated by an increase in the number of mast cells per sample. These results suggest a very narrow range of therapeutic potential for cloxacepride.
IT 65569-29-1, Cloxacepride
RL: BIOL (Biological study)
(histamine release by human mastocyte response to)
RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 125 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:150329 CAPLUS
DN 110:150329
TI Electron-topological study of the structure-activity relationship of various inhibitors of α-chymotrypsin
AU Dimoglo, A. S.; Gorbachev, M. Yu.; Chumakov, Yu. M.; Barsuker, I. B.; Gitlina, L. S.; Golender, V. E.; Rozenblit, A. B.
CS Inst. Khim., Kishinev, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1988), 22(11), 1355-61
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
GI



I

AB An electron topol. technique was used to examine the structure-activity relationship of a group of α-chymotrypsin inhibitors (I, R = H, halo, NO2, CH2CH:CH2, CN, Me, Ph, etc.; R1 = H, CO2H; R2 = H, SO2F, CO2H, Cl, Br; R3 = H, SO2F, C6H4-mR4m; R4 = H, Cl, Me; Y = NHCO, CO; Z = NH, CHBr, CHCl, CO; m = 1-2; n = 0-1) . The inhibitory activity of these compds. depended on the electron distribution in the system and on the spatial arrangement of its atoms and functional groups. The electron topol. indexes for the activity of the tested compds. are reported.
IT 20167-19-5 20209-72-7 21447-17-6
21447-21-2 21447-22-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(α-chymotrypsin inhibition by, structure-activity relationship in, electron topol. study of)
RN 20167-19-5 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 20209-72-7 CAPLUS
CN Benzenesulfonyl fluoride, 3-[[[[[4-[[(3-chlorophenoxy)acetyl]amino]phenyl]

L9 ANSWER 125 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 21447-17-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[4-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-21-2 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)-4-methylphenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-22-3 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[2-chloro-5-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 125 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 126 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:125210 CAPLUS
DN 110:125210
TI Silver halide photographic materials containing pyrazolobenzimidazole magenta coupler and stabilizer for improved dye image stability
IN Kaneko, Yutaka
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62291656	A2	19871218	JP 1986-135206	19860610 <--
PRAI JP 1986-135206		19860610		

GI



I

II



III



IV

AB The title materials contain ≥1 pyrazolo[1,5-a]benzimidazole magenta couplers I, and dye image stabilizer II (R1 = alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, acylamino, anilino, ureido; R2 = halo, alkyl, alkenyl, cycloalkyl, aryl, OH, carboxy, CN, NO2, alkoxy, aryloxy, acyl, acylamino, acyloxy, ureido, alkoxycarbonyl, aryloxycarbonyl, carbamoyl, sulfonamido, sulfamoyl; n = 0-4; X = H or releasing group; R3-R4, R6 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; R7 = alkyl, cycloalkyl, alkenyl, aryl; R5 = substituting group(s); m = 1-4; J = COO, CS, CO, CONR8, CSNR8, CR8R9, SO, C(:O)S, P(:O)(OR8)O; R8-R9 = H, alkyl, aryl; n = 0-1; R3-R4 may jointly form 5-6-membered ring; 1 of Rn5 may form N-containing ring with R3 or R4). This combination increases the stability of the magenta dye image, and decreases staining. Thus, 1 L green-sensitive Ag(Cl,Br) emulsion was mixed with the dispersed magneta coupler III 25 g and 10 g dye stabilizer IV 10 g. A photog. paper with a layer of the above emulsion was sensitometrically exposed and normally processed to show much higher

L9 ANSWER 126 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
resistance of the dye image against fading and discoloration.
IT 115581-53-8
RL: USES (Uses)
(photog. dye image stabilizer, pyrazolobenzimidazole color coupler and)
RN 115581-53-8 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 127 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:38985 CAPLUS
DN 110:38985
TI Preparation of 1-aryl-3-acyl-aminopyrazolin-5-ones
IN Boeckelmann, Juergen; Fanghaenel, Egon; Grossmann, Norbert; Ruehl, Heidrun; Kraft, Fred; Schabrodt, Bernd; Leistner, Joachim; Ebisch, Ralf
PA VEB Filmfabrik Wolfen, Ger. Dem. Rep.
SO Ger. (East), 9 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 253619	A1	19880127	DD 1983-257673	19831209 <--
PRAI DD 1983-257673		19831209		

OS CASREACT 110:38985; MARPAT 110:38985
GI



I



II

AB 1-Aryl-3-aminopyrazoline-5-ones I [R = halo, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl; R1 = H, alkyl, alkoxy; n = 0, 1] were acylated by ClCO(CH2)nCHR2R3 [R2 = H, C1-40 alkyl, substituted aryloxyalkyl; R3 = H, alkyl, alkenyl, substituted aryloxy, alkyl, alkenyl) in MeCN at 75-80°. Thus, 1-(2,4,6-trichlorophenyl)-3-aminopyrazolin-5-one in MeCN at 70° was treated with stearoyl chloride to give 86% amide II.
IT 118291-50-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 118291-50-2 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-N-(4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 127 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 128 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:601299 CAPLUS
DN 109:201299
TI Silver salt diffusion transfer image formation
IN Inoue, Akiyuki; Idota, Yoshio; Yagihara, Morio
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63103238	A2	19880507	JP 1986-248967	19861020 <--
	JP 06001363	B4	19940105		
	US 4803146	A	19890207	US 1987-110300	19871020 <--
PRAI	JP 1986-248967	A	19861020		

AB A diffusion-transfer photog. material is processed in the presence of a fogging agent (a nucleation agent) to prevent the reduction of the maximum d. of images even when the developing time is long. The fogging agent such as H2NNHCOMe may be included in the photosensitive unit.
IT 77887-29-7
RL: USES (Uses)
(photog. fogging agent, diffusion-transfer photog. material containing)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 129 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:601298 CAPLUS
DN 109:201298
TI Negative-type silver halide photographic material and processing to obtain super high contrast images
IN Inoue, Nobuaki; Sasaoka, Senzo; Yoshida, Tetsuo
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63103232	A2	19880507	JP 1986-249161	19861020 <--
	JP 06052382	B4	19940706		
	US 5051336	A	19910924	US 1990-522400	19900511 <--
PRAI	JP 1986-249161	A	19861020		
	US 1987-110386	B1	19871020		

GI



AB In a neg.-type Ag halide photog. material possessing ≥1 Ag halide emulsion layers with the Ag halide emulsion layer sensitized by Au and S, a hydrazine derivative and compound I [Z = N, C-X(X = alkyl, aryl); Y = alkyl, aryl; M = H, metal NH4] are incorporated in the emulsion layer(s) or other hydrophilic colloid layer. The above material is imagewise exposed and developed with a developer solution containing SO32- ≥0.15 mol/L and with a pH 10.5-12.3 to yield a super-high contrast neg. image during photolithog.
IT 77887-29-7
RL: USES (Uses)
(photog. emulsions containing, for high contrast images)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 129 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 130 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:560493 CAPLUS
DN 109:160493
TI Photographic materials and developers for superhigh contrast images
IN Yoshida, Tetsuo; Sasaoka, Senzo; Inoue, Nobuaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63104047	A2	19880509	JP 1986-251482	19861022 <--
PRAI	JP 1986-251482		19861022		

OS MARPAT 109:160493
AB The following photog. material and developer provide superhigh contrast images with improved edge smoothness and reduced black dots in white lines suitable for a platemaking. The photog. material contains a hydrazine derivative in ≥1 Ag halide photosensitive emulsion layer or nonphotosensitive hydrophilic colloidal protective layer. The protective layer contains a matting agent have an average particle size <0.2 μm. After an imagewise exposure the photog. material is developed in a developer having a pH 10.5-12.3 containing sulfite ions >0.15 M.
IT 77887-29-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. materials containing, for superhigh contrast images, for platemaking)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:549061 CAPLUS
DN 109:149061
TI Preparation of phenoxypropanolamines as antiarrhythmic agents
IN Koeppe, Herbert; Esser, Franz; Kobinger, Walter; Lillie, Christian
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3640829	A1	19880609	DE 1986-3640829	19861128 <--
	SU 1574169	A3	19900623	SU 1987-4203680	19871120 <--
	ZA 8708917	A	19890726	ZA 1987-8917	19871121 <--
	EP 269985	A2	19880608	EP 1987-117374	19871125 <--
	EP 269985	A3	19900704		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 275241	A5	19900117	DD 1987-309421	19871125 <--
	CS 270576	B2	19900712	CS 1987-8507	19871125 <--
	US 4948812	A	19900814	US 1987-125308	19871125 <--
	FI 8705212	A	19880529	FI 1987-5212	19871126 <--
	DK 8706252	A	19880529	DK 1987-6252	19871127 <--
	NO 8704958	A	19880530	NO 1987-4958	19871127 <--
	AU 8781874	A1	19880602	AU 1987-81874	19871127 <--
	AU 594840	B2	19900315		
	JP 63150253	A2	19880622	JP 1987-299614	19871127 <--
	HU 49112	A2	19890828	HU 1987-5356	19871127 <--
	HU 200319	B	19900528		
PRAI	DE 1986-3640829	A	19861128		

OS MARPAT 109:149061
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph, aryloxy, pyridyl, anilino; R2 = H, halo, alkyl, alkoxy, cyano, atoms to complete a(n) (un)saturated fused

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT 116689-06-6P 116720-45-7P 116720-46-8P
116720-47-9P 116720-48-0P 116720-49-1P
116720-50-4P 116720-57-1P 116720-65-1P
116720-66-2P 116720-68-4P 116720-69-5P
116720-71-9P 116720-72-0P 116720-74-2P
116720-77-5P 116720-87-7P 116720-90-2P
116720-91-3P 116720-95-7P 116720-96-8P
116743-87-4P 116743-88-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiarrhythmic agent fml: 700,701,702(antiarrhythmic tablet)
RN 116689-06-6 CAPLUS
CN Acetamide, N-[4-[3-(diethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(2,6-dimethylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-45-7 CAPLUS
CN Acetamide, N-[4-[3-(dipropylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ring; R3 = H, halo, alkyl; R4 = alkyl, hydroxyalkyl; R5 = R4, (un)substituted phenylalkyl, phenoxyalkyl; NR4R5 = heterocyclyl] were prepd. as antiarrhythmic agents (no data). Phenoxyoxirane II (R6R7 = O) and Et2NH were refluxed 1.5 h in EtOH to give II (R6 = OH, R7 = NEt2) (III). Capsules were prepd. each contg. 150 mg III.HCl and 150 mg starch.
IT 116689-06-6P 116720-43-5P 116743-86-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic agent)
RN 116689-06-6 CAPLUS
CN Acetamide, N-[4-[3-(diethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(2,6-dimethylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-43-5 CAPLUS
CN Acetamide, N-[4-[3-(dimethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 116743-86-3 CAPLUS
CN Acetamide, N-[4-[3-(diethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 116720-46-8 CAPLUS
CN Acetamide, N-[4-[3-(ethylpropylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-47-9 CAPLUS
CN Acetamide, N-[4-[3-[bis(1-methylethyl)amino]-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-48-0 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-[methyl(1-methylethyl)amino]propoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 116720-49-1 CAPLUS
CN Acetamide, N-[4-[3-(dibutylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-50-4 CAPLUS
CN Acetamide, N-[4-[3-[bis(1-methylpropyl)amino]-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 116720-57-1 CAPLUS
CN Acetamide, N-[4-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

OMe

RN 116720-65-1 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[3-(dimethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 116720-66-2 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[3-(diethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 116720-68-4 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]-2-(2,6-dimethylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116720-69-5 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-2-(2,6-dimethylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-71-9 CAPLUS
CN Acetamide, 2-(2,6-dichlorophenoxy)-N-[4-[3-(dimethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-72-0 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116720-74-2 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-2-(3-methylphenoxy)-, ethanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116720-73-1
CMF C22 H28 Cl2 N2 O4



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 116720-77-5 CAPLUS
CN Acetamide, N-[4-[3-(dimethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(2,6-dimethylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-87-7 CAPLUS

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[3,5-dichloro-4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]-2-(2,6-dichlorophenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-90-2 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 116720-91-3 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-2-(4-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116720-95-7 CAPLUS
CN Acetamide,' N-[3,5-dichloro-4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]-2-(2-methylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

L9 ANSWER 131 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116720-96-8 CAPLUS
CN Acetamide, N-[3,5-dichloro-4-[3-(diethylamino)-2-hydroxypropoxy]phenyl]-2-(2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 116743-87-4 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-(methylpropylamino)propoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 116743-88-5 CAPLUS
CN Acetamide, N-[4-[3-(ethylmethylamino)-2-hydroxypropoxy]-3,5-dimethylphenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 132 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:519511 CAPLUS
DN 109:119511
TI Silver halide color photographic materials with improved dye image stability
IN Kaneko, Yutaka; Kadokura, Kenji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62253168	A2	19871104	JP 1986-97611	19860425 <--
PRAI JP 1986-97611		19860425		

GI For diagram(s), see printed CA Issue.
AB The title color photog. materials contain ≥1 pyrazoloazole-type magenta coupler I (Z = heterocyclic ring; X = H, substituent released during coupling reaction; R = H, substituent), ≥1 compound of the formula II (R = aliphatic moiety, cycloalkyl, aryl, heterocyclyl; Y = pyrrolidene, piperidine, homopiperidine ring), and ≥1 compound of the formula III (R2, R3, R5 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; R4 = substituent; R6 = alkyl, cycloalkyl, alkenyl, aryl; Z = CO2, CS, CO, CONR7, CSNR7, CR7R8, SO2, COS, P(O)(OR7)O; R7, R8 = H, alkyl, aryl; m = 0-4; n = 0, 1; R2R3 combination may form a heterocycle; when m≥1 R4 may combine with R2 to form a condensed heterocycle). The color photog. materials give magenta dye images with excellent lightfastness and heat resistance and very few stains.
IT 115581-53-8
RL: USES (Uses)
(photog. stabilizer compns. containing, for magenta dye image stabilization)
RN 115581-53-8 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-(4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 133 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:483216 CAPLUS
DN 109:83216
TI Silver halide color photographic material for images with reduced stains and improved heat and light resistance
IN Takada, Shun; Onodera, Kaoru; Yoshimoto, Shinji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62291653	A2	19871218	JP 1986-135152	19860611 <--
PRAI JP 1986-135152		19860611		

GI For diagram(s), see printed CA Issue.
AB At least one Ag halide photog. emulsion of the title material contains (1) ≥1 coupler selected from I, II, and III [Z1-Z3 = nonmetallic atoms to form a N-containing heterocyclic ring; X1-X3 = H, group to be released upon reaction with an oxidized color developer; R1-R7 = H, substituent wherein R7 = substituent not to be released upon reaction with the oxidized color developer; Y1 = C, N; Y2 = C, hetero atom; i, j, k, l, m, n, p = 0, 1; if Y1 = C and the bonding is a double bond, then k = 1, l = 0 and R3 = substituent not to be released upon reaction with the oxidized color developer; if Y1 = C and the bonding is a single bond, then k = l = 1; if Y1 = N and the bonding is a double bond, then k = l = 0 and Y2 = hetero atom; if Y1 = N and the bonding is a single bond, then k = 1 and l = 0; the coupling reaction occurs at X1-X3] and (2) ≥1 compound IV [R8, R9 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; R10 = substituent; R11 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; R12 = alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; J = CO, CS, SO2, CO2, COS, CONR13, CSNR13, COCR13R14(CH2)sO, COCR13R14(CH2)sSO2, PO2(OR15); R13, R14 = H, alkyl; R15 = alkyl, aryl; q = 0-4; r = 0, 1; s = 0-2; R8 and R9 together may form a 5- or 6-membered ring; when q ≥ 2, R10 and R8 and/or R9 together may for a 5- or 6-membered ring or R10 and R11 together may form a 5- or 6-membered ring]. The Ag halide color photog. material provides images with reduced stains and improved light resistance.
IT 115581-53-8
RL: USES (Uses)
(photog. stabilizer)
RN 115581-53-8 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 133 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 134 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:464166 CAPLUS
DN 109:64166
TI Silver halide photographic material providing stabilized images
IN Kaneko, Yutaka; Kadokura, Kenji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62253169	A2	19871104	JP 1986-97612	19860425 <--
PRAI JP 1986-97612		19860425		

GI For diagram(s), see printed CA Issue.
AB A Ag halide photog. material contains ≥1 magenta coupler selected from I [Z = nonmetal atoms to form a (substituted) N-containing heterocyclic ring; X = H, a substituent to be released upon reaction with an oxidized color developer; R = H, a substituent], ≥1 compound selected from II [R1 = aliphatic group, cycloalkyl, aryl, heterocyclyl; Y = nonmetal atoms to form a morpholine or thiomorpholine ring with N], and ≥1 compound selected from III [R2, R3, R5 = H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl; R6 = alkyl, cycloalkyl, alkenyl, aryl; R4 = a substituent; m = 0-4; J = CO2, CS, CO, CONR7, CSNR7, CR7R8, SO2, COS, PO2(OR7); R7, R8 = H, alkyl, aryl; n = 0, 1; R2 and R3 may form a 5- or 6-membered ring; when m ≥ 2, R4 may be the same or different; when m = 1-4, 1 of R4 may be connected to R2 or R3 to form a ring with N connected to R2 and R3; when m ≥ 2, 2 of R4 may be connected to R2 and R3 each to form a ring with N connected to R2 and R3]. The photog. material provides stabilized images with improved light resistance and no stains.
IT 115581-53-8
RL: USES (Uses)
(photog. stabilizer, silver halide photog. material containing pyrazole derivative magenta coupler and)
RN 115581-53-8 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 135 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:464158 CAPLUS
DN 109:64158
TI Processing of silver halide color photographic photosensitive materials
IN Ishikawa, Masao; Koboshi, Shigeharu; Kobayashi, Kazuhiro
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 37 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62246051	A2	19871027	JP 1986-91113	19860419 <--
PRAI JP 1986-91113		19860419		

GI



AB Imagewise exposed color photog. materials having emulsion layers with ≥80 mol% AgCl and containing ≥1 cyan coupler selected from I, II, and III (X, Z = H, group released during coupling reaction, ≥1 of R and R1 is H and other is C2-12 alkyl; R2, R3 = ballest group; Y = COR4, CONR4R5, SO2R4, CSNR4R5, SO2NR4R5, CONHCOR4, CONHSO2R4; R4 = alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl; R5 = H, R4; R4R5 in combination may complete a 5- or 6-membered ring) are developed in a color developer containing R6NR7OH (R6, R7 = C1-3 alkyl) and R8NR9R10 (R8 = C2-6 hydroxyalkyl; R2, R3 = H, C1-6 alkyl, C2-6 hydroxyalkyl, PhCH2, CnH2nNR11R12; R11, R12 = H, C1-6 alkyl, C2-6 hydroxyalkyl; n = 1-6). The color developer may also contain a chelating agent selected from 1,2-dihydroxybenzene derivs., 2,3-dihydroxynaphohalene, and OH group-containing tertiary amines. The preferred content of SO32- in the developer is 4 + 10-3 mol/L. The method gives dye images with high optical d. and low fog.
IT 115127-97-4
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 115127-97-4 CAPLUS
CN Benzamide, N-dodecyl-4-[2-[[3-hydroxy-4-[[[[4-(1-oxopropyl)-2-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 135 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L9 ANSWER 136 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L9 ANSWER 136 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:229494 CAPLUS
DN 108:229494
TI Silver halide color photographic materials containing pyrazolotriazole derivatives as magenta couplers
IN Ishii, Fumio; Wada, Hajime
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62205348	A2	19870909	JP 1986-47405	19860306 <--
PRAI	JP 1986-47405		19860306		

GI



I

AB Magenta coupler(s) from derivs. of 1H-pyrazolo[3,2-C]-s-triazole substituted at 6-position with a ACONr-group (R = H, alkyl, acyl, aryl; A = alkyl), is contained in the layer(s) of the color photog. materials. The use of the couplers provide high colorfastness and resistance to HCHO, beside good coloration. Thus, a green-sensitive Ag(I,Br) emulsion was added with a gelatin-I emulsion and a hardener, and applied on a polyester base. The content of I in the layer was 0.1 mol/mol Ag. Exposure and processing of the film, using developer either containing or not containing PhCH2OH, produced magenta images that showed high colorfastness. High resistance of the unexposed film to HCHO was also observed

IT 114809-28-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, photog. coupler from)

RN 114809-28-8 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[2-[4-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]-1-oxobutyl]hydrazino]-5-[(2,2-dimethyl-1-oxopropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 137 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:88074 CAPLUS
DN 108:88074
TI Preparation of adenosine and xanthine derivatives and their activity as adenosine receptor agonist and antagonist prodrugs
IN Jacobson, Kenneth A.; Kirk, Kenneth L.; Daly, John W.
PA United States Dept. of Health and Human Services, USA
SO U. S. Pat. Appl., 55 pp.
CODEN: XAXXAV
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 229	A0	19870715	US 1987-229	19870102 <--
	US 4968672	A	19901106		
PRAI	US 1987-229		19870102		

GI



I



II

AB Functionalized congeners of adenosine receptor agonists and antagonists are reported which show improved selectivity of action as prodrugs by virtue of selectivity in delivery and/or cleavage at a particular desired site of action. For example, the xanthine amine congener I, a theophylline analog, is much more potent than theophylline as an A1 receptor antagonist and diuretic. Blocking the amino group of I, e.g. with a γ-glutamyl group, inhibits its diuretic activity; the inhibition is reversed by cleavage at the desired site of action (kidney). Alternatively, attachment of the functionalized drug to a carrier (e.g. a lipid) alters its distribution in the body (e.g. by making it less polar and more readily absorbed from the gut and taken up by the lymphatic system and brain). Acyl prodrugs of the adenosine receptor agonist II, an N6-derivatized adenosine amine congener, are also prepared; these compds. inhibit renin release by the kidney and are useful as antihypertensives. I was converted to its N-acetyl-γ-glutamyl derivative (III) in 4 steps beginning with reaction of I with t-butyloxycarbonyl-L-glutamic acid α-benzyl ester. In rats treated with N6-cyclohexyladenosine, Na+

L9 ANSWER 137 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
excretion and glomerular filtration were markedly inhibited; the inhibition was partially reversed by administration of III.
IT 104576-53-6P 104576-54-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine receptor ligand prodrug)
RN 104576-53-6 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 104576-54-7 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(1,3-diethyl-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 137 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

L9 ANSWER 138 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:68297 CAPLUS
DN 108:68297
TI Synthesis and hypoglycemic activity of 4-(β-acylaminoethyl)benzenesulfonamides
AU Khlaponina, L. N.; Moroz, V. V.; Brutov, V. D.; Selichenko, A. G.
CS Khar'k. NIIEndokrinol. Khim. Gormon., Kharkov, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1987), 21(8), 965-8
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
GI



I

AB I (R = Me, 2-methoxy-5-chlorophenyl, 3-ClC6H4CH:CH, 3-ClC6H4, phenylethyl, PhCH:CMe, 3-MeOC6H4CH:CH, or 4-ClC6H4OCH2, R1 = cyclohexyl, phenylethyl, 5-alkyl-1,3,4-thiadiazolyl, 1-adamantyl, etc.) were prepared by acylation of the corresponding amines followed by conversion to sulfonyl chlorides and reaction with amines. The hypoglycemic activity of the compds. (50-200 mg/kg) was studied in normal male rats. I (R = Me and R1 = different groups) did not show any activity. I (R = 2-methoxy-5-chlorophenyl, R1 = cyclohexyl, 5-isopropyl-1,3,4-thiadiazolyl and 1-adamantyl) were the most active. Conversion of the sulfonamide group to sulfonylurea group-containing
compds. enhanced the activity.
IT 25210-96-2P 112557-26-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and hypoglycemic activity of)
RN 25210-96-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 112557-26-3 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[(cyclohexylamino)sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 138 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 139 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:31565 CAPLUS
DN 108:31565
TI Calmodulin antagonism: a pharmacological approach for the inhibition of mediator release from mast cells
AU Gigl, G.; Hartweg, D.; Sanchez-Delgado, E.; Metz, G.; Gietzen, K.
CS Dep. Pharmacol. Toxicol., Univ. Ulm, Ulm, D-7900, Fed. Rep. Ger.
SO Cell Calcium (1987), 8(5), 327-44
CODEN: CECADV; ISSN: 0143-4160
DT Journal
LA English
AB Several Ca2+ antagonists with either Ca2+-entry-blocking or calmodulin (CaM)-antagonistic properties, as well as antiallergic drugs, were investigated for their effects on mediator release from mast cells by different secretagogs (compound 48/80, concanavalin A, antigen-IgE and Ca2+ ionophore A23187) and for their ability to inhibit the function of CaM- or phospholipid/Ca2+-dependent protein kinase (C-kinase). The effects of the different agents (with the single exception of cromolyn Na) on histamine release elicited by compound 48/80 correlated well with their actions on 2 CaM-dependent enzymes, whereas the activity of C-kinase was far less altered or not altered at all. CaM antagonism by cloxacepride, picumast, oxatomide, fendiline, and bepridil correlated not only with the inhibition of exocytosis evoked by compound 48/80 but also with that induced by A23187, concanavalin A, and antigen-IgE. This indicates an action of these substances distal to the generation of the Ca2+ signal, since the various secretagogs elevate the intracellular Ca2+ concentration by different mechanisms.
However, prenylamine and thioridazine inhibited concanavalin A- and antigen-IgE-induced mediator release more potently and more effectively than that elicited by compound 48/80 or A23187. Therefore, inhibition of allergic histamine release by these drugs may in part be dependent on an impairment of the Ca2+ signal. Since inhibition of histamine release paralleled that of serotonin release, it may be concluded that these mediators are secreted via the same mechanism. These results, with agents exhibiting different pharmacol. properties but which share 1 common property, namely, antagonism of CaM, strengthen the view that CaM is involved in exocytosis of mediators from mast cells.
IT 65569-29-1, Cloxacepride
RL: BIOL (Biological study)
(histamine and serotonin release by mast cell response to, calmodulins in)
RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 139 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 140 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:497090 CAPLUS
DN 107:97090
TI Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl]glycines
AU Mayfield, Charles A.; DeRuiter, Jack
CS Sch. Pharm., Auburn Univ., Auburn, AL, 36849, USA
SO Journal of Medicinal Chemistry (1987), 30(9), 1595-8
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 107:97090
GI



I

AB Title glycines I [R = 2-BzNH, 3-BzNH, 4-Me2N, 4-R1NH (R1 = Bz, Ac, PhCH2, PhCH2CO, PhCH2CH2CO, PhCH:CHCO, PhNHCO, PhNHCSNH, PhCH2O2C, PhOCH2CO, PhCH2OCH2CO)] were prepared as inhibitors of the title enzyme (II). Glycine was sulfonylated with 2-, 3-, and 4-nitrobenzenesulfonyl chlorides to give I (R = 2-, 3-, and 4-NO2), which were reduced by hydrogenation to give I (R = 2-, 3-, and 4-NH2). The latter were used in the synthesis of the title substituted amino derivs., e.g., the above amines were N-acylated with BzCl to give the corresponding N-benzoyl derivs. I (R = 2-BzNH) was less potent than I (R = 2-NH2) as an inhibitor of II, but I (R = 3- and 4-BzNH) were substantially more potent than I (R = 3- and 4-NH2). I (R = 4-BzNH) was more active than I (R = 4-AcNH, 4-PhCH2NH, Me2N), suggesting that both the addnl. carbonyl moiety and aromatic ring in I (R = 4-BzNH) may bind to complementary sites present in II.
IT 109065-78-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and aldose reductase-inhibiting activity of)
RN 109065-78-3 CAPLUS
CN Glycine, N-[[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 141 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:67250 CAPLUS
DN 106:67250
TI Xanthine functionalized congeners as potent ligands at A2-adenosine receptors
AU Jacobson, Kenneth A.; Ukena, Dieter; Padgett, William; Daly, John W.; Kirk, Kenneth L.
CS Lab. Chem., Natl. Inst. Arthritis, Diab. Dig. Kidney Dis., Bethesda, MD, 20892, USA
SO Journal of Medicinal Chemistry (1987), 30(1), 211-14
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 106:67250
GI



I

AB Amide derivs. of a carboxylic acid congener of 1,3-dialkylxanthine, having a 4-[(carboxymethyl)oxy]phenyl substituent at the 8-position, have been prepared in order to identify potent antagonists at A2-adenosine receptors stimulatory to adenylate cyclase in platelets. Distal structural features of amide-linked chains and the size of the 1,3-dialkyl groups have been varied. 1,3-Di-Et groups, more than 1,3-di-Me or 1,3-di-Pr groups, favor A2 potency, even in the presence of extended chains attached at the 8-(p-substituted-phenyl) position. Polar groups, such as amines, on the chain simultaneously enhance water solubility and A2 potency. Among the most potent A2 ligands are an amine congener, I, and its D-lysyl conjugate, which have KB values of 21 and 23 nM, resp., for the antagonism of N-ethyladenosine-5'-uronamide-stimulated adenylate cyclase activity in human platelet membranes. Strategies for the selection and tritiation of new radioligands for use in competitive binding assays at A2-adenosine receptors have been considered.
IT 104576-53-6P 104576-54-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and potency of, at A2 and A1 adenosine receptors)
RN 104576-53-6 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 141 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—CH_2—NH_2

RN 104576-54-7 CAPLUS
CN Benzeneacetamide, N-(2-aminoethyl)-4-[[[4-(1,3-diethyl-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2—NH_2

L9 ANSWER 142 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of)
RN 105411-07-2 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-N-[4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-4-(triphenylphosphoranylidene)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 105411-10-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with triphenylphosphine, ylide from)
RN 105411-10-7 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-N-[4-bromo-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 142 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:627006 CAPLUS
DN 105:227006
TI New phosphorus ylides
IN Pasbrig, Erwin; Fanghaenel, Egon; Grossmann, Norbert; Walczak, Baerbel
PA VEB Filmfabrik Wolfen, Ger. Dem. Rep.
SO Ger. (East), 4 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 234680	A1	19860409	DD 1983-257100	19831125 <--
PRAI DD 1983-257100		19831125		

GI



AB Ylides I and II (R = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, carbamoyl, heterocyclyl, thiocarbamoyl; R1 = R, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ureido, thioureido, etc.; R2-R4 = (substituted) alkyl, cycloalkyl, aryl; R5 = H, halo, alkyl, alkoxy, amido, carbamoyl, sulfamoyl; n = 1-4) are prepared by addition of PR2R3R4 to halopyrazolinones III or IV (X = halo, Y = H, halo) to give a phosphonium salt, which is then treated with base. Thus, 2.53 g III (R = Ph, R1 Me, X = Br, Y = H) in MeCN was treated with 2.62 g Ph3P and the mixture was refluxed for 20 min and then treated with 0.01 M NaOH to give 80% I (R = R2-4 = Ph R1 = Me).
IT 105411-07-2P
RL: SPN (Synthetic preparation); PREP (Preparation)

L9 ANSWER 143 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:470094 CAPLUS
DN 105:70094
TI Method of silver image formation
IN Hanyu, Takeshi; Yorozudo, Hidetoshi
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61047952	A2	19860308	JP 1984-170938	19840814 <--
PRAI JP 1984-170938		19840814		

AB Photog. materials having ≥1 Ag halide emulsion layer containing hydrazine compds. and 3-pyrazolidinone compds. are treated with developers containing dihydroxybenzene-like compds., sulfites, and amines. The method provides high-contrast, high-quality images with low fog d. by rapid processing, and is suitable for reproduction of halftone neg. originals. Thus, a Ag(Cl,Br,I) emulsion (39.7 mol% AgBr, 0.3 mol% AgI) containing a H2O-soluble Ir compound was Au- and S-sensitized, 3-carboxymethyl-5-[2-(3-ethylthiazolinylidene)ethylidene]rhodanine, 4-hydroxy-6-methyl-1,3,3a,7-tetrazaindene, 1-formyl-2-(4-acetamidophenyl)hydrazine (200 mg/mol Ag), 1-phenyl-3-pyrazolidinone (3.5 g/mol Ag), saponin, and mucochloric acid added, and the emulsion coated on a PET film to form a layer containing 3.5 g Ag. A protective layer containing gelatin 1.5 g/m2 was then coated on the emulsion layer. The sensitometrically exposed material was subsequently treated with a developer containing hydroquinone, Na2SO3, 2-diethylaminoethanol, and other additives at 35° for 30 s to show a relative sensitivity of 520, a gamma value of 18.51, and a fog d. of 0.04 vs. 100, 2.63, and 0.03, resp., for a control containing neither the hydrazine nor the 3-pyrazolidinone compound
IT 77887-29-7
RL: USES (Uses)
(photog. film with emulsion containing pyrazolidinone compound and, for high-contrast image)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 144 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:470078 CAPLUS
DN 105:70078
TI Silver halide color photographic materials
IN Kimura, Toshihiko; Kaneko, Yutaka; Sasaki, Takashi
PA Konishiroku Photo Industry Co.,*Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61032054	A2	19860214	JP 1984-152586	19840723 <--
	JP 04021179	B4	19920408		
PRAI	JP 1984-152586		19840723		

GI



I



II



III

AB A phenolic cyan coupler having the general formula I (R = monovalent group; R1 = H, alkyl; R2 = alkyl; R3, R4 = H, monovalent group; R5 = monovalent group; R6 = Ph having ≥1 tertiary group; n = 0-4) is contained in ≥1 Ag halide layer of photog. materials. The coupler provides good coloration, stability of cyan color in exhausted bleaching solution, and stability of the image in high temperature and humidity. Thus, 0.01 mol of II dissolved in 1:3 di-Bu phthalate-EtOAc mixture was emulsified in

L9 ANSWER 144 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

—Et

L9 ANSWER 144 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
aq. soln. of Alkanol-B and gelatin. The dispersion was added to Ag(I,Br) emulsion contg. 0.1 mol Ag, and the mixt. was coated on a polyethylene-laminated paper to obtain a photog. film. Sensitometric exposure, color development, bleaching, and stabilization of the film gave cyan image having image d. 2.73, with relative sensitivity 123 (the sensitivity of a control material using III was 100).
IT 103520-89-4 103520-94-1
RL: USES (Uses)
(color photog. material containing)
RN 103520-89-4 CAPLUS
CN Acetamide, 2-[2-cyclopentyl-4-(1,1-dimethylethyl)phenoxy]-N-[5-hydroxy-4-[[[[2-methyl-4-(methylsulfonyl)phenyl]amino]carbonyl]amino]-2-(1-methyl-2-oxobutoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 103520-94-1 CAPLUS
CN Butanoic acid, 2-[5-[[[[3-(acetyloxy)-4-(hexadecylsulfonyl)phenyl]amino]carbonyl]amino]-4-hydroxy-2-[[[2,4,6-tris(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenoxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 145 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:432893 CAPLUS
DN 105:32893
TI Silver halide photographic materials containing development inhibitor-releasing photographic couplers
IN Ono, Mitsunori; Sasaki, Noboru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60230139	A2	19851115	JP 1984-85835	19840427 <--
	JP 05058177	B4	19930825		
PRAI	JP 1984-85835		19840427		

GI For diagram(s), see printed CA Issue.
AB The claimed Ag halide photog. photosensitive material contains a photog. useful compound-releaser of the formula I (R = coupler moiety; Z = heteroatom which forms an anion when R is released, Z1 = a group of atoms which transport charges toward R1 and forms an electrophilic center; R1 = electron attracting group, atom, or radical; R2 = a photog. useful group; R3 = Z3R4; R4 = nucleophilic group whose reaction with the electrophilic center results in release of R2; Z2, Z3 = bond or a divalent linkage).
IT 102827-67-8
RL: USES (Uses)
(photog. development inhibitor-releasing coupler)
RN 102827-67-8 CAPLUS
CN Benzamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-N-[4-[3-[(1-ethyl-1H-tetrazol-5-yl)thio]-4-[(hydroxymethyl)sulfonyl]phenoxy]-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 145 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L9 ANSWER 146 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 146 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:119875 CAPLUS
DN 104:119875
TI Silver halide photographic material
IN Kameoka, Kimitaka; Inagaki, Yoshio; Inoe, Nobuaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60140339	A2	19850725	JP 1983-248912	19831228 <--
	JP 04004578	B4	19920128		
PRAI	JP 1983-248912		19831228		

GI



AB A Ag halide photog. material is comprised of a support bearing ≥1 layer of a photosensitive Ag halide emulsion composed of ultrafine particles of Ag halide with an average size of ≤0.15 μ and contains in ≥1 coated layer a compound represented by the general formula R(NH)2ZR1 [R = aryl; R1 = H, aryl, alkyl, alkoxy, aryloxy; Z = carbonyl, sulfonyl, sulfoxy, phosphoryl, (N-substituted) imino]. The material provides ultrahigh contrast neg. images required for lithog. film under conditions of low Ag coverage and use of a stable developer solution Thus, a monodispersed Ag(Cl,Br) emulsion of an average grain size of 0.11 μ was prepared and chemical sensitized with Au + S. The emulsion containing a sensitizing dye, 5-methylbenzotriazole, 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene, poly(Et acrylate), and I was coated on a poly(ethylene terephthalate) support together with a protective layer to form a lithog. film. The film was sensitometrically exposed and developed by a stabilized developer composition containing hydroquinone, 4,4-dimethyl-1-phenyl-3-pyrazolidone, and a large amount of Na2SO3 to form a dot image which was shown to have high contrast, high quality and blackness, and good performance for reduction processing in comparison with a control without I.

IT 77887-29-7
RL: USES (Uses)
(ultrafine-grain photog. emulsions containing, for lithog.)

RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 147 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:79257 CAPLUS
DN 104:79257
TI Lith developing method
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60129746	A2	19850711	JP 1983-237318	19831216 <--
PRAI	JP 1983-237318		19831216		

GI



AB A neg.-type Ag halide photog. material is exposed and developed in the presence of a hydrazine compound by a solution of pH ≥12.3 containing a developing compound, a sulfite ≥0.25 mol/L, and a thioether-bond-containing amino compound or its salt with an organic or an inorg. acid. The method provides ultrahigh-contrast images, suitable for lithog. original negatives, with high sensitivity and short developing time. Thus, a Rh-containing AgCl0.7Br0.3 emulsion of an average grain size 0.3 μ was chemical (Au + S) sensitized, hydrazine derivative I, a sensitizing dye, 5-methylbenzotriazole, and 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene added, and mixed with a poly(Et acrylate) dispersion. The emulsion was coated on a triacetylcellulose support to give a photog. film. The film was wedge-exposed and developed by a composition comprising hydroquinone 40.0, 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidone 0.4, Na2SO3 75.0, NaHCO3 7.0, Na2EDTA 1.0, KBr 3.5, and 5-methylbenzotriazole 0.8 g and PhS(CH2)2NH2.HCl 5 + 10-4 mol per 1 L H2O (pH 12.0) to give an image with good dot quality and stable sensitivity during continuous processing up to 200 sheets of film.

IT 77887-29-7
RL: USES (Uses)
(lithog. material containing, continuous development of, in solution containing thioether compound)

RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 147 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 148 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:43107 CAPLUS

DN 104:43107

TI Silver halide photographic material

IN Kameoka, Kimitaka; Inagaki, Yoshio; Inoe, Nobuaki

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60140340	A2	19850725	JP 1983-248913	19831228 <--
	JP 04002935	B4	19920121		
PRAI	JP 1983-248913		19831228		

GI



I

AB A Ag halide photog. material comprises a support bearing ≥1 photosensitive Ag halide emulsion layer and contains in ≥1 of the emulsion layers or other coated layers an amine derivative in addition to a compound of general formula R(NH)2ZR1 [R = aryl; R1 = H, aryl, alkyl, alkoxy, aryloxy; Z = carbonyl, sulfonyl, sulfoxy, phosphoryl, (N-substituted)imino]. The material provides an ultrahigh contrast neg. image useful for lithog. by use of a stable processing composition Thus, a monodisperse Ag(Br,Cl,I) emulsion containing Rh 2.7 + 10-7 mol/mol Ag was prepared and chemical sensitized with Au + S. The emulsion containing a sensitizing dye, 5-methylbenzotriazole, 4-hydroxy-6-methyl-1,3,3a,7-tetrazaindene, poly(Et acrylate), I, and 2-diethylaminoethanol (II) was coated on a poly(ethylene terephthalate) support to form a lithog. film. The film was then sensitometrically exposed and developed by using a stabilized developer composition containing hydroquinone, 4,4-diethyl-1-phenyl-3-pyrazolidone, and a large amount of Na2SO3 to form a dot image which was shown to have high sensitivity, high contrast, and high quality and blackness as compared to a control not employing II along with I.

IT 77887-29-7
RL: USES (Uses)
(lith photog. films containing amine derivative and, for high-contrast images)

RN 77887-29-7 CAPLUS

CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 148 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 149 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:12992 CAPLUS

DN 104:12992

TI Silver halide photographic photosensitive material

PA Konishiroku Photo Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60111244	A2	19850617	JP 1983-220209	19831121 <--
PRAI	JP 1983-220209		19831121		

GI



I

AB A Ag halide photog. material comprises a support and ≥1 Ag halide emulsion layer containing a phenol-type cyan coupler in which the phenol ring bears a phenyl-ureido group with a SO2SR (R = aliphatic, aromatic, heterocyclic group) group at the 2-position, H, or a group releasable on coupling reaction with an oxidized color developer at the 4-position and an acylamino group at the 5-position. The material contains a new-type cyan dye-forming coupler which has no unfavorable optical absorption in the green region and little dependence of reactivity on the developer composition, such as benzyl alc. content. Thus, a coupler-gelatin dispersion containing the cyan coupler I and Alkanol B was mixed with a Ag(Br,I) (5% AgI) emulsion and then coated on a cellulose acetate support to form a color photog. film. The film was wedge-exposed, color-developed, bleached, fixed, and stabilized to give a cyan image with sensitivity and maximum d. both higher than those of a control using a known coupler. Also, good color reproduction was observed due to the presence of a sharp absorption band in the cyan coupler.

IT 99504-54-8
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 99504-54-8 CAPLUS

CN Benzenesulfonothioic acid, 4-[[[[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]amino]carbonyl]amino]-, S-ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 149 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 150 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:12990 CAPLUS
DN 104:12990
TI Silver halide photographic material
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60107650	A2	19850613	JP 1983-215630	19831116 <--
PRAI	JP 1983-215630		19831116		

GI



I

AB A Ag halide photog. material is composed of a support bearing ≥ 1 Ag halide emulsion layer containing a phenol-type cyan coupler in which a phenol ring has a phenylureido group with SO2X (X = halo) at the 2-position, H or a group releasable on a coupling reaction with an oxidized color developer at the 4-position, and an acylamino group at the 5-position. The material exhibits a cyan color with a sharp red absorption band not accompanied by addnl. absorption in the green region, resulting in desirable color reproduction Thus, a coupler-gelatin dispersion containing I and Alkanol B (alkylnaphthalenesulfonate) was mixed with an Ag(Br,I) (5 mol% I) emulsion and coated on a cellulose acetate support to form a color photog. film. The film was wedge-exposed, color-developed, bleached, fixed, and stabilized to give a cyan dye image with a sensitivity and Dmax both higher than controls prepared by using known couplers. The cyan image also showed good color reproduction

IT 99469-37-1
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 99469-37-1 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-chloro-2-hydroxyphenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 150 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 151 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:624373 CAPLUS
DN 103:224373
TI Silver halide photographic material
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60108845	A2	19850614	JP 1983-218221	19831118 <--
PRAI	JP 1983-218221		19831118		

GI



I

AB A Ag halide photog. material has ≥1 emulsion layer containing a phenolic cyan coupler having a phenylureido group substituted by a SO2R (R = cation) group at the 2-position, H or a coupling-off group at the 4-position, and an acylamino group at the 5-position of the phenolic ring. By reaction with an oxidized developing agent, the coupler forms a cyan dye which has a sharp absorption in the red region with a low level of undesirable green absorption. The dye-forming ability is insensitive to the concentration of benzyl alc. in the developer and the exhaustion of the processing solution Thus, a Ag(Br,I) emulsion (AgI 5 mol%) containing I exhibited good photog. properties upon processing by a typical neg. color process even when a fairly exhausted bleach was used and formed a dye with excellent spectral absorption.

IT 99346-73-3 99346-74-4
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler, for producing dye images with sharp absorption in red region)
RN 99346-73-3 CAPLUS
CN Benzenesulfinic acid, 4-[[[[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]amino]carbonyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 151 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 99346-74-4 CAPLUS
CN Benzenesulfinic acid, 4-[[[[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-5-chloro-2-hydroxyphenyl]amino]carbonyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L9 ANSWER 152 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 152 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:624372 CAPLUS
DN 103:224372
TI Silver halide photographic material
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60108846	A2	19850614	JP 1983-218222	19831118 <--
PRAI	JP 1983-218222		19831118		

GI



I

AB A Ag halide photog. material has ≥1 emulsion layer containing a phenolic cyan coupler having an arylureido group having a Ph ring to which a heterocyclic ring is condensed through -S- or -SO2- (the -S- or -SO2- is directly linked with the phenol ring) at the 2-position, a H or a coupling-off group at the 4-position, and an acylamino group at the 5-position of the phenol ring. By reacting with an oxidized developing agent, it forms a cyan dye which has a sharp spectral absorption in the red region with a low level of unwanted green absorption. The dye-forming activity is also insensitive to benzyl alc. concentration in a developer or to the exhaustion of processing solns. Thus, a Ag(Br,I) emulsion (AgI 5 mol%) containing I had a good developability upon development by a typical color neg. process, even when a fairly exhausted bleach solution was used, and formed a cyan dye image with excellent spectral absorption.

IT 99346-68-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler, for producing dye images with sharp spectral absorption in red region)

RN 99346-68-6 CAPLUS
CN Acetamide, N-[2-chloro-4-[[[(2,3-dihydro-2-oxobenzo[b]thien-6-yl)amino]carbonyl]amino]-5-hydroxyphenyl]-2-(3-pentadecylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 153 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:624370 CAPLUS
DN 103:224370
TI Silver halide photographic material
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60107649	A2	19850613	JP 1983-215629	19831116 <--
PRAI	JP 1983-215629		19831116		

GI



I II

AB A Ag halide photog. material is composed of a support bearing ≥1 Ag halide emulsion layer containing a phenol-type cyan coupler in which a phenol ring has a phenylureido group with a cycloalkylsulfonyl at the 2-position, H or a group releasable on a coupling reaction with an oxidized color developer at the 4-position, and a group represented by the formula I [R, R1 = branched alkyl, H (either of R, R1); Z = O, S; Z1 = alkylene] at the 5-position. The material exhibits a cyan dye image with a sharp red absorption band not accompanied by addnl. absorption in the green region, hence giving desirable color reproduction Thus, a gelatin dispersion containing the cyan coupler II and Alkanol B (alkylnaphthalenesulfonate) was mixed with a Ag(Br,I) (5 mol% I) emulsion and coated on a cellulose acetate support to form a color photog. film. The film was wedge-exposed, color-developed, bleached, fixed, and stabilized to give a cyan dye image with a sensitivity and Dmax both higher than controls using known couplers.

IT 99330-33-3
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 99330-33-3 CAPLUS
CN Acetamide, N-[4-[[[[4-[[4-(acetylamino)-2,3-dihydro-1-oxo-1H-inden-2-yl]sulfonyl]phenyl]amino]carbonyl]amino]-2-chloro-5-hydroxyphenyl]-2-(2,4-di-tert-nonylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 153 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 154 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:550974 CAPLUS
DN 103:150974
TI Silver halide plate developing method
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60093433	A2	19850525	JP 1983-202000	19831027 <--
	JP 03005730	B4	19910128		
	US 4569904	A	19860211	US 1984-663924	19841023 <--
PRAI	JP 1983-202000	A	19831027		

OS MARPAT 103:150974
GI



AB A developing method for Ag halide halftone neg. carried out in the presence of hydrazine derivative uses contrast developers having pH 10.5-12.3 and containing developing agent, ≥ 0.25 M sulfite, and ≥ 0.1 M of a compound having 1 + 10-11-3 + 10-13 acid dissociation constant The last component may be conveniently chosen from sugars, oximes, phenols, and fluoroalcs. Also claimed are developers containing an additive composition consisting of ≥ 1 dihydroxybenzene derivative and ≥ 1 1-phenyl-3-pyrazolidone derivative The method provides high contrast negatives stably in automatic developing system, regardless of Ag content and degree of exposure of Ag halide materials. Thus, a Ag halide plate was prepared by coating a cellulose triacetate film support with a ripened Ag(Cl,Br) emulsion (containing Rh), hydrazine derivative I (1 mmol/1 mol Ag), 3-ethyl-5-[2-(3-ethyl-2(3H)-thiazolinylideneethylidene] rhodanine (sensitizer), 5-methylbenzotriazole, 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene, poly(Et acrylate), and 2-hydroxy-4,6-dichloro-1,3,5-triazine Na salt. The sensitometrically exposed plate was developed in a pH 12 developer containing hydroquinone 40, 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidone 0.4, KBr 3.5, 5-methylbenzotriazole 0.8, Na2SO3 75, NaHCO3 7.0, di-Na EDTA salt 1.0, and glucose 54 g per L in an automatic developing system. The sensitivity after developing 200 large full size plates was 95% of that obtained using fresh developer, and the quality of the halftone neg. was unchanged and high. With a control developer not containing glucose, the spent developer gave 70% sensitivity and markedly inferior quality of neg. not practically usable.

IT 77887-29-7
RL: TEM (Technical or engineered material use); USES (Uses)

L9 ANSWER 154 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(photog. emulsion contg., for halftone neg. prodn., developer for)

RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 155 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:479419 CAPLUS
DN 103:79419
TI Silver halide photographic photosensitive material
IN Kasama, Yasuo; Inoue, Nobuaki
PA Fuji Photo Film Co., Ltd. , Japan
SO Eur. Pat. Appl., 78 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 143436	A2	19850605	EP 1984-114096	19841122 <--
	EP 143436	A3	19871209		
	R: DE, GB				
	JP 60112034	A2	19850618	JP 1983-219800	19831122 <--
	JP 04035055	B4	19920609		
	US 4999275	A	19910312	US 1986-925945	19861015 <--
PRAI	JP 1983-219800	A	19831122		
	US 1984-673642	B1	19841121		

OS MARPAT 103:79419
GI



AB A photog. material is described which permits formation of a super contrast neg. image useful for photomech. process. The material contains ≥1 Ag halide emulsion layer and ≥1 light-insensitive top layer which is hardened so as to have a melting time ≥50 s longer than that of the emulsion layer. The element contains a hydrazine compound RNHNHZR1 (R = aryl; R1 = H, alkyl, aryl, alkoxy, aryloxy; Z = CO, sulfonyl, sulfoxy, phosphonyl, imino group) in ≥1 of its layers. Thus, a Ag(Cl,Br) emulsion (AgCl 70 mol%) which was S-Au sensitized and contained 45 weight% gelatin was mixed with I at 4.5 + 10-3 mol/mol Ag, 3-ethyl-5-[2-(3-ethyl-2(3H)-thiazolinidene)ethylidene]rhodanine, 5-methylbenzotriazole, 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene, poly(Et acrylate), 2-hydroxy-4,6-dichloro-1,3,5-triazine Na salt and coated on a poly(ethylene terephthalate) support, by a two-layer simultaneous coating method where a top layer was formed from a composition containing 5% solution of acid-treated gelatin, a polymer latex (US Patent 3,525,620, example 3), surfactant, PMMA latex, and polymeric hardening agent (CH2CHCONHCMe2CH2SO3Na). The film was imagewise exposed, developed for 25 s in a solution containing hydroquinone 40, 4,4-dimethyl-1-phenyl-3-pyrazolidone 0.4, K3PO4 75, K2SO3 90, Na EDTA 1, KBr 6, 5-methylbenzotriazole 0.6 g, H2O to 1L, stopped, fixed, washed and dried, to give an image with relative sensitivity 91, γ = 10.5, fog d. 0.08. Melting times of emulsion layer and top layer were 780 and 1560 s, resp.

IT 77887-29-7
RL: USES (Uses)
(photog. high-contrast film for photomech. processes containing, polymeric

L9 ANSWER 155 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hardening agents for top layer of)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 156 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:462466 CAPLUS
DN 103:62466
TI Silver halide photographic material and method for forming a high contrast negative image
IN Inoue, Nobuaki; Inagaki, Yoshio; Kameoka, Kimitaka
PA Fuji Photo Film Co., Ltd. , Japan
SO Eur. Pat. Appl., 62 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 138200	A2	19850424	EP 1984-112235	19841011 <--
	EP 138200	A3	19871209		
	EP 138200	B1	19900117		
	R: DE, GB				
	JP 60083028	A2	19850511	JP 1983-191245	19831013 <--
	JP 03007929	B4	19910204		
	US 4681836	A	19870721	US 1986-933258	19861120 <--
PRAI	JP 1983-191245	A	19831013		
	US 1984-660580	A1	19841012		

OS MARPAT 103:62466
GI



I

AB A Ag halide material is described exhibiting high contrast neg. gradation (γ > 10) when processed with a stable developer. The material contains ≥1 emulsion layer containing Ag halide grains which contain Rh salt at 10-8-8 + 10-6 mol/mol Ag, and containing in the emulsion layer or another hydrophilic colloidal layer a compound RNHNHR1R2 (R = aliphatic aromatic group; R1 = carbonyl, sulfonyl, sulfoxy, phosphonyl, imino; R2 = H, alkyl, aryl, alkoxy, aryloxy). Thus, a Ag(Cl,Br) emulsion (Cl 90 mol%, Rh 2.7 + 10-7 mol/mol Ag, mean grain size 0.3 μm), was chemical S-Au sensitized, mixed with I 4.5 + 10-3 mol/mol Ag, then with a spectral sensitizer, an antifoggant and polyethylene acrylate stabilizing dispersion. The emulsion was coated on a cellulose triacetate support, imagewise exposed, developed at 38° for 20 s in a solution containing hydroquinone 40, 4,4-dimethyl-1-phenyl-3-pyrazolidone 0.4, Na2SO3 75, NaHCO3 7, di-Na ethylenediaminetetraacetate 1, KBr 6, 5-methylbenzotriazole 0.6 g, H2O to 1 L (pH adjusted with KOH to 11.5), followed by stopping, fixing, washing and drying steps. The material provided excellent image with γ = 18, fog 0.04.
IT 77887-29-7
RL: USES (Uses)
(photog. high contrast neg. gradation emulsion containing, for rapid processing)

L9 ANSWER 156 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 157 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:212590 CAPLUS
DN 102:212590
TI Treatment of a light-sensitive color photographic silver halide recording material
IN Koboshi, Shigeharu; Kurematsu, Masayuki
PA Konishiroku Photo Industry Co., Ltd. , Japan
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3412684	A1	19841004	DE 1984-3412684	19840404 <--
	DE 3412684	C2	19920527		
	JP 59184343	A2	19841019	JP 1983-57903	19830404 <--
	JP 62040698	B4	19870829		
	US 4567134	A	19860128	US 1984-593634	19840326 <--
PRAI	JP 1983-57903	A	19830404		

OS MARPAT 102:212590
GI



I II

III

AB A practically H2O-free and inexpensive stabilization of color images is achieved by using a Ag halide recording layer containing a cyan coupler of the formula I or II (R = a ballast group; R1 = COR3, CONR3R4, SO2R3, OSNR3R4, SO2NR3R4, SO2NHCONR3R4, CONHCOR3, or CONHSO2R3; R2 = H or a group eliminatable during the coupling of the oxidation product of a primary aromatic amine color developer compound; R3 = alkyl, alkenyl, cycloalkyl, aryl, or heterocyclyl; R4 = H, alkyl, alkenyl, cycloalkyl, aryl, or heterocyclyl; or R3 and R4 together form a 5- or 6-membered ring) and treating the exposed and developed image in a stabilizer bath containing 3-30 times the normal amount of stabilizer at pH 0.1-10 for 20 s to 10 min at 15-60°. Thus, III 6, di-Bu phthalate 3, and EtOAc 18 g were dissolved in DMF at 60°; this solution was mixed with 100 mL of a 5% gelatin solution and 10 mL of an alkylnaphthalene sulfonate and ultrasonically dispersed; this dispersion was mixed with a Ag(Cl,Br) emulsion containing 1,2-bis(vinylsulfonyl)ethane; and it was coated on polyethylene-laminated paper to give a film which was exposed through a step wedge, developed, bleach-fixed, stabilized in a bath containing

L9 ANSWER 157 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1-hydroxyethylene-1,1-diphosphoric acid, CaCl2, 2-octyl-4-isothiazolin-3-one, 5-chloro-2-methyl-4-isothiazolin-3-one, and aq. KOH at 25-30° for 3 min, and dried at 75-80° for 2 min to give an image which was stable after 300 h of light exposure.
IT 95524-31-5
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 95524-31-5 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 158 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1985:87570 CAPLUS
DN 102:87570
TI Photosensitive silver halide color photographic material
IN Yamada, Yoshitaka; Iijima, Toshifumi; Kumashiro, Kenji; Kamio, Takashi; Shimura, Shinya
PA Konishiroku Photo Industry Co., Ltd. , Japan
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 124861	A2	19841114	EP 1984-104902	19840502 <--
	EP 124861	A3	19860611		
	EP 124861	B1	19890125		
	R: DE, FR, GB				
	JP 59204038	A2	19841119	JP 1983-78288	19830506 <--
	US 4724198	A	19880209	US 1986-942025	19861215 <--
PRAI	JP 1983-78288	A	19830506		
	US 1984-605571	A1	19840430		

OS MARPAT 102:87570
AB Color photog. film assemblies exhibiting excellent graininess, sharpness, and sensitivity characteristics have red-sensitive, green-sensitive, and blue-sensitive layers, each layer consisting of ≥2 layers with different sensitivities and arranged according to color and sensitivity. The couplers used are diffusion resistant and are capable of forming mobile dyes.
IT 94816-34-9
RL: USES (Uses)
(color photog. film assembly containing diffusion-resistant coupler of, forming mobile dye, for improved graininess and sharpness and sensitivity)
RN 94816-34-9 CAPLUS
CN Benzamide, N-(4-cyanobenzoyl)-2-hydroxy-5-[[4-[(1-oxononyl)amino]phenyl]thio]-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 159 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:209309 CAPLUS
DN 100:209309
TI Some novel sulfanilyl derivatives
AU Cremlyn, R. J.; Swinbourne, F. J.; Batchelor, A.; Honeyman, R.; Nash, D.; Shode, O. O.; Patel, A.
CS Sch. Nat. Sci., Hatfield Polytech., Hatfield/Hertfordshire, UK
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1983), 22B(10), 1029-43
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
OS CASREACT 100:209309
AB Benzoic acid anilide and p-chloro, m-nitro, together with the 2,4-, 2,5- and 3,4-dichloro derivs., reacted with chlorosulfonic acid (I) in 1:4 molar ratios to give the corresponding sulfanilyl chlorides. However, nicotinic acid and isonicotinic acid anilides reacted with I, in 1:6 molar ratios only for conversion into the sulfanilyl chlorides.
2,4-Dichlorophenoxyacetic acid anilide reacted with I in 1:3 molar ratios to give the sulfanilyl chloride; this reaction when carried out in 1:7 molar ratios of the reactants gave the disulfonyl chloride. The various sulfanilyl chlorides were treated with amines, azide ion, and hydrazine to give a range of sulfonyl compds. The compds. prepared have been subjected to preliminary biol. screening.
IT 89565-58-2P 89565-59-3P 89565-60-6P
89565-64-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 89565-58-2 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[4-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 89565-59-3 CAPLUS
CN Benzenesulfonic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



RN 89565-60-6 CAPLUS
CN Benzenesulfonic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 159 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 89565-64-0 CAPLUS
CN Acetamide, 2-[2,4-dichloro-6-(dimethylamino)phenoxy]-N-[4-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 160 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:167887 CAPLUS
DN 100:167887
TI Inhibitory effect of cloxacepride on compound 48/80-induced histamine and serotonin release from rat mast cells
AU Friedrich, G.; Haas, R.; Metz, G.
CS Contract-Research Dr. Gerhard Friedrich, Denzlingen, D-7809, Fed. Rep. Ger.
SO Archives Internationales de Pharmacodynamie et de Therapie (1984), 267(2), 264-8
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English
GI



I

AB Cloxacepride (I) [65569-29-1], a potent inhibitor of passive cutaneous anaphylaxis in the rat, was evaluated for in vitro inhibitory effect on compound 48/80-induced histamine [51-45-6] and serotonin [50-67-9] release from rat masenteric mast cells. Significant inhibition and a linear relation between concentration and effect were found in the concentration range 10-50 μM. The mean inhibitory concentration (IC50) was 21 and 19 μM with respect to histamine and serotonin, resp. There was simultaneous liberation of both mediators, as indicated by the nearly identical IC50 values. Higher concns. of cloxacepride (>50 μM) resulted in cell damage. The reference compds. cromolyn Na and theophylline were inactive at higher concns. of compound 48/80 (10 μg/mL), whereas the activity of cloxacepride was not affected under these conditions. The results are discussed in the light of the antiallergic potential of cloxacepride.
IT 65569-29-1
RL: BIOL (Biological study)
(histamine and serotonin release from mast cell response to, antiallergic mechanism in relation to)
RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 160 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 161 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:531295 CAPLUS
DN 99:131295
TI Color photographic image formation
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 58106539	A2	19830624	JP 1981-205703	19811218 <--
JP 05000695	B4	19930106		
PRAI JP 1981-205703		19811218		

GI



I

II



III



IV

AB A multilayered color photog. material having a Ag halide photog. emulsion layer containing a cyan coupler of the general formula I (R = OH, CO2H, alkyl, aryl, alkoxy, aryloxy, arylsulfamoyl, alkylsulfamoyl, alkylsulfamoylamino, arylsulfamoylamino, alkylsulfonamido, arylsulfonamido, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, acyloxy; R1 = acyl, carbamoyl; R2 = H, halo; Z1 = phenylene; Z2 = alkylene; R3 = H or a moiety to be eliminated on coupling; m= 1-3) is imagewise exposed, developed with a solution containing a color developer of the general formula II [R4 = H, alkyl, R5; R5 = (Z3O)n(Z4O)pR7 (Z3, Z4 = alkylene and may be identical; n, p = 0-4, but are not simultaneously zero; R7 = H, aryl, alkyl; R7 = aryl, alkyl when n or p = 0; R4 = C3-4 alkyl when R7 = H); R6 = H, halo, alkyl, OH, alkoxy, alkylsulfonamido, acylamido, amino], and then treated with a bleach-fixing solution of pH ≤6 to give a high-quality color photog. image showing no stains and with improved stability. Thus, a polyethylene-coated support was coated with a Ag(Cl,Br) photog. emulsion (AgBr 20 mol%) containing

L9 ANSWER 161 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
the coupler III to obtain a photog. material which was exposed through an optical wedge, color-developed with a soln. contg. IV, and bleach-fixed (pH = 5.0) to give excellent results.
IT 86949-87-3
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler, for stain free images and improved stability)
RN 86949-87-3 CAPLUS
CN Acetic acid, [5-[[[[[2,4-bis(1,1-dimethylpropyl)phenoxy]methyl]amino]carbonyl]amino]-2-[[[3-[(hexylamino)sulfonyl]phenoxy]acetyl]amino]-4-hydroxyphenoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 162 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:470404 CAPLUS
DN 99:70404
TI 1-Aryloxy-3-alkynylamino-2-propanol
IN Koeppe, Herbert; Kummer, Werner; Staehle, Helmut; Muacevic, Gojko; Traunecker, Werner
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Ger. Offen., 23 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3133719	A1	19830310	DE 1981-3133719	19810826 <--
	NO 8202221	A	19830228	NO 1982-2221	19820629 <--
	NO 152604	B	19850715		
	NO 152604	C	19851023		
	US 4442121	A	19840410	US 1982-398578	19820715 <--
	CA 1163641	A1	19840313	CA 1982-407690	19820721 <--
	EP 73011	A1	19830302	EP 1982-107519	19820818 <--
	EP 73011	B1	19860402		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 18903	E	19860415	AT 1982-107519	19820818 <--
	FI 8202913	A	19830227	FI 1982-2913	19820823 <--
	FI 76784	B	19880831		
	FI 76784	C	19881212		
	IL 66632	A1	19860131	IL 1982-66632	19820824 <--
	DK 8203803	A	19830227	DK 1982-3803	19820825 <--
	AU 8287719	A1	19830303	AU 1982-87719	19820825 <--
	AU 555636	B2	19861002		
	JP 58046056	A2	19830317	JP 1982-147517	19820825 <--
	ES 515246	A1	19830801	ES 1982-515246	19820825 <--
	ZA 8206182	A	19840425	ZA 1982-6182	19820825 <--
	ES 520092	A1	19831201	ES 1983-520092	19830225 <--
	ES 520093	A1	19831201	ES 1983-520093	19830225 <--
PRAI	DE 1981-3133719	A	19810826		
	EP 1982-107519	A	19820818		

OS CASREACT 99:70404; MARPAT 99:70404
GI



I



II

L9 ANSWER 162 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[3-cyano-4-[3-[(1,1-dimethyl-2-propynyl)amino]-2-hydroxypropoxy]phenyl]-2-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 162 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB Alkynylpropanolamines I [R = cycloalkyl, (un)substituted alkyl, Ph; R1 = H, alkyl, alkoxy; R2 = H, alkyl; R3 = alkyl; R2R3 = alkylene) were prepared Thus, 9 g II (R4 = Cl) was treated with 12.5 mL H2NCMe2C.tplbond.CH to give 2.8 g II (R4 = NHCMe2C.tplbond.CH). I are β-sympatholytics with good heart selectivity (no data).
IT 86342-44-1P 86342-46-3P 86342-49-6P
86342-50-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86342-44-1 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[3-cyano-4-[3-[(1,1-dimethyl-2-propynyl)amino]-2-hydroxypropoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 86342-46-3 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[3-cyano-4-[3-[(1,1-dimethyl-2-propynyl)amino]-2-hydroxypropoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 86342-49-6 CAPLUS
CN Acetamide, N-[3-cyano-4-[3-[(1,1-dimethyl-2-propynyl)amino]-2-hydroxypropoxy]phenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 86342-50-9 CAPLUS

L9 ANSWER 163 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:461680 CAPLUS
DN 99:61680
TI Cyan couplers for photographic films
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58031334	A2	19830224	JP 1981-130459	19810819 <--
	JP 63029732	B4	19880615		
PRAI	JP 1981-130459		19810819		

GI



I II



III

AB Cyan coupler having superior color development sensitivity and developed image d. without the addition of benzyl alc. have the general structure I and
II (R,R1 = H, alkyl, alkenyl, aryl, heterocycle, cycloalkyl, acyl; R2 is a ballast group; and R3 is a group which is released upon reaction with the oxidation product of a color developer. E.g., cyan coupler III provides the above desired characteristics for color photog. systems.
IT 86451-82-3
RL: USES (Uses)
(photog. film cyan coupler, for superior color development sensitivity and developed image d.)
RN 86451-82-3 CAPLUS
CN Acetamide, N-[5-chloro-4-[[(diethylamino)carbonyl]amino]-2-hydroxyphenyl]-2-[4-(dodecyloxy)phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 163 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:432761 CAPLUS
DN 99:32761
TI Cloxacepride and related compounds: a new series of orally active antiallergic compounds
AU Metz, Gunter; Pindell, M. H.; Chen, H. L.
CS Dep. Res. Dev., MERCKLE G.m.b.H., Blaubeuren, 7902, Fed. Rep. Ger.
SO Journal of Medicinal Chemistry (1983), 26(7), 1065-70
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 99:32761
GI



I



II

AB I (R = H, Cl, F, I, CF3, Me, MeO; R1 = H or Cl; R2 = H, Me, 4-ClC6H4O; R3 = H or Me; R4 = OH, OEt, NHCH2CH2NEt2, etc.; X = O or NH) and II (R = H, Cl, F; R1 = H, Cl, MeO, AcO) and their salts were prepared by acidation with the appropriate acid chloride of either an aminobenzoic acid or by acylation with an acid chloride of com. metoclopramide [364-62-5]. I and II were investigated for antiallergic activity in rats. Cloxacepride (I, R = Cl; R1 = H; R2 and R3 = H; R4 = NHCH2CH2NEt2; X = O) and its Me analog (I, R = Cl; R1 = H; R2 = Me; R3 = H; R4 = NHCH2CH2NEt2; X = O) administered 15-240 min before antigenic challenge, inhibited the passive cutaneous anaphylaxis reaction at all time intervals with the peak effect at 3-6 h after administration. Structure-activity relations are discussed.

IT 65569-29-1P 65569-32-6P 65569-40-6P
65569-41-7P 65569-42-8P 65569-43-9P
65569-50-8P 65569-51-9P 65569-53-1P
65569-54-2P 65569-57-5P 70853-42-8P
70853-43-9P 70853-47-3P 70853-48-4P
85630-48-4P 85630-52-0P 85630-53-1P
85630-54-2P 85630-55-3P 85630-56-4P
85630-57-5P 85630-58-6P 85630-59-7P
85630-60-0P 85630-61-1P 85630-62-2P
85630-64-4P 85630-65-5P 85630-66-6P
85630-67-7P 85630-71-3P 85630-72-4P
85630-78-0P 85630-79-1P 85630-80-4P
85630-81-5P 85630-82-6P

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and allergy-inhibiting activity of)

RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-32-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-40-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-41-7 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 65569-42-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 65569-43-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-50-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 65569-51-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-53-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 65569-54-2 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-57-5 CAPLUS

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 70853-47-3 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-48-4 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 70853-47-3
CMF C21 H26 Cl N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 85630-48-4 CAPLUS
CN Butanedioic acid, compd. with 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-29-1

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



RN 70853-42-8 CAPLUS
CN Benzamide, 2-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-43-9 CAPLUS
CN Benzamide, 2-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 70853-42-8
CMF C21 H25 Cl2 N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C22 H27 Cl2 N3 O4



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 85630-52-0 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-fluorophenoxy)acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 85630-53-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-fluorophenoxy)acetyl]amino]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-54-2 CAPLUS
CN Benzamide, 5-chloro-4-[[(3,4-dichlorophenoxy)acetyl]amino]-N-[2-

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 85630-55-3 CAPLUS
CN Benzamide, 5-chloro-4-[[(3,4-dichlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-56-4 CAPLUS
CN Benzamide, 5-chloro-4-[[(2,4-dichlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 85630-57-5 CAPLUS
CN Benzamide, 5-chloro-4-[[(2,4-dichlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 85630-58-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(2,3-dichlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 85630-59-7 CAPLUS
CN Benzamide, 5-chloro-4-[[(2,3-dichlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-60-0 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methoxyphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 85630-61-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methoxyphenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-62-2 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-64-4 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 85630-65-5 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-66-6 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



RN 85630-67-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-71-3 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 85630-72-4 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-78-0 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxy-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 85630-79-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxy-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 164 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 85630-80-4 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxy-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 85630-81-5 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[3-(diethylamino)propyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 85630-82-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[3-(diethylamino)propyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 165 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:422144 CAPLUS
DN 99:22144
TI 1-Aryloxy-3-alkylamino-2-propanols
IN Koeppe, Herbert; Kummer, Werner; Staehle, Helmut; Muacevic, Gojko; Traunecker, Werner
PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 73016	A1	19830302	EP 1982-107536	19820818 <--
	EP 73016	B1	19851127		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DE 3133678	A1	19830317	DE 1981-3133678	19810826 <--
	NO 8202220	A	19830228	NO 1982-2220	19820629 <--
	NO 152603	B	19850715		
	NO 152603	C	19851023		
	US 4442120	A	19840410	US 1982-398577	19820715 <--
	CA 1165324	A1	19840410	CA 1982-408021	19820726 <--
	AT 16700	E	19851215	AT 1982-107536	19820818 <--
	FI 8202912	A	19830227	FI 1982-2912	19820823 <--
	FI 75150	B	19880129		
	FI 75150	C	19880509		
	IL 66633	A1	19860228	IL 1982-66633	19820824 <--
	DK 8203804	A	19830227	DK 1982-3804	19820825 <--
	AU 8287718	A1	19830303	AU 1982-87718	19820825 <--
	AU 558338	B2	19870129		
	JP 58059957	A2	19830409	JP 1982-147518	19820825 <--
	ES 515245	A1	19830801	ES 1982-515245	19820825 <--
	ZA 8206183	A	19840425	ZA 1982-6183	19820825 <--
	ES 520094	A1	19831201	ES 1983-520094	19830225 <--
	ES 520095	A1	19831201	ES 1983-520095	19830225 <--
PRAI	DE 1981-3133678	A	19810826		
	EP 1982-107536	A	19820818		

OS CASREACT 99:22144; MARPAT 99:22144
GI



I



II

L9 ANSWER 165 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB β-Sympatholytic (no data) phenoxypropanolamines I [R = cycloalkyl, (un)substituted Ph, aryloxyalkyl; R1 = H, halo, alkoxy; R2 = alkyl] were prepared Thus, 7 g 1-[2-cyano-4-[2-(3-methylphenoxy)acetamido]phenoxy]-2,3-epoxypropane was treated with Me3CNH2 to give 2.6 g II.
IT 86265-38-5P 86265-49-8P 86265-50-1P
86265-51-2P 86265-52-3P 86265-53-4P
86265-54-5P 86265-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86265-38-5 CAPLUS
CN Acetamide, N-[3-cyano-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 86265-49-8 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[3-cyano-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 86265-50-1 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[3-cyano-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 86265-51-2 CAPLUS
CN Acetamide, N-[3-cyano-4-[2-hydroxy-3-[(1-methylpropyl)amino]propoxy]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 165 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 86265-55-6 CAPLUS
CN Acetamide, 2-(4-bromophenoxy)-N-[3-cyano-4-[2-hydroxy-3-[(1-methylpropyl)amino]propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 165 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 86265-52-3 CAPLUS
CN Acetamide, N-[3-cyano-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-2-(3-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 86265-53-4 CAPLUS
CN Acetamide, N-[3-cyano-4-[2-hydroxy-3-[(1-methylpropyl)amino]propoxy]phenyl]-2-(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 86265-54-5 CAPLUS
CN Acetamide, 2-(4-bromophenoxy)-N-[3-cyano-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 166 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:491969 CAPLUS
DN 97:91969
TI Herbicidal N4-(phenoxyalkanoyl)sulfanilamides
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57059855	A2	19820410	JP 1980-136648	19800929 <--
	JP 62022981	B4	19870520		
PRAI	JP 1980-136648		19800929		

OS CASREACT 97:91969
GI



I

AB Seven herbicidal sulfanilamides I (R = H, halo, nitro, alkyl; R1 = H, Me; R2 = Me, OMe) were prepared I inhibited the sprouting but not the growth of weeds. Thus, 18 mmol 1-(2-methyl-4-chlorophenoxy)propionic acid was heated with SOCl2 and the acid chloride treated with 32 mmol N1-(methoxycarbonyl)sulfanilamide in C5H5N to give 71.6% I (R = 2-Me, 4-Cl; R1 = Me; R2 = OMe).
IT 78357-58-1P 78357-59-2P 78357-60-5P
78357-61-6P 78357-62-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and herbicidal activity of)
RN 78357-58-1 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]phenyl]-2-(4-chloro-2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 78357-59-2 CAPLUS
CN Carbamic acid, [[4-[[(3,5-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 166 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 78357-60-5 CAPLUS
CN Carbamic acid, [[4-[[(3,5-dimethylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-61-6 CAPLUS
CN Carbamic acid, [[4-[[(4-nitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-62-7 CAPLUS
CN Carbamic acid, [[4-[[(3-nitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 78373-24-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 78373-24-7 CAPLUS
CN Carbamic acid, [[4-[[(2,4-dinitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 166 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 167 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:451808 CAPLUS
DN 97:51808
TI Photographic microquantitation of enzymes
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57047493	A2	19820318	JP 1980-120600	19800902 <--
	JP 61001118	B4	19860114		
	EP 48834	A1	19820407	EP 1981-106826	19810901 <--
	EP 48834	B1	19850619		
	R: CH, DE, FR, GB				
	US 4414325	A	19831108	US 1981-298814	19810902 <--
PRAI	JP 1980-120600	A	19800902		

GI



I

AB A synthetic substrate (having a mol. structure that specifically reacts with the enzyme to be determined and also that has a spectral sensitizing mol. structure) is contacted with the enzyme to be determined Then, either the enzymic reaction product or the unreacted synthetic substrate remaining is reacted with an Ag halide, exposed to the spectrum of light that corresponds to the spectral sensitivity of the substrate, photog. developed, and the concentration of the Ag image and (or) the color developed is determined as an enzyme activity and (or) the enzymic content of the sample. This method is suitable for determining protein-decomposing enzymes, peptide-decomposing enzymes, nucleic acid-decomposing enzymes, sugar-decomposing enzymes, and lipid-decomposing enzymes. Thus, 1 mL each of I-modified glycylphenylalaninamide (1 mg/mL) in 0.05M Tris-HCl buffer (pH 8.5) containing 1% surfactant and bovine pancreas α-chymotrypsin at 2, 20, and 200 pg/mL in 0.05M Tris-HCl buffer (pH 8.5) were mixed, incubated at 40° for 5 min, and mixed with 0.1 mg tosylamidophenylalanylchlorome thylketone to stop the enzyme reaction. Each reaction mixture was passed through CM-Sephadex C-50, the column washed with 1 mL 0.05M Tris-HCl buffer (pH 8.5) and the eluent and washings collected. The collected liquid (25 μL each) was applied to the unexposed AgBrCl film in a spot 5 mm diameter The film was allowed to stand at room temperature in the dark for 20 min and exposed to a light through Fuji Film Filter SC-66 at 108 lx for 10-3 s, conventionally developed, and the intensity of darkness of the spot determined The darkness of the spots was directly proportional to the concentration of α-chymotrypsin.

L9 ANSWER 167 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 77887-29-7
RL: BIOL (Biological study)
(photosensitizing enhancer, for enzyme assay)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:480477 CAPLUS
DN 95:80477
TI N4-Phenoxyalkanoylsulfanilamides and their use
IN Ito, Kanji; Ikawa, Kenji; Yukinaga, Hisajiro; Sugita, Jitsuo
PA Shionogi and Co., Ltd., Japan
SO Ger. Offen., 41 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3034063	A1	19810409	DE 1980-3034063	19800910 <--
	JP 56049347	A2	19810502	JP 1979-122423	19790921 <--
	JP 60055062	B4	19851203		
	AU 8061937	A1	19810924	AU 1980-61937	19800901 <--
	AU 534963	B2	19840223		
	CA 1140569	A1	19830201	CA 1980-359541	19800904 <--
	US 4314845	A	19820209	US 1980-185965	19800909 <--
	GB 2061923	A	19810520	GB 1980-29181	19800910 <--
	GB 2061923	B2	19840229		
	FR 2465719	A1	19810327	FR 1980-19764	19800912 <--
	FR 2465719	B1	19831125		
	ES 495058	A1	19811001	ES 1980-495058	19800915 <--
	CH 644843	A	19840831	CH 1980-7002	19800918 <--
	BR 8006038	A	19810407	BR 1980-6038	19800919 <--
PRAI	JP 1979-122423	A	19790921		

OS CASREACT 95:80477
GI



I



II

AB The title sulfanilamides I (R1, R2, R3, R4 independently = H, halo, NO2, alkyl; R5 = H, alkyl; R6 = H, CONH, alkoxycarbonyl, alkanoyl) and their alkali or alkaline earth metal or NH4 salts, useful as herbicides (extensive data tabulated), were prepared by N4-acylation of 4-H2NC6H4SO2NHR6 with 2,3,4,5-R4R3R2R1C6HOCHR5COX (X = halo, OH, alkoxy). Treating 4-H2NC6H4SO2NHCO2Me in pyridine <20° with 2,4-MeClC6H3OCH2COCl and keeping the mixture 60 min at 20° gave 78% (phenoxyacetyl)sulfanilamide II.
IT 78357-43-4P 78357-44-5P 78357-45-6P
78357-46-7P 78357-47-8P 78357-48-9P

L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 78357-47-8 CAPLUS
CN Carbamic acid, [[4-[[(2,4-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-48-9 CAPLUS
CN Carbamic acid, [[4-[[(4-chloro-2-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-49-0 CAPLUS
CN Carbamic acid, [[4-[[(4-chloro-2-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 78357-50-3 CAPLUS

L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
78357-49-0P 78357-50-3P 78357-51-4P
78357-52-5P 78357-53-6P 78357-54-7P
78357-55-8P 78357-56-9P 78357-58-1P
78357-59-2P 78357-60-5P 78357-61-6P
78357-62-7P 78370-90-8P 78531-16-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)
RN 78357-43-4 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(4-chloro-2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 78357-44-5 CAPLUS
CN Carbamic acid, [[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-45-6 CAPLUS
CN Carbamic acid, [[4-[[(4-chlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-46-7 CAPLUS
CN Carbamic acid, [[4-[[(3,4-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Carbamic acid, [[4-[[(4-chloro-2-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 78357-51-4 CAPLUS
CN Acetamide, N-[4-[[(aminocarbonyl)amino]sulfonyl]phenyl]-2-(4-chloro-2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 78357-52-5 CAPLUS
CN Carbamic acid, [[4-[[(4-bromophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-53-6 CAPLUS
CN Carbamic acid, [[4-[[(3-chlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 78357-54-7 CAPLUS
CN Carbamic acid, [[4-[[(2-chlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-55-8 CAPLUS
CN Carbamic acid, [[4-[[(3-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-56-9 CAPLUS
CN Carbamic acid, [[4-[[(2-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-58-1 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]phenyl]-2-(4-chloro-2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 78357-59-2 CAPLUS

L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Carbamic acid, [[4-[[(3,5-dichlorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-60-5 CAPLUS
CN Carbamic acid, [[4-[[(3,5-dimethylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-61-6 CAPLUS
CN Carbamic acid, [[4-[[(4-nitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78357-62-7 CAPLUS
CN Carbamic acid, [[4-[[(3-nitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78370-90-8 CAPLUS
CN Carbamic acid, [[4-[[(4-methylphenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 168 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 78531-16-5 CAPLUS
CN Carbamic acid, [[4-[[(4-fluorophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 78357-64-9P 78373-24-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 78357-64-9 CAPLUS
CN Carbamic acid, [[4-[[(2-nitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78373-24-7 CAPLUS
CN Carbamic acid, [[4-[[(2,4-dinitrophenoxy)acetyl]amino]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 169 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:415909 CAPLUS
DN 95:15909
TI Formation of a negative dot image
IN Yoshihiro, Takagi; Yoshitaka, Akimura; Hiroyuki, Mifune; Eiichi, Okutsu
PA Fuji Photo Film Co., Ltd., Japan
SO Ger. Offen., 67 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3023099	A1	19810108	DE 1980-3023099	19800620 <--
	JP 56001936	A2	19810110	JP 1979-78338	19790621 <--
	JP 62004700	B4	19870131		
	JP 56009743	A2	19810131	JP 1979-85660	19790706 <--
	JP 62004701	B4	19870131		
	US 4385108	A	19830524	US 1980-162350	19800623 <--
PRAI	JP 1979-78338	A	19790621		
	JP 1979-85660	A	19790706		

OS MARPAT 95:15909
AB Neg. point images can be produced by imagewise exposure through a contact screen of a photog. material of the latent surface-image type containing either in the emulsion layer or another hydrophilic layer a developer derived from hydroquinone and a compound of the formula R1NHNHCOR2 (R1 = aryl; R2 = H, alkyl, aryl) in such an amount that is does not act as a developing agent. The exposed material is processed in an aqueous activator solution with a pH of >11.5 and (optionally) containing a compound of the formula NH2NR3R4 (R3 = H or lower alkyl; R4 = H, lower alkyl, alkoxycarbonyl, heterocycle, carbamoyl, carbazolyl, acyl, or Ph). Thus, to a gelatin-AgBr emulsion of the latent surface-image type (average grain size 0.25 μ; 120 g gelatin/mol AgBr) were added 5-methylbenzotriazole (antifoggant), 2-hydroxy-4,6-dichloro-1,3,5-triazine Na salt (hardener), hydroquinone 52.8, p-MeC6H4NHNHCHO 1.0 + 10-3, and p-C9H19C6H4O(CH2CH2O)30H 0.4 g/mol Ag and the resulting mixture was coated on cellulose triacetate support at 45 g/100 cm2. Upon sensitometric exposure using a 150 line magenta screen and processing in an activator solution Na2SO3 2, KBr 5, K2CO3 40, NaOH 30 g and water to 1 L, a relative sensitivity of 100, a point quality of 1, and a screen area of 1.45 were obtained vs. 32, 5, and 1.20 for a control containing only hydroquinone.
IT 77887-29-7
RL: USES (Uses)
(photog. materials containing hydroquinone and, for neg. dot image production)
RN 77887-29-7 CAPLUS
CN Acetamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 169 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 170 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:174621 CAPLUS

DN 94:174621

TI Phenylethylamine derivatives and their use

IN Gillet, Claude; Roba, Joseph; Cordi, Alexis; Van Dorsser, William; Lambelin, Georges

PA Continental Pharma, Belg.

SO Ger. Offen., 75 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3016827	A1	19801120	DE 1980-3016827	19800502 <--
	BE 883068	A1	19800818	BE 1980-200432	19800430 <--
	BE 883069	A1	19800818	BE 1980-200433	19800430 <--
	DK 8001878	A	19801105	DK 1980-1878	19800430 <--
	DK 8001879	A	19801105	DK 1980-1879	19800430 <--
	SE 8003277	A	19801105	SE 1980-3277	19800430 <--
	SE 8003278	A	19801105	SE 1980-3278	19800430 <--
	FR 2455572	A1	19801128	FR 1980-9846	19800430 <--
	FR 2455572	B1	19860725		
	FR 2455587	A1	19801128	FR 1980-9847	19800430 <--
	FR 2455587	B1	19830624		
	US 4338330	A	19820706	US 1980-145144	19800430 <--
	IL 59973	A1	19850331	IL 1980-59973	19800501 <--
	FI 8001428	A	19801105	FI 1980-1428	19800502 <--
	FI 8001429	A	19801105	FI 1980-1429	19800502 <--
	NO 8001285	A	19801105	NO 1980-1285	19800502 <--
	NO 150916	B	19841001		
	NO 150916	C	19850116		
	NO 8001286	A	19801105	NO 1980-1286	19800502 <--
	NL 8002567	A	19801106	NL 1980-2567	19800502 <--
	NL 8002568	A	19801106	NL 1980-2568	19800502 <--
	GB 2055091	A	19810225	GB 1980-14645	19800502 <--
	GB 2055360	A	19810304	GB 1980-14647	19800502 <--
	GB 2055360	B2	19830706		
	ES 491142	A1	19810316	ES 1980-491142	19800502 <--
	ES 491143	A1	19810416	ES 1980-491143	19800502 <--
	CA 1146563	A1	19830517	CA 1980-351169	19800502 <--
	CH 644599	A	19840815	CH 1980-3453	19800502 <--
	CH 645090	A	19840914	CH 1980-3452	19800502 <--
	AU 8058095	A1	19801106	AU 1980-58095	19800505 <--
	AU 537573	B2	19840705		
	AU 8058096	A1	19801106	AU 1980-58096	19800505 <--
	AU 542596	B2	19850228		
	ZA 8002694	A	19810826	ZA 1980-2694	19800505 <--
	ZA 8002695	A	19810826	ZA 1980-2695	19800505 <--
	AT 8002387	A	19840315	AT 1980-2387	19800505 <--
	AT 376210	B	19841025		
	AT 8002386	A	19840415	AT 1980-2386	19800505 <--
	AT 376418	B	19841126		
	JP 56005465	A2	19810120	JP 1980-59846	19800506 <--
	JP 56063946	A2	19810530	JP 1980-59847	19800506 <--
	JP 60033424	B4	19850802		
PRAI	LU 1979-81225	A	19790504		

L9 ANSWER 170 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

OS MARPAT 94:174621

GI



I

II

AB Sixty one title compds. I (R = C1-16 alkyl C3-8 cycloalkyl, halo-, alkyl-, or alkoxy- phenyl or phenoxy-substituted C1-4 alkyl; R1 = H, C1-3 alkyl; R2 = C1-16 alkyl, C3-8 cycloalkyl, C3-12 alkenyl, C3-8 alkynyl, C1-4 alkyl substituted with C1-6 alkylcarboxamino, C3-8 cycloalkylcarboxamido, halo-, alkyl-, or alkoxy- substituted phenyl or phenoxy groups; X = O or H2), were prepared and in many cases tested as blood platelet aggregation inhibitors. Thus, 4-PhCH2OC6H4CH2CH2NH2 was treated with octanoyl chloride, hydrogenolyzed, treated with epichlorohydrin, then with Me2CHNH2, and reduced with diborane to give II.

IT 76977-45-2P 76977-46-3P 76977-47-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 76977-45-2 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[[3-[4-[2-[[(4-chlorophenoxy)acetyl]amino]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 76977-46-3 CAPLUS

CN Propanamide, N-[2-[[3-[4-[2-[[(4-chlorophenoxy)acetyl]amino]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 170 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 76977-47-4 CAPLUS

CN Benzeneacetamide, N-[2-[[3-[4-[2-[[(4-chlorophenoxy)acetyl]amino]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 171 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:65461 CAPLUS
DN 94:65461
TI 4-Unsubstituted azetidinone derivatives
IN Hashimoto, Masashi; Hemmi, Keiji; Kamiya, Takashi; Komori, Tadaaki; Nakaguti, Osamu; Saito, Yoshihisa; Shiokawa, Youichi; Takasugi, Hisahi; Takaya, Takao; Teraji, Tsutomu
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S., 130 pp. Cont.-in-part of U.S. Ser. No. 694,891, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4207234	A	19800610	US 1977-858375	19771207 <--
	US 4472300	A	19840918	US 1980-130205	19800313 <--
PRAI	US 1975-593668	A2	19750707		
	US 1976-694891	A2	19760610		
	US 1977-858375	A3	19771207		

OS CASREACT 94:65461; MARPAT 94:65461
GI



I

AB Lactacillanic acids and analogs I (R = NH2, acylamino, benzenesulfonamido; R1 = CO2H, pharmaceutically acceptable salt or ester derivative of CO2H; R2 = H, NH2, NO2, halo, alkoxy, alkylthio; R3 = H, OH, alkyl, alkylthio, OCH2Ph; R4 = H, Halo, alkoxy, alkylthio), which showed bactericidal activity, were prepared Thus, 3-aminolactacillanic acid reacted with PhCH2COCl in water-Me2CO containing NaHCO3 to yield I (R = PhCH2CONH, R1 = CO2H, R3 = OH, R2 = R4 = H).
IT 59509-23-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59509-23-8 CAPLUS
CN 1-Azetidineacetic acid, α-(4-hydroxyphenyl)-2-oxo-3-[[4-[(phenoxyacetyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 171 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 172 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:39519 CAPLUS
DN 94:39519
TI High-contrast photographic materials
IN Mifune, Hiroyuki; Hirano, Shigeo; Minami, Ashigara
PA Fuji Photo Film Co., Ltd., Japan
SO Ger. Offen., 50 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2952587	A1	19800710	DE 1979-2952587	19791228 <--
	DE 2952587	C2	19900823		
	JP 55090940	A2	19800710	JP 1979-82	19781228 <--
	JP 59052818	B4	19841221		
	GB 2039377	A	19800806	GB 1979-43546	19791218 <--
	GB 2039377	B2	19830119		
	US 4272614	A	19810609	US 1979-105689	19791220 <--
	BE 880942	A1	19800416	BE 1979-198806	19791228 <--
PRAI	JP 1979-82	A	19781228		

GI For diagram(s), see printed CA Issue.
AB A photog. material contains ≥1 emulsion layer with Ag halide grains essentially of the latent surface image type, and the emulsion layer or ≥1 other hydrophilic colloid layer contains a compound of formula I (R, R1 = H, aliphatic group, aromatic group; Z = group of atoms necessary to complete a 5- or 6-membered heterocyclic ring; Z1 = divalent group; Z2 = divalent aromatic group; n = 0, 1). In photog. processes using this material the developer solution has ≤0.05 mol/L sulfite ion and pH 10.5-12.3 and contains dihydroxybenzene and/or poly(ethylene oxide). Thus, to an aqueous gelatin solution (50°) was simultaneously added aqueous AgNO3 and aqueous KBr for 30 min, during which time the pAg reached 8.0. The AgBr emulsion thus obtained had a particle size of 0.22 μ. After the soluble salts were removed the emulsion was chemical ripened for 75 min at 60° by addition of Na2S2O3 48 mg/mol AgBr to give an emulsion containing 100 g gelatin/mol AgBr. To this emulsion was added 1-formyl-2-[4-[3-(2-mercaptoethyl)benzothiazolin-2-ylideneamino]phenyl]hydrazine (II) 0.07 g/mol AgBr, and also 5-methylbenzotriazole as antifoggant, 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene as stabilizer, a poly(Et acrylate) dispersion for dimensional stability, and 2-hydroxy-4,6-dichloro-1,3,5-triazine Na salt as hardener. The mixture was coated on a cellulose triacetate film to give 48 mg Ag/100 cm2. Samples of the film were exposed 1 s under an optical wedge. After development of samples at 20° under 3 different stirring conditions, fixing, washing, and drying, the sensitivity, E, and γ values were determined The stirring conditions were: 1) the system was stirred by passing a N stream at 200 mL/min for 5 min immediately after beginning of development and then allowed to stand; 2) the system was stirred for 5 min by the N stream, allowed to stand 15 s, and then the stirring repeated for 5 min; 3) the system was stirred during the entire time of development. The developer solution consisted of: p-(methylamino)phenol hemisulfate 5, hydroquinone 10, Na2SO3 75, NaBO2.4H2O 30, poly(ethylene glycol) (average mol. weight 1500) 1, KOH 12 g, and H2O to 1 L. The E and γ values obtained with development conditions 1, 2, and 3 were 100 and 20, 100 and 20, and 110 and 20, resp., whereas with a comparison film containing 1-formyl-2-p-tolylhydrazine 3.3 g/mol AgBr in place of II the results were 132 and 20, 105 and 17, and 72 and 12, resp.

L9 ANSWER 172 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 76148-24-8
RL: USES (Uses)
(photog. emulsions containing, for production of high-contrast images without effects of development stirring conditions)
RN 76148-24-8 CAPLUS
CN Acetamide, N-[4-(2-formylhydrazino)phenyl]-2-[4-[(3-methyl-2(3H)-benzothiazolylidene)amino]phenoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 173 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:9957 CAPLUS
DN 94:9957
TI Light-sensitive photographic material for contrasty negative images
IN Mifune, Hiroyuki; Takada, Shinji; Akimura, Yoshitaka; Hirano, Shigeo
PA Fuji Photo Film Co., Ltd., Japan
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2941428	A1	19800430	DE 1979-2941428	19791012 <--
	DE 2941428	C2	19910103		
	JP 55052050	A2	19800416	JP 1978-125602	19781012 <--
	JP 60015261	B4	19850418		
	GB 2034908	A	19800611	GB 1979-34781	19791008 <--
	GB 2034908	B2	19821103		
	US 4243739	A	19810106	US 1979-83750	19791011 <--
PRAI	JP 1978-125602	A	19781012		

AB Photog. materials which use a stable developer to produce an extremely contrasty neg. image and whose sensitivity and gradation are not altered by a change in the processing, e.g., stirring the developer, are composed of ≥1 gelatin-Ag halide emulsion layer containing Ag halide grains of the latent surface image forming type and a hydrazide of the formula R(Z2)nZ2NHNHCOR1 (R = a group containing the CSNH linkage; R1 = H, alkyl, or substituted or unsubstituted aryl; Z, Z2 = substituted or unsubstituted arylene groups; Z1 = a divalent group) incorporated therein or in a hydrophilic colloid layer. Thus, a Na2S2O4-sensitized gelatin-AgBr emulsion containing 1-formyl-2-[4-(S-methyldithiocarbamido)phenyl]hydrazide 0.048, a poly(Et acrylate) dispersion 20, 2-hydroxy-4,6-dichlorotriazine Na salt 1 g, 5-methylbenzotriazole 2 + 10-3 and 4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene 7 + 10-3 mol/mol Ag was coated at 48 mg Ag/100 cm2 on a cellulose triacetate support, dried, and exposed for 1 s through a step wedge. Portions of this material were then developed at 20° for 5 min in a developer containing N-methyl-p-aminophenol hemisulfate 5, hydroquinone 10, Na2SO3 75, borax 30, polyethylene glycol (average mol. weight 1500) 1, KOH 12 g, and water to 1 L under conditions of N2 stream stirring 5 s at the beginning of development (stirring conditions A), stirring 5 s, stopping 15 s, and repeating this process for 5 min (stirring conditions B), and stirring for the total 5 min (stirring conditions C). The resulting film showed a relative sensitivity and γ under these conditions of 82 and 20, 85 and 20, and 90 and 20, resp., vs. 138 and 20, 110 and 17, and 75 and 12, resp., for a control containing 1-formyl-2--p-tolylhydrazide.

IT 72684-94-7P 75753-07-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 72684-94-7 CAPLUS
CN Acetamide, 2-[4-[[(ethylamino)thioxomethyl]amino]phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 173 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 75753-07-0 CAPLUS
CN Acetamide, N-[4-(2-formylhydrazino)phenyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 174 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:119677 CAPLUS
DN 92:119677
TI Direct positive photographic materials
IN Yasufuku, Yoshitaka
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 54136821	A2	19791024	JP 1978-45052	19780417 <--
PRAI	JP 1978-45052	A	19780417		

GI



I

II

AB Internal latent image type direct-pos. Ag halide photog. emulsions contain fogging agents of the general formula RN(COR1)NR2COR3 and/or R4N(COR5)N=CHR6 [R, R4 = aryl; R1, R5 = alkyl, aryl, PhO, alkoxycarbonyl; R2 = H, COR7 (R7 = alkyl, aryl, PhO, alkoxycarbonyl); R3 = H, alkyl, aryl, cycloalkyl, heterocyclic moiety; R6 = aryl, heterocyclic moiety]. The photog. emulsions exhibit good shelf life. Thus, a 2% solution of I was added to an internal latent image type Ag halide emulsion containing a cyan coupler, a sensitizer dye, and other additives, then and the emulsion as coated on a paper support to give a direct-pos. photog. paper. The photog. paper was kept 24 h at 24° and 80% relative humidity, sensitometrically exposed, and developed to give Dmax and Dmin of 2.02 and 0.13, resp., vs. 1.75 and 0.14 for a control with II instead of I.

IT 73006-24-3P 73006-34-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73006-24-3 CAPLUS
CN Acetic acid, trichloro-, 2-acetyl-1-[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)

L9 ANSWER 174 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 73006-34-5 CAPLUS
CN Benzenebutanoic acid, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-, 2-phenyl-2-(trifluoroacetyl)hydrazide (9CI) (CA INDEX NAME)



L9 ANSWER 175 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:102281 CAPLUS
DN 92:102281
TI Silver halide color photographic materials
IN Kimura, Kazuhiko; Wada, Hajime; Endo, Takaya
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 54130024	A2	19791009	JP 1978-37128	19780330 <--
	JP 61015423	B4	19860424		
PRAI	JP 1978-37128	A	19780330		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Ag halide color photog. materials contain color couplers of the general formula I [R = naphthol derivative type cyan coupler moiety, R1 = H, C1-4 alkyl, acyl; R2 = C1-4 alkyl, C2-4 alkenyl; M, M1 = H, alkali metal, NH4; Z = C1-4 alkylene, C2-4 alkenylene; Z1 = II (R3 = H, C1-4 alkyl; Z2 = C1-4 alkylene), III (R4 = C1-4 alkyl, C2-4 alkenyl; n = 0, 1]. Thus, IV 4 g was dissolved in di-Bu phthalate-EtOAc mixture, dispersed in a gelatin solution, and added to a high-sensitivity Ag(Br,I) emulsion. The photog. film prepared by using the emulsion was sensitometrically exposed and developed to give relative sensitivity, fog, and Dmax of 120, 0.16, and 1.17, resp., vs. 100, 0.22, and 1.10 for a control with V instead of IV.
IT 72848-26-1P 72848-30-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 72848-26-1 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(acetylamino)-3-[[4-[2-[[4-[[[[[3-[[[4-[2,4-bis(2,2-dimethylpropyl)phenoxy]butyl]amino]carbonyl]-4-hydroxy-1-naphthalenyl]oxy]carbonyl]amino]methyl]phenyl]amino]-2-oxoethoxy]phenyl]azo]-4-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 175 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



●2 Na

PAGE 1-B



RN 72848-30-7 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(acetylamino)-3-[[4-[2-[[4-[2-[[[[3-[[[4-[2,4-bis(2,2-dimethylpropyl)phenoxy]butyl]amino]carbonyl]-4-hydroxy-1-naphthalenyl]oxy]carbonyl]amino]ethyl]phenyl]amino]-2-oxoethoxy]phenyl]azo]-4-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 175 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



●2 Na

PAGE 1-B



L9 ANSWER 176 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:94103 CAPLUS
DN 92:94103
TI Tumor chemotherapy. XXXV. Syntheses of derivatives of some plant growth regulators and their antitumor activity
AU Zhang, Hong-Liang; Qu, Chong-Jie; Chen, Run-Lian; Gao, Yi-Sheng
CS Shanghai Inst. Mat. Med., Acad. Sin., Shanghai, Peop. Rep. China
SO Yaoxue Xuebao (1979), 14(5), 302-8
CODEN: YHHPAL; ISSN: 0513-4870
DT Journal
LA Chinese
GI



AB Naphthaleneglycolic acid derivs. (I; R = arylamino, alkoxy, aryloxy), phenoxyacetic acid derivs. (II; same R; R1 = H, Cl), and naphthaleneacetic acid derivs. (III, R2 = OH, MeO, OCH2CO2H), effective antitumor agents against Sarcoma 180 and 37, were prepared Thus, 2.2 g 2-naphthoxyacetyl chloride was added to a solution of 2.0 g procaine in Et2O and 6 N NaOH at 10° and the mixture stirred 0.5 h to give 70% I (R = p-NHC6H4CO2CH2CH2NEt2). A total of 34 I, II, and III were prepared
IT 10441-32-4P 72836-60-3P 72836-62-5P
72836-64-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 10441-32-4 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 72836-60-3 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-dichlorophenoxy)acetyl]amino]benzoyl]- (9CI)

L9 ANSWER 176 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 72836-62-5 CAPLUS
CN Acetamide, N-[4-[3-(diethylamino)-1-oxopropyl]phenyl]-2-(2,4,5-trichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 72836-64-7 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4,5-trichlorophenoxy)acetyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 177 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 72684-93-6 CAPLUS
CN Acetamide, N-[4-(2-formylhydrazino)phenyl]-2-[3-[[(phenylamino)thioxomethyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 72684-94-7 CAPLUS
CN Acetamide, 2-[4-[[(ethylamino)thioxomethyl]amino]phenoxy]-N-[4-(2-formylhydrazino)phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 177 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:67705 CAPLUS
DN 92:67705
TI Direct positive photosensitive photographic silver halide material
IN Hirano, Shigeo; Adachi, Keiichi; Tsujino, Nobuyuki
PA Fuji Photo Film Co., Ltd., Japan
SO Ger. Offen., 59 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 2913567	A1	19791018	DE 1979-2913567	19790404	<--
	DE 2913567	C2	19900308			
	JP 54133126	A2	19791016	JP 1978-40621	19780406	<--
	JP 59030257	B4	19840726			
	GB 2022273	A	19791212	GB 1979-10551	19790326	<--
	GB 2022273	B2	19820623			
	US 4255511	A	19810310	US 1979-26962	19790404	<--
PRAI	JP 1978-40621	A	19780406			

AB Direct-pos. photog. materials are described which contain a Ag halide emulsion layer of the inner image type and a hydrophilic colloid layer, ≥1 of which contains a fogging agent of the general formula RNHCSNH2[1]ZCONHZ2NHNHCOR1 [R = aliphatic or aromatic; R1 = H, aliph, or aromatic; Z = Q, OQ, or SQ, where Q = a bivalent aliphatic group and O or S is bonded to Z1; Z1 and Z2 = bivalent aromatic groups; and Z1 and Z2 may the same or different]. Thus, on a transparent poly(ethylene terephthalate) support the following layers were applied: a mordant layer; a white reflecting layer containing TiO2; a light-screening layer containing C black; a layer containing a magenta DRR compound; a layer containing a green-sensitive direct-pos. Ag(Br,I) emulsion of the inner image type, Na 5-pentadecylhydroquinone-2-sulfonate, and a fogging agent HCONHNHC6H4-p-NHCOCH2OC6H4-p-NHCSNHPh 14.2 mg/mol Ag; and a gelatin layer. A protective layer containing a neutralizing layer and a timing layer was laminated onto the film and the film was then exposed on the protective layer side to a color test diagram; the developer solution was spread between the 2 layers to a thickness of 75 pm by means of a roller and the processing was carried out at 25°. One h after development the green d. of the images produced on the image-receiving layer was determined with a Macbeth Reflexion densitometer. The film containing the fogging agent had a Dmax and Dmin of 1.96 and 0.27, resp., as compared with the same film without the fogging agent which had Dmax and Dmin of 0.28 and 0.27, resp.

IT 72684-92-5 72684-93-6 72684-94-7
RL: USES (Uses)
(photog. fogging agent)

RN 72684-92-5 CAPLUS
CN Acetamide, N-[4-(2-formylhydrazino)phenyl]-2-[4-[[(phenylamino)thioxomethyl]amino]phenoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:507816 CAPLUS
DN 91:107816
TI Aminobenzoic acid derivatives
IN Metz, Gunter; Specker, Manfred
PA Merckle, Ludwig, K.-G., Chem.-Pharm. Fabrik, Fed. Rep. Ger.
SO Ger. Offen., 35 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 2730174	A1	19790222	DE 1977-2730174	19770704	<--
	DE 2730174	C2	19811210			
	EP 174	A1	19790110	EP 1978-100206	19780621	<--
	EP 174	B1	19811230			
	R: BE, CH, DE, FR, GB, LU, NL, SE					
	US 4294851	A	19811013	US 1978-919747	19780627	<--
	AT 7804776	A	19800715	AT 1978-4776	19780630	<--
	AT 360972	B	19810210			
	CA 1108139	A1	19810901	CA 1978-306600	19780630	<--
	AT 7906653	A	19810115	AT 1979-6653	19791011	<--
	AT 363480	B	19810810			
PRAI	DE 1977-2730174		19770704			
	AT 1978-4776	A	19780630			

OS MARPAT 91:107816
GI



I



II



III

AB Aminobenzoic acid derivs. I (R = H, Cl, OH, AcO, C1-3-alkoxy; R1 = H, Cl, H2NSO2; R2 = H, Me; R3 = H, C1-3-alkyl; R4 = H, halo, CF3; R5 = H; R6 = C1-4-alkyl, R7 = H, C1-3-alkyl, HCO; R8 = H, halo- or Ph-substituted C1-4-alkyl or C1-4-alkenyl; R5R6 = C2-3-alkylene; X = C1-3-alkylene; n = 0, 1; NR5XNR6R7 can form an aliphatic or aromatic ring system) and quinazoline derivs. II were prepared as anticholesteremics and hypolipemics. Thus,

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-H2NC6H4CO2H was N-acylated with 4-ClC6H4OCH2COCl to give 76.5% 4-ClC6H4OCH2CONC6H4CO2H-3, which was amidated with H2NCH2CH2NEt2 by phosphoroxy chloride to give 83.2% benzamide III. Data are given for several I derivs. for lowering cholesterol and triglyceride levels in rats.

IT 70847-10-8P 70847-11-9P 70847-12-0P
70847-18-6P 70847-19-7P 70847-48-2P
70853-42-8P 70853-43-9P 70853-47-3P
70853-48-4P 70853-54-2P 70853-55-3P
70853-56-4P 70853-57-5P 70853-60-0P
70853-61-1P 70853-62-2P 70853-63-3P
70853-64-4P 70853-65-5P 70853-66-6P
70853-67-7P 70853-72-4P 70853-73-5P
70853-74-6P 70883-47-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 70847-10-8 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 70847-11-9 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 70847-12-0 CAPLUS
CN Pyrrolidinium, 2-[[[4-[[(4-chlorophenoxy)acetyl]amino]benzoyl]amino]methyl]-1-ethyl-1-methyl-, iodide (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 70853-42-8 CAPLUS
CN Benzamide, 2-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-43-9 CAPLUS
CN Benzamide, 2-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 70853-42-8
CMF C21 H25 Cl2 N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 70853-47-3 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● I⁻

RN 70847-18-6 CAPLUS
CN Benzamide, 2-(acetyloxy)-4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 70847-19-7 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 70847-48-2 CAPLUS
CN Benzamide, 2-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 70853-48-4 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 70853-47-3
CMF C21 H26 Cl N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 70853-54-2 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 70853-55-3 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 70853-56-4 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-57-5 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 70853-56-4
CMF C21 H26 Br N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Br⁻

RN 70853-64-4 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 70853-65-5 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 70853-66-6 CAPLUS
CN Benzamide, 4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-67-7 CAPLUS
CN Benzamide, 4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 70853-60-0 CAPLUS
CN Benzamide, 4-[[(3-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 70853-61-1 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[(4-fluorophenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 70853-62-2 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[(4-fluorophenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 70853-63-3 CAPLUS
CN 1-Butanaminium, N,N-diethyl-N-[2-[[4-[[(4-fluorophenoxy)acetyl]amino]benzoyl]amino]ethyl]-, bromide (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 70853-66-6
CMF C21 H26 Cl N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 70853-72-4 CAPLUS
CN Benzamide, 2-(acetyloxy)-4-[[(4-chlorophenoxy)acetyl]amino]-N-[4-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NEt2

RN 70853-73-5 CAPLUS
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[4-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—NEt_2

RN 70853-74-6 CAPLUS
CN Ethanaminium, 2-[[4-[[4-[[(4-chlorophenoxy)acetyl]amino]-2-hydroxybenzoyl]amino]benzoyl]amino]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A



● I^-

PAGE 1-B

Cl

RN 70883-47-5 CAPLUS

L9 ANSWER 178 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, 4-[[(4-chlorophenoxy)acetyl]amino]-N-[4-[[[2-(diethylamino)ethyl]amino]carbonyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NEt_2

L9 ANSWER 179 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:420067 CAPLUS
DN 91:20067
TI Synthesis of 4-substituted aminobenzoate quaternary salts as potent antispasmodic agents
AU Ibrahim, El Sebai A.; Soliman, Raafat; Gabr, Mohamed
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO Journal of Pharmaceutical Sciences (1979), 68(3), 332-5
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
OS CASREACT 91:20067
GI



AB Title salts I [R = H, R1 = Ph, ClC6H4, PhOCH2, 1-naphthyl, R2 = Et2NCH2CH2O or I-Et3N+CH2CH2O, (12 compds.); R = H, R1 = o-ClC6H4, R2 = Et2NCH2CH2NH, I-Et3N+CH2CH2NH; R = H, R1 = ClC6H4, PhOCH2, 1-naphthyl, R2 = Et2N, pyrrolidino, piperidino, morpholino, N-methylpiperazino, (18 compds.); R = OH, R1 = Ph, R2 = C3H7NH, C4H9NH, piperidino, morpholino, N-methylpiperazino] were prepared from procaine, procainamide, or 2,4-R(H2N)C6H3CO2H (R = H, OH) by known reactions. Preliminary pharmacol. tests on isolated guinea pig ileum showed that I gave nonspecific inhibition on smooth muscles.
IT 27474-42-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and quaternization of, with Et iodide)
RN 27474-42-6 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



IT 70204-66-9P 70204-67-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70204-66-9 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, 2-(diethylamino)ethyl ester, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27474-42-6
CMF C21 H26 N2 O4

L9 ANSWER 179 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 70204-67-0 CAPLUS
CN Ethanaminium, N,N,N-triethyl-2-[[4-[(phenoxyacetyl)amino]benzoyl]oxy]-, iodide (9CI) (CA INDEX NAME)



● I^-

L9 ANSWER 180 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:95360 CAPLUS
DN 90:95360
TI A silver halide color photographic material
AU Anon.
CS UK
SO Research Disclosure (1978), 176, 31 (No. 17613)
CODEN: RSDSBB; ISSN: 0374-4353
DT Journal; Patent
LA English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 176013		19781210		

PRAI RD 1978-176013 19781210

AB Color photog. materials containing a colored coupler for masking purposes are described. The materials give high d. images with low fog and show good stability in bleaching solns. of high pH. Typical colored couplers used are 1-hydroxy-4-[3-[4-(1-hydroxy-3,6-disulfo-8-acetamido-2-naphthylazo)phenoxyacetamido]anilinocarboxyloxy]-N-[δ-(2,4-di-tert-amylphenoxy)butyl]-2-naphthamide di-Na salt (I) and 1-hydroxy-4-[4-[4-(1-hydroxy-3,6-disulfo-8-acetamido-2-naphthylazo)phenoxyacetamido]benzylamino carbonyloxy]-N-[δ-(2,4-di-tert-amylphenoxy)butyl]-2-naphthamide di-Na salt. Thus, a solution containing 1-hydroxy-N-[δ-(2,4-di-tert-amylphenoxy)butyl]-2-naphthamide 4, I 4 g, di-Bu phthalate 4, and EtOAc 8 mL was mixed with 10% aqueous gelatin 2 mL and dispersed in a colloid mill. The dispersion was then added to a gelatin-Ag(Br, I) emulsion, coated on a support, dried, imagewise exposed, and developed to show a fog of 0.16, a maximum absorption wavelength of the mask of 555-70 nm, and a max d. of 1.20.

IT 69319-65-9
RL: USES (Uses)
(photog. colored masking coupler, photog. films containing, for improved image quality)

RN 69319-65-9 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(acetylamino)-3-[[4-[2-[[4-[[[[[3-[[[4-[2,4-bis(1,1-dimethylpropyl)phenoxy]butyl]amino]carbonyl]-4-hydroxy-1-naphthalenyl]oxy]carbonyl]amino]methyl]phenyl]amino]-2-oxoethoxy]phenyl]azo]-4-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 180 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 181 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:79108 CAPLUS
DN 90:79108
TI Silver halide color photographic materials
IN Endo, Takaya; Wada, Hajime; Kikuchi, Shoji; Ishikawa, Hisashi; Ninomiya, Hidetaka
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53061332	A2	19780601	JP 1976-137058	19761115 <--
JP 60013166	B4	19850405		

PRAI JP 1976-137058 A 19761115

GI For diagram(s), see printed CA Issue.

AB Ag halide color photog. materials contain a colorless 2-naphthamide-type cyan coupler having a substituent on the active site and a colored coupler of the general formula I [R = H, C1-6 alkyl; R1, R2 = C2-6 alkyl; R3 = C1-4 alkyl; M = cation; Z = O2CNR4Z1, OCR5R6CO2Z1, OCR7R8CONR9Z1, O3SZ1, OCR10R11CO2Z1, OCO2Z1, OZ2Z1, or II where R4-R11 = H, a monovalent organic moiety; Z1 = divalent organic moiety; Z2 = alkylene, haloalkylene, alkylalkylene; Z3 = group of atoms required to complete nonarom. C ring or heterocyclic ring]. The Ag halide color photog. materials exhibit excellent internal color correction characteristics. Thus, a colorless cyan coupler III 10 and a colored coupler IV 1 g were dissolved in an EtOAc-di-Bu phthalate mixture, the solution was dispersed in a gelatin solution, then the dispersion was added to 500 g of a high-sensitivity Ag(Br,I) emulsion, and the emulsion was coated on a photog. film support. The photog. film was sensitometrically exposed and developed to give relative sensitivity, fog, and Dmax of 121, 0.16, and 2.58, resp., vs. 100, 0.18, and 2.32, resp., for a control with V instead of IV.

IT 67951-48-8
RL: USES (Uses)
(colored photog. coupler, for color photog. emulsions containing cyan coupler for improved color correction characteristics)

RN 67951-48-8 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(acetylamino)-3-[[4-[2-[[4-[[[[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-3-chloro-4-hydroxy-2-methylphenoxy]carbonyl]amino]methyl]phenyl]amino]-2-oxoethoxy]phenyl]azo]-4-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 181 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



●2 Na

PAGE 1-B



L9 ANSWER 182 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:571823 CAPLUS
DN 89:171823
TI Silver halide color photographic materials
IN Wada, Hajime; Endo, Takaya; Kikuchi, Shoji; Ishikawa, Hisashi; Ninomiya, Hidetaka
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 53060627	A2	19780531	JP 1976-135895	19761112 <--
	JP 55036137	B4	19800918		
PRAI	JP 1976-135895	A	19761112		

GI For diagram(s), see printed CA Issue.
AB Ag halide color photog. materials have a red-sensitive emulsion layer containing a colorless 4-equivalent 2-naphthamide cyan coupler and a colored cyan coupler of the general formula I (R = H, C1-6 alkyl; R1,R2 = C2-6 alkyl; R3 = C1-4 alkyl; M = cation; Z = O2CNR4Z1, OCR5R6CO2Z1, OCR7R8CONR9Z1, O3SZ1, OCR10R11CO2Z1, OCO2Z1, O2Z2Z1, II; R4, R5, R6, R7, R8, R9, R10, R11 = H, monovalent organic moiety; Z1 = divalent organic moiety; Z2 = alkylene, haloalkylene, alkylalkylene; Z3 = group of atoms required to complete a nonarom. C ring or heterocyclic ring). The colored couplers I exhibit excellent color-correction effects without decreasing the sensitivity of the material and also have a good coupling speed. The colored couplers also provide a flat masking effect even when only relatively small amts. of the couplers are used. Thus, a mixture of colorless cyan coupler III 96.7 and colored cyan coupler IV 3.3 mol% were dissolved in an EtOAc-di-Bu phthalate mixture, the solution was dispersed in an aqueous gelatin solution, the dispersion was added to a Ag(Br,I) emulsion, and coated on a photog. film support. The film was then sensitometrically exposed and developed to give a relative sensitivity, fog, Dmax, λmax, and DG of 128, 0.14, 2.38, 575 nm, and 0.33, resp., vs. 114, 0.20, 2.29, 575 nm, and 0.26, resp., for a control with V instead of of IV.
IT 67951-48-8
RL: USES (Uses)
(colored photog. cyan coupler, for color corrections in silver halide photog. emulsions)
RN 67951-48-8 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(acetylamino)-3-[[4-[2-[[4-[[[[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-3-chloro-4-hydroxy-2-methylphenoxy]carbonyl]amino]methyl]phenyl]amino]-2-oxoethoxy]phenyl]azo]-4-hydroxy-, disodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 182 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



●2 Na

PAGE 1-B



L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:424158 CAPLUS
DN 89:24158
TI Substituted N-acyl benzamides
IN Metz, Gunter; Specker, Manfred
PA Merckle, Ludwig, K.-G., Chem.-Pharm. Fabrik, Fed. Rep. Ger.
SO Belg., 23 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 854683	A1	19771116	BE 1977-177612	19770516 <--
	DE 2623228	A1	19771201	DE 1976-2623228	19760524 <--
	DE 2623228	B2	19790621		
	DE 2623228	C3	19810910		
PRAI	DE 1976-2623228	A	19760524		

GI



I



II

AB Benzamides I (X = CH, N; X1 = O, NH, S; X2 = C1-5 alkylene, alkenylene, optionally substituted by alkyl, alkenyl, Ph, cycloalkyl, Ac, NH2, or halophenoxy; R = H, alkyl, halogen, CF3, alkoxy, OPh, OAc; R1 = H, C1-4 alkyl, alkenyl optionally substituted by halogen, Ph, halophenyl; m,n,p = 0,1) were prepared Thus metoclopramide was treated with nicotinic acid to give II. I have antiinflammatory, bactericidal, antiallergic activity.
IT 65569-32-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)
RN 65569-32-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT 65569-29-1P 65569-30-4P 65569-31-5P
65569-33-7P 65569-40-6P 65569-41-7P
65569-42-8P 65569-43-9P 65569-44-0P
65569-45-1P 65569-46-2P 65569-47-3P
65569-50-8P 65569-51-9P 65569-53-1P
65569-54-2P 65569-55-3P 65569-57-5P
65569-60-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-30-4 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-29-1
CMF C22 H27 C12 N3 O4



L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 65569-31-5 CAPLUS
CN Benzamide, 5-chloro-4-[[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-29-1
CMF C22 H27 Cl2 N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 65569-33-7 CAPLUS
CN Ethanaminium, 2-[[5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxybenzoyl]amino]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 65569-43-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-44-0 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-45-1 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● I⁻

RN 65569-40-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-41-7 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-42-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 65569-46-2 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-44-0
CMF C22 H27 Br Cl N3 O4



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 65569-47-3 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-44-0
CMF C22 H27 Br Cl N3 O4



CM 2

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 65569-50-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-51-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-53-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 65569-60-0 CAPLUS
CN 1-Butanaminium, N-[2-[[5-chloro-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]benzoyl]amino]ethyl]-N,N-diethyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

L9 ANSWER 183 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 65569-54-2 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-55-3 CAPLUS
CN Ethanaminium, 2-[[5-chloro-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]benzoyl]amino]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 65569-57-5 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:89399 CAPLUS
DN 88:89399
TI N-Acyl-substituted benzamides
IN Metz, Gunter; Specker, Manfred
PA Merckle, Ludwig, K.-G., Chem.-Pharm. Fabrik, Fed. Rep. Ger.
SO Ger. Offen., 27 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2623228	A1	19771201	DE 1976-2623228	19760524 <--
	DE 2623228	B2	19790621		
	DE 2623228	C3	19810910		
	CH 633259	A	19821130	CH 1977-5754	19770509 <--
	BE 854683	A1	19771116	BE 1977-177612	19770516 <--
	AT 7703488	A	19780815	AT 1977-3488	19770516 <--
	AT 348990	B	19790312		
	GB 1555723	A	19791114	GB 1977-21342	19770520 <--
	NL 7705630	A	19771128	NL 1977-5630	19770523 <--
	NL 187437	B	19910501		
	NL 187437	C	19911001		
	FR 2352791	A1	19771223	FR 1977-15663	19770523 <--
	FR 2352791	B1	19790309		
	US 4146637	A	19790327	US 1977-799166	19770523 <--
	CA 1091247	A1	19801209	CA 1977-278971	19770524 <--
PRAI	DE 1976-2623228	A	19760524		

OS MARPAT 88:89399
GI



I



II

AB Benzamides I (R = Ph, 3-pyridyl, optionally substituted by alkyl, halogen, CF3, alkoxy, phenoxy, OAc; R1 = H, C1-4 alkyl or alkenyl, optionally substituted by halogen, Ph, halophenyl; X = O, NH, S; X1 = C1-5 alkylene or alkenylene, optionally substituted by alkyl, alkenyl, Ph, cycloalkyl, Ac, NH2, halophenoxy; m, n,x = 0, 1) were prepared Thus, metoclopramide was treated with 4-ClC6H4OCMe2COCl to give II, whose hydrochloride had β-sympatholytic, platelet aggregation-inhibiting, muscle relaxant, and bactericidal activity. Other I had antiinflammatory, central nervous system depressant, antiasthmatic, antithrombic, and antiallergic activities.

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 65569-29-1P 65569-32-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)

RN 65569-29-1 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-32-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 65569-30-4P 65569-31-5P 65569-33-7P
65569-40-6P 65569-41-7P 65569-42-8P
65569-43-9P 65569-44-0P 65569-45-1P
65569-46-2P 65569-47-3P 65569-50-8P
65569-51-9P 65569-53-1P 65569-54-2P
65569-55-3P 65569-57-5P 65569-60-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65569-30-4 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-29-1
CMF C22 H27 Cl2 N3 O4

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 65569-33-7 CAPLUS
CN Ethanaminium, 2-[[5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-2-methoxybenzoyl]amino]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I-

RN 65569-40-6 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-41-7 CAPLUS
CN Benzamide, 5-chloro-4-[[(2-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 65569-31-5 CAPLUS
CN Benzamide, 5-chloro-4-[[(4-chlorophenoxy)acetyl]amino]-N-[2-(diethylamino)ethyl]-2-methoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-29-1
CMF C22 H27 Cl2 N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 65569-42-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 65569-43-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-44-0 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 65569-45-1 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-46-2 CAPLUS
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-44-0
CMF C22 H27 Br Cl N3 O4



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 65569-47-3 CAPLUS

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 65569-53-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 65569-54-2 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 65569-55-3 CAPLUS
CN Ethanaminium, 2-[[5-chloro-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]benzoyl]amino]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, 4-[[(4-bromophenoxy)acetyl]amino]-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 65569-44-0
CMF C22 H27 Br Cl N3 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 65569-50-8 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)



RN 65569-51-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-4-[[(4-iodophenoxy)acetyl]amino]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 184 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● I⁻

RN 65569-57-5 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



RN 65569-60-0 CAPLUS
CN 1-Butanaminium, N-[2-[[5-chloro-2-methoxy-4-[[(4-methylphenoxy)acetyl]amino]benzoyl]amino]ethyl]-N,N-diethyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

L9 ANSWER 185 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:509397 CAPLUS
DN 87:109397
TI Color images by means of light-sensitive photographic silver halide recording materials
IN Fujiwhara, Mitsuto; Matsuo, Syunju; Kawasaki, Mikio; Kaneko, Yutaka; Masukawa Toyoaki
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Ger. Offen., 47 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2650764	A1	19770518	DE 1976-2650764	19761105 <--
JP 52057827	A2	19770512	JP 1975-133879	19751107 <--
JP 60011342	B4	19850325		
GB 1539779	A	19790207	GB 1976-46077	19761105 <--
US 4137080	A	19790130	US 1978-899893	19780426 <--
PRAI JP 1975-133879	A	19751107		
US 1976-739330	A1	19761105		

AB Images of high maximum d., requiring less Ag for their formation, are obtained by using a p-aminophenol- or p-phenylenediamine-based polyfunctional developer and a polyfunctional coupler, e.g. a polyhydric phenol, which reacts during development to form black dye in image areas. Thus, a Ag(I,Br) emulsion for preparation of a black-and-white neg. was coated on an acetate support, exposed, and treated with a developer prepared by mixing a solution containing N,N'-ethylenebis[4-amino-N-(β-hydroxyethyl)aniline] with an alc. solution of resorcinol. The image obtained had a relative sensitivity of 115, a γ value of 0.44, a fog value of 0.10, and a maximum d. of 2.6, as compared to 100, 0.46, 0.04, and 2.7, resp., for a film containing twice as much Ag and developed with a solution of p-(methylamino)phenol (I), and 66, 0.22, 0.04, and 1.0, resp., for a film containing the same amount of Ag and also developed with I.
IT 63969-40-4
RL: USES (Uses)
(photog. developer containing phenylenediamine derivative and, for images of high maximum d.)
RN 63969-40-4 CAPLUS
CN Propanediamide, N,N'-bis[4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 185 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 186 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:139649 CAPLUS
DN 86:139649
TI 4-(p-Chlorophenoxyacetylamino)benzoic acid diethylaminoethyl ester p-chlorophenoxyisobutyrate salt
IN Specker, Manfred; Metz, Gunter
PA Merckle, Ludwig, K.-G., Chem.-Pharm. Fabrik, Fed. Rep. Ger.
SO Austrian, 5 pp.
CODEN: AUXXAK
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI AT 333727	B	19761210	AT 1974-3495	19740426 <--
AT 7403495	A	19760415		
PRAI AT 1974-3495	A	19740426		

AB 4-ClC6H4OCH2CO2H reacted with PCl3 and 4-H2NC6H4CO2CH2CH2NEt2 to give 4-ClC6H4OCH2CONHC6H4CO2CH2CH2NEt2-4, which formed a salt (I) with 4-ClC6H4CMe2CO2H. A dose of 250 mg/kg I in the rat showed a 24.9% cholesterol lowering and LD50 mg/kg toxicity, compared to 3.0% and 1150 mg/kg for clofibrate.
IT 27474-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and salt formation of)
RN 27474-45-9 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



IT 54393-06-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54393-06-5 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, mono[2-(4-chlorophenoxy)-2-methylpropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

L9 ANSWER 186 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 882-09-7
CMF C10 H11 Cl O3



L9 ANSWER 187 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:421078 CAPLUS
DN 85:21078
TI Azetidinone derivatives
IN Kamiya, Takashi; Yoshihisa, Takarazuka; Hashimoto, Masashi; Teraji, Tsutomu; Takaya, Takao; Komori, Tadaaki; Nakaguti, Osamu; Oku, Teruo; Shiokawa, Youichi; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Ger. Offen., 318 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 2529941	A1	19760408	DE 1975-2529941	19750704	<--
	JP 51125061	A2	19761101	JP 1974-77091	19740704	<--
	JP 51125062	A2	19761101	JP 1974-85526	19740724	<--
	JP 51125064	A2	19761101	JP 1974-88452	19740731	<--
	JP 51075056	A2	19760629	JP 1975-2650	19741223	<--
	BE 830934	A1	19760102	BE 1975-157924	19750702	<--
	CH 618161	A	19800715	CH 1975-8634	19750702	<--
	DK 7503023	A	19760105	DK 1975-3023	19750703	<--
	FI 7501949	A	19760105	FI 1975-1949	19750703	<--
	NO 7502419	A	19760106	NO 1975-2419	19750703	<--
	FR 2278335	A1	19760213	FR 1975-20990	19750703	<--
	FR 2278335	B1	19821217			
	SE 428799	B	19830725	SE 1975-7683	19750703	<--
	SE 428799	C	19831103			
	NL 7508008	A	19760106	NL 1975-8008	19750704	<--
	AU 7582778	A1	19770106	AU 1975-82778	19750704	<--
	ES 439134	A1	19770301	ES 1975-439134	19750704	<--
	ZA 7504306	A	19770525	ZA 1975-4306	19750704	<--
	GB 1519495	A	19780726	GB 1975-28394	19750704	<--
	HU 172476	P	19780928	HU 1975-FU336	19750704	<--
	AT 7505170	A	19790715	AT 1975-5170	19750704	<--
	AT 355034	B	19800211			
	CA 1063108	A1	19790925	CA 1975-230828	19750704	<--
	AT 7806099	A	19790915	AT 1978-6099	19780822	<--
	AT 7806098	A	19800415	AT 1978-6098	19780822	<--
	AT 359514	B	19801110			
	SE 7903460	A	19790419	SE 1979-3460	19790419	<--
	SE 7903504	A	19790420	SE 1979-3504	19790420	<--
	CH 637924	A	19830831	CH 1980-5357	19800711	<--
PRAI	JP 1974-77091	A	19740704			
	JP 1974-85526	A	19740724			
	JP 1974-88452	A	19740731			
	JP 1975-2650	A	19741223			
	JP 1974-100159	A	19740830			
	JP 1974-101712	A	19740902			
	JP 1974-102288	A	19740904			
	JP 1974-136561	A	19741126			
	JP 1974-138137	A	19741129			
	JP 1975-3779	A	19741225			
	JP 1975-1272	A	19741228			
	JP 1975-16584	A	19750207			
	JP 1975-18241	A	19750212			

L9 ANSWER 187 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	JP 1974-30356	A	19750312
	JP 1975-30356	A	19750312
	JP 1975-32702	A	19750317
	JP 1975-32703	A	19750317
	JP 1975-33292	A	19750318
	JP 1975-34830	A	19750319
	JP 1975-33821	A	19750320
	JP 1975-33822	A	19750320
	CH 1975-8634	A	19750702
	AT 1975-5170	A	19750704

GI



I

II

AB After the antibiotic FR-1923 (obtained from fermentation liquor of Nocardia) was identified as I, 543 analogs [II; R = NH2 or acylamino; R1 = alkyl (saturated or unsatd., straight-chain or branched) with substituents, e.g., CO2H (or its derivs.), CN, OH, NH2, Ph or substituted Ph] were prepared by standard procedures and shown to be effective against, e.g., Bacillus subtilis, Escherichia coli, and Staphylococcus aureus.
IT 59509-23-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59509-23-8 CAPLUS
CN 1-Azetidineacetic acid, α-(4-hydroxyphenyl)-2-oxo-3-[[4-[(phenoxyacetyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 188 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:116338 CAPLUS
DN 84:116338
TI Nitrogen-substituted amides of the phenoxyacetic acid series
AU Ariesan, V.; Cojocaru, Zenaida; Ghiran, Doina; Chindris, Elena; Gagiu, F.; Nistor, C.; Cacoveanu, A.
CS Fac. Farm., Cluj, Rom.
SO Farmacia (Bucharest, Romania) (1975), 23(3), 135-40
CODEN: FRMBAZ; ISSN: 0014-8237
DT Journal
LA Romanian
OS CASREACT 84:116338
GI



I II

AB Seventeen phenoxyacetic acid derivs. I [R = 4-C6H4CO2H, 4-C6H4CO2Et, 4-CH2C6H4SO2NH2, 3,4-C6H3(OH)CO2H, 4-C6H4SO2NHAc, etc.; X = H or Cl] were prepared and tested for antimitotic activity on Lepidium sativum root meristems. The highest activity was shown by I (R = 4-C6H4CO2H, X = Cl) [54393-15-6], and the lowest by I (R = 4-C6H4SO2NH2; X = H) [58590-29-7]. I was synthesized by aminolysis of the corresponding 1-acetyl-3,5-dimethylpyrazole derivs. II (Takeda, 1964) by RNH2.
IT 25196-37-6P 58590-27-5P 58590-29-7P
58590-30-0P 58590-31-1P 58590-32-2P
58590-34-4P 58590-35-5P 58590-36-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antimitotic activity of)
RN 25196-37-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 58590-27-5 CAPLUS
CN Glycine, N-[4-[(phenoxyacetyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 188 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 58590-29-7 CAPLUS
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 58590-30-0 CAPLUS
CN Acetamide, N-[4-[(acetylamino)sulfonyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 58590-31-1 CAPLUS
CN Acetamide, 2-phenoxy-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 58590-32-2 CAPLUS
CN Acetamide, N-[4-[[(aminoiminomethyl)amino]sulfonyl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 58590-34-4 CAPLUS

L9 ANSWER 188 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[4-(aminosulfonyl)phenyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 58590-35-5 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 58590-36-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 189 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:83991 CAPLUS
DN 84:83991
TI Hypolipemic activity of clofibrate-related compounds
AU Metz, G.; Specker, M.
CS Res. Dev. Dep., L. Merckle K.-G., Blaubeuren, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1975), 25(11), 1686-92
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Seventy clofibrate-related compds. with general structures, I, II, III, or IV, were prepared and their hypolipemic activity was compared to that of clofibrate [637-07-0] in normal and hyperlipemic rats. Many of the compds. were as effective or more effective than clofibrate, and many of them were less toxic than clofibrate. The nature of the acid group seems to be more important for efficacy than the influence of α-methyl substitution. α-Substitution seems to be important for the differentiation of anticholesteremic and antitriglyceridemic activity.
IT 27474-45-9P 27474-68-6P 54393-05-4P
54393-09-8P 54393-10-1P 58327-31-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipemic activity of)
RN 27474-45-9 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-68-6 CAPLUS
CN Benzoic acid, 4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 54393-05-4 CAPLUS
CN 3-Pyridinecarboxylic acid, compd. with 2-(diethylamino)ethyl 4-[[(4-chlorophenoxy)acetyl]amino]benzoate (1:1) (9CI) (CA INDEX NAME)

CM 1

L9 ANSWER 189 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

CRN 59-67-6
CMF C6 H5 N O2



RN 54393-09-8 CAPLUS
CN Benzoic acid, 4-[[(2-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 54393-10-1 CAPLUS
CN Benzoic acid, 4-[[(4-fluorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 58327-31-4 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, compd. with ethyl 2-(4-chlorophenoxy)-2-methylpropanoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9

L9 ANSWER 189 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C21 H25 Cl N2 O4



CM 2

CRN 637-07-0
CMF C12 H15 Cl O3



IT 27474-46-0P 54393-04-3P 58327-32-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 27474-46-0 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 54393-04-3 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4

L9 ANSWER 189 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 58327-32-5 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, mono[2-(4-chlorophenoxy)propanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

CRN 3307-39-9
CMF C9 H9 Cl O3



L9 ANSWER 189 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 190 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:73863 CAPLUS
DN 84:73863
TI Alkanolamine derivatives
IN Smith, Leslie Harold; Longbridge, Jethro L.
PA Imperial Chemical Industries Ltd., UK
SO Brit., 9 pp. Addn. to Brit. 1,078,852.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1413794	A	19751112	GB 1971-56208	19721106 <--
	JP 48064038	A2	19730905	JP 1972-121431	19721204 <--
PRAI	GB 1971-56208	A	19711203		

AB Sixteen title compds. 2,4-R(R1CONH)C6H3OCH2CH(OH)CH2NHR2 [1; R = H, OH, OCH2Ph, OMe, allyl, allyloxy, NO2; R1 = alkyl, aryl, PhCH2, PhOCH2, cyclopropyl, CH2:CH; R2 = Me2CH, Me3C, Ph(CH2)2CHMe] and 3 related compds., useful as β-adrenergic blocking agents (no data), were prepared from I (R2 = H) by treatment with Me2CHBr or with an appropriate ketone under reducing conditions, or from 2,4-R(R1CONH)C6H3OH by treatment with ClCH2CH(OH)CH2NHR2. Thus, I (R = H, R1 = Me, R2 = Me2CH) was prepared from I (R = R2 = H, R1 = Me) by refluxing 18 hr with Me2CHBr, Na2CO3, and PrOH.
IT 24789-00-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(sympatholytic, preparation of)
RN 24789-00-2 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-2-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 191 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:38578 CAPLUS
DN 84:38578
TI Correlation analysis of Baker's studies on enzyme inhibition. 2. Chymotrypsin, trypsin, thymidine phosphorylase, uridine phosphorylase, thymidilate synthetase, cytosine nucleoside deaminase, dihydrofolate reductase, malate, glutamate, lactate, and glyceraldehyde-phosphate dehydrogenase
AU Yoshimoto, Masafumi; Hansch, Corwin
CS Dep. Chem., Pomona Coll., Claremont, CA, USA
SO Journal of Medicinal Chemistry (1976), 19(1), 71-98
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB The inhibitory activity of .apprx.1000 inhibitors of the title enzymes, α-chymotrypsin [9004-07-3], trypsin [9002-07-7], thymidine phosphorylase [9030-23-3], uridine phosphorylase [9030-22-2], thymidylate synthetase [9031-61-2], cytosine nucleoside deaminase [9025-06-3], dihydrofolate reductase [9002-03-3], malate dehydrogenase [9001-64-3], glutamate dehydrogenase [9001-46-1], glyceraldehyde-phosphate dehydrogenase [9001-50-7], and lactate dehydrogenase [9001-60-9], were formulated in 13 equations correlating chemical structure with inhibiting potency. Two types of regions in enzymes were defined by means of π and molar refractive consts. The correlation equations showed that substituent effects are additive to a 1st approximation Examples are given of use of the equations in comparing structural features of different systems.
IT 20167-19-5 20209-72-7 21447-17-6
RL: BIOL (Biological study)
(α-chymotrypsin inhibition by, correlation anal. in relation to)
RN 20167-19-5 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 20209-72-7 CAPLUS
CN Benzenesulfonyl fluoride, 3-[[[[[4-[[(3-chlorophenoxy)acetyl]amino]phenyl]methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 21447-17-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[4-(fluorosulfonyl)phenyl]amino]carbon

L9 ANSWER 191 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 192 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:496783 CAPLUS
DN 83:96783
TI Manufacture of alkanolamine derivatives
IN Deegan, Anthony; Hull, Roy; Warren, Peter; Smith, Leslie Harold
PA Imperial Chemical Industries Ltd., UK
SO Brit., 13 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1391444	A	19750423	GB 1971-32854	19710713 <--
DD 100461	C	19730920	DD 1972-164336	19720711 <--
CH 573393	A	19760315	CH 1972-10572	19720713 <--
CH 575908	A	19760531	CH 1975-14175	19720713 <--
JP 55037544	B4	19800929	JP 1972-70361	19720713 <--
PRAI GB 1971-32854	A	19710713		

GI For diagram(s), see printed CA Issue.
AB Forty-six title compds. I (R = carbamoyl, carbamoylalkyl, amido; R1 = H, halo, alkyl, NO2, OH, substituted alkyl, Ph, PhO, alkoxy, MeS, CO2Me, CN; R2 = alkyl, substituted alkyl) or their acid addition salts having β-adrenergic blocking activity (no data) were prepared by acid hydrolysis of the corresponding oxazolidines II. Thus, II (R = 4-AcNH, R1 = H, R2 = Me2CH) in EtOAc was stirred 15 min with 20 weight % aqueous AcOH to
give corresponding I. The preparation of a number of oxazolidines was detailed.
IT 24789-00-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(β-adrenergic blocking agent, preparation of)
RN 24789-00-2 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-2-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 193 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:43070 CAPLUS
DN 82:43070
TI 4-(Phenoxyacetamido)benzoates
IN Metz, Gunter; Specker, Manfred
PA Merckle, Ludwig, K.-G., Chem.-Pharm. Fabrik
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2316914	A1	19741024	DE 1973-2316914	19730404 <--
DE 2316914	B2	19760212		
DE 2316914	C3	19760923		
PRAI DE 1973-2316914	A	19730404		

AB Fifteen x-RC6H4-OCR1R2CONHC6H4CO2R3-4 (I, x-R = 2- or 4-Cl or 3-F3C; R1, R2 = H or Me; R3 = H, Et, CH2CH2NMe2, CH2CH2NEt2, or CH2CH2CHMe2) and some of their salts were prepared and useful as anticholesteremics and hypolipemics (no data). Thus, 4-ClC6H4OCH2CO2H and 4-H2NC6H4CO2CH2CH2NEt2 were refluxed in PhMe containing PCl3 to give 72.2% I x-R = 4-Cl, R1 = R2 = H,
R3 = CH2CH2NEt2).
IT 27474-45-9P 27474-46-0P 27474-68-6P
54393-03-2P 54393-04-3P 54393-05-4P
54393-06-5P 54393-09-8P 54393-10-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 27474-45-9 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-46-0 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 27474-68-6 CAPLUS
CN Benzoic acid, 4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-,

L9 ANSWER 193 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 54393-03-2 CAPLUS
CN Ethanaminium, 2-[[4-[[(4-chlorophenoxy)acetyl]amino]benzoyl]oxy]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 54393-04-3 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

CRN 77-92-9
CMF C6 H8 O7



L9 ANSWER 193 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 54393-05-4 CAPLUS
CN 3-Pyridinecarboxylic acid, compd. with 2-(diethylamino)ethyl 4-[[(4-chlorophenoxy)acetyl]amino]benzoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

CRN 59-67-6
CMF C6 H5 N O2



RN 54393-06-5 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, mono[2-(4-chlorophenoxy)-2-methylpropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 27474-45-9
CMF C21 H25 Cl N2 O4



CM 2

CRN 882-09-7
CMF C10 H11 Cl O3

L9 ANSWER 193 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 54393-09-8 CAPLUS
CN Benzoic acid, 4-[[(2-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 54393-10-1 CAPLUS
CN Benzoic acid, 4-[[(4-fluorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:505059 CAPLUS
DN 81:105059
TI Benzenesulfonylureas
IN Aumueller, Walter; Weber, Helmut; Weyer, Rudi; Muth, Karl; Schmidt, Felix H.
PA Farbwerke Hoechst A.-G.
SO Ger., 11 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 1518877	B2	19740704	DE 1965-F47366	19651007 <--
DE 1518877	C3	19750327		
PRAI LU 1964-47099	A	19641007		

AB 4-(RCON-HCH2CH2)C6H4SO2NHCONHR1 (I; R = e.g., Me2CHCHPh, Et2CPh, PhCH2CHEt, 3,4-Cl2C6H3CH:CH, 2,4-Cl2C6H3OCH2; R1 = Bu, cyclohexyl, 4-methylcyclohexyl) were prepared by the reaction of 4-(RCONHCH2CH2)C6H4SO2NH2 and R1NCO in the presence of a base. Thus, 4-(Me2CHCHPhCONHCH2CH2)-C6H4SO2NH2 reacted with BuNCO in K2CO3 and Me2CO to give I (R = Me2CHCHPh, R1 = Bu). About 40 I were prepared, useful as antidiabetic agents (no data).
IT 25199-35-3P 25199-37-5P 25199-41-1P
25256-84-2P 25256-85-3P 25256-86-4P
25256-87-5P 25330-27-2P 53393-81-0P
53446-59-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25199-35-3 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-37-5 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-41-1 CAPLUS

L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25256-84-2 CAPLUS
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-85-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-86-4 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



RN 25256-87-5 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25330-27-2 CAPLUS
CN Acetamide, 2-(3,4-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 25199-34-2 25199-36-4 25199-38-6
25199-40-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with isocyanate)
RN 25199-34-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-36-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-38-6 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichlorophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 53393-81-0 CAPLUS
CN Acetamide, 2-(3,4-dimethylphenoxy)-N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 53446-59-6 CAPLUS
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 53393-86-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with cyclohexyldiphenylurea)
RN 53393-86-5 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,5-dimethylphenoxy)-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 194 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 25199-40-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



IT 53393-87-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylcyclohexylamine)
RN 53393-87-6 CAPLUS
CN Carbamic acid, [[4-[2-[[(2,4-dichlorophenoxy)acetyl]amino]ethyl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 195 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:49278 CAPLUS
DN 80:49278
TI Benzoylacetanilides as two-equivalent yellow couplers in color photographic film
IN Quaglia, Andrea
PA Minnesota Mining and Manufacturing Co.
SO Ger. Offen., 36 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2263587	A1	19730719	DE 1972-2263587	19721227 <--
IT 945697	A	19730510	IT 1971-55062	19711228 <--
CA 993887	A1	19760727	CA 1972-158711	19721213 <--
US 3884700	A	19750520	US 1972-318561	19721226 <--
FR 2166047	A1	19730810	FR 1972-46301	19721227 <--
JP 48077832	A2	19731019	JP 1973-4075	19721227 <--
GB 1421181	A	19760114	GB 1972-59651	19721227 <--
CH 607108	A	19781130	CH 1972-18916	19721227 <--
BE 793424	A1	19730628	BE 1972-125913	19721228 <--
PRAI IT 1971-55062	A	19711228		

AB Benzoylacetanilide couplers (I) containing a F, Cl, or Br atom (R) at the ortho position of the benzoyl group and a Cl or Br atom (R1) at the active methylene group were prepared These compds. form yellow dyes essentially free of orange shades and also develop less color fog than known 2-equivalent yellow couplers. Other groups present in I include R2 : Cl, alkyl, alkoxy, or dialkylamino and R3 (position 4 or 5') = H, phenoxyacetamido, phenylsulfamoyl, alkanoyl, or benzenesulfonamido; at least one of R2 and R3 contains a higher-alkyl group. For example, reaction of 4,3-Cl(O2N)C6H3NH2 with (2,4-di-tert-amylphenoxy)acetyl chloride, hydrogenation of the resultant nitroanilide to the aminoanilide, reaction of the aminoanilide with 2-ClC6H4COCH2CO2Et, and treatment of the product with SO2Cl2 gave yellow coupler II [49556-74-3]. Fourteen other I were similarly prepared
IT 50671-31-3
RL: USES (Uses)
(chlorination of, with sulfuryl chloride)
RN 50671-31-3 CAPLUS
CN Benzenepropanamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-2-fluoro-N-(2-methoxyphenyl)-β-oxo- (9CI) (CA INDEX NAME)



L9 ANSWER 195 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 50670-98-9P
RL: PREP (Preparation)
(manufacture and use as photog. coupler)
RN 50670-98-9 CAPLUS
CN Benzenepropanamide, 4-[[[2,4-bis(1,1-dimethylpropyl)phenoxy]acetyl]amino]-α-chloro-2-fluoro-N-(2-methoxyphenyl)-β-oxo- (9CI) (CA INDEX NAME)



L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1973:425721 CAPLUS
DN 79:25721
TI Heterogeneous photopolymerizable compositions for intaglio printing plates
IN Gervay, Joseph Edmund
PA du Pont de Nemours, E. I., and Co.
SO Fr. Demande, 32 pp. Addn. to Fr. 2,020,258 (See Ger. 1,950,120, CA 73;61252n).
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2124341	A6	19720922	FR 1972-3281	19720201 <--
FR 2124341	B2	19771223		
BE 778857	A4	19720802	BE 1972-113537	19720202 <--
GB 1364972	A	19740829	GB 1972-4956	19720202 <--
JP 55029414	B4	19800804	JP 1972-11449	19720202 <--
US 3879204	A	19750422	US 1973-358526	19730509 <--
JP 55000594	A2	19800105	JP 1979-67361	19790530 <--
JP 57000975	B4	19820108		
PRAI US 1971-112085	A	19710202		
BE 1969-739978	A	19691008		

AB Intaglio printing plates with improved antihalation properties are prepared by exposing a support which is coated with a composition containing an organic hydrophilic colloid, such as gelatin, a wetting agent, and antihalation compound, followed by a layer containing a hydrophilic binder and photopolymerizable composition The organic colloid layer may be coated over the photopolymer layer to provide improved antiabrasion properties.
IT 25196-38-7P 25196-39-8P 25196-40-1P
25202-89-5P 25203-04-7P 25203-05-8P
25203-06-9P 25210-61-1P 25210-62-2P
25210-63-3P 25210-71-3P 25210-92-8P
25210-93-9P 25210-96-2P 25210-97-3P
25325-95-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25196-38-7 CAPLUS
CN Acetamide, N-[[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-39-8 CAPLUS
CN Acetamide, N-[[4-[[[[[4-(1-methylethyl)cyclohexyl]amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25196-40-1 CAPLUS
CN Acetamide, N-[[4-[[[[(2-methylpropyl)amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-89-5 CAPLUS
CN Acetamide, N-[1-methyl-2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl)phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-04-7 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-05-8 CAPLUS
CN Acetamide, N-[3-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]propyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 25203-06-9 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-61-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-62-2 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-63-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-71-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25325-95-5 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]- (9CI) (CA INDEX NAME)



IT 25196-37-6 25202-88-4 25202-94-2
25210-60-0 25210-91-7 25210-95-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with alkyl and cycloalkyl isocyanates)
RN 25196-37-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-88-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-94-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-92-8 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-93-9 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-96-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 25210-97-3 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-60-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-91-7 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-95-1 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



IT 25196-37-6 41352-71-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with cyclohexylamine)
RN 25196-37-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 196 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 41352-71-0 CAPLUS
CN Acetamide, N-[[4-[[(aminocarbonyl)amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1973:147618 CAPLUS
DN 78:147618
TI Benzenesulfonylureas
IN Weber, Helmut; Aumueller, Walter; Weyer, Rudi; Schmidt, Felix Helmut
PA Farbwerke Hoechst A.-G.
SO Ger., 9 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1443878	A	19681212	DE 1964-F42062	19640220 <--
	DE 1443878	B2	19730201		
	DE 1443878	C3	19730830		
	IL 22259	A1	19690528	IL 1964-22259	19641014 <--
	DK 119052	B	19701109	DK 1964-5061	19641014 <--
	SE 311151	B	19690602	SE 1964-12459	19641016 <--
	AT 278027	B	19700126	AT 1967-1149	19641016 <--
	SE 334603	B	19710503	SE 1966-16074	19641016 <--
	SE 334604	B	19710503	SE 1966-16075	19641016 <--
	SE 334605	B	19710503	SE 1966-16076	19641016 <--
	SE 334606	B	19710503	SE 1966-16077	19641016 <--
	SE 334607	B	19710503	SE 1966-16078	19641016 <--
	SE 334608	B	19710503	SE 1966-16079	19641016 <--
	CH 512449	A	19710915	CH 1964-512449	19641016 <--
	CH 513137	A	19710930	CH 1964-513137	19641016 <--
	CH 513138	A	19710930	CH 1964-513138	19641016 <--
	CH 513139	A	19710930	CH 1964-513139	19641016 <--
	CH 521952	A	19720430	CH 1964-521952	19641016 <--
	CH 521953	A	19720430	CH 1964-521953	19641016 <--
	CH 529115	A	19721015	CH 1964-529115	19641016 <--
	NO 118548	B	19700112	NO 1964-155188	19641017 <--
	NL 6412137	A	19650420	NL 1964-12137	19641019 <--
	FI 44597	B	19710831	FI 1964-2196	19641019 <--
	DK 119105	B	19701116	DK 1965-5418	19651022 <--
	DK 119455	B	19710111	DK 1965-5416	19651022 <--
	DK 120534	B	19710614	DK 1965-5419	19651022 <--
	DK 120588	B	19710621	DK 1965-5420	19651022 <--
	DK 120741	B	19710712	DK 1965-5415	19651022 <--
	DK 120742	B	19710712	DK 1965-5417	19651022 <--
	NO 118550	B	19700112	NO 1965-160301	19651102 <--
	NO 118551	B	19700112	NO 1965-160302	19651102 <--
	NO 118552	B	19700112	NO 1965-160303	19651102 <--
	NO 118553	B	19700112	NO 1965-160304	19651102 <--
	NO 118554	B	19700112	NO 1965-160305	19651102 <--
	NO 118555	B	19700112	NO 1965-160306	19651102 <--
	NO 118556	B	19700112	NO 1965-160307	19651102 <--
	US 3507961	A	19700421	US 1968-766008	19680809 <--
	NL 7304103	A	19730625	NL 1973-4103	19730323 <--
	NL 7304104	A	19730625	NL 1973-4104	19730323 <--
	NL 7304105	A	19730625	NL 1973-4105	19730323 <--
	NL 7304106	A	19730625	NL 1973-4106	19730323 <--
	NL 7304107	A	19730625	NL 1973-4107	19730323 <--
	NL 7304108	A	19730625	NL 1973-4108	19730323 <--
	NL 7304109	A	19730625	NL 1973-4109	19730323 <--
	NL 7304110	A	19730625	NL 1973-4110	19730323 <--
PRAI	DE 1963-F41042	A	19631019		
	DE 1964-F42062	A	19640220		
	DE 1964-F42933	A	19640521		
	DE 1964-F43268	A	19640626		

AB Benzenesulfonylureas (86) having a p-(carboxamidoalkyl) group on the benzene ring and an alkyl or cycloalkyl substituent in the N3-position were prepared by treating a benzenesulfonamide with the appropriate isocyanate; similar compds. were prepared by treating a benzenesulfonylurea with cyclohexylamine, or form pseudourea or thiourea analogs. Thus, p-(PhOCH2CONHCH2CH2)C6H4SO2NH2 with cyclohexyl isocyanate gave p-(PhOCH2-CONHCH2CH2)C6H4SO2NHCSN- HR (R = cyclohexyl); p-(PhCH:CHCONHCH2CH2)C6H4SO2 NHCSNHR (R = cyclohexyl) (prepared from the sulfonamide and the isothiocyanate) was treated with H2O2 in aqueous NaOH to give the O-containing analog.

IT 25196-38-7P 25196-39-8P 25196-40-1P
25202-89-5P 25203-04-7P 25203-05-8P
25203-06-9P 25210-61-1P 25210-62-2P
25210-63-3P 25210-71-3P 25210-92-8P
25210-93-9P 25210-94-0P 25210-96-2P
25210-97-3P 25325-95-5P 41352-71-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 25196-38-7 CAPLUS
CN Acetamide, N-[[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-39-8 CAPLUS
CN Acetamide, N-[[4-[[[[[4-(1-methylethyl)cyclohexyl]amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-40-1 CAPLUS
CN Acetamide, N-[[4-[[[[(2-methylpropyl)amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25202-89-5 CAPLUS
CN Acetamide, N-[1-methyl-2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-04-7 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-05-8 CAPLUS
CN Acetamide, N-[3-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]propyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-06-9 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 25210-61-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-62-2 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-63-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-71-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-92-8 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25325-95-5 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]- (9CI) (CA INDEX NAME)



RN 41352-71-0 CAPLUS
CN Acetamide, N-[[4-[[(aminocarbonyl)amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



IT 25210-60-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with butyl and cyclohexyl isocyanates)
RN 25210-60-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



IT 25196-37-6 25202-94-2 25210-91-7
25210-95-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with cyclohexyl isocyanate)
RN 25196-37-6 CAPLUS

L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-93-9 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-94-0 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-96-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 25210-97-3 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-94-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25210-91-7 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-95-1 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



IT 25196-46-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with cyclohexylamine)
RN 25196-46-7 CAPLUS

L9 ANSWER 197 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Carbamic acid, [[4-[[(phenoxyacetyl)amino]methyl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 25202-88-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylcyclohexyl isocyanate)
RN 25202-88-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 198 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:488156 CAPLUS
DN 77:88156
TI 1-Hydroxy-N-[2,4-bis(acylamino)phenethyl]-2-naphthamides as coupling agents in the color photography
IN Kunitz, Friedrich Wilhelm; Salzmann, Heinrich
PA Agfa-Gevaert A.-G.
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2062350	A	19720622	DE 1970-2062350	19701218 <--
	FR 2118813	A5	19720728	FR 1971-45624	19711217 <--
PRAI	DE 1970-2062350	A	19701218		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R = Me or CHMe2), prepared by reaction of QOPh (Q = 1-hydroxy-2-naphthoyl) with H2NCH2CH2C6H3(NH2)NO2-4,2 (II), reduction of the nitro group, and acylation, were used as soluble bluegreen couplers in color developing baths. Thus, heating II and QOPh 30 min at 130° in THF gave QNHCH2CH2C6H3(NH2)NO2-4,2, which on hydrogenation in THF gave QNHCH2CH2C6H3(NH2)2-2,4 (III). Reaction of III with Ac2O in THF gave I (R = Me). A grey-scale exposure was performed with a red sensitive Ag halide emulsion layer behind a red filter. The layer was developed in a bath containing I (R = Me) and 3,4-Me(H2N)C6H3NEtCH2CH2-NHSO2Me to give a brilliant
bluish green color scale with absorption maximum at 675 nm and less by-absorption than obtained with usual couplers.
IT 36773-64-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36773-64-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-[2-[2-(acetylamino)-4-[[(2-chlorophenoxy)acetyl]amino]phenyl]ethyl]-1-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 199 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:437937 CAPLUS
DN 75:37937
TI Color couplers for photographic film
IN Iwama, Masakuni; Yamamoto, Toshihiko; Inoue, Isaburo; Hanzawa, Teruo
PA Konishiroku Photo Industry Co., Ltd.
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2039970	A	19710311	DE 1970-2039970	19700812 <--
	JP 48025932	B4	19730802	JP 1969-67622	19690828 <--
	GB 1290423	A	19720927	GB 1970-1290423	19700827 <--
	US 3785828	A	19740115	US 1972-286718	19720906 <--
PRAI	JP 1969-67622	A	19690828		
	US 1970-66140	A2	19700821		

GI For diagram(s), see printed CA Issue.
AB Couplers of type I, where Q is a coupler group, R1 = H or lower alkyl, R2 = C8-18 hydrocarbyl, n = 1-4, and A = NHCO or CONH (when A = CONH, R1 = H and n = 3 or 4), highly soluble in tricresyl phosphate or di-Bu phthalate and
readily dispersed in AgCl/AgBr emulsions, are prepared Thus, m-NaOC6H4OC12H25 was treated with MeCH2CHBrCO2H to give m-C12H25OC6H4OCHEtCO2H which reacted with PC15 and then with 3-H2NC6H4COCH2CONHC6H4OMe-2 to give II. Nineteen other couplers were similarly prepared II was dispersed in gelatin, added to an AgI/AgBr emulsion, coated, exposed, and developed to give a brilliant yellow image with λmax 440 mμ.
IT 33100-90-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 33100-90-2 CAPLUS
CN 2-Naphthamide, 1-hydroxy-N-[p-[2-[m-(9-octadecenyloxy)phenoxy]acetamido]phenethyl]- (8CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L9 ANSWER 200 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:87777 CAPLUS
DN 74:87777
TI Irreversible enzyme inhibitors. 180. Irreversible inhibitors of the C'1a component of complement derived from m-(phenoxypropoxy) benzamidine and phenoxyacetamide
AU Baker, Bernard Randall; Cory, Michael
CS Dep. Chem., Univ. California, Santa Barbara, CA, USA
SO Journal of Medicinal Chemistry (1971), 14(2), 119-25
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Twenty-three substituted pyridines (I) quaternized with fluorosulfonylbenzyl bromide, and 12 phenoxyacetamides (II) (R is, e.g., 4-FSO2C6H4NHCONHC6H4CH2-3) were good inhibitors of whole guinea pig complement. Many of the I were also excellent irreversible inhibitors of the C'1a component of complement, suggesting that the main site of action by I was inhibition of C'1a. In contrast, the lack of correlation of irreversible inhibition of C'1a and inhibition of whole complement by 21 benzamidines (III) suggested that the main site of action of III was one of the other 8 components of the complement. III (n = 3, R = m-NHCONHC6H4SO2F-p), the most potent inhibitor of whole complement, was about 1000 and 3000 times as active as benzamidine and N-tosyl-L-arginine Me ester, resp.
IT 20167-19-5 21447-17-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(complement inhibition by)
RN 20167-19-5 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-17-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[4-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:53270 CAPLUS
DN 74:53270
TI Phenoxy acetamides and their pharmacological activity
PA Etablissements Clin-Byla
SO Fr. M., 16 pp.
CODEN: FMXXAJ
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 6485		19690106	FR	19661222 <--

GI For diagram(s), see printed CA Issue.
AB Phenoxyacetyl chlorides are treated with amino esters, p-H2NC6H4CO2(CH2)n-NR2, to give amides (I) which are useful in lipid metabolism. II are prepared by the treatment of phenols with α-halo carboxylic acids, XCR1R2CO2H.
IT 10441-32-4P 27469-00-7P 27469-03-0P
27469-04-1P 27469-05-2P 27469-07-4P
27469-11-0P 27469-13-2P 27469-15-4P
27469-18-7P 27469-21-2P 27469-22-3P
27469-25-6P 27469-26-7P 27469-30-3P
27469-31-4P 27469-34-7P 27469-36-9P
27469-38-1P 27469-39-2P 27469-40-5P
27469-41-6P 27469-42-7P 27469-43-8P
27474-42-6P 27474-43-7P 27474-45-9P
27474-46-0P 27474-52-8P 27474-53-9P
27474-54-0P 27474-55-1P 27474-56-2P
27474-57-3P 27474-62-0P 27474-69-7P
27474-70-0P 27474-71-1P 27474-72-2P
27474-73-3P 27474-74-4P 27474-76-6P
27474-81-3P 27526-73-4P 27526-75-6P
27529-80-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 10441-32-4 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27469-00-7 CAPLUS
CN Benzoic acid, p-[2-(2-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 27469-07-4 CAPLUS
CN Benzoic acid, p-[2-(m-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, oxalate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27469-08-5
CMF C22 H28 N2 O5



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 27469-11-0 CAPLUS
CN Benzoic acid, p-[2-(4-allyl-2-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-13-2 CAPLUS
CN Benzoic acid, p-[2-(p-ethoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-03-0 CAPLUS
CN Benzoic acid, p-[2-(p-hydroxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-04-1 CAPLUS
CN Benzoic acid, p-[2-(p-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-05-2 CAPLUS
CN Benzoic acid, p-[2-(p-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27469-15-4 CAPLUS
CN Benzoic acid, p-[2-(p-(allyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-18-7 CAPLUS
CN Benzoic acid, p-[2-(p-butoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-21-2 CAPLUS
CN Benzoic acid, p-[2-[p-(pentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-22-3 CAPLUS
CN Benzoic acid, p-[2-[p-(pentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-25-6 CAPLUS
CN Benzoic acid, p-[2-[p-(hexyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-26-7 CAPLUS
CN Benzoic acid, p-[2-[p-(hexyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-30-3 CAPLUS
CN Benzoic acid, p-[2-[p-(cyclopentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-38-1 CAPLUS
CN Benzoic acid, p-[2-(p-propionylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-39-2 CAPLUS
CN Benzoic acid, p-[2-(p-nitrophenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-40-5 CAPLUS
CN Benzoic acid, p-[2-(p-nitrophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27469-31-4 CAPLUS
CN Benzoic acid, p-[2-[p-(cyclopentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-34-7 CAPLUS
CN Benzoic acid, p-[2-(p-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-36-9 CAPLUS
CN Benzoic acid, p-[2-(o-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-41-6 CAPLUS
CN Benzoic acid, p-[2-(p-aminophenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-42-7 CAPLUS
CN Benzoic acid, p-[2-(p-aminophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 27469-43-8 CAPLUS
CN Benzoic acid, p-[2-(p-sulfamoylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-42-6 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27474-43-7 CAPLUS
CN Benzoic acid, p-(2-phenoxyacetamido)-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-45-9 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-46-0 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27474-56-2 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(dimethylamino)-1-methylethyl ester (8CI) (CA INDEX NAME)



RN 27474-57-3 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(dimethylamino)-1-methylethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-62-0 CAPLUS
CN Benzoic acid, p-[2-(2,4-dichlorophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 27474-52-8 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(diisopropylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-53-9 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(diisopropylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-54-0 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 3-(dimethylamino)propyl ester (8CI) (CA INDEX NAME)



RN 27474-55-1 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 3-(dimethylamino)propyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27474-69-7 CAPLUS
CN Benzoic acid, p-[2-[(α,α,α-trifluoro-m-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-70-0 CAPLUS
CN Benzoic acid, p-[2-(2,4-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-71-1 CAPLUS
CN Benzoic acid, p-[2-(2,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27474-72-2 CAPLUS
CN Benzoic acid, p-[2-(2,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-73-3 CAPLUS
CN Benzoic acid, p-[2-(3,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-74-4 CAPLUS
CN Benzoic acid, p-[2-[(4-chloro-o-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester, fumarate (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27529-80-2
CMF C22 H27 Cl N2 O4

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 27469-09-6
CMF C23 H30 N2 O6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 27526-75-6 CAPLUS
CN Benzoic acid, p-[2-(p-butoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, fumarate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27469-18-7
CMF C25 H34 N2 O5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 27474-76-6 CAPLUS
CN Benzoic acid, p-[2-(p-tert-butylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-81-3 CAPLUS
CN Benzoic acid, p-[2-(4-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27526-73-4 CAPLUS
CN Benzoic acid, p-[2-(2,4-dimethoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, fumarate (1:1) (8CI) (CA INDEX NAME)

L9 ANSWER 201 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 27529-80-2 CAPLUS
CN Benzoic acid, p-[2-[(4-chloro-o-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:520372 CAPLUS
DN 73:120372
TI Phenylsulfonyl ureas as antidiabetic agents
IN Weber, Helmut; Aumuller, Walter; Weyer, Rudi; Muth, Karl; Schmidt, Felix Helmut
PA Farbwerke Hoechst A.-G.
SO U.S., 26 pp. Division of U.S. 3426067
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3507961	A	19700421	US 1968-766008	19680809 <--
	DE 1443878	A	19681212	DE 1964-F42062	19640220 <--
	DE 1443878	B2	19730201		
	DE 1443878	C3	19730830		
	DE 1443890	A	19690220	DE 1964-F42933	19640521 <--
	DE 1443890	B2	19730201		
	DE 1443890	C3	19730830		
	DE 1443894	A	19690424	DE 1964-F43268	19640626 <--
	DE 1443894	C3	19730315		
PRAI	DE 1963-F41042	A	19631019		
	DE 1964-F42062	A	19640220		
	DE 1964-F42933	A	19640521		
	DE 1964-F43268	A	19640626		

AB The disclosure is the same, but the claims are different.
IT 25196-37-6P 25196-38-7P 25196-39-8P
25196-40-1P 25196-46-7P 25199-34-2P
25199-35-3P 25199-36-4P 25199-37-5P
25199-38-6P 25199-39-7P 25199-40-0P
25199-41-1P 25202-88-4P 25202-89-5P
25202-94-2P 25203-04-7P 25203-05-8P
25203-06-9P 25210-60-0P 25210-61-1P
25210-62-2P 25210-63-3P 25210-71-3P
25210-91-7P 25210-92-8P 25210-93-9P
25210-94-0P 25210-95-1P 25210-96-2P
25210-97-3P 25256-84-2P 25256-85-3P
25256-86-4P 25256-87-5P 25325-95-5P
25330-27-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 25196-37-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25199-35-3 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-36-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-37-5 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-38-6 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichlorophenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 25196-38-7 CAPLUS
CN Acetamide, N-[[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-39-8 CAPLUS
CN Acetamide, N-[[4-[[[[[4-(1-methylethyl)cyclohexyl]amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-40-1 CAPLUS
CN Acetamide, N-[[4-[[[[(2-methylpropyl)amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-46-7 CAPLUS
CN Carbamic acid, [[4-[[(phenoxyacetyl)amino]methyl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 25199-34-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25199-39-7 CAPLUS
CN Urea, 1-cyclohexyl-3-[[p-[2-[2-(2,4-dichlorophenoxy)acetamido]ethyl]phenyl]sulfonyl]- (8CI) (CA INDEX NAME)



RN 25199-40-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-41-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25202-88-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25202-89-5 CAPLUS
CN Acetamide, N-[1-methyl-2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-94-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25203-04-7 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-05-8 CAPLUS
CN Acetamide, N-[3-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]propyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25203-06-9 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-60-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-61-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-62-2 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-63-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-71-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-91-7 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-92-8 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-93-9 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-94-0 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-95-1 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25210-96-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-97-3 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 25256-84-2 CAPLUS
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-85-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
sulfonyl]phenyl]-1-methylethyl]- (9CI) (CA INDEX NAME)



RN 25330-27-2 CAPLUS
CN Acetamide, 2-(3,4-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 202 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25256-86-4 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-87-5 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25325-95-5 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]

L9 ANSWER 203 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:112808 CAPLUS
DN 72:112808
TI Pyrazolinone color couplers
IN Anderson, Brian
PA Ilford Ltd.
SO Brit., 8 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1173513		19691210	GB 1967-27035	19670612 <--
	DE 1770631			DE	
	FR 1570843			FR	

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are magenta color couplers. Thus, a mixture of 2.44 parts 1-(3,4-dichlorophenyl)-3-amino-2-pyrazolin-5 -one (II), 3.1 parts 2,4-(tert-C5H11)2C6H3OCH2COCl, and 50 parts MeCN was refluxed for 2 hr to give I (X1 = X2N = Cl, X3 = R = H, R1 = tert-C5H11(Q)] (III), m. 120-2°. A photographic layer containing III, when exposed to green light, developed in a black and white developer, reexposed to light, and developed with 4-H2NC6H4NEtCH2CH2OH gave a magenta image, λmaximum 545 nm. Similarly were prepared other I (X1, X2, X3, R, R1, and m.p. given): Cl, H, Cl, H, Q, 124-6° (petroleum ether); Cl, Cl, Cl, H, Q, 144 -6°; Cl, Cl, H, H, H, 206-8°; Cl, Cl, H, Et, Q, 137-9° (petroleum ether); Cl, H, Cl, H, H, 107-10° (30% aqueous EtOH); Cl, H, Cl, Et, Q, 120-2°; Cl, Cl, Cl, Et, Q, 149-50°; Br, Br, H, H, Q, 166° (PhMe-petroleum ether). Also prepared were IV (X, R, and m.p. given): H, H, 244-6°; Cl, H, 143-5°, H, Et, 192-3°. Also prepared were V (X, Y, R, and m.p. given): Cl, H, C17H35, 180- 2°; H, Cl, C11H23, 154-6°; Cl, Cl, C11H23, 164-6°; Cl, H, (CH2)3OC6H3Q2-2,4, 205-7°; Cl, H, 4-C6H4NHCOCH2OC6H4Q-4, 269-72°. The 3,5-Cl2 isomer of II, m. 204-8° (PhMe), was prepared from 3,5-Cl2C6H3NHNH2.HCl and EtO2CCH2C(:NH)OEt.HCl. The 3,4,5-trichlorophenyl analog, m. 222-4°, was prepared similarly.
IT 26492-00-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 26492-00-2 CAPLUS
CN Acetanilide, 4'-[[1-(3,4-dichlorophenyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]-2-(p-tert-pentylphenoxy)- (8CI) (CA INDEX NAME)



L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:90099 CAPLUS
DN 72:90099
TI Blood fatty acid removing phenoxyacetamides
IN Schmitt, Josef; Raveux, Roger; Brunald, Marcel D. P.
PA Etablissements Clin-Byla
SO Fr., 15 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1552793		19690110	FR	19661207 <--
	DE 1643317			DE	
	GB 1197597			GB	
	US 3551478		19701229	US	19671204 <--

GI For diagram(s), see printed CA Issue.

AB I, which exert a favorable action on cell and tissue respiration and lipid metabolism, are prepared by standard methods. Refluxing a mixture of 12.6 g 4-C5H11OC6H4OH, 19 g K2CO3, 13.5 g BrCH2CO3Et, and 60 ml Me2CO 6 hr gave 4-C5H11OC6H4OCH2CO2Et (II), b0.1 180-5°. Hydrolysis of II gave 4-C5H11OC6H4OCH2CO2H, m. 115° (iso-Pr2O). The following III were similarly prepared (R1, R2, X, and m.p. given): Cl, Cl, CHPh, 136-7° (C6H6); iso-PrO, H, CMe2, 57°[petroleum ether (PE)]; BuO, H, CMe2 (IV), 76° (PE); C5H11O, H, CHEt, 58° (PE); C5H11O, H, CMe2, 73° (PE); C6H13O, H, CH2, 114° (C6H6); cyclopentyloxy, H, CMe2, 100° (iso-Pr2O); and PhCH2O, H, CMe2, 137° (iso-Pr2O). Heating a mixture of 12 g IV, 7.2 g SOCl2, and 30 ml C6H6 underreflux 2 hrs gave the acid chloride, b0.1 145°. To a solution of 10.3 g 4-cyclo-pentyloxyphenoxyacetyl chloride in 60 ml Me2CO was added 8.6 g proeaine base in 40 ml Me2CO, as the temperature rose to boiling, and the mixture cooled to give room-temperature 11 g I (R1 = iso-BuO, R2 = R3 = R4 = H, X = CMe2, Y = CH2CH2NEt2) HCl salt, m. 134-5° (Me2CO); free base m. 104-5° (iso-Pr2O). The following I were similarly prepared (R1, R2, R3, R4, X, Y, m.p. base, salt, and m.p. salt given): H, H, H, H, CH2, (CH2)2-NEt2, 86°, HCl, -; H, H, H, H, CHEt, (CH2)2NEt2, - (oil), fumarate, 155-6°; Cl, H, H, H, CH2, (CH2)2NEt2,131°, HCl, 172°; Cl, H, H, H, CHMe, (CH2)2NEt2, - (oil), acid oxalate, 180°; Cl, H, H, H, CHEt, (CH2)2Et2, -(oil), acid oxalate 181°; Cl, H, H, H, CMe2, (CH2)2NEt2, -, acid oxalate, 107°; Cl, H, H, H, CH2, (CH2)2N(CHNe2)2, 144°, HCl, 195°; Cl, H, H, H, CH2, (CH2)3NMe2, 125°, HCl, 175°; Cl, H, H, H, CH2, CHMeCH2NMe2, 104°,HCl, 211°; Cl, H, H, H, CH2, pyrrolidinoethyl, 148°, HCl, 205°; Cl, H, H, H, CH2, pyrrolidinoethyl, 130° (C6H6), HCl, 222° (70%EtOH); Cl, Cl, H, H, CH2, CH2CH2NEt2 (A), 130° (EtOH), HCl, 178° (MeOH); Cl, Cl, H, H, CHMe, A, - (oil), acid fumarate, 155-6°; Cl, Cl, H, H, CHEt, A, - (oil), acid fumarate, 156° (EtOH); Cl, Cl, H, H, CHEt, A, - (oil), acid fumarate, 156°; Cl, Cl, H, H, CMe2, A, 90°, acid fumarate, 156°; Cl, Cl, H, H, "CH(CMe2)," A, - (oil), acid fumarate, 95°; Cl, Cl, H, H, CHPh, A, 102°, fumarate, 167°; H, H, CF3, H, CH2, A, - (oil), HCl, 148°; Me, Me, H, H, CH2, A, 101°, -, -; H, Me, H, Me, CH2, A, 112°, HCl, 173°; H, H, Me, Me, CH2, A, 116°, -, -; Cl, Me,H, H, CH2, A, 117°, fumarate, 114-15°; Cl, Me, H, H,

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CHEt, A, oil, fumarate, 145°; Cl, Me, H, H, CMe2, A, oil, fumarate, 133°; Me3C, H, H, H, CH2, A, 98°, -, -; Me3C, H, H, H, CHEt, A, - (oil), -, -; Me3C, H, H, H, CMe2, A, - (oil), HCl, 195°; Ph, H, H, H, CH2, A, - (oil), HCl, 177°; H, Ph, H, H, CH2, A, - (oil), HCl, 174°; PhCH2, H, H, H, CMe2, A, - (oil), -, -; H, PhCH2, H, H, CMe2, A, - (oil), -, -; PhCMe2, H,H, H, CMe2, A, 104°, -, -; HO, H, H, H, CH2, A, 105°, -, -; MeO, H, H, H, CH2, A, 92°, HCl, 158°; MeO, H, H, H, CHEt, A, - (oil), acid oxalate, 118-19°; H, H, MeO, H, CH2, A, - (oil), acid oxalate, 196°; MeO, MeO, H, H, CH2, - (oil), acid fumarate, 161°; CH2:CHCH2, MeO, H, H, CH2, A, - (oil), HCl, 127°; CH2:CHCH2, MeO, H, H, CMe2, A, - (oil), -, -; EtO, H, H, H,CH2, A, 78°, -, -; CH2:CHCH2O, H, H, H, CH2, A, - (oil), HCl, 123°; CH2:CHCH2O, H, H, H, CMe2, A, - (oil), fumarate, 142°; Me2CHO, H, H, H, CMe2, A, 88°, -, -; BuO, H, H, H, CH2, A, 93°, acid fumarate, 124°; BuO, H, H, H, CHEt, A, - (oil), -, -; BuO, H, H, H, CMe2, A, - (oil), neutral fumarate, 139°; C5H11O, H, H, H, CH2, A, 93°, HCl.H2O, 103°; C5H11O, H, H, H, CHEt, A, - (oil), -, -; C5H11O, H, H, H, CMe2,A, - (oil), acid fumarate, 109°; C6H13O, H, H, H, CH2, A, 89°, HCl.H2O, 95°; cyclopentyloxy, H, H, H, CMe2, A, 104-5°, HCl, 134°; cyclopentyloxy, H, H, H, CHEt, A, - (oil),-, -; cyclopentyloxy, H, H, H, CH2, A, 76°, HCl, 129°; PhCH2O, H, H, H, CMe2, A, - (oil), acid fumarate, 108°; Ac, H, H, H, CH2, A, - (oil), HCl, 202°; H, Ac, H, H, CH2, A, - (oil), HCl, 152°; EtCO, H, H, H, CH2, A, - (oil), HCl, 197°, NO2, H, H, H, CH2, A, 118°, HCl, 228°; H2N, H, H, H, CH2, A, 66°, 2HCl.H2O, 230°; and H2NSO2, H, H, H, CH2, A, 170°, -, -. Results are given showing the effects of I in reducing blood fatty acid levels in rats, and on the metabolism of Aspergillus niger.

IT 10441-32-4P 27468-99-1P 27469-00-7P
27469-03-0P 27469-04-1P 27469-05-2P
27469-07-4P 27469-08-5P 27469-09-6P
27469-10-9P 27469-11-0P 27469-13-2P
27469-14-3P 27469-15-4P 27469-18-7P
27469-21-2P 27469-22-3P 27469-25-6P
27469-26-7P 27469-30-3P 27469-31-4P
27469-33-6P 27469-34-7P 27469-35-8P
27469-36-9P 27469-37-0P 27469-38-1P
27469-39-2P 27469-40-5P 27469-41-6P
27469-42-7P 27469-43-8P 27474-42-6P
27474-43-7P 27474-45-9P 27474-46-0P
27474-52-8P 27474-53-9P 27474-54-0P
27474-55-1P 27474-56-2P 27474-57-3P
27474-62-0P 27474-68-6P 27474-69-7P
27474-70-0P 27474-71-1P 27474-72-2P
27474-73-3P 27474-74-4P 27474-76-6P
27474-80-2P 27474-81-3P 27526-73-4P
27526-75-6P 27529-80-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 10441-32-4 CAPLUS
CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27468-99-1 CAPLUS
CN Benzoic acid, p-[2-(2-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-00-7 CAPLUS
CN Benzoic acid, p-[2-(2-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



RN 27469-03-0 CAPLUS
CN Benzoic acid, p-[2-(p-hydroxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-04-1 CAPLUS
CN Benzoic acid, p-[2-(p-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27469-05-2 CAPLUS
CN Benzoic acid, p-[2-(p-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



RN 27469-07-4 CAPLUS
CN Benzoic acid, p-[2-(m-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, oxalate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27469-08-5
CMF C22 H28 N2 O5



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 27469-08-5 CAPLUS
CN Benzoic acid, p-[2-(m-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27469-09-6 CAPLUS
CN Benzoic acid, p-[2-(2,4-dimethoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-10-9 CAPLUS
CN Benzoic acid, p-[2-(4-allyl-2-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-11-0 CAPLUS
CN Benzoic acid, p-[2-(4-allyl-2-methoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-13-2 CAPLUS
CN Benzoic acid, p-[2-(p-ethoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-14-3 CAPLUS
CN Benzoic acid, p-[2-[p-(allyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-15-4 CAPLUS
CN Benzoic acid, p-[2-[p-(allyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-18-7 CAPLUS
CN Benzoic acid, p-[2-(p-butoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-21-2 CAPLUS
CN Benzoic acid, p-[2-(p-(pentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-22-3 CAPLUS
CN Benzoic acid, p-[2-[p-(pentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 27469-25-6 CAPLUS
CN Benzoic acid, p-[2-[p-(hexyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-26-7 CAPLUS
CN Benzoic acid, p-[2-[p-(hexyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-30-3 CAPLUS
CN Benzoic acid, p-[2-[p-(cyclopentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-31-4 CAPLUS
CN Benzoic acid, p-[2-[p-(cyclopentyloxy)phenoxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27469-33-6 CAPLUS
CN Benzoic acid, p-[2-(p-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-34-7 CAPLUS
CN Benzoic acid, p-[2-(p-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-35-8 CAPLUS
CN Benzoic acid, p-[2-(o-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27469-40-5 CAPLUS
CN Benzoic acid, p-[2-(p-nitrophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-41-6 CAPLUS
CN Benzoic acid, p-[2-(p-aminophenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-42-7 CAPLUS
CN Benzoic acid, p-[2-(p-aminophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 27469-43-8 CAPLUS
CN Benzoic acid, p-[2-(p-sulfamoylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 27469-36-9 CAPLUS
CN Benzoic acid, p-[2-(o-acetylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-37-0 CAPLUS
CN Benzoic acid, p-[2-(p-propionylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27469-38-1 CAPLUS
CN Benzoic acid, p-[2-(p-propionylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27469-39-2 CAPLUS
CN Benzoic acid, p-[2-(p-nitrophenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27474-42-6 CAPLUS
CN Benzoic acid, 4-[(phenoxyacetyl)amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-43-7 CAPLUS
CN Benzoic acid, p-(2-phenoxyacetamido)-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-45-9 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-46-0 CAPLUS
CN Benzoic acid, 4-[[(4-chlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 27474-52-8 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(diisopropylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-53-9 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(diisopropylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-54-0 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 3-(dimethylamino)propyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27474-55-1 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 3-(dimethylamino)propyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-56-2 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(dimethylamino)-1-methylethyl ester (8CI) (CA INDEX NAME)



RN 27474-57-3 CAPLUS
CN Benzoic acid, p-[2-(p-chlorophenoxy)acetamido]-, 2-(dimethylamino)-1-methylethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 27474-62-0 CAPLUS
CN Benzoic acid, p-[2-(2,4-dichlorophenoxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-68-6 CAPLUS
CN Benzoic acid, 4-[[[3-(trifluoromethyl)phenoxy]acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 27474-69-7 CAPLUS
CN Benzoic acid, p-[2-[(α,α,α-trifluoro-m-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-70-0 CAPLUS
CN Benzoic acid, p-[2-(2,4-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 27474-71-1 CAPLUS
CN Benzoic acid, p-[2-(2,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-72-2 CAPLUS
CN Benzoic acid, p-[2-(2,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27474-73-3 CAPLUS
CN Benzoic acid, p-[2-(3,5-xylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-74-4 CAPLUS

L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, p-[2-[(4-chloro-o-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester, fumarate (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27529-80-2
CMF C22 H27 Cl N2 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 27474-76-6 CAPLUS
CN Benzoic acid, p-[2-(p-tert-butylphenoxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



RN 27474-80-2 CAPLUS
CN Benzoic acid, p-[2-(4-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 27469-18-7
CMF C25 H34 N2 O5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 27529-80-2 CAPLUS
CN Benzoic acid, p-[2-[(4-chloro-o-tolyl)oxy]acetamido]-, 2-(diethylamino)ethyl ester (8CI) (CA INDEX NAME)



L9 ANSWER 204 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 27474-81-3 CAPLUS
CN Benzoic acid, p-[2-(4-biphenylyloxy)acetamido]-, 2-(diethylamino)ethyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 27526-73-4 CAPLUS
CN Benzoic acid, p-[2-(2,4-dimethoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, fumarate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 27469-09-6
CMF C23 H30 N2 O6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 27526-75-6 CAPLUS
CN Benzoic acid, p-[2-(p-butoxyphenoxy)acetamido]-, 2-(diethylamino)ethyl ester, fumarate (1:1) (8CI) (CA INDEX NAME)

CM 1

L9 ANSWER 205 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:89905 CAPLUS
DN 72:89905
TI Alicyclic bisphenyleneoxydicarboxylic acids, salts, and esters useful in preparation of polyamides
IN Jackson, Winston J., Jr.; Caldwell, John R.
PA Eastman Kodak Co.
SO U.S., 3 pp. Continuation-in-part of U.S. 3226362
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3470235	A	19690930	US 1965-506587	19651105 <--
PRAI US 1965-506587	A	19651105		

AB Continuation-in-part of U.S. 3,226,362 (CA 64: 8344f). The disclosure is similar, but the claims are different.
IT 25853-05-8P, Poly[oxy-p-phenylene(2-norbornylmethylene)-p-phenyleneoxymethylenecarbonyliminomethylene-p-phenylenemethyleneiminocarbonylmethylene]
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25853-05-8 CAPLUS
CN Poly[oxy-1,4-phenylene(bicyclo[2.2.1]hept-2-ylmethylene)-1,4-phenyleneoxy(1-oxo-1,2-ethanediyl)iminomethylene-1,4-phenylenemethyleneimino(1-oxo-1,2-ethanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 206 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:21515 CAPLUS
DN 72:21515
TI 3-Phenoxy-1-aminopropan-2-ol derivatives in treatment of cardiac irregularities
PA Imperial Chemical Industries Ltd.
SO Fr., 11 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1543689		19681025	FR 1967-126990	19671103 <--
DE 1643425			DE	
FR 7272			FR	
GB 1185044			GB	
US 3562297		19710209	US	19671016 <--
ZA 6706611		19670000	ZA	<--
PRAI GB		19661103		

OS MARPAT 72:21515
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) (R2 = R6CONH) have β-adrenal blocking activity and are useful for the treatment of angina pectoris, cardiac irregularities, hypertension, and phaeochromocytone. The β-adrenal blocking activity shows selectivity for the cardiac β-receptors over those of the blood vessels and chest muscles. In the following examples the units are parts by weight PrCOCl 0.5, Et2O 75, and I (R1 = Bz, R2 = 4-NH2, R3 = R4 = H, R5 = iso-Pr) 1.55 was kept 2 hr at 15°, evaporated in vacuo, and hydrogenated in 50 parts EtOH over 0.4 part 5% Pd/C at 20°/100 atmospheric to give I (R1 = R3 = R4 = H, R2 = 4-PrCONH, R5 = iso-Pr) m. 135-7° (EtOAc). Similarly were prepared I (R1 = R4 = H, R2 = 4-AcNH, R3 = Me, R5 = iso-Pr) m. 165° (MeCOEt) [from I (R1 = Bz, R2 = 4-NH2, R3 = 3-Me, R4 = H, R5 = iso-Pr) (II); I.HCl (R1 = R3 = R4 = H, R2 = PhOCH2NH, R5 = iso-Pr), m. 168-70° (iso-PrOH); I (R1 = R3 = R4 = H, R2 = 2-AcNH, R5 = iso-Pr), m. 98-100 (MeCOEt); I (R1 = R3 = R4 = H, R2 = ClCH2CONH, R5 = iso-Pr) m. 146-8° (iso-PrOH); and I (R1 = R3 = R4 = H, R2 = p-MeC6H4CONH, R5 = iso-Pr) m. 176° (iso-PrOH). Epichlorohydrin 15.6, R1R2C6H3OH (III) (R1 = 3-Me, R2 = 4-NO2) 4.5, NaOH 1.32, and H2O 50 kept 16 hr at 15° gave IV (R1 = 3-Me, R2 = 4-NO2). This 6 and BzNHPr-iso 4.5 heated 2 hr at 100° gave I (R1 = Bz, R2 = 4-NO2, R3 = 3-Me, R4 = H, R5 = iso-Pr), which was reduced with Fe/HCl in EtOH to give II. Similarly, III (R1 = 2-Bu, R2 = 5-AcNH) gave IV (R1 = 2-Bu, R2 = 5-AcNH) which with iso-PrNH2 gave I.0.5H2O (R1 = R4 = H, R2 = 6-AcNH, R3 = 2-Bu, R5 = iso-Pr), m. 131-2° (30:1 EtOAc-H2O). III (R1 = H, R2 = 4-m-O2NC6H4CH2) gave IV (R1 = H, R2 = 4-m-O2NC6H4CH2) which gave I (R1 = R3 = R4 = H, R2 = 4-m-O2NC6H4CH2, R5 = iso-Pr) m. 162-4° (iso-PrOH). Also prepared were I (R1 = R3 = R4 = H, R2 = 4-AcNH, R5 = cyclopropyl), m. 114-16° (EtOAc); I (R1 = R3 = R4 = H, R2 = 4-AcNH, R5 = Me), m. 122° (6:1 EtOAc-EtOH); I (R1 = PhCH, R2 = cyclohexylcarboxamido, R3 = R4 = H, R5 = iso-Pr), which on hydrogenation, gave the I (R1 = H) analog, m. 159-61° (EtOAc); I (R1 = R3 = R4 = H, R2 = X, R5 = iso-Pr) [X = HOCH2CONH, m. 125-8° (EtOAc); X = 2-furoylamido, m. 138-41° (C6H6); and X = cyclopropylcarboxamide, m. 159-60° (EtOAc)]; I.HCl (R1 = PhCH2, R2 = p-O2NC6-H4CONH, R3 = R4 = H, R5 = iso-Pr), m. 230-2° (MeOH); I (R1 = R3 = R4 = H, R2 = p-H2NC6H4CONH, R5 = iso-Pr) m. 210-12° (MeOH); I.2H2O (R1 = R3 = R4

L9 ANSWER 206 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= H, R2 = HCONH, R5 = iso-Pr), m. 18 9-92° (EtOH); I.0.25H2O(R1 = R3 = R4 = H, R2 = CH2:CHCONH, R5 = iso-Pr), m. 127-32°; I (R1 = R4 = H, R2 = 3-AcNH, R3 = 5-Me, R5 = iso-Pr) m. 134.5-37° (EtOAc); I (R1 = R3 = R4 = H, R2 = PrCONH, R5 = tert-Bu), m. 99-101.5° (EtOAc-C6H14); and V I.HCl (R1 = R3 = H, R2 = 4-AcNH, R4 = Ac, R5 = iso-Pr), m. 134-6° (decompn.).
IT 24789-00-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24789-00-2 CAPLUS
CN Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-2-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:3228 CAPLUS
DN 72:3228
TI Benzenesulfonyl ureas
IN Weber, Helmut; Aumueller, Walter; Weyer, Rudi; Muth, Karl; Schmidt, Felix Helmut
PA Farbwerke Hoechst A.-G.
SO U.S., 25 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3426067	A	19690204	US 1964-403641	19641013 <--
PRAI DE 1963-F41042	A	19631019		

AB An addnl. 200 compds., chemical and physiol. similar to those reported earlier (CA 62: 13092a; CA 66: 18606z), are described.
IT 25196-37-6P 25196-38-7P 25196-39-8P
25196-40-1P 25196-46-7P 25199-34-2P
25199-35-3P 25199-36-4P 25199-37-5P
25199-38-6P 25199-39-7P 25199-40-0P
25199-41-1P 25202-88-4P 25202-89-5P
25202-94-2P 25203-04-7P 25203-05-8P
25203-06-9P 25210-60-0P 25210-61-1P
25210-62-2P 25210-63-3P 25210-71-3P
25210-91-7P 25210-92-8P 25210-93-9P
25210-94-0P 25210-95-1P 25210-96-2P
25210-97-3P 25256-84-2P 25256-85-3P
25256-86-4P 25256-87-5P 25325-95-5P
25330-27-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25196-37-6 CAPLUS
CN Acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-38-7 CAPLUS
CN Acetamide, N-[[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 25196-39-8 CAPLUS
CN Acetamide, N-[[4-[[[[[4-(1-methylethyl)cyclohexyl]amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-40-1 CAPLUS
CN Acetamide, N-[[4-[[[[(2-methylpropyl)amino]carbonyl]amino]sulfonyl]phenyl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25196-46-7 CAPLUS
CN Carbamic acid, [[4-[[(phenoxyacetyl)amino]methyl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 25199-34-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-35-3 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25199-36-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-37-5 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(3,4-dimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-38-6 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25199-39-7 CAPLUS

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[1-methyl-2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-94-2 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25203-04-7 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-05-8 CAPLUS
CN Acetamide, N-[3-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]propyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25203-06-9 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Urea, 1-cyclohexyl-3-[[p-[2-[2-(2,4-dichlorophenoxy)acetamido]ethyl]phenyl]sulfonyl]- (8CI) (CA INDEX NAME)



RN 25199-40-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25199-41-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(2,4-dichloro-6-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25202-88-4 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]-1-methylethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25202-89-5 CAPLUS

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-60-0 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-61-1 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-62-2 CAPLUS
CN Acetamide, N-[2-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-63-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-71-3 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RN 25210-91-7 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-92-8 CAPLUS
CN Acetamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-93-9 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25256-84-2 CAPLUS
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-85-3 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25256-86-4 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25210-94-0 CAPLUS
CN Acetamide, N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 25210-95-1 CAPLUS
CN Acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 25210-96-2 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 25210-97-3 CAPLUS
CN Acetamide, 2-(4-chlorophenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 25256-87-5 CAPLUS
CN Acetamide, 2-(2,4-dichloro-6-methylphenoxy)-N-[2-[4-[[[[(4-ethylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 25325-95-5 CAPLUS
CN Acetamide, 2-(2-chlorophenoxy)-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-1-methylethyl]- (9CI) (CA INDEX NAME)



RN 25330-27-2 CAPLUS
CN Acetamide, 2-(3,4-dimethylphenoxy)-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L9 ANSWER 207 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 208 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:526012 CAPLUS
DN 71:126012
TI 2-Equivalent couplers
IN Sawdey, George W.
PA Eastman Kodak Co.
SO Ger. Offen., 59 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1800420	B2	19740829	DE 1968-1800420	19681001 <--
	DE 1800420	C3	19750417		
	US 3617291	A	19711102	US 1967-674090	19671010 <--
	FR 1585559	A	19700123	FR 1968-1585559	19681008 <--
	GB 1250318	A	19711020	GB 1968-1250318	19681010 <--
PRAI	US 1967-674090	A	19671010		

GI For diagram(s), see printed CA Issue.
AB The preparation of 2-equivalent couplers of the general formula I which absorb uv rays, fluoresce blue, and are resistant to discoloration and spot formation is described. I are prepared by Zn dust reduction of a suitable O-nitrophenylazo compound Thus, a mixture of 5.2 g. 1-phenyl-3-pentadecyl-4-(2-nitrophenylazo)-5-pyrazolone, 25 ml. 40% aqueous NaOH solution, and 400 ml. EtOH is refluxed and stirred, treated with 8 g. Zn dust, refluxed until colorless,, cooled slowly, stirred for 1.5 hrs., excess Zn dust filtered and the solution acidified with HCl to give 82% I (R = 3-pentadecyl-1-phenyl-5-pyrazolone-4-yl), m. 106-8° (MeOH). Similarly other I are prepared (RH, and m.p. given): 1,2-HOC10H6CONH(CH2)4OC6H3(C5H11-tert)2-2,4, 146-7°; BzCHCONHPh, 214-16°; tert-BuCOCH2CONHPh, 161-2°; cyanoacetyl-coumarone, 220-2°; 3-methyl-1-phenyl-5-pyrazolone, 154-6°; 3-[3-[α-(2,4-diamylphenoxy)acetamido]benzamido] - 1-(2,4,6-trichlorophenyl)-5-pyrazolone, 165-6°.
IT 25779-31-1P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 25779-31-1 CAPLUS
CN Acetanilide, 4'-[[4-(2H-benzotriazol-2-yl)-5-oxo-1-(2,4,6-trichlorophenyl)-2-pyrazolin-3-yl]carbamoyl]-2-(2,4-di-tert-pentylphenoxy)- (8CI) (CA INDEX NAME)

L9 ANSWER 208 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L9 ANSWER 209 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:428983 CAPLUS
DN 71:28983
TI Irreversible enzyme inhibitors. CLIII. Proteolytic enzymes. 11. Inhibition of guinea pig complement by substituted phenoxyacetamides
AU Baker, Bernard Randall; Hurlbut, Jeffrey A.
CS Univ. of California, Santa Barbara, CA, USA
SO Journal of Medicinal Chemistry (1969), 12(3), 415-19
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB A series of 89 compds. derived from phenoxyacetamide and phenoxyacetone were investigated as inhibitors of the guinea pig complement system. Only 2 of the compds. without a terminal SO2F moiety showed 30-50% inhibition at 1-3mM, namely, α-naphthoxyacetone and N-benzyl-N-carboxymethyl-3,4-dichlorophenoxyacetamide; however, these concns. were lower than the 10-20mM needed for N-acetyl-L-tyrosine Et ester and N-tosyl-L-arginine Me ester. Several compds. derived from N-benzyl- and N-phenyl-phenoxyacetamide with a CO2H group ortho to the ether linkage accelerated complement-induced lysis, perhaps by inhibition of the destruction of one or more of the sensitive components of complement such as C'-1, C'-4, or C'-6. When the N-phenylor N-benzyl-2-carboxy-4-chlorophenoxyacetamides were bridged to benzenesulfonyl fluoride with a ureido moiety, some excellent irreversible inhibitors emerged such as N-[m-(3-chloro-4-fluorosulfonylphenylureido)benzyl] - 2 - carboxy - 4 - chlorophenoxyacet-amide (I) which at 0.25mM gave 82% gave 82% inhibition of the complement system; it was further established that the SO2F moiety on a mol. such as I was necessary for activity, but the abbreviated p-acetamidobenzenesulfonyl fluoride showed no activity.
IT 20167-19-5 21447-17-6 21447-21-2
RL: BIOL (Biological study)
(complement inhibition by)
RN 20167-19-5 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-17-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[4-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-21-2 CAPLUS

L9 ANSWER 209 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)-4-methylphenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 210 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:87843 CAPLUS
DN 70:87843
TI Antidiabetic sulfonamides
IN Heerdt, Ruth; Huebner, Manfred; Schmidt, Felix H.; Stach, Kurt; Aumueller, Walter
PA Boehringer, C. F., und Soehne G.m.b.H.
SO S. African, 23 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6800662		19680627		<--
	DE 1670188			DE	
	FR 1595528			FR	
	GB 1148287			GB	
PRAI	DE		19670201		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are prepared by known methods. Method A: reaction of II with the appropriate sulfonyl chloride and oxidation to I; method B: phenylsulfonylguanidines are reacted with a β-dicarbonyl compound; method C: acylation of the appropriate amine; and method D: reaction of a substituted sulfonamide with a pyrimidine having a reactive ester group or a low mol. weight trialkylammonium group. Thus, a solution of 3.2 g. 4-[N-methyl-β-(5 - chloro - 2 -methoxybenzoylamino)ethyl]benzenesulfonyl chloride in 5 ml. pyridine was added to a solution of 1.35 g. 2-amino-5-(propylthio)pyrimidine (m. 107-9°) in 5 ml. pyridine to give 4-[N-methyl-β-(5-chloro-2-methoxybenzoylamino)ethyl]-5[-5-(propylthio)pyrimidin-2-yl]benzenesulfonamide, 80-2°. Similarly were prepared the following I(X = C2H4) (Q, R, m.p., and method given): 2,5-(MeO)ClC6H3 (A), Pr, 135°, A; A, iso-Pr, 90°, A; A, iso-Bu, 134-6, A; A, C2H4OMe, 121-2°, A; C6H11, Pr, 175°, A; EtO, iso-Pr, 127-8°, A; Me, Pr, 137-40°, B; Me, Et, 140°, B; Me, iso-Bu, 166-7°, B; A, Et, 166-70°, C; 2,5-(MeO)Br-C6H3, iso-Bu, 151-3°, C; 2,5-(MeO)MeC6H3, Et, 171-3°, C; 3-ClC6H4, Pr, 150-2°, C; 2-MeOC6H4, iso-Pr, 135-7°, C; 1-indolinyl, Pr, 153°, C; 3-methyl-3-phenylcarbamoyl, Pr, 130°, C; Ph, Pr, 186-7°, C; 4-ClC6H4, Pr, 176-7°, C; m-tolyl, Pr, 163°, C; phenethyl, Pr, 123-4°, C; PhSCH2, Pr, 129-30°, C; PhOCH2, Pr, 136-7°, C; 2,5-(MeO)2C6H3, Pr, 138°, C; 2,5-(EtO)ClC6H3, Pr, 145-7°, A; A, CH2SEt, 156-7°, A; A, C6H11, 167-9°, A; 2-EtOC6H4, Pr, 130°, C; 2,4-(MeO)ClC6H3, Pr, 158-60°, C. Also prepared by method A were I[Q = 2,5-(MeO)ClC6H3, R = Pr] (X and m.p. given): (CH2)3, 144-6°; CH2, 183-5°. I has long lasting antidiabetic action.
IT 21721-67-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21721-67-5 CAPLUS
CN Acetamide, 2-phenoxy-N-(p-[[5-(propylthio)-2-pyrimidinyl]sulfamoyl]phenethyl]- (8CI) (CA INDEX NAME)

L9 ANSWER 210 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 211 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:47485 CAPLUS
DN 70:47485
TI 4-(ω-Amido-alkyl)-N-(2-pyrimidinyl)benzenesulfonamides
PA Boehringer, C. F., und Soehne G.m.b.H.
SO Brit., 6 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1136190		19681211	GB 1967-53841	19671127 <--
	CA 951733			CA	
	DE 1670168			DE	
	FR 1571294			FR	
	US 3520887		19700721	US	19671115 <--
	ZA 6707166		19670000	ZA	<--
PRAI	DE		19661129		

GI For diagram(s), see printed CA Issue.
AB I are prepared from p-XO2SC6H4(CH2)nNR1COR (II), III, and IV. A mixture of 3.4 g. 4-[β-(5-chloro-2-methoxybenzamido)-ethyl]benzenesulfonyl chloride, 1.7 g. 2-amino-4-methyl-5-iso-butylpyrimidine, and 6 ml. pyridine is kept at room temperature 1.5 hrs. and heated 2 hrs. to give 33% 4-[β-(5-chloro-2-methoxybenzamido)ethyl]-N-(4-methyl-5-isobutyl-2-pyrimidinyl)benzenesulfonamide, m. 174-5°. II [R = Me, R1 = H, n = 2, X = NHC(:NH)NH2] (22.7 g.) is treated with 15.1 g. pyrrolidinocyclohexene, 11 g. COCl2, 7.3 g. HCONMe2, and CH2Cl2 to give 20% I [R = Me, R1 = H, n = 2, (R2 R3=) (CH2)4], m. 184°. IV (R2 = Me, R3 = iso-Bu) (V) (3.48 g.) is treated with 2.1 g. 4,2-Cl(MeO)C6H3COCl to give 3.9 g. I [R = 4,2-Cl(MeO)C6H3, R1 = H, n = 2, R2 = Me, R3 = iso-Bu], m. 180-3°. II [R = Ph, R1 = H, n = 2, X = NHC(:NH)NH2] (4.15 g.) is treated with 2.0 g. 2-formylcycloheptanone to give 40.6% 4-(β-benzamidoethyl) - N - [6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidin-2-yl]benzenesulfonamide, m. 206-7°. Also prepared, according to the above methods, are the following I (R1 = H, n = 2) (R, R2, R3, and m.p. given): 5,2-Cl(MeO)C6H3 (A), Bu, H, 139-40°; A, iso-Bu, H, 166°; A, Me, Pr, 188-9°; A, Me, iso-Pr, 178-80°; A, (R2R3=) (CH2)4, 204-7°; Ph, (R2R3=)(CH2)4, 218-20°; 5,2-Cl(EtO)C6H3 (B), MeO, iso-Pr, 173°; (B), Me, iso-Pr, 183°; EtO, (R2R3=)(CH2)4, 168-9°; EtO, Me, iso-Bu (VI), 166°; 5,2-Br(MeO)C6H3, Me, iso-Bu, 179-80°; 3-methoxy-2-thienyl, Me, iso-Bu, 157°; m-ClC6H4, (R2R3=) (CH2)4, 180-1°; 5,2-Me(MeO)C6H3, (R2R3=) (CH2)4, 194-5°; PhSCH2, (R2R3=) (CH2)4, 191-3°; cyclohexyl, (R2R3=) (CH2)4, 240°; o-MeC6H4, (R2R3)= (CH2)4, 201-2°; MePhN, Me, iso-Bu, 154-6°; indolin-1-yl, (R2R3=) (CH2)4, 236-8°; p-FC6H4, Me, Pr, 187-8°; A, (R2R3=) (CH2)5, 187-9°; PhOCH2, Me, iso-Bu, 130°; phenethyl, Me, iso-Bu, 167°; 2,5-(MeO)2C6H3, Me, iso-Bu, 169°; o-tolyl, Me, iso-Bu, 170°; m-tolyl, Me, iso-Bu, 180-2°; A, Et, Et, 176-7°; and the following compds. (m.p. given): I (R = A, R1 = Me, n = 2, (R2R3=) (CH2)5], 195-6°; I [R = A, R1 = H, n = 1, R2 = Me, R3 = iso-Bu], 147-8°; 4-[β-(5-chloro-2-methoxybenzamido)ethyl]-N-(7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-yl]benzenesulfonamide, 183-4°. VI is hydrolyzed to give V, m. 197-9°. Similarly prepared is IV [(R2R3=) (CH2)4], m. 210-12°.
IT 21786-74-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21786-74-3 CAPLUS

L9 ANSWER 211 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetamide, N-[p-[(5-isobutyl-4-methyl-2-pyrimidinyl)sulfamoyl]phenethyl]-2-phenoxy- (8CI) (CA INDEX NAME)



L9 ANSWER 212 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:37403 CAPLUS
DN 70:37403
TI Irreversible enzyme inhibitors. CXLV. Proteolytic enzymes. 8. Active-site-directed irreversible inhibitors of α-chymotrypsin derived from α-(2-carboxy-4-chlorophenoxy)acetamide bearing a terminal sulfonyl fluoride
AU Baker, Bernard Randall; Hurlbut, Jeffrey A.
CS Univ. of California, Santa Barbara, CA, USA
SO Journal of Medicinal Chemistry (1969), 12(1), 118-22
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Thirteen candidate irreversible inhibitors derived from N-benzyl- or N-phenyl-α-(2-carboxy-4-chlorophenoxy)-acetamide with a terminal SO2F group on the N substituent were synthesized and evaluated. A number of these at a Ki concentration gave essentially complete inactivation of α-chymotrypsin in 60 min. at 37°. The best compound was 3-[4,2-Cl(HO2C)C6H3- OCH2CONHCH2]C6H4NHCONHC6H4SO2F-3 which showed a half-life of inactivation of 2 min. when a Ki = 81 μM concentration was incubated with 1 μM chymotrypsin.
IT 20167-19-5 20209-72-7 21447-17-6
21447-21-2 21447-22-3 21505-36-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(as chymotrypsin inhibitor)
RN 20167-19-5 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 20209-72-7 CAPLUS
CN Benzenesulfonyl fluoride, 3-[[[[[4-[[(3-chlorophenoxy)acetyl]amino]phenyl]methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 21447-17-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[4-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

L9 ANSWER 212 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 21447-21-2 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[3-(fluorosulfonyl)-4-methylphenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21447-22-3 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[[[4-[[[[2-chloro-5-(fluorosulfonyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



RN 21505-36-2 CAPLUS
CN Sulfanilyl fluoride, N-[[α-[2-(m-chlorophenoxy)acetamido]-p-tolyl]carbamoyl]- (8CI) (CA INDEX NAME)



L9 ANSWER 212 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 213 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:487984 CAPLUS
DN 69:87984
TI Photographic couplers
PA Fuji Photo Film Co., Ltd.
SO Fr., 10 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1497720		19671013	FR 1966-79751	19661012 <--
GB 1149514			GB	
US 3558700		19710126	US	19661012 <--
PRAI JP		19651012		

GI For diagram(s), see printed CA Issue.
AB Compds. of the general formula I, containing a 2,4-(sec-C5H11)2C6H3OCH2CONH (QNH) substituent, and compds. of the formulas II, III, and IV are couplers for color photography having lower m.ps. and 2-10 times greater solubility in AcOEt at 25° than the isomeric compds. containing tert-C5H11 groups. A mixture of 2,4-(sec-C5H11)2C6H3ONa and ClCH2CO2Et in PhMe is refluxed 2 hrs., filtered, and distilled to give 78% QOEt, b2·5 150-62°, which is saponlfied to QOH, b1·5 150-67°, in 75% yield and converted with SOCl2 to QCl, b200 150-5°, in 71% yield. A mixture of 28 g. 4-H2NC6H4COCH2CONHC6H4OMe-2, 10 g. anhydrous NaOAc, and 300 ml. AcOH was treated at room temperature with 31 g. QCl, stirred for 5 hrs., clarified, and diluted with iced water to give 30 g. (54% yield) I (R = 4-QNHC6H4, X = OMe, Y = Z = H) (V), m. 120-1° (EtOH), solubility 29.2% in AcOEt at 25° (tert-C5H11 isomer m. 149°, solubility 3.7%). Similarly, other I were prepared (R, X, Y, Z, m.p., % soly in AcOEt at 25°, and m.p. and solubility of tert-isomer given): 4-MeOC6H4, H, NHQ, H, 165°, 2.7, 185°, 0.27; 4-MeOC6H4, Cl, NHQ, H, 110°, >30, 140°, 4.7; Me3C, Cl, H, NHQ, -, -, -, -. Similarly were prepared II (X, Y, Z, n, m.p., % solubility, and m.p. and % solubility of tert-isomer given): H, H, H, 0, 135°, 19.1, 223°, 1.9; H, H, H, 1 (VI), 140-2° (C6H6-EtOH), 224, 185-6°, 2.9; Me, Cl, H, 0, 190°, 9.8, 220°, 3.1. Similarly were prepared III, m. 25-7° (MeCN), solubility 28.7% (tert-isomer m. 158°, solubility 12.2%) and IV, m. 120-2° (EtOH), solubility 18.5% (isomer m. 144-6°, solubility 7.1%). Coupling diazotized 4-MeOC6H4NH2 with VI gave 81% II (X = Y = H, Z = N:NC6H4OMe-4, n = 1) (VII), m. 150-2° (EtOH), solubility 2.4% (isomer m. 201-3°, solubility 0.3%). AgX emulsions containing III, IV, and V were developed with 2,4-Me(Et2N)C6H3NH2 (VIII) to give dyes having λmaximum at 445, 665, and 695 mμ, resp. Coatings of VI developed with 3,4-Me(H2N)C6H3NEtCH2NHSO2Me gave λmaximum at 532 mμ. A coating containing VII and an orthochromic sensitizing dye developed with VIII gave a negative magenta image and a yellow positive image with λmaximum at 435 mμ.
IT 20364-04-9P 27497-03-6P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

L9 ANSWER 213 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 20364-04-9 CAPLUS
CN o-Acetanisidide, 2-[p-[2-(2,4-di-tert-pentylphenoxy)acetamido]benzoyl]- (6CI, 8CI) (CA INDEX NAME)



RN 27497-03-6 CAPLUS
CN o-Acetanisidide, 2-[p-[2-(2,4-di-sec-pentylphenoxy)acetamido]benzoyl]- (8CI) (CA INDEX NAME)



L9 ANSWER 214 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:464778 CAPLUS
DN 69:64778
TI Irreversible enzyme inhibitors. CXXXII. Proteolytic enzymes. 6. Tolerance for polar groups on the phenoxyacetanilide type of inhibitor of α-chymotrypsin
AU Baker, B. R.; Hurlbut, Jeffrey A.
CS Univ. of California, Santa Barbara, CA, USA
SO Journal of Medicinal Chemistry (1968), 11(5), 1054-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Candidate irreversible inhibitors derived from phenoxyacetanilide (I), such as N-[m-(m-fluorosulfonylphenylureido)phenyl]-3-chlorophenoxyacetamide (II), are too insol. in water for enzymic evaluation; therefore, a study was conducted on positioning of polar groups on I that would not interfere with complex formation. Three useful classes of compds. emerged. The first class of compds. consisted of introduction of RCO2 or CH2N+H3 groups on the N-phenyl moiety; this N-phenyl moiety is apparently complexed to a polar region of α-chymotrypsin since no binding was lost. The 2nd class derived from I consisted of introduction of a CO2- group on the phenoxy moiety, which is complexed in a hydrophobic region. An o-CO2- group was well tolerated in the complex, and inhibition could be further enhanced by introduction of a 4- or 5-chloro or 4-bromo atom. The 3rd class consisted of a replacement of the phenoxymethyl moiety of I by a quaternized pyridylvinyl or pyridylethyl moiety; only N-methyl-2-pyridylacrylanilide in this class was satisfactory, being complexed to the enzyme .apprx.33% as well as I. The 2-carboxy-4-chlorophenoxy group of III was a suitable replacement for the 3-chlorophenoxy group of II in order to increase solubility; not only was III about 100 times as soluble as II, but irreversible inhibition was readily detected with III at 15% of its maximum solubility 16 references.
IT 18705-07-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with α-chymotrypsin)
RN 18705-07-2 CAPLUS
CN Acetamide, N-[4-(aminomethyl)phenyl]-2-(3-chlorophenoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 215 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:402648 CAPLUS
DN 69:2648
TI Sulfanilamide derivatives based on acetylenic amines
AU Azerbaev, I. N.; Kim, D. G.; Tsoi, L. A.
SO Trudy Instituta Khimicheskikh Nauk, Akademiya Nauk Kazakhskoi SSR (1967), 19, 60-3
CODEN: TIKNAG; ISSN: 0568-5087
DT Journal
LA Russian
AB The following 4-RC6H4SO2NHCMeR'C:CH were prepared by treating acetylenic amines with appropriate sulfonylating agents (R, R', and m.p. given): H, Me, 61°; Me, Me, 89°; MeO, Me, 95°; Cl, Me, 95°; 3-NO2, Me, 80°; NH2, Me, 198°; NHAc, Me, 197°; H, Et, 72°; Me, Et, 90°; MeO, Et, 68°; Cl, Et, 96°; 3-NO2, Et, 80°; NH2, Et, 123°; NHAc, Et, 163°. The following 4-RNHC6H4SO2NHCMeR'C:CH were also prepared (same data given): CHO, Me, 107°; CHCl2CO, Me, 169°; Bz, Me, 218°; PhCH2CO, Me, 146°; PhCH:CHO, Me, 203°; PhOCH2CO, Me, 133°; PhSO2, Me, 173°; AcNHC6H4SO2, Me, 222°; CHO, Et, 115°; CHCl2CO, Et, 171°; Br, Et, 230°; PhCH2CO, Et, 153°; PhCH:CHCO, Et, 199°; PhOCH2CO, Et, 164°; PhSO2, Et, 178°; AcNHC6H4SO2, Et, 216°.
IT 17047-22-2P 17047-23-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17047-22-2 CAPLUS
CN Acetanilide, 4'-[(1,1-dimethyl-2-propynyl)sulfamoyl]-2-phenoxy- (8CI) (CA INDEX NAME)



RN 17047-23-3 CAPLUS
CN Acetanilide, 4'-[(1-ethyl-1-methyl-2-propynyl)sulfamoyl]-2-phenoxy- (8CI) (CA INDEX NAME)



L9 ANSWER 216 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:84559 CAPLUS
DN 68:84559
TI Irreversible enzyme inhibitors. CXIV. Proteolytic enzymes. 4. Additional active-site-directed irreversible inhibitors of α-chymotrypsin derived from phenoxyacetamides bearing a terminal sulfonyl fluoride
AU Baker, Bernard Randall; Hurlbut, Jeffrey A.
CS Univ. of California, Santa Barbara, CA, USA
SO Journal of Medicinal Chemistry (1968), 11(2), 241-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Fifteen candidate irreversible inhibitors of α-chymotrypsin derived from N-phenyl- or N-benzyl-3-chloro- or 3,4-dichlorophenoxyacetamide were synthesized that contained a fluorosulfonylbenzamido or fluorosulfonylphenylureido group on the N-aryl ring. Of these, ten showed irreversible inhibition of α-chymotrypsin; due to lack of solubility compared to their reversible binding consts., none of these compds. could completely inactivate α-chymotrypsin at their maximum solubility The kinetics of activation indicated that these compds. were being enzymically hydrolyzed to the corresponding sulfonic acids as well as causing inactivation of α-chymotrypsin by the active-site-directed mechanism. 17 references.
IT 20209-62-5P 20209-72-7P 20209-75-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and chymotrypsin inhibition by)
RN 20209-62-5 CAPLUS
CN Metanilyl fluoride, N-[[α-[2-(m-chlorophenoxy)acetamido]-p-tolyl]carbamoyl]- (8CI) (CA INDEX NAME)



RN 20209-72-7 CAPLUS
CN Benzenesulfonyl fluoride, 3-[[[[[4-[[(3-chlorophenoxy)acetyl]amino]phenyl]methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 20209-75-0 CAPLUS
CN p-Acetotoluidide, α-amino-2-(m-chlorophenoxy)-, monohydrochloride (8CI) (CA INDEX NAME)

L9 ANSWER 216 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

L9 ANSWER 217 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:49663 CAPLUS
DN 68:49663
TI 3-(Halophenyl-oxoaliphatic)benzothiadiazine 1,1-dioxides
IN Novello, Frederick C.
PA Merck and Co., Inc.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3325485		19670613	US 1960-71456	19601125 <--

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), which possess diuretic, natriuretic, and (or) saluretic properties, were prepared by treating an alcoholic solution of the appropriate disulfamoyl-N-haloacylamine compound with a tertiary amine. A solution of 17.1 g. II (R = Cl, R1 = SO2NH2, X = H) (IIa), and 7.5 g. ClCH2COCl in 225 ml. dioxane was refluxed 24 hrs. and concentrated to dryness in vacuo, and the residue crystallized to give II (R = Cl, R1 = SO2NH2, X = ClCH2CO), m. 240-2° (EtOH-H2O). 5-Chloroaniline-2,4-disulfonyl chloride (6.6 g.) was added portionwise to 50 ml. 40% aqueous MeNH2 and the mixture heated 1 hr. on the steam bath and cooled to give II (R = Cl, R1 = SO2NHMe, X = H), m. 175.5-8°. m-Butyl-N-propylaniline (0.5 mole) was added dropwise with stirring to 375 ml. ClSO3H cooled in an ice bath, the mixture treated with 350 g. NaCl 1-2 hrs., heated gradually to 150°, kept 3 hrs. at 150-60°, cooled in an ice bath, treated with 1 l. cold H2O, and extracted with Et2O, and the extract worked up to give the corresponding 5-butylaniline-2,4-disulfonyl chloride (III), m. 130-2° (C6H6-hexane). III was added portionwise to BuNH2 as above to give 5-butyl-2,4-bis(N-butylsulfamoyl)aniline, which was converted as above to 5-butyl-2,4-bis(N-butylsulfamoyl)-N-(β-chloropropionyl)aniline. 2-Amino-4-trifluoromethylbenzenesulfonic acid (32 g.) was added portionwise during 5-10 min. with stirring to 100 ml. ClSO3H cooled in an ice bath, the mixture heated 3 hrs. at 150°, cooled to 20, treated with 40 ml. SOCl2, heated 1 hr. on the steam bath, cooled to 0°, and poured cautiously onto ice, the aqueous layer decanted, the solid heated 2 hrs. on the steam bath with 500 ml. 28% NH4OH, and the mixture cooled and worked up to give II (R = F3C, R1 = SO2NH2, X = H), m. 241-2° (aqueous EtOH). A suspension of 3.6 g. IIa in 50 ml. EtOH was added to a solution of 1.47 g. p-ClC6H4SH in 50 ml. EtOH containing 0.23 g. Na and the mixture heated 2 hrs. on the steam bath to give II (R = Cl, R1 = SO2NH2, X = p-chlorophenylthioacetyl), m. 236-7° (Me2CO-petr. ether). A stirred suspension of 25.7 g. IIa in a mixture of 100 ml. H2O, 200 ml. AcOH, and 150 ml. concentrated HCl was heated on the steam bath till solution was complete, cooled to 75°, treated with 30% H2O2, allowed to come to room temperature, and refrigerated to give 16 g. 5,6-dichloro-2,4-disulfamoylaniline (IV), m. 288-9° (EtOH-H2O). IV was converted as above to 5,6-dichloro-2,4-disulfamoyl-N-bromoacetylaniline, and the latter cyclized by treatment with methanolic MeNH2 to give 3-bromomethyl-5,6-dichloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide. The following II were similarly prepared according to the various procedures described above (R, R1, and X given). Cl, SO2NH2, COCH2CH2Cl, m. 233-4°; Cl, SO2NHMe, COCH2CH2Cl; MeO, SO2NH2, COCH2CH2Cl; F3C, SO2NH2, COCH2CH2Cl; PrO, SO2Cl, H; PrO, SO2NH2, H; PrO, SO2NH2, (p-chlorophenylthio)acetyl; NO2, SO2NH2, COCH2Cl; NO2SO2NH2, (p-chlorophenylthio)acetyl; Br, SO2NH2, COCH2Cl; Br, SO2NH2, (p-chlorophenylthio)acetyl; Cl, SO2NH2, p-ClC6H4OCH2CO, m. 297-8°; Cl, SO2NH2, o-ClC6H4OCH2CO, m. 285-6°; Cl, SO2NH2, (p-chlorobenzylthio)acetyl, m. 225-6°; Cl, SO2NH2, (p-chlorobenzylsulfonyl)acetyl, m. 275-6°. A soln. of 3.3 g. IIa in 250 ml. 25% methanolic Et2N was kept 2 hrs. at room temp. and concd. to dryness in vacuo to give I (R = Cl, R1 = SO2NH2, R2 = CH2Cl), m. 323-6° (EtOH-H2O). The following I were similarly prepd. from the corresponding II listed above (R, R1, and R2 given): Cl, SO2NH2, CH2CH2Cl; MeO, SO2NH2, CH2CH2Cl; SO2NH2, Cl, CH2CH2Cl; F3C, SO2NH2, CH2CH2Cl; Cl, SO2NH2, (p-chlorophenylthio)methyl, m. 281-2°; PrO, SO2NH2, (p-chlorophenylthio)methyl; NO2, SO2NH2, (p-chlorophenylthio)methyl; Br, SO2NH2, (p-chlorophenylthio)methyl; Cl, SO2NH2, p-ClC6H4OCH2; Cl, SO2NH2, o-ClC6H4OCH2; Cl, SO2NH2, (p-chlorobenzylthio)methyl; Cl, SO2NH2, (p-chlorobenzylsulfonyl)methyl. Similarly obtained were 3-(β-chloroethyl)-6-chloro-2-methyl-7-(N-methylsulfamoyl)-1,2,4-benzothiadiazine 1,1-dioxide, and 2,6-dibutyl-3-(β-chloroethyl)-7-(N-butylsulfamoyl)-1,2,4-benzothiadiazine 1,1-dioxide.
IT 17713-92-7P 17713-93-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17713-92-7 CAPLUS
CN Acetanilide, 5'-chloro-2-(p-chlorophenoxy)-2',4'-disulfamoyl- (8CI) (CA INDEX NAME)



RN 17713-93-8 CAPLUS
CN Acetanilide, 5'-chloro-2-(o-chlorophenoxy)-2',4'-disulfamoyl- (8CI) (CA INDEX NAME)



L9 ANSWER 218 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:39267 CAPLUS
DN 68:39267
TI Synthesis of sulfamide compounds on the basis of acetylene series. II. Acetyl derivatives of acetylenic sulfanilamides
AU Azerbaev, I. N.; Kim, D. G.; Von, G. P.
SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1967), 17(4), 67-8
CODEN: IASKA6; ISSN: 0002-3353
DT Journal
LA Russian
AB Cl3CCHO (0.01 mole) added at 0° to a solution of 0.01 mole p-RNHC6H4SO2NHCMeR1C.tplbond.CH (I, R = H, R1 = Me) in C6H6, the mixture kept a few hrs. at room temperature, heated 30 min. at 60-80°, the precipitate filtered off and air dried gave 96% I (R = HCO, R1 = Me), m. 107° (1:1:1 C6H6-CHCl3-Me2CO). Similarly was prepared I (R = HCO, R1 = Et), m. 115°. An acid chloride (0.01 mole) added to an ice-cooled solution of I (R = H) in C6H6, the mixture heated on the water bath to 40-60° to eliminate HCl, the precipitate filtered off, washed with petroleum ether and dried gave 95-8% of crude I which was crystallized from a mixture of 3:1 C6H6-Me2CO. The following I were prepared (R, R1, and m.p. given): CHCl2CO, Me, 169°; CHCl2CO, Et, 171°; Bz, Me, 218°; Bz, Et, 230°; PhCH2CO, Me, 146°; PhCH2CO, Et, 153°; PhCH:CHCO, Me, 208°; PhCH:CHCO, Et, 199°; PhOCH2CO, Me, 133°; PhOCH2CO, Et, 164°; PhSO2, Me, 173°; PhSO2, Et, 178°; p-AcNHC6H4SO2, Me (II), 222°; AcNHC6H4SO2, Et (III), 216°. Basic hydrolyses of II and III gave resp. I (R = p-H2NC6H4SO2, R1 = Me), m. 188° (hydrochloride m. 187°), and I (R = p-H2NC6H4SO2, R1 = Et), m. 188°; hydrochloride m. 186°.
IT 17047-22-2P 17047-23-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17047-22-2 CAPLUS
CN Acetanilide, 4'-[(1,1-dimethyl-2-propynyl)sulfamoyl]-2-phenoxy- (8CI) (CA INDEX NAME)



RN 17047-23-3 CAPLUS
CN Acetanilide, 4'-[(1-ethyl-1-methyl-2-propynyl)sulfamoyl]-2-phenoxy- (8CI) (CA INDEX NAME)

L9 ANSWER 218 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 219 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1967:421674 CAPLUS
DN 67:21674
TI Benzenesulfonylsemicarbazides
PA Farbwerke Hoechst A.-G.
SO Neth. Appl., 24 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6605654		19661107	NL 1966-5654	19660427 <--
DE 1545810			DE	
FR 1478953			FR	
FR 5655			FR	
GB 1128382			GB	
PRAI DE		19650506		

GI For diagram(s), see printed CA Issue.
AB Title compds. I are prepared by treating a hydrazine R'NH2 (II) with a RCONH(CH2)2-substituted benzenesulfonyl-carbamic acid ester or-urea, treating a RCONH(CH2)2-substituted benzenesulfonamide with an iminourea or imonocarbamic acid ester containing R1, hydrolysis of a benzenesulfonyliminoparabanic acid ester, or acylation of other benzenesulfonylsemicarbazides. Thus, 2.8 g. 1,1-pentamethylenehydrazine was added with stirring to a suspension of 10 g. N-[4 - [β - (3 - chlorobenzamido)ethyl]benzenesulfonyl]methylurethane (m. 173-5°) in 100 cc. dioxane. The mixture was kept at 120-30° for 1 hr., during which the MeOH formed distilled off with some dioxane. After cooling, purification, and recrystn. (MeOH-HCONMe2), 4-[4-[β-(3-chlorobenzamido)ethyl]benzenesulfonyl]- 1,1 - pentamethylenesemicarbazide, m. 229-31° (decomposition), was obtained. The I similarly prepared were (RCONH, R1, and m.p. given): 3-chlorobenzamido, 1,1-hexamethylene, 207-9° (decomposition); 3-chlorobenzamido, 1-methyl-1-benzyl, 112-14° (decomposition); 4-chlorobenzamido, 1,1-pentamethylene, 220-3° (decomposition); 4-chlorobenzamido, 1,1-hexamethylene, 195-8° (decomposition); 4-fluorobenzamido, 1,1-pentamethylene, 238-40° (decomposition); 4-fluorobenzamido, 1,1-hexamethylene, 208-10° (decomposition); 3-methylbenzamido, 1,1-pentamethylene, 241-3° (decomposition); 3-methylbenzamido, 1,1-hexamethylene, 209-11°; 2-methoxybenzamido, 1,1-pentamethylene, 157-9°; 2-methoxybenzamido, 1,1-hexamethylene, 155-7°; 2-methylbenzamido, 1,1-tetramethylene, 172-4°; 3-methoxybenzamido, 1,1-pentamethylene, 230-2°; 3-methoxybenzamido, 1,1-hexamethylene, 207-9°; 2-allyloxybenzamido, 1,1-pentamethylene, 157-9°; 2-methoxy-5-methylbenzamido, 1,1-pentamethylene, 176-8° (decomposition); β-phenylpropionamido, 1,1-pentamethylene, 173-5° (decomposition); 3-trifluoromethylbenzamido, 1,1-pentamethylene, 209-11° (decomposition); 3-trifluoromethylbenzamido, 1,1-hexamethylene, 201-2°; 3-methoxythiophene-2-carboxamido 1,1-hexamethylene, 181-2°; 3-methoxythiophene-2-carboxamido, 1,1-pentamethylene, 202-4°; phenoxyacetamido, 1,1-pentamethylene, 150-1°; phenoxyacetamido, 1,1-hexamethylene, 111-13°; phenoxyacetamido, 1,1-(3-methylpentamethylene), 153-5°; β-phenylpropionamido, 1,1-hexamethylene, 148-50°; β-phenylpropionamido, 1,1-tetramethylene, 167-8°; β-phenylpropionamido, 1-methyl-1-benzyl, 158-60°; β-phenylpropionamido, 1,1-(3-methylpentamethylene), 180-2°; cinnamoylamido, 1,1-(3-methylpentamethylene), 198-200°; Δ3-tetrahydrobenzamido, 1,1-hexamethylene, 170-1° (decomposition); Δ3-tetrahydrobenzamido, 1,1-(3-methylpentamethylene), 184-6° (decompn.); 3-trifluoromethylbenzamido, 1,1-(3-methylpentamethylene), 222-4°; 3-fluorobenzamido, 1,1-pentamethylene, 210-12° (decompn.); 3-fluorobenzamido, 1,1-hexamethylene, 198-200°; 3-fluorobenzamido, 1,1-tetramethylene, 200-2°; 3-chlorobenzamido, 1,1-(1-methylpentamethylene), 210-11°; 3-chlorobenzamido, 1-methyl-1-isopropyl, 176-7°; 4-fluorobenzamido, 1,1-(3-methylpentamethylene), 215-17° (decompn.); β-caproamidoethyl, 1,1-(3-methylpentamethylene), 163-5: 3-ethoxythiophene-2-carboxamido, 1,1-pentamethylene, 159-61°; 3-ethoxythiophene-2-carboxamido, 1,1-hexamethylene, 152-3°; 3-methoxybezamido, 1,1-(3-methylpentamethylene), 237-9° (decompn.); 2-ethoxybenzamido, 1,1-pentamethylene, 153-4°; 2-ethoxybenzamido, 1,1-hexamethylene, 135-7°; 2-ethoxybenzamido, 1,1-(1-methylpentamethylene), 137-9; 2-propoxybenzamido,1,1-(3-methylpentamethylene) 171-3°; 2-methoxy-5-chlorobenzamido, 1,1-pentamethylene, 164-6°; 2-methoxy-5-chlorobenzamido, 1,1-hexamethylene, 161-3°; 2-methoxy-4-chlorobenzamido, 1,1-(3-methylpentamethylene), 177-9°; 2-methoxy-3-chlorobenzamido, 1,1-pentamethylene, 173-5°; 3-ethoxybenzamido, 1,1-pentamethylene, 207-8° (decompn.); 3-ethoxybenzamido, 1,1-hexamethylene, 177-9°; 3-ethoxybenzamido, 1,1-(3-methylpentamethylene), 224-6° (decompn.); 2-methoxy-5-methylbenzamido, 1,1-hexamethylene, 155-7°; 2-methoxy-5-methylbenzamido, 1,1-(3-methylpentamethylene), 176-8°; 2-(β-methoxyethoxy)benzamido, 1,1-pentamethylene, 143-5°; 2-(β-methoxyethoxybenzamido, 1,1-(3-methylpentamethylene), 157-9°; 2-ethoxy-5-chlorobenzamido, 1,1-pentamethylene, 163-5°; 2-ethoxy-5-chlorobenzamido, 1,1-hexamethylene, 164-6°; 2-methoxy-3-methylbenzamido, 1,1-(3-methylpentamethylene), 170-2°; 2-(β-methoxyethoxy)-5-methylbenzamido, 1,1-(3-methylpentamethylene), 151-3°; 3-chlorophenoxyacetamido, 1,1-(3-methylpentamethylene), 106-8° (decompn.); β-(4-chlorophenylpropionamido, 1,1-pentamethylene, 179-81° (decompn.); β-(4-chlorophenylpropionamido, 1,1-(3-methylpentamethylene), 163-5°; β-(3-chlorophenylpropionamido, 1,1-hexamethylene, 161-3°; β-(3-chlorophenyl)propionamido, 1,1-(3-methylpentamethylene), 137-9°; 3,4-tetramethylenethiophene-2-carboxamido, 1,1-pentamethylene, 149-51°; 3,4-tetramethylenethiophene-2-carboxamido, 1,1-(3-methylpentamethylene), 168-9°; 2-methoxy-3,5-dichlorobenzamido, 1,1-(3-methylpentamethylene), 161-3°; 2-methoxybenzamido, γ-dimethylpentamethylene, 155-7°; 2-methoxybenzamido, 1-isonorgranatanyl, 170-1°; 2-methoxybenzamido, 1,1-(2,6-dimethylpentamethylene), 203-4°; 2-methoxybenzamido, 1,1-(β-pentamethylene), 175-6°; β-benzamido, 1,1-(γ-methylpentamethylene), 212°; β-benzamido, 1-methyl-1-isopropyl, 204°; β-benzamido, 1,1-(γ-methoxypentamethylene), 212°; β-benzamido, 1,1-(γ-isopropoxypentamethylene), 210°; β-acetamido, 1,1-pentamethylene, 203°; β-acetamido, 1,1-(γ-methylpentamethylene), 187-9°; 4-chlorobenzamido, 1,1-pentamethylene, 220-3° (decompn.). Also prepd. were N1-4-[4-[β-(2-methoxybenzamido)ethyl]benzenesulfonyl]-N2-[norgranat-9-yl]urea, m. 190-1°, N1-4-[4-[β-(2-methoxybenzamido)ethyl]benzenesulfonyl]-N2-[nortropan-8 - yl]-urea m. 213-14°, N1-4-[4-[β-(2-methoxybenzamido)ethyl]benzenesulfonyl]-N2-[1,2,5,6-tetrahydropyperid-1-yl]urea, m. 156-7°, and N1-[p-(β-benzamidoethyl)benzenesulfonyl] - N2 - [norgranatan-9-yl]urea, m. 229-30°. A suspension of 14.7 g. 4,4-diphenyl-1,1-pentamethylenesemicarbazide and 16.3 g. 4-(β-benzamidoethyl)benzenesulfonamide (Na salt) in 100 cc. dimethylformamide

L9 ANSWER 219 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 219 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
was heated at 100° for 3 hrs. to yield 4-[4-(β-benzamidoethyl)benzenesulfonyl] - 1,1 - pentamethylenesemicarbazide, m. 217-18°. The compds. similarly prepd. were (RCONH, R1, and m.p. given): β-benzamido, 1,1-hexamethylene, 233-6°; 3-methyl-4-chlorobenzamido 1,1-pentamethylene, 204-6°; 3-methyl-4-chlorobenzamido 1,1-tetraethylene, 174-6°; α-methoxyphenylacetamido, 1,1-pentamethylene, 146-8°. Hydrolysis of 4-[4-(β-benzamidoethyl)benzenesulfonyl]-3-pentamethyleneiminoparabaric acid yielded 4-[4-(β-benzamidoethyl)benzenesulfonyl]-1,1-pentamethylenesemicarbazide, m. 218°. A soln. of 0.013 mole 4-[4-(β-aminoethyl)benzenesulfonyl]-1,1-pentamethylenesemicarbazide, 15 cc. CHCl3, 0.024 cc. pyridine, and 0.013 cc. BzCl was kept at 35° for 6 hrs. to form 4-[4-(β-benzamidoethyl)benzenesulfonyl]-1,1-pentamethylenesemicarbazide, m. 216-18° (Na2CO3/HCl). The compds. similarly were prepd. (RCONH, R1, and m.p. given): 2-methoxybenzamido, 1,1-pentamethylene, 156°; trimethylacetamido, 1,1-pentamethylene, 187-9°; 3'-toluylamido, 1,1-(γ-methylpentamethylene), 234-5°; 3'-chlorobenzamido, 1,1-(γ-methylpentamethylene), 223-4°; 2-methoxybenzamido, 1,1-(γ-methylpentamethylene), 164°; 5'-chloro-2'-methoxybenzamido, 1,1-(γ-methylpentamethylene), 165-8°; 3'-methoxythiophene-2-carbamido, 1,1-(γ-methylpentamethylene), 174-7°; 2'-ethoxybenzamido, 1,1-(γ-methylpentamethylene), 169-71°; 2'-methoxybenzamido, 1,1-(γ-ethylpentamethylene), 160°. The compds. are useful as pharmaceuticals, esp. in lowering blood sugar.

IT 14497-87-1P 14555-57-8P 14658-88-9P
14711-21-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 14497-87-1 CAPLUS

CN Urea, 1-[[p-[2-[2-(m-chlorophenoxy)acetamido]ethyl]phenyl]sulfonyl]-3-(4-methylpiperidino)- (8CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 14555-57-8 CAPLUS

CN Urea, 1-(4-methylpiperidino)-3-[[p-[2-(2-phenoxyacetamido)ethyl]phenyl]sulfonyl]- (8CI) (CA INDEX NAME)

L9 ANSWER 219 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 14658-88-9 CAPLUS

CN Urea, 1-[[p-[2-(2-phenoxyacetamido)ethyl]phenyl]sulfonyl]-3-piperidino- (8CI) (CA INDEX NAME)



RN 14711-21-8 CAPLUS

CN Urea, 1-(hexahydro-1H-azepin-1-yl)-3-[[p-[2-(2-phenoxyacetamido)ethyl]phenyl]sulfonyl]- (8CI) (CA INDEX NAME)



L9 ANSWER 220 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:451494 CAPLUS

DN 65:51494

OREF 65:9656a-c

TI Studies off insect chemosterilants. IV. Screening of insect chemosterilants

AU Ts'ao, Tan-P'u; Chang, J. Tsung-Ping

CS Univ. Peking, Peop. Rep. China

SO Kunchong Xuebao (1966), 15(1), 13-27
CODEN: KCHPA2; ISSN: 0454-6296

DT Journal

LA Chinese

AB cf. CA 62, 11089g. One hundred and two chemicals, mostly newly synthesized, were tested as insect chemosterilants, using the same technique and host (housefly) as previously reported (ibid. 12(5-6), 538-42(1963). The following results were obtained. (1) Of the substituted purines and pyrimidines tested, 5-fluoroorotic acid is an effective chemosterilant. When fed at a 1% concentration (weight/weight in milk powder)for 24 hours, it induced complete sterility in females only. (2) Pyrimethamine and related compds. were not effective as insect chemosterilants. The number of eggs laid was slightly decreased, but there was no effect on the percentage of emergence. (3) Quinoline compds. were mostly ineffective. (4) A few carbamates showed high toxicity, but they were ineffective as sterilants. (5) Several new mustard compds. tested were ineffective, except 1 which has 2 ethylenimino groups. However, this compound was partially degraded. (6) N-Methyl hydroxyurea retarded egg laying for only one. day, and reduced the number of eggs laid to 40% of normal when fed for 96 hrs. at a 1% concentration (7) Bis(p-chlorophenyl)trifluoromethylcarbinol was ineffective as a chemosterilant either by feeding, contact, or topical application, in contradiction to Ascher's original observation. (8) Colchicine was an effective chemosterilant when fed in minute amts. (0.01% weight/weight in milk powder) for a long duration. A high concentration (0.5%) did not result in complete sterility (.apprx.80%), and a higher concentration (1.0%) caused complete mortality. The relationship between anti-cancer activity and sterilizing action is briefy discussed.

IT 10441-32-4, Benzoic acid, p-[2-(2,4-dichlorophenoxy)acetamido]-, 2-(diethylamino)ethyl ester
(housefly sterilization by)

RN 10441-32-4 CAPLUS

CN Benzoic acid, 4-[[(2,4-dichlorophenoxy)acetyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:429295 CAPLUS

DN 65:29295

OREF 65:5406b-h,5407a-h,5408a-h,5409a-h,5410a-h,5411a-h,5412a-h,5413a-d

TI (2-Alkylidene acyl)phenoxy- and (2-alkylidene)phenylthiocarboxylic acids

IN Schultz, Everett M.; Sprague, James M.

PA Merck & Co., Inc.

SO 48 pp.

DT Patent

LA Unavailable

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3255241		19660607	US 1961-155961	19610119 <--
PRAI US		19610119		

OS MARPAT 65:29295

AB Methods for preparing the title compds. are described. The compds. possess diuretic, natriuretic, and chloruretic properties and are useful in the treatment of hypertension, edema, and other conditions associated with electrolyte and fluid retention. For example, 61 g. phenoxyacetic acid was added in portions with stirring to 160 g. AlCl3 and 200 ml. CS2. Then 53.5 g. isobutyryl chloride was added dropwise with stirring over 0.5 hr. at 22-6°. After stirring 1 hr. at room temperature, the mixture was warmed at 50° for 3 hrs., the CS2 decanted, and the Al complex added to a mixture of 500 g. ice and 125 ml. concentrated HCl to give 51.6 g. 4-isobutyrylphenoxyacetic acid (I), b1 185-90°. Similarly prepared were 4-isobutyryl-3chlorophenoxyacetic acid (17.3% yield), m. 137-9°; 4-propionyl3-chlorophenoxyacetic acid (II), m. 108-9.5°; 3-chloro-4-acetylphenoxyacetic acid, m. 107-9° (C6H6); 4-propionyl-2-chlorophenoxyacetic acid, m. 147-8° (C6H6); and other related compounds. 3-hydroxy-4-butyrylphenoxyacetic acid (VI) (61% yield), m. 120-1° (C6H6-cyclohexane); 2-methyl3-chloro-4-butyrylphenoxyacetic acid (94% yield), m. 91-2.5° (methylcyclohexane); 4-n-valeryl-3-chlorophenoxyacetic acid m. 82.5-3.5° (2:1 ligroine-C6H6); 4-isovaleryl-3-chlorophenoxyacetic acid, m. 107-8° (C6H6); 3-chloro-4-isovalerylphenoxy-acetic acid (VII); 4-caproyl-3-chlorophenoxyacetic acid, m. 889° (2:1 hexane-C6H6); 4-enanthyl-3-chlorophenoxyacetic acid, m. 102.5-3.5° (1:1 hexane-C6H6); 2-butyryl-3,5-dimethylphenol, m. 57-8° (cyclohexane); 2-butyryl-3,5-dichlorophenol, m. 47-8.5° (ligroine); 2-isobutyryl-5-chlorophenol, b11 133-8°; 2-propionyl-5-chlorophenol. m. 45-7° b60 130-40°; 3,5-dichloro-4-butyrylphenoxyacetic acid (65% yield), m. 111.5-13° (C6H6-cyclohexane); 2-(4-propionyl-3-chlorophenoxy)propionic acid, m. 115-17° (3:1 C6H6-hexane); 2-(4-butyryl-3-chlorophenoxy)propionic acid, m. 82.5-4° (ligroine-C6H6); 3-(4-propionyl-3-chlorophenoxy)propionic acid, m. 91.7-93° (C6H6); Br (25.7 g.) in 30 ml. AcOH was added dropwise to 35.6 g. I in 125 ml. AcOH at 25° with stirring during 1 hr. Stirring was continued for an addnl. hr. and the mixture was added to a mixture of ice and H2O and filtered to give 33 g. 4-(2-bromoisobutyryl) phenoxyacetic acid (IX), m. 144-5° (C6H6). Similarly prepared were 4-(2-bromoisobutyryl)-3-chlorophenoxyacetic acid (63% yield), m. 124.5-25° (C6H6-hexane); 4-(2-bromopropionyl)-3-chlorophenoxyacetic acid, m. 152-4° (5:2 hexane-iso-PrOH); 3-chloro-4-[2-bromo-2-(bromomethyl)butyryl] phenoxyacetic acid (92% yield), m. 153.5-55° (MeCN); 4-(2-bromo-2-methylisovaleryl)-3-chlorophenoxyacetic acid, m. 151.5-52° (C6H6); 3-chloro-4-(2-bromoisovaleryl)phenoxyacetic acid (X), m. 171-2° (iso-PrOH); 2-(2-bromoisobutyryl)-5-chlorophenoxyacetic acid, m. 109-11°; (3:1 hexane-C6H6); 4-(2-bromo-2-methylbutyryl)-3-chlorophenoxyacetic acid, m. 123-4° (C6H6); 4-(2-ethyl-2-bromobutyryl)-3-chlorophenoxyacetic

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
acid, m. 130-1°; Me 3-(bromoethyl)benzoate (50% yield), b8 136-7°; methyl 2(bromomethyl)benzoate (95% yield); 4-(2-bromobutyryl)-3-chlorophenoxyacetic acid, m. 154-5° (30:1 C6H6-iso-PrOH); 3-chloro-4-(1-bromocyclopentylcarbonyl)phenoxyacetic acid, m. 149-50°; 3-methyl-4-(2,3-dibromobutyryl)phenoxyacetic acid, m. 119-21° (C6H6-methylcyclohexane); 2,3-dichloro-4-(2-bromo-2-ethylbutyryl)phenoxyacetic acid (99% yield), m. 151.5-2.5° (C6H6); 4-(2-bromo-2-ethylbutyryl)-2-methyl-3-chlorophenoxyacetic acid (85% yield), m. 136-7° (1:3.5 C6H6-cyclohexane); 4-(2-bromo-2-ethylbutyryl)-2,3-dimethylphenoxyacetic acid (110% yield), m. 117-18° (cyclohexane); 3-chloro-4-(2-bromo-2-methylvaleryl)phenoxyacetic acid, m. 115-17° (2:1 cyclohexane-C6H6); 3-chloro-4-(2-propyl-2-bromovaleryl)phen-oxyacetic acid, m. 125-5.5° (9:25 cyclohexane-C6H6); 3-chloro-4-(2-bromo-2-isopropylbutyryl)phenoxyacetic acid, m. 126-7° (C6H6-hexane); 3-chloro-4- (2-bromo-2-isobutyrylpropionyl)phenoxyacetic acid, m. 115-16°; 3-chloro-4-(2,3-dibromo-3phenylpropionyl)phenoxyacetic acid (XI), m. 157-8° (C6H6); and 3-methyl-4-(2-bromo-2-isopropyl-3-methylbutyryl)phenoxyacetic acid, m. .apprx.140-1° (decompn.). AgOAc (15 g.) was added to 12 g. IX dissolved in 800 ml. C6H6, the mixt. was stirred and refluxed for 4 hrs., cooled, 150 ml. of H2O and 15 ml. concd. HCl were added, the Ag salts were sepd. by filtration, and the C6H6 was evapd. to give 4.1 g. 4-methacryloylphenoxyacetic acid, m. 124.5-6.5° (C6H6). Similarly prepd. were 4-methacryloyl-3-chlorophenoxyacetic acid (XII), m. 128-9° (C6H6), L.D.50 453 mg./kg. (intravenous); 2-methacryloyl-5-chlorophenoxyacetic acid, m. 100-1° (C6H6-hexane); 4-[2-ethylidenebutyryl)-3-chlorophenoxyacetic acid, m. 118-19° (C6H6); 3-chloro-4-(1cyclopentylcarbonyl)phenoxyacetic acid; and 3-chloro-4-(cyclohexenylcarbonyl)phenoxyacetic acid. To a soln. of 75 g. NaOH in 150 ml. H2O was added 64.27 g. m-chlorophenol. To this was added slowly at 40° a soln. of 80.5 g. chloroacetic acid in 80.5 ml. H2O, the mixt. was heated with stirring on a steam bath for 1 hr., cooled, and 1 l. H2O added. The soln. was filtered, acidified to Congo red with concd. HCl, extd. with Et2O, and the Et2O soln. extd. with 10% NaHCO3 soln. to give 67.8 g. (73% yield) 3chlorophenoxyacetic acid, m. 110-11°. Similarly prepd. were 3-ethoxyphenoxyacetic acid (38% yield), m. 90-1° (C6H6); (4-butyryl-m-phenylenedioxy)diacetic acid, m. 159.2-60° (H2O); 3-(3-chlorophenylthio)propionic acid, m. 117-18° (heptane); 3-(2,4-dimethyl-5-butyrylphenoxy)propionic acid, m. 97.5-9.0° (aq. EtOH); and 2,6-dichloro-4-butyrylphenoxyacetic acid (40% yield), m. 136-7° (C6H6). An intimate mixt. comprising II 14.52, paraformaldehyde 2.1, dry MeNH2.HCl 5.34 g., and 4 drops HOAc was heated on a steam bath for .apprx.1.5 hrs. during which period suction was applied for .apprx.1-min. intervals 5 or 6 times. The mixt. was cooled and triturated with Et2O to give 4- [2 -dimethylaminomethyl]propionyl]-3-chlorophenoxyacetic acid-HCl (XIII), m. 158-60° (MeOH). Similarly prepd. were 3-chloro-4-[3 -(dimathylamino)propionyl] phenoxyacetic acid-HCl, m. 143-5° (MeOH); 4-[2-(dimethylaminomethyl)propionyl]-2-chlorophenoxyacetic acid-HCl, m. 175.5-6.5° (isoPrOH); 4-[2-(dimethylaminomethyl)butyryl]phenoxyacetic acidHCl, m. 160-1° and other related compounds. A soln. of 1 g. XIII in 25 ml. H2O was made slightly alk. by addn. of 10% NaHCO3 soln. heated on a steam bath for 25 min., the mixt. cooled, and acidified with 6N HCl to give XII, m. 127-8° (C6H6). Similarly prepd. were 4-methacryloyl-2-chlorophenoxyacetic acid, m. 122-4°(C6H6); 4-(2-

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
C6H6-cyclohexane); 4-(2-ethylidenebutyryl)-2,3-dimethylphenoxyacetic acid (74% yield), m. 103-4° (methylcyclohexane); 3-chloro-4-(2-propylidenepropionyl)phenoxyacetic acid, m. 96-7° (Et2O-ligroine); 3-chloro-4-(2-propylidenevaleryl)phenoxyacetic acid, m. 114-14.5° (C6H6); 3-chloro-4-(2-isopropylidenepropionyl)phenoxyacetic acid, m. 144-6° (C6H6); 3-chloro-4-(2-isobutylidenepropionyl)phenoxyacetic acid, m. 123-4° (C6H6); 3-methyl-4-(1-isopropylidene-2-methylbutyryl)phenoxyacetic acid, m. 110-12° (hexane-C6H6); 4-(2-ethylidenepropionyl)-3-chlorophenoxyacetic acid, m. 114-16° (C6H6); and a 1:1 mixt. of 3-chloro-4-(2-isopropylidenebutyryl)-and 3-chloro-4-(2-ethylidene-3-methylbutyryl)phenoxyacetic acids, m. 95-7°. A soln. of 0.1 mole 3-propionylphenol in 60 cc. ethylene glycol dimethyl ether (XXI) was added to a suspension of 0.1 mole NaH in 40 cc. XXI. Then 0.11 mole Et bromoacetate was added during 25 min., the mixt. was refluxed for 1 hr., the pptd. NaBr was sepd., and the solvent distd. in vacuo. To the residue was added 10% NaOH, the mixt. was heated on a steam bath for 10 min., and the soln. acidified to give 3-propionylphenoxyacetic acid, m. 72-8° (C6H6-cyclohexane). Similarly prepd. were 2,4-dimethyl-5-butyrylphenoxyacetic acid, m. 98.5-9.5° (C6H6-cyclohexane); 3-chloro-4-phenylacetylphenoxyacetic acid, m. 117-18° (C6H6); 3-chloro-4-(2-propylvaleryl)phenoxyacetic acid, m. 134-5° (C6H6); 2-butyryl-3,5-dimethylphenoxyacetic acid, m. 108-9° (aq. HOAc); 2-butyryl-3,5-dichlorophenoxyacetic acid, m. 99-101° (C6H6-cyclohexane); 2-isobutyryl-5-chlorophenoxyacetic acid, m. 86-8°; (2:1 hexane-C6H6); 2-propionyl-5-chlorophenoxyacetic acid, m. 118.5-19.5° (C6H6); 4-(2-ethylbutyryl)-3-chlorophenoxyacetic acid, m. 147-9° (C6H6); 3-chloro-4-(cyclopentylcarbonyl)phenoxyacetic acid, m. 138-9° (Me2CO-Et2O); 3-chloro-4-(cyclohexylcarbonyl)phenoxyacetic acid, m. 139-40° (C6H6); 3-butyrylphenoxyacetic acid, m. 103-5° (methylcyclohexane); 4-butyryl-2-nitro-3-methylphenoxyacetic acid (53% yield), m. 134-6° (1:6 HOAc-H2O); 2-chloro-3-butyrylphenoxyacetic acid, m. 74.5-6.5°; 2-butyryl-3-methylphenoxyacetic acid, m. 112.5-14.5°; 3-chloro-4-(3,3-dimethylbutyryl)phenoxyacetic acid, m. 103-4° (C6H6); 2,3-dichloro-4-cyclopentaneacetylphenoxyacetic acid (76% yield), m. 127-8° (Et2O-hexane); 2,3-dichloro-4-(cyclopentaneacetyl)phenoxyacetic acid, m. 147-8°; 3-chloro-4-(isopropylbutyryl)phenoxyacetic acid, m. 136-7° (C6H6); 2-(3-chloro-4-butyrylphenoxy)ethoxyacetic acid, b0.5, 190-260°; 2,3-tetramethylene-4-butyrylphenoxyacetic acid, m. 106-8° (C6H6-hexane); and Et 4-butyryl-2,3-dichlorophenoxyacetate (95% yield), m. 53-4°, b0.5 180-95°. To 84.5 g. of 2-chloropropiophenone was added 300 cc. of fuming HNO3 (d. 1.5) at 5-10° during 18 min. The mixt. was allowed to stand at 0-5° for 30 min. and poured into ice water to give 75 g. 2-chloro-5-nitropropiophenone (XIII), m. 54-6° (iso-PrOH). A soln. of XXII in 60 cc. HOAc was added to 240 cc. 7.5N HCl soln. in which was dissolved 100 g. SnCl2.H2O. The soln. was heated for 1 hr. on a steam bath and made alk. by addn. of NaOH soln. The oily product was taken up with Et2O, and the Et2O was evapd. to give 2-chloro-5-aminopropiophenone (XXIII), b0.5 143-6°. Diazotization of XXIII gave 4-chloro-3-propionylphenol (XXIV), b0.5 135-40°. Alkylation of XXIV gave 4-chloro-3-propionylphenoxyacetic acid, m. 77.5-80.5°. Similarly prepd. was 2,4-dimethyl-5-butyrylphenol, m. 95-100 (EtOH). 3-Chlorophenol was added gradually to 1.1 moles propionyl chloride and the mixt. heated on a steam bath for 1 hr. and distd. to give 3-chlorophenyl propionate, b16 122.5, n25,D 1.5105. A mixt. of 5.36 g. III, 4.76 g. SOCl2, and 15 ml. dry C6H6 was refluxed 1 hr., the volatile materials were removed by distn. at 60°, and the residual oil was added with stirring to 100 ml. cold 28% NH4OH. The ppt. was sepd. by

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methylenebutyryl)phenoxyacetic acid, m. 110-11°(C6H6); and other related compounds. Equiv. amts. of XII and thioglycolic acid was heated on a steam bath for .apprx.5 min. to give 4-[2-(carboxymethylthiomethyl)propionyl]-3-chlorophenoxyacetic acid, m. .apprx.102° (C6H6). Similarly prepd. was 3-chloro-4-[2-(carboxymethylthiomethyl)butyryl]phenoxyacetic acid, m. 75° (hot C6H6). MeI (52 g.) was added dropwise over 2 hrs. to a mixt. of 10.3 g. XIV and 100 ml. 0.31M NaOH in iso-PrOH while stirring and heating at 90°. The alc. and excess MeI was removed in vacuo, the residue was dissolved in 150 ml. H2O and 50 ml. satd. aq. NaHCO3, and heated on a steam bath for 75 min. After cooling, the soln. was acidified with concd. HCl, extd. with 300 ml. of Et2O, and the Et2O ext. was dried over anhyd. Na2SO4. The Et2O was removed in vacuo, and the residue (5.4 g.) was dissolved in 40 ml. hot C6H6, treated with 125 ml. warm cyclohexane, and cooled to give 3-fluoro-4-(2-methylenebutyryl)phenoxyacetic acid, m. 84-5.5° (C6H6-cyclohexane). A soln. contg. 5 g. III dissolved in 25 ml. of dry Et2O was treated with dry Et2O satd. with dry HBr at 25° and allowed to stand for 1 hr. to give 3-chloro-4-[2-(bromomethyl)butyryl]phenoxyacetic acid, m. 140.5-2.5° (C6H6). III similarly treated with dry Et2O satd. with dry HCl gave 3-chloro-4-[2-(chloromethyl)butyryl]phenoxyacetic acid, m. 142-3° (C6H6). Similarly prepd. were ethyl 4-chloromethylbenzoate (74% yield), b0.6 91-3° and Me 4-(3-chlorophenoxy)benzoate (84% yield), b0.1 159-62°. III (4.03 g.) and ethyl mercaptan 12.4 g. were dissolved in 15 ml. of dry Et2O and the stoppered soln. allowed to stand at room temp. for 48 hrs. The volatile materials were evapd. at room temp. to give 70% 3-chloro-4-[2-(ethylthiomethyl)butyryl]phenoxyacetic acid, m. 88-90° (C6H6-cyclohexane). XV (5 g.), 1.39 g. NaHCO3, and 50 ml. H2O were combined to give a clear soln. which was evapd. in vacuo to give 100% Na salt of XV. To a soln. of 10.9 g. V dissolved in 100 ml. H2O contg. 4 g. NaOH was added 5.78 g. Me2SO4 (XX) during 15 min. at 25-8° with stirring. The temp. was raised to 50° and the reaction soln. was treated simultaneously with 8.67 g. XX and a soln. contg. 6 g. of NaOH in 35 ml. H2O during 45 min. at 50-60°. The reaction soln. was then refluxed with stirring for an addnl. 2 hrs. and acidified with concd. HCl to give 95% 3-methoxy-4-butyrylphenoxyacetic acid, m. 137-8° (C6H6). XVI (8.19 g.) was dissolved in 250 ml. iso-PrOH and 3 g. 5% Pd-charcoal was added. The mixt. was hydrogenated at an initial pressure of 35 psi. When the required amt. of H was absorbed, the soln. was warmed and filtered to remove the catalyst and the alc. was evapd. to give 4.8 g. 4-(2-methyl-n-valeryl)-3-chlorophenoxyacetic acid, m. 123-4.5°(C6H6). Similarly prepd. were 4-(2-methyleneisovaleryl)-3-chlorophenoxyacetic acid, m. 138-9° (C6H6); 4-(2-methylbutyryl)-3-chlorophenoxyacetic acid, m. 139-40° (C6H6); 3-chloro-4-(3-phenylpropionyl)phenoxyacetic acid (59.3% yield), m. 113-15° (C6H6); 3-chloro-4-(3-(4-chlorophenyl)propionyl]phenoxyacetic acid: 3-chloro-4-[3-(4-propylphenyl)propionyl]phenoxyacetic acid; and 3-chloro-4-[3-(4-methoxyphenyl)-propionyl]phenoxyacetic acid. A mixt. of 5.8 g. VI and 2.12 g.LiCl was dissolved in 60 ml. dimethylformamide and heated on a steam bath for 3 hrs. The colorless soln. obtained was added to 500 ml. H2O to give 4 g. 3-chloro-4-(2-chloroisovaleryl)phenoxyacetic acid, m. 146-7° (C6H6). Similarly prepd. were 4-(2 ethylidenebutyryl)-3-chlorophenoxyacetic acid, m. 119-20°; 2,3-dichloro-4-(2-ethylidenebutyryl)phenoxyacetic acid (92% yield), m. 124-5.5° (C6H6-cyclohexane); 4-(2-ethylidenebutyryl)-2-methyl-3-chlorophenoxyacetic acid (96% yield), m. 132.5-3.5° (1:3

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
filtration, washed with H2O, and dried in vacuo to give 77% 3-chloro-4-(2-methylenebutyryl)phenoxyacetamide, m. 103.5-5.0° (C6H6-cyclohexane). Similarly prepd. were 4-chloro-6-[3-chloro-4-(2-methylacryloyl)phenoxyacetamido]-1,3-benzenedisulfonamide, m. 232-5° (aq. EtOH) and 2-(3-chloro-4-butyrylphenoxy)ethyl chloride. V (39.73 g.) was added to a soln. of 4.8 g. Na in 150 ml. abs. EtOH, the soln. was heated to boiling, and 39.01 g. Et α-bromobutyrate added dropwise with stirring during 0.5 hr. The mixt. was stirred and refluxed for 4.5 hrs. and the solvents distd. on a steam bath. To the residue was added 16 g. NaOH in 150 ml.H2O and the mixt. was heated with stirring for 2.25 hrs., cooled, extd. with Et2O, and acidified with HCl. The oil that sepd. was extd. with Et2O, the soln. dried over anhyd. Na2SO4, and the Et2O evapd. to give 81% 2-(4-butyryl-3-chlorophenoxy)butyric acid, b0.2 173-97°. Similarly prepd. were Et 4-(3-chloro-4-propionylphenoxymethyl)benzoate (XXV) (86% yield), m. 58-60° (EtOH); Me 3-(3-chloro-4-butyrylphenoxymethyl)benzoic acid (64% yield), m. 144-5° (aq. EtOH); Me 2-(3-chlorophenoxy)benzoate (45% yield), b0.5 130-40°; Et 2-phenylphenoxyacetate; 3-chloro-4-phenylacetylphenoxyacetic acid, m. 117-18° (C6H6); 2,3-dichloro-4-(2-ethylbutyryl)phenoxyacetic acid (90% yield), m. 144.5-5.5° (C6H6-cyclohexane); 3-methyl-4-(isopropyl-3-methylbutyryl)phenoxyacetic acid, m. 95-5.5° (C6H6-cyclohexane); and 2-(3-chloro-4-butyrylphenoxy)-3-methylbutyric acid, m. 68-9°, b1 183-200°. IV 4.4 and PhCHO 2.1 were dissolved in a mixt. of NaOH 1.8 g. in 160 ml. of H2O and 10 ml. of EtOH. The soln. was kept at 25-30° for 16 hrs., acidified, and the solid that sepd. was collected and dried at 65° to give 1.2 g. 3-chloro-4-(3-phenylacryloyl)phenoxyacetic acid, m. 139-40° (C6H6).
Similarly prepd. were 3-chloro-4-[3-(o-chlorophenyl)acryloyl]phenoxyacetic acid, m. 166-8° (MeCN); 4-(2-benzylidenepropionyl)-3-chlorophenoxyacetic acid, m. 140-1.5° (C6H6); and other related compounds. Cl was passed at a moderate rate into 100 g. p-tolunitrile while stirring at 120-30° and the reaction was activated by an incandescent lamp. The addn. was continued for .apprx.2 hrs., the material allowed to stand overnight in air, washed twice with EtOH, dried in air, and the EtOH soln. was concd. to half its vol. to give 57% 4-chloromethylbenzonitrile (XXVI), m. 75-7°. XXVI (25 g.) was refluxed and stirred with 500 ml. concd. HCl for 14 hrs. Upon cooling, a solid pptd. and was sepd. to give 94.5% 4-chloromethylbenzoic acid, m. 202-3°. 3-Chlorophenol 16.2 and solid KOH 8.3 were combined and heated to 150° under aspirator vacuum for 3 hrs., 4-bromoacetophenone (25 g.) and 0.2 g. Cu powder were added, and the mixt. heated to 190-200° for 3 hrs. After cooling, the reaction mixt. was extd. with a mixt. of Et2O and 5% NaOH soln. The Et2O layer was sepd. to give 29% 4'-(3-chlorophenoxy)acetophenone (XXVII), b2 162-4°; semicarbazone m. 165-6.5°. XXVII was suspended in a soln. comprising 9.75 g. KMnO4 in 40 ml. 10% NaOH soln. and heated on a steam bath with stirring for 3 hrs. The excess KMnO4 was reduced with 30% H2O2 and the MnO2 was sepd. by filtration. The soln. was acidified with concd. HCl to give 80% 4-(3-chlorophenoxy)benzoic acid, m. 135-6° (aq.EtOH). A mixt. comprising 15 g. III, 100 ml. abs. MeOH, and 10 drops 6N ethanolic HCl was allowed to stand at 25° for 6 days. The solvent was then removed in vacuo and the residue dissolved in Et2O. Traces of free acid were removed by extn. with satd. NaHCO3 soln. and the Et2O soln. was sepd. to give 88.4% Me 3-chloro-4-(2-methylenebutyryl)phenoxyacetate, b0.5 160°, n25D 1.5389. The product solidifies to a waxy solid on standing at 25° in a N atm. Similarly prepd. were 3-chloro-4-(2-methylvaleryl)phenoxyacetic acid, m. 123-4.5° (C6H6); 3-chloro-4-(2-isobutylpropionyl)phenoxyacetic acid, m. 127-8.5° (C6H6); 3-chloro-4-[2-(4-

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
chlorobenzyl)acryloyl]phenoxyacetic acid; 3-chloro-4-[2-(4-propylbenzyl)acryloyl]phenoxyacetic acid; and 3- chloro-4-[2-(4-methoxybenzyl)acryloyl]phenoxyacetic acid. To a soln. of PrMgBr in 600 cc. Et2O, prepd. from 72.4 g. PrBr and 14.4 g. Mg was added 109 g. 2,6-dichloro-3-methoxybenzaldehyde during 0.5 hr. The mixt. was refluxed for 1.5 hrs. and then worked up in the usual manner to give 126 g. 2,6-dichloro-3-methoxy-α-propylbenzyl alc. (XXVIII) as a yellowish oil. A soln. of 126 g. XXVIII and 98.5 g. Na2Cr2O7.2H2O in 150 cc. H2O and 400 cc. HOAc was heated for 1 hr. on a steam bath and dild. with H2O to give an oily product which was taken up with Et2O to give 119 g. 2',6'-dichloro-3'-methoxybutyrophenone as a yellowish oil. Similarly prepd. were 2-chloro-3-methoxy-α-propylbenzyl alc. (97% yield); 2'-chloro-3'-methoxybutyrophenone, b22 174-80°, n25D 1.5375; and 2'-methoxy-6'-methylbutyrophenone. Na chloroacetate (XXIX) (2.92 g.) in 5 ml. H2O was added over 10 min. to a soln. comprising 5.25 g. XVII and 1 g. NaOH in 10 ml. H2O while heating on a steam bath. The soln. was heated for 1 hr., then treated simultaneously with 1 g. NaOH in 5 ml. of H2O and 2.92 g. XXIX in 5 ml. of H2O, heating was continued for 3 hrs., the soln. was filtered, cooled, and acidified with concd. HCl to pH 4. The soln. was extd. with Et2O which in turn was extd. aq. NaHCO3. The latter then was acidified to pH 4, extd. with Et2O, to give 3-chloro-4-(2-methylenebutyryl)phenoxyacetic acid (39% yield), m. 109-10° (C6H6-cyclohexane). A soln. contg. 1 g. XVIII in 20 ml. Me2CO and 5 ml. of 6N HCl was refluxed for 1.5 hrs. and then concd. to dryness in vacuo to give XIX, m. 125-8° (C6H6-petroleum ether). A soln. of 1.5 g. VIII in 10 ml. MeOH contg. freshly fused KOAc 1.5 g. was allowed to stand at room temp. for 5 hrs. and concd. to dryness in vacuo at room temp. The residue was dissolved in H2O, acidified with dil. HCl, the product extd. with Et2O to give 3-chloro-4-(3-methylacryloyl)phenoxyacetic acid, m. 117-19° (C6H6-methylcyclohexane). Similarly prepd. was 3-methyl-4-(2-bromo-3-methylacryloyl)phenoxyacetic acid, m. 137-40° (petroleum ether). To a soln. of 23.6 g. Me3N in 150 ml. abs. EtOH was added 12.3 g.X. The soln. was sealed in a glass-lined autoclave and heated at 80° for 18 hrs. On cooling, the solid was sepd. and the filtrate was concd. The residue was added to H2O, acidified with 6N HCl, and the ppt. which formed was sepd. and dissolved in dil. NaHCO3. The soln. was shaken with decolorizing C, filtered, and acidified with HCl to give 1.4 g. 3-chloro-4-senecioylphenoxyacetic acid, m. 134-6° (C6H6). To a dried Et2O soln. of XI was added 300 ml. HOAc, the mixt. heated on a steam bath to evap. the Et2O, and 18.8 g. anhyd. K2CO3 added. The mixt. was heated on a steam bath for 5 hrs., cooled, poured into H2O, filtered, and the residue washed with H2O to give 18 g. 3-chloro-4-(2-bromo-3-phenylacryloyl)phenoxyacetic acid, m. 160-1° (aq. iso-PrOH). To a soln. of 10 g. 3-chloro-4-(methylenebutyryl)phenoxyacetyl chloride in 12 ml. Et2O was added dropwise 4.16 g. 1,1-dimethylhydrazine and then 100 ml. H2O, and the mixt. dried over Na2SO4. After removal of the Na2SO4, 2 ml. 6N HCl alc. was added, the supernatant Et2O was decanted, 3 ml. alc. HCl added, and the solid which pptd. was sepd. to give 4.99 g. 1,1-dimethyl-2-[3-chloro-4-(2-methylenebutyryl)phenoxyacetyl]hydrazine-HCl, m. 141-4° (iso-PrOH-Et2O). To a soln. of 40 g. KOH in 250 ml. abs. EtOH was added 120 g. 3'-chloro-4'-hydroxybutyrophenone and then 48 g. ethylenechlorohydrin. The soln. was heated at 150° for 6 hrs. in a glass-lined autoclave, the NaCl that formed was sepd., the filtrate was evapd., the residue poured into 100 ml. H2O, and extd. with Et2O to give 118.5 g. 2-(3-chloro-4-butyrylphenoxy)ethyl alc., b0.6 156-70°.

L9 ANSWER 221 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
KOH (1.32 g.) was dissolved in 15 ml. abs. MeOH and added to 3 g. Et 4-butyryl-2,3-dichlorophenoxyacetate. The solid was sepd., dissolved in H2O, and the soln. was acidified with HCl to give 54% 4-butyryl-2,3-dichlorophenoxyacetic acid, m. 110-11° (C6H6). The prepn. of dry-filled capsules and compressed tablets contg. the title compds. are described. Cf. preceding abstr.

IT 6501-53-7, Acetanilide, 5'-chloro-2-(3-chloro-4-methacryloylphenoxy)-2',4'-disulfamoyl- (preparation of)

RN 6501-53-7 CAPLUS

CN Acetanilide, 5'-chloro-2-(3-chloro-4-methacryloylphenoxy)-2',4'-disulfamoyl- (7CI, 8CI) (CA INDEX NAME)



L9 ANSWER 222 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:404045 CAPLUS

DN 65:4045

OREF 65:729c-h,730a-c

TI Sulfonamides

PA C. F. Boehringer & Soehne G.m.b.H.

SO 12 pp.

DT Patent

LA Unavailable

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6506379		19651122	NL 1965-6379	19650519 <--
PRAI DE		19640520		

GI For diagram(s), see printed CA Issue.

AB 2-Amino-5-propoxypyrimidine (4 g.) and 17 g. benzamidoethylbenzene sulfochloride (II) were added to 60 ml. CH2Cl2, then Me3N was added with stirring during 1.5 hrs., the solvent evaporated and the residue heated 1 hr. over a steam bath with 100 ml. 10% NaOH. The solution was neutralized with dilute HCl to give an oil, which was stirred with AcOEt to give 2-(4-(β-benzamidoethyl)benzenesulfonamido)-5-propoxypyrimidine I (R1 = propoxy, R2 = β-benzamidoethyl) m. 194°. Similarly prepared were the following I (R1, R2, and m.p. given): methoxyethoxy, β-benzamidoethyl, 186-7°; phenyl, β-benzamidoethyl, 230°; phenyl, β-(p-chlorobenzamidoethyl), 228-30°; p-chlorophenyl, β-benzamidoethyl, 230°. 2-Amino-5-methoxypyrimidine (4 g.) in 33 ml. absolute pyridine was treated with 10.3 g. II with stirring and cooling; after 2 hrs., the temperature was raised to room temperature and the whole was stirred another 5 hrs. and kept overnight, the whole was heated 1 hr. at 100°, evaporated, the residue stirred with cooling with dilute HCl, and the acid solution decanted from the residue to give I (R1 = methoxy, R2 = β-benzamidoethyl), m. 198-200° (NH4OH-AcOH). Similarly prepared were the following I (R1, and m.p. given, R2 = β-benzamidoethyl): BuO, 195-6°; Pr, 207-8°; EtO, 182°, EtO, 221-2°; Et, 222°; iso-Bu, 222°; Bu, 181°; cyclohexyl, 233°; 3-pentyl, 176-9°; benzyl, 204-5°; hexahydrobenzyl, 196°; and R1 = β-methoxyethoxy, R2 = β-p-chlorobenzamidoethyl, 193-6°; R1 = Pr, R2 = benzamidomethyl, 242°, R1 = Pr, R2 = β-isovalerylamidoethyl, 179-80°; R1 = Pr, R2 = β-p-chlorobenzamidoethyl, 227°. COCl2 (10 g.) was added with stirring and cooling (0-5°) to 7.3 g. HCONMe2 in 50 ml. CH2Cl2, 16.6 g. methoxyethoxyacetaldehyde dimethoxyethyl acetal added dropwise, the mixture boiled 5 hrs. (stirring), then cooled and brought to pH 8 with a 20-30% MeONa solution, the salt separated and the filtrate evaporated in vacuo (<60°). The residue was added dropwise to a boiling mixture of 2.3 g. Na and 17.3 g. 4(β-benzamidoethyl)benzenesulfonylguanidine (m. 265°, prepared by melting 4(β-benzamidoethyl)benzenesulfonamide with guanidine carbonate). The whole was refluxed (stirring) and then poured into H2O, the solid filtered off, and the filtrate acidified to give I (R1 = β-methoxyethoxy, R2 = β-benzamidoethyl), m. 187° (EtOH). Similarly prepared were the following I: R1 = β-methoxyethoxy, R2 = benzamidomethyl, m. 195-7°; R1 = Pr, R2 = acetylamidoethyl, m. 182-3°, and R1 = iso-Pr, R2 = β-benzamidoethyl, m. 189°. p-ClC6H4COCl (III) (0.7 g.) was added to 1.4 g. 2-(4-(β-aminoethyl)benzenesulfonamido)butoxypyrimidine (m. 223°) in 2 ml. 2N NaOH, the whole stirred 3 hrs. at 40°, 0.2 ml. 2N NaOH and 0.1 g. III added and the whole heated again 2 hrs. The resulting mixt. was filtered, the solid washed with Et2O and dissolved in NaOH, C added, and filtered, and HCl added to the filtrate to give I (R1 = BuO, R2 = β-p-chlorobenzamidoethyl), m. 202°. Similarly prepd. were the following I: (R1, R2, and m.p. given): PrO, β-hexahydrobenzamidoethyl, 219°; Pr, β-m-toluylamidoethyl, 188-9°; Pr, β-phenylmercaptoacetamidoethyl, 193-4°; iso-Bu, β-m-chlorobenzamidoethyl, 173°; iso-Bu, β-p-methoxybenzamidoethyl, 216; iso-Bu, β-o-methoxybenzamidoethyl, 155-7°; iso-Bu, β-m-trifluoromethylbenzamidoethyl, 198-202; iso-Bu, β-hexahydrobenzamidoethyl, 186; iso-Bu, β-m-methoxybenzamidoethyl, 148-50°; iso-Bu, β-m-toluylamidoethyl, 175-7°; iso-Bu, β-o-toluylamidoethyl, 159-60°; iso-Bu, β-m-fluorobenzamidoethyl, 202-3°; iso-Bu, β-o-ethoxybenzamidoethyl, 145-7°; sec-Bu, β-methoxybenzamidoethyl, 144-7°; 3-methylbutyl, β-methoxybenzamidoethyl, 157-8°; iso-Bu, β-phenylmercaptoacetamidoethyl, 174°; iso-Bu, β-2-naphtoylamidoethyl, 198°; sec-Bu, β-benzamidoethyl, 203-5°. 4-(β-Benzamidoethyl)benzenesulfonamide sodium (0.95 g.) and 0.5 g. 2-chloro-5-isobutylpyrimidine heated slowly to 240°, kept 30 min. at 220-40°, the cooled mixt. stirred with dil. NaOH, filtered, and the filtrate acidified gave I (R1 = iso-Bu, R2 = β-benzamidoethyl), m. 217° (IV). Similarly prepd. was I (R1 = iso-Bu, R2 = β-o-methoxybenzamidoisopropyl), m. 142-4°. 2-(4-(β-Aminoethyl)benzenesulfonamido)-5-propylpyrimidine (2 g.) was dissolved in 6 ml. pyridine and treated with 1 ml. o-methoxybenzoyl chloride, after 12 hrs. the whole heated 30 min. over a steam bath, cooled, poured onto ice, and acidified with HCl, the solid dissolved in NaOH, filtered over C, and repptd. to give a 70% yield of I (R1 = Pr, R2 = β-(o-methoxybenzamidoethyl), m. 174°. Similarly prepd. were the following I (R1, R2, and m.p. given): iso-Bu, β-phenoxyacetamidoethyl, 166-70°; iso-Bu, β-2,6-dimethoxybenzamidoethyl, 170-1°; iso-Bu, β-o-methoxybenzamidoethyl, 192-5°; iso-Bu, β-2-methoxy-5-chlorobenzamidoethyl, 166-7°. COCl2 (44 g.) was introduced in an ice-cooled soln. of 73 g. HCONMe2 in 320 ml. CH2Cl2, 69.6 g. isobutylacetaldehyde diethyl acetal added dropwise, the whole heated 15 min. at 70°, and then allowed to cool slowly; when the temp. reached room temp. ice was added and 320 ml. satd. K2CO3 added dropwise, the CH2Cl2 distd. and the residue kept 15 min. at 90-5°. The cooled mixt. was extd. several times with C6H6Et2O (2:1) the combined exts. were dried over K2CO3 and distd. in vacuo to give α-isobutyl-β-dimethylaminoacroleine (V), b0.05 98-102°. 4-(β-benzamidoethyl)benzenesulfonylguanidine (5.5 g.), 1 g. MeONa, and 3.2 g. V in 100 ml. abs. MeOH were boiled 25 min. with stirring, the alc. was evapd. and the residue dissolved in H2O, filtered over C, and HCl added to give IV as a ppt. similarly obtained was I (R1 = phenyl, R2 = β-benzamidoethyl), m. 230°. The products show antidiabetic activity.

L9 ANSWER 222 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 6175-75-3, Acetamide, N-[p-[(5-isobutyl-2-pyrimidinyl)sulfamoyl]phenethyl]-2-phenoxy- (preparation of)

RN 6175-75-3 CAPLUS

CN Acetamide, N-[p-[(5-isobutyl-2-pyrimidinyl)sulfamoyl]phenethyl]-2-phenoxy- (7CI, 8CI) (CA INDEX NAME)

L9 ANSWER 222 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 223 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 3743-38-2, Acetanilide, 4'-[[3-[[p-(diethylamino)phenyl]imino]-6-oxo-1,4-cyclohexadien-1-yl]carbamoyl]-2-phenoxy- (spectrum and stability of)
RN 3743-38-2 CAPLUS
CN Acetanilide, 4'-[[3-[[p-(diethylamino)phenyl]imino]-6-oxo-1,4-cyclohexadien-1-yl]carbamoyl]-2-phenoxy- (7CI, 8CI) (CA INDEX NAME)



L9 ANSWER 223 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1965:499097 CAPLUS
DN 63:99097
OREF 63:18311c-h
TI Azomethine dyes. VII. Photographic properties of some substituted phenols of the benzene series
AU Portnaya, B. S.; Tkachenko, T. G.; Bobkova, T. P.; Chel'tsov, V. S.; Levkoev, I. I.
SO Zhurnal Nauchnoi i Prikladnoi Fotografii i Kinematografii (1965), 10(4), 278-86
CODEN: ZNPFAG; ISSN: 0044-4561
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB The behavior of several simple phenolderivs. (I) and some 2- and 3-acylaminophenols (II, R4 is acyl) was studied in color development. The absorption spectra of azomethine dyes formed in the gelatin layer from these compds. and their relative stability were also studied. The phenols were introduced into p-Et2NC6H4NH2 (III) developer in which pos. MZ film was developed. The developing solution had the following composition: III,H2SO4 2.75 g., phenolic component 0.005 mole, NaOH 0.1 mole, anhydrous Na2CO3 21 g., EtOH 140 ml., H2O to make 1 l. PhOH has very low activity in color development compared with 1-C10H7OH. o- and m- MeC6H4OH have considerably higher reactivity which is further increased by introducing a 2nd Me group into the cresol mol. Still higher reactivity is obtained with o-PhC6H4OH. There were only traces of color image with 2- and 3-MeOC6H4OH, 2,5(MeO)2C6H3OH, 2- and 3-AcNHC6H4OH, 2-RSO2NHC6H4OH (R = Me or 4-MeC6H4), resorcinol containing strong electrondonating substituents, and 2- and 3-H2NC6H4OH. Substituted phenols considerably accelerate the process of black-and-white development analogous to the active color component 2,4,1-C12C10H5OH although in the light-sensitive layer of these compds. only traces of color images are formed. 2-AcNHC6H4OH and 4-MeC6H4SO2NHC6H4OH-2, as well as m-C6H4-(OH)2 do not accelerate color development of the light-sensitive layer containing the active non-diffused component, 1-(p-phenoxym-sulfophenyl)-3-heptadecyl-5-pyrazolone, i.e., they do not cause superadditivity of the developing action with III. Acceleration of the black-and-white development by these compds. shows that they easily bind the oxidation products of the developing substance. From 2-HOC6H4N(Ac)Et and 2-AcNHC6H4OH in color development only traces of image are formed. 2-HOC6H4-NHCOCH2OPh and 2-HOC6H4NHBz are sufficiently active compds. with 4-AcNHC6H4OH and especially with 4-BzNHC6H4OH and 2-(4-PhOCH2CONHC6H4CONH)C6H4OH high-contrast blue images are obtained. Introduction of the Me-group into the 5-position of 2-acylaminophenols, as in the case of unsubstituted phenols, considerably increases the reactivity of the components. In 3-acylaminophenols an increase in reactivity is observed in going from the AcNH-derivative to the PhOCH2CONH- and BzNH-derivs. The majority of the 2-acetaminophenols studied formed dyes with an absorption maximum at 630-40 mμ. The stability of the color image to constant temperature storage (70° and 75% relative humidity) is very low. Only the dyes from 4-AcNHC6H4CONHC6H4OH-2 and 4-AcNHC6H4CONHC6H3-(OH)Me-2,4 shows greater stability.
IT 3743-71-3, Benzanilide, 2'-hydroxy-4-(2-phenoxyacetamido)- (in photographic development, activity of)
RN 3743-71-3 CAPLUS
CN Benzanilide, 2'-hydroxy-4-(2-phenoxyacetamido)- (7CI, 8CI) (CA INDEX NAME)

L9 ANSWER 224 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1965:74781 CAPLUS
DN 62:74781
OREF 62:13290d-h,13291a
TI Photographic color couplers
IN Loria, Anthony
PA Eastman Kodak Co.
SO 14 pp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1187477		19650218	DE 1963-E26031	19631214 <--
	FR 1385696			FR	
	GB 1040710			GB	
PRAI	US		19621226		

AB Yellow color couplers of the general formula RCOCH(O2CR')R'', where R and R' are alkyl or aryl groups and R'' is a carbamoyl group, were prepared BzCHClCONHPh (8 g.), 5 g. AcONa, and 150 cc. AcOH refluxed 18 h. gave BzCH(OAc)CONHAr (Ia) (Ar = Ph), m. 139-9.5°. Similarly were prepared the following compds. (m.p. given): Ia (Ar = o-MeOC6H4), 128-9°; Ia (Ar = 3,5-(MeO2C)2C6H3), 169-71°; Ia (Ar = 3,5-(HO2C)2C6H3), 108-10°; α-acetoxy-α-(o-methoxybenzoyl)-4-[2-(2,4-di-tert-amylphenoxy)-5-(3-sulfobenzamido)benzamido]acetanilide Na salt, >170° (decomposition); α-acetoxy-α-(o-methoxybenzoyl)-4-[α-(2,4-di-tert-amylphenoxy)butyramido]acetanilide, 91-2°; α-acetoxy-α-pivalyl-2-chloro-5-[4 - (2,4 - di - tert - amylphenoxy)butyramido]acetanilide, 77-9°. 3,5-(HO2C)C6H3NHCOCHBrCOCMe3, acetylated with m-C15H33C6H4OCH2CO2Na (I) in EtOH gave α-pivalyl-α-[α-(3-pentadecylphenoxy)acetoxy]-3,5-dicarboxyacetanilide, m. 90°. o-MeOC6H4NHCOCHFBz (II) with I gave similarly α-benzoyl-α-[α-(3-pentadecylphenoxy)acetoxy]-o-methoxyacetanilide, m. 82-7°. II with 5-[3-(chlorosulfonyl)benzamido]-2-(2,4-di-tert-amylphenoxy)benzoic acid in EtOH with subsequent hydrolysis yielded α-benzoyl-α-[2-(2,4-di-tert-amylphenoxy)-5-(3-sulfobenzamido)benzoyloxy]-o-methoxyacetanilide Na salt, m. >180°. 3,5(HO2C)2C6H3NHCOCHBrBz acylated with C17H35CO2Na in HCONMe2 yielded 3,5-(HO2C)2C6H3NHCOCH(O2CC17,H35)Bz, m. >200°. o-ClC16H4NHCOCHFBz gave similarly o-ClC6H4NHCOCH(O2CC17H35)Bz, m. 62-3°. α-Chloro-α-[3-[4-(2,4-di-tert - amylphenoxy)butyramido]benzoyl] - 2 - methoxyacetanilide (III) acylated with HO2CCH2CH2CO2Na in dioxane yielded α(3-carboxypropionoxy)-α-[3-[4-(2,4-di-tert-amylphenoxy)butyramido]benzoyl]-2-methoxyacetanilide, m. >180°. II acylated with 2,4-tert-Am2C6H3OCH2CO2H in MeCN yielded α-benzoyl-α[a-(2,4-di-tert-amylphenoxy)acetoxy]-2-methoxyacetanilide, m. 106-8°. m-ClC6H4NHCOCHFBz condensed with C17H35CO2Na in HCONMe2 gave m-ClC5H4NHCOCH(O2CC17Ha2)Bz, m. 75-7°. II with 2,4-tert-Am2C6H3OCHEtCO2Na yielded α-benzoyl-α-[α-(2,4-di-tert-amylphenoxy)butyryl]-o-methoxyacetanilide, m. 123-5°. The following compds. were obtained by the acylation in MeCN with the appropriate free acid in the presence of Et3N as a condensing agent (m.p. given): BzCH(O2CC17H35)CONHC6H4OMe-2, 66-8°, α-acetoxy-α-[3-[2-(2,4-di-tert-amylphenoxy)butyramido]benzoyl]-o-methoxyacetanilide (IIIa), >200°; the 3-[4-(2,4-di-tert-amylphenoxy)butyramido] isomer of IIIa, 98-9°; α-(pivalyloxy)-α-[3-[4-(2,4-di-tert-amylphenoxy]butyramido]benzoyl]-o-methoxyacetanilide, 107-8°; a-benzoyl-α-[p-[α-(2,4-di-tert-amylphenoxy)acetamido]benzoyloxy]-o-methoxyacetanilide, 161-2°. Similarly were prepared in HCONMe2 the following compds.

L9 ANSWER 224 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(m.p. given): α-benzoyl-[α-(2,4-diamylphenoxy)acetoxy]-o-methoxyacetanilide, 89-91°; α-benzoyl-α-(stearoyloxy)-p-sulfamoylacetanilide, 116-18°; α-pivalyl-α-(stearoyloxy)-p-sulfamylacetanilide, 108-10°; α-[α-(2,4-diamylphenoxy)acetoxy]-α-pivalyl-o-chloroacetanilide, 52-4°; α-pivalyl-α-(stearoyloxy)-3,5-dicarboximidoacetanilide (IV), 118-20°; m-chloroacetanilide analog of IV, 66-7°; p-(dimethylsulfamoyl)acetanilide analog of IV, 100-1°; p-(methylsulfonamido)acetanilide analog of IV, 74-6°; α-benzoyl-α-stearoyl-5-chloro-2-methoxyacetanilide (V), 72-4°; o-toluidide analog of V, 81-2°; α-(benzoyloxy)-α-pivalyl2-chloro-5-[4-(2,4-di-tert-amylphenoxy)butyramido] acetanilide, 140-2°. Examples of the use of the yellow color couplers in color photog. emulsion layers are given.

IT 2279-50-7, Benzoic acid, p-[2-(2,4-di-tert-pentylphenoxy)acetamido]-, ester with 2-benzoyl-o-glycolanisidide (preparation of)

RN 2279-50-7 CAPLUS

CN Benzoic acid, p-[2-(2,4-di-tert-pentylphenoxy)acetamido]-, ester with 2-benzoyl-o-glycolanisidide (7CI, 8CI) (CA INDEX NAME)



L9 ANSWER 225 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:468942 CAPLUS

DN 59:68942

OREF 59:12712a-h,12713a-b

TI 4-(α-Alkylideneacyl)-3-halophenoxyacetic acids

IN Schultz, Everett M.; Sprague, James M.

PA Merck & Co., Inc.

SO 162 pp.

DT Patent

LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI BE 612755		19620717	BE	<--
GB 998835			GB	
PRAI US		19610119		

AB 4-Acyl-3-halophenoxyacetic acids are treated with H2CO and a secondary amine to give 3,4-X[R(R'R''NCH2)CHCO]C6H3OCH2CO.2H, which are treated with weak bases to give the title compds., which can be used as diuretics and in the treatment of hypertension. Thus, 93.29 g. m-ClC6H4OCH2CO2H is treated with 57.8 g. EtCOCl in 400 ml. CS2 and 216 g. AlCl3 1 hr. at room temperature and 3 hrs. at 50° to give 77 g. 3,4-Cl(EtCO)C6H3OCH2CO2H (I), m. 108-9.5°. A mixture of 2.1 g. I, 14.52 g. (H2CO)3, 5.34 g. Me2NH.HCl, and a few drops HOAc is heated 1.5 hrs. on a steam bath to give 3,4-Cl[Me(Me2NCH2)CHCO]C6H3OCH2CO2H (II).HCl, m. 158-60° (MeOH). II (1 g.) is dissolved in 25 ml. H2O, the solution made slightly alkaline with 10% NaHCO3, heated 25 min. on a steam bath, cooled, and acidified with 6N HCl to give 66% 4-methacryloyl-3-chlorophenoxyacetic acid, m. 127-8° (C6H6). The following III (R, X, X', m.p. given) are also prepared: Et, H, H, 110-11°; Et, Cl, Cl, 118.5-20.5°; Et, H, Cl, 109-11°; Et, Me, H, 72-4°; Et, H, Me, 77.5-9.5°; Et, Me, Me, 83.5-4.5°; Et, Me, Cl, 113-14°; iso-Pr, H, Cl, 122.5-3.5°; Pr, H, Cl, 101-2°; Bu, H, Cl, 98-9°; Am, H, Cl, 81-2°; Et, H, Br, 111-12°; El, H, iodo, 106.5-7.5°; Et, H, Et, 71.5-2.5°; Et, H, F, 84-5.5°; Et, H, MeO, 110-11°; Et, H, OH, 115.5-17.5°; Et, H, OCH2CO2H, 49.5-51.5°; Et, H, Cl, -(amide m. 103.5-5°) (C6H6-cyclohexane); PhCH2, H, Cl, 104-5°; CH2CO2H, H, Me, -; Et, H, CF3, -; Et, H, Me, - (Me ester n25D 1.5389); Et, Ph, H, -; Et, Br, Cl, 128-30°; Et, H, AcNH, 99-102°; iso-Bu, Cl, Cl, 107-9°; Et, Cl, Me, 89-91°; Et, NO2, Me, 103-5°; tert-Bu, H, Cl, 122-40 (C6H6); Me(F3C)CH, H, Me, 116-18° (ether-petr. ether); iso-Bu, H, Cl, 115-16° (C6H6); Ph, H, Cl, 124-5° (C6H6); PhO, H, Me, 103-6° (C6H6-petr. ether); PhCH2S, H, Me, 112-13° (C6H6petr. ether); cyclopentyl, H, Cl, 127-8°; cyclohexyl, H, Cl, 142-3°; cyclopentyl, Cl, Cl, 142-4° (C6H6-cyclohexane); cyclohexyl, Cl, Cl, 154-5° (C6H6); PhS(CH2)2, H, Me, 81-3°; Me2NCH2, H, Me, -(HCl salt m. 199-202°) (aqueous iso-PrOH); 2-morpholinoethyl, H, Me, -(Et ester HCl salt m. 160-2°); OH, H, Me, 125-8° (C6H6-petr. ether); Me, H, Cl, -(2,4-disulfamoyl-5-chloroanilide m. 232-5°) (alc.-H2O); and Et, H, Cl, -(N',N'-dimethylhydrazide HCl salt m. 141-4°) (iso-PrOH-ether). The following IV (R, Z, R', X, X', m.p. given) are also prepared: Me, O, CHMeCO2H, H, Cl, 115.5-16.5°; Et, O, CHMeCO2H, H, Cl, -; Me, O, (CH2)2CO2H, H, Cl, 72.5-3.5°; Me, S, CH2CO2H, H, Cl, 110-12°; Me, S, CH2CO2H, H, Me, 87.5-9.5°; Me, S, (CH2)2CO2H, H, Cl, 81-3° (cyclohexane-C6H6); Me, O,

L9 ANSWER 225 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
p-(HO2C)C6H4CH2, H, Cl, 166.5-68° (abs. EtOH); Et, O, m-(HO2C)C6H4CH2, H, Cl, 120.5-2° (MeOHH2O); Et, O, o-(MeO2C)C6H4CH2, H, Cl, -; Et, O, p-(HO2C)C6H4CH2, H, Cl, 163-5° (EtOH-H2O); Et, O, p-(HO2C)C6H4, H, Cl, 143-4° (EtOH-H2O); Et, O, o-(HO2C)C6H4, H, Cl, -; Et, S, iso-PrCH(CO2H), H, Cl, 94-5.5° (iso-PrOH); and El, O, (CH2)2OCH2CO2H, H, Cl, - (b0.2 180-210°). Also prepd. are (m.p. given): 2,5,4-Me2[EtC(:CH2)CO]C6H2OCH2CO2H, 88-9.5°; 2,6,4-Me2[EtC(:CH2)CO]C6H2OCH2CO2H, 89.5-90.5°; 2,3,6-trimethyl-4-(2-methylenebutyryt)phenoxyacetic acid, 124-5°; 2,3,5,6-tetramethyl-4-(2-methylenebutyryl)phenoxyacetic acid, 140.5-1.5°; 2,5,4-Cl2[EtC(:CH2)CO]C6H2OCH2CO2H, 125.7-7.7°; 2,6,4-Cl2[EtC(:CH2)CO]C6H2OCH2CO2H, 92-3°; 3,5,4-Me2[EtC(:CH2)CO]C6H2OCH2CO2H, 76.6-7.6°; 5,2,4-Me(iso-Pr)[EtC(:CH2)CO]C6H2OCH2CO2H, 105.5-6.5° (methylcyclohexane); 2,3,5-trimethyl-4-(2-methylenebutyryl)phenoxyacetic acid, 103.5-6.5°; 3-[CH2:CMeCO]C6H4OCH2CO2H, -; 4,3-Cl[MeC(:CH2)CO]C6H3OCH2CO2H, 98.-9.5° (cyclohexane-C6H6); 2,4,5-Me2[EtC(:CH2)CO]C6H2OCH2CO2H, 131-3°; 2,4,5-Me2EtC(:CH2)CO]C6H2O(CH2)3CO2H, 75-7°; 3,5,2-Me2[EtC(:CH2)CO]C6H2OCH2CO2H, 109.511; 3,5,2-Cl2[EtC(:CH2)CO]C6H2OCH2CO2H, 103.5-4.5°; 5,2Cl[MeC(:CH2)CO]C6H3OCH2CO2H, 110-11°; (PhCH2)2NCH2-CH2NHe bis[3,4-Cl(EtC(:CH2)CO]C6H3OCHEtCO2H] salt, 137-7.5° (iso-PrOH); 3,4-Cl[MeC(:CHMe)CO]C6H3OCH2CO2H, 114-16° (C6H6); 3,4-Cl[EtC(:CHMe)CO]C6H3OCH2CO2H, 11819° (C6H6); 3,4-Cl(PhCH:CHCO)C6H3OCH2CO2H, 139-40° (C6H6); 3,4-Cl[(o-ClC6H4)CH:CHCO]C6H3OCH2CO2H, 166-8° (MeCN); 3,4-Cl[MeC(:CHPh)CO]C6H3OCH2CO2H, 140-1.5° (C6H6); 3,4-Cl[(o-HOC6H4)CH:CHCO]C6H3OCH2CO2Na, -; 3,5,4-Cl2[EtC(:CH2)CO]C6H2OCH2CO2H, 117-19° (C6H6-cyclohexane); 3-chloro-4-(1-cyclopentenylcarbonyl)phenoxyacetic acid, -; 3-chloro4-(1-cyclohexenylcarbonyl)phenoxyacetic acid, -; 2,4,3-Cl2[EtC(:CH2)CO]C6H2OCH2CO2H, 135.5-7.5°; 2,3Cl[EtC(:CH2)CO]C6H3OCH2CO2H, 118-19°; 3,2-Me[EtC(:CH2)CO]C6H3OCH2CO2H, 81.5-2.5°; 3,4-Cl(MeCH: CHCO)C6H3OCH2CO2H, 117-19° (C6H6-cyclohexane); 3,4-Me(MeCH:CHCO)C6H3OCH2CO2H, 85-7° (C6H6-cyclohexane); 3,4-Cl[MeCH: CBrCO]C6H3OCH2CO2H, 137-40°; 2,3,4-Cl2[EtC(:CHMe)CO]C6H2OCH2CO2H, 124-5.5°; 3,2,4-ClMe[EtC(:CHMe)CO]C6H2OCH2CO2H, 132.5-3.5°; 2,3,4-Mc22[EtC(:CHMe)CO]C6H2OCH2CO2H, 103-4°; 3,4-Cl[MeC(:CHEt)CO]C6H3OCH2CO2H, 96-7°;3,4-Cl[PrC(:CHEt)CO]C6H3OCH2-CO2H, 114-14.5°; 3-chloro-4-seneciolylphenoxyacetic acid, 134-6° (C6H6-cyclohexane); 3,4-Cl[MeC(:CHMe)CO]C6H3O-CH2CO2H, 144-6°; a mixt. of 3,4-Cl[iso-PrC(:CHMe)CO]C6-H3OCH2CO2H and 3,4-Cl[EtC(:CMe2)CO]C6H3OCH2CO2H, 95-7°; 3,4-Cl[MeC(:CHCHMe2)CO]C6H3OCH2CO2H, 123-4°; 3,-4-Cl[PhCH:CBrCO]C6H3OCH2CO2H, 60-1° (iso-PrOH-H2O); 3,4-Cl[PhCH:C(OH)CO]C6H3OCH2CO2H, 147-8° (iso-PrOH); 3,4-Me[iso-PrC(:CMe2)CO]C6H3OCH2CO2H, 110-12° (hexane-C6H6); 2,3-tetramethylene-4-(2-methylenebutyryl)phenoxyacetic acid, 89-91° (BuCl); and 2,3-trimethylene-4-(2-methylene-butyryl)phenoxyacetic acid, 80-2°.

IT 6501-53-7, Acetanilide, 5'-chloro-2-(3-chloro-4-methacryloylphenoxy)-2',4'-disulfamoyl- (preparation of)

RN 6501-53-7 CAPLUS

CN Acetanilide, 5'-chloro-2-(3-chloro-4-methacryloylphenoxy)-2',4'-disulfamoyl- (7CI, 8CI) (CA INDEX NAME)

L9 ANSWER 225 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 226 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:21679 CAPLUS
DN 54:21679
OREF 54:4222f-i,4223a-e
TI Developers for color photography
IN Anon.
PA Kodak Soc.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI BE 560859		19571015	BE	<--

AB Ag halide emulsions are treated by a solution containing a primary aromatic amine
type developer and one of the following chromogenic couplers, (absorption maximum in mμ of the dye obtained by coupling with 2-amino-5-(diethylamino)toluene-HCl, is given in parentheses): 1-methyl-3-{α-(4-[α-(2,4-di-tert-amylphenoxy)butyramido]phenoxy)acetamido}-5-pyrazolone (I) (520); 1-methyl-3-{α-(4-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy)acetamido}-5-pyrazolone (II) (520); 1-methyl-3-{γ-(4-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy)-butyramido}-5-pyrazolone (III) (524); 1-dodecyl-3-[α-(2,4-di-tert-amylphenoxy)acetamido]-5-pyrazolone (IV) (524); 1-hexyl-3-[α-(2,4-diamylphenoxy)acetamido]-5-pyrazolone (V) (523); 1-hexyl-3-{α-(p-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy)acetamido}-5-pyrazolone (VI) (522); 1-dodecyl-3-[α-(2,4-diamylphenoxy)acetamido]-5-pyrazolone (VII) (523); 1-dodecyl-3-{m-[α-(2,4-diamylphenoxy)acetamido]benzamido}-5-pyrazolone (VIII) (523). I is prepared by stirring for 30 min. a mixture of 2 g. 1-methyl-3-[α-(4-aminophenoxy)acetamido]-5-pyrazolone (IX) and 5 g. α-(2,4-di-tert-amylphenoxy)butyryl chloride in 50 cc. anhydrous MeCN and 2 cc. pyridine. The product is treated with 2 g. KOH in 50 cc. EtOH for 15 min. Acidification is followed by 50 cc. H2O addition and 2.5 g. white powdered I,
m. 78-80° (ligroine), is obtained. II, m. 221-3° (EtOH), is similarly prepared III is prepared by refluxing for 65 hrs. a mixture of 322 g.
p-nitrophenol Na salt, 207 g. γ-chlorobutyronitrile, 3 l. PrOH and 1 l. H2O. Two l. solvent is distilled and the residue is poured into 4 l. H2O.
The reaction product is crystallized from EtOH, m.p. 53-4°, then hydrolyzed in γ(p-nitrophenyl)butyric acid (one night on steam bath) by a mixture 3 AcOH/1 HCl. The acid, m. 127-8°, is converted into the corresponding acyl chloride, m. 56-7°. A 4.1 g. sample is added to a boiling solution of 2.5 g. 1-methyl-3-amino-5-pyrazolone in 100 cc. anhydrous MeCN. Pyridine 2 cc. is added 5 min. later and the mixture is refluxed for 30 min., H2O added, and the precipitate is crystallized from absolute EtOH,
m.p. 198-203°. Reduction in absolute EtOH with H 1.4 kg./sq. cm. in presence of Raney Ni at 50° and evaporation yields the 1-methyl-3-[γ-(p-aminophenoxy)butyramido]-5-pyrazolone, m. 140-2° (H2O). Condensation with 2 mol. equivs. 2,4-di-tert-amylphenoxyacetyl chloride (X) in the presence of 2 mol. equivs. pyridine in anhydrous MeCN at 30° (30 min.), hydrolysis with 2 mol. equivs. alc. KOH at room temperature (30 min.), and excess AcOH addition yield

L9 ANSWER 226 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
III, m. 135-7° (C6H6). IV is prepd. by refluxing for 18 hrs. a mixt. of 400 g. 1-chlorodecane, 1840 cc. EtOH, and 340 g. aq. hydrazine 95%. EtOH is distd. under reduced pressure and the residue is extd. with 3 l. Et2O; the dodecylhydrazine, b1 154-8°, is allowed to react at room temp. for 5 hrs., then under reflux during 30 min. with Et β-ethoxy-β-aminoacrylate in abs. EtOH. The 1-dodecyl-3-amino-5-pyrazolone, m. 77.5-8.5° (abs. EtOH), is treated for 3 1/2 hrs. with 2 mol. equivs. X and 2 mol. equivs. N,N-dimethylaniline in boiling MeCN. Hydrolysis and acid addn. yields IV, m. 78-80° (C6H6). V, m. 75-6.5° (MeOH), is prepd. by converting first hexylhydrazine into 1-hexyl-3-amino-5-pyrazolone, m. 59-62°, which is then treated for 45 min. with 1 mol. equiv. 2,4-diamylphenoxyacetyl chloride (XI) in boiling MeCN. VI is similarly prepd., m.p. 166-7°. Prepn. of VII m. 59-61° is similar to the prepn. of IV. VIII, m. 116.5-18°, has been prepd. from m-[α-(2,4-diamylphenoxy)acetamido]benzoyl chloride obtained by reaction of m-aminobenzoic acid with XI in dioxane in presence of quinoline and subsequent SOCl2 treatment. IX is prepd. by refluxing for 1 hr. 3.4 g. 1-methyl-3-amino-5-pyrazolone and 7.5 g. α-(4-nitrophenoxy)acetyl chloride in 100 cc. anhyd. MeCN; the ppt. is crushed with 50 cc. MeCN, filtered and heated at 50° in 300 cc. H2O contg. 5 g. AcONa. After filtration, 8 g. 1-methyl-3-[α-(4-nitrophenoxy)acetamido]-5-pyrazolone, m. 213-15°, is obtained. A 7-g. sample is reduced in autoclave at 70-80° with Raney Ni yielding 4.1 g. IX m. 100-2°. These couplers are also used together with couplers of the benzoylaceto-o-alkoxyanilide type, thus avoiding the gap of absorption between the usual yellow dyes and magenta dyes.
IT 103277-39-0, p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- 103390-16-5, p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-hexyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- 105912-78-5, Acetanilide, 2-(2,4-di-tert-pentylphenoxy)-4'-[3-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]propoxy]-
(preparation of)
RN 103277-39-0 CAPLUS
CN p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- (6CI) (CA INDEX NAME)



RN 103390-16-5 CAPLUS
CN p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-hexyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- (6CI) (CA INDEX NAME)

L9 ANSWER 226 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PAGE 1-A



PAGE 1-B

RN 105912-78-5 CAPLUS
CN Acetanilide, 2-(2,4-di-tert-pentylphenoxy)-4'-[3-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]propoxy]- (6CI) (CA INDEX NAME)



L9 ANSWER 227 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:21676 CAPLUS
DN 54:21676
OREF 54:4221e-i,4222a-c
TI Couplers for color photography
IN Anon.
PA Kodak Soc.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI BE 561952		19571114	BE	<--

AB Couplers of the 3-acylamido-5-pyrazolone and the 3-acylamido-5-acyloxypyrazole series having a 1-hydroxyalkyl or 1-acyloxyalkyl substituent, are particularly useful in color photography.
1-(2-Hydroxyethyl) - 3 - [(p - palmitoylaminophenoxy)acetamido]-5-pyrazolone (I) is prepared from 1-(2-hydroxyethyl)-3-(p-nitrophenoxyacetamido)-5-pyrazolone (II); reduction in AcOH at 45° with H, 2.1 kg./sq. cm. and 10% Pd catalyst, is followed by treatment with 3 equivs. palmitoyl chloride in boiling MeCN in the presence of 3 equivs. N,N-dimethylaniline for 90 min. A 20-g. sample of the triacyl product is heated at 65° for 15 min. with 10 cc. aqueous 30% NaOH solution and 400 cc. EtOH. The filtrate is acidified (AcOH) and the precipitate is crystallized from
HCONMe2/MeCN mixture and washed with Et2O, m.p. 182-4°.
1-[2-(2,4-Diamylphenoxyacetoxy)ethyl]-3-(2,4-diamylphenoxyacetamido)-5-(2,4-diamylphenoxyacetoxy)pyrazole (III) is prepared by refluxing for 3 hrs. a stirred mixture of 2.84 g. 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, 100 cc. anhydrous MeCN, 18.7 g. 2,4-diamylphenoxyacetyl chloride, and 7.3 g. N,N-dimethylaniline; the mixture is poured into H2O and the precipitate crystallized
from EtOH, m.p. 61-3°. 1-(2-Octanoyloxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(octanoyloxy)pyrazole (IV), m. 50-2° (from MeOH), is prepared by hydrolyzing III (NaOH in aqueous EtOH) and acylating
the 1-(2-hydroxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-pyrazolone, m. 143-4°. 1-(2-Phenylacetoxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(phenylacetoxy)pyrazole, m. 72-3°, 1-(2-hydroxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-pyrazolone, m. 143-4°, 1-(2-phenoxyacetoxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(phenoxyacetoxy)pyrazole, m. 89.5-91°, 1-[2-(2,4-di-tert-amylphenoxyacetoxy)ethyl]-3-(2,4-di-tert-amylphenoxyacetamido)-5-(2,4-di-tert-amylphenoxyacetoxy)pyrazole, m. 113-16°, 1-(2-phenyl-2-hydroxyethyl)-3-(p-nitrophenoxyacetamido)-5-pyrazolone, m. 199-202°, and 1-(2-hydroxypropyl)-3-(p-nitrophenoxyacetamido)-5-pyrazolone, m. 255-6°, have also been prepared 1-(2-Hydroxyethyl)-3-(p-[m-(2,4-di-tert-amylphenoxyacetamido)benzamido]phenoxyacetamido)-5-pyrazolone, m. 156-63° (from EtOH), is prepared by refluxing for 24 hrs. 18.5 g. II, 50 cc. MeCN, 17.5 g. benzoyl chloride, and 16.6 g. N,N-dimethylaniline; 5 g. of the reaction product previously crystallized from
MeCN is reduced at room temperature in tetrahydrofuran with H 3 kg./sq. cm., and
Pd. Subsequent treatment with 4.1 g. m-(2,4-di-tert-amylphenoxyacetamido)benzoyl chloride and 1.2 g. N,N-dimethylaniline and hydrolysis yields the coupler. 1-(2-Hydroxyethyl)-3-[(2,4-di-tert-amylphenoxy)acetamido]-5-pyrazolone, m. 105-6° (from toluene), is prepared from 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, m. 160-2°, obtained by mixing and cooling (>50°) 71 g. 2-hydroxyethylhydrazine 70%, 112 g. Et 2-ethoxy-2-iminopropionate, and 1 cc. AcOH; after 1 hr. the

L9 ANSWER 227 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ppt. is washed with cold H2O and crystd. from EtOH. 1-(2-Hydroxyethyl)-3-lauroylamino-5-pyrazolone, m. 112-15°, 1-(2-benzoyloxyethyl)benzamido-5-pyrazolone, m. 204-5°, 1-(2-hydroxypropyl)-3-[4-(2,4-di-tert-amylphenoxyacetamido)phenoxyacetamido]-5-pyrazolone, and 1-(2-hydroxyethyl)-3-tetracosanoylamino-5-pyrazolone, m. 167-9°, have also been prepd.
IT 105912-80-9, p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[[1-(2-hydroxypropyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]- (preparation of)
RN 105912-80-9 CAPLUS
CN p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[[1-(2-hydroxypropyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]- (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L9 ANSWER 228 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 20364-04-9 CAPLUS
CN o-Acetanisidide, 2-[p-[2-(2,4-di-tert-pentylphenoxy)acetamido]benzoyl]- (6CI, 8CI) (CA INDEX NAME)



RN 108846-21-5 CAPLUS
CN Isophthalic acid, 5-[[[p-[2'-(octadecyloxy)malonanilo]phenyl]carbamoyl]methoxy]-, dimethyl ester (6CI) (CA INDEX NAME)



L9 ANSWER 228 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:15495 CAPLUS
DN 54:15495
OREF 54:3022h-i,3023a-d
TI Benzoylaceto-o-alkoxyanilide couplers for color photography
IN McCrossen, Fred C.; Vittum, Paul W.; Weissberger, Arnold
PA Eastman Kodak Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2875057		19590224	US 1956-575099	19560330 <--

AB Yellow dye image-forming coupler compds. have been prepared having the general structure 2,x-(RO)(Y)C6H3NHOCCH2COC6H4X, where R is an alkyl group of 1-20 carbons, and either X or Y is H, and the other an acylamido group. Thus, 2-benzoyl-2'-methoxy-4'-nitroacetanilide (I), yellow solid, m. 179-80°, is prepared by adding to a 250-ml. round bottomed flask equipped with a partial condensing stillhead 33.6 g. 2-methoxy-4-nitroaniline and 75 ml. histological xylene. After refluxing for 5 min., 40 ml. Et benzoylacetate was added, and the mixture distilled at such a rate that 9 ml. distillate was collected in 2 hrs. The warm residual brown solution was filtered, and allowed to stand at room temperature overnight. The precipitate was filtered off, washed with 100 ml. petr. ether, slurried with 200 ml. denatured alc., and dried; yield = 39 g. (62%). The product was reduced; its hydrochloride and 2,4-di-tert-amylphenoxyacetyl (II) derivs. were prepared, m.p. 206-9° (decompose) and 163-5°, resp. Similarly are prepared the 5'-nitro analog of I (III), m. 177-9° (HOAc), from 4-nitro-2-aminoanisole; the 5'-amino analog of I, m. 108-10° and its II derivative m. 132-4°; 2-(m-nitrobenzoyl)-2'-methoxyacetanilide (IV), m.p. 166-7°, from Et 2-(m-nitrobenzoyl)acetate (Bulow and Hailer, Ber. 35, 915(1902)); the m-amino analog of IV, m. 139.5-40°, and II derivative, m. 126-7°; 2-(4-nitrobenzoyl)-2'-octadecyloxyacetanilide (V), m. 80-1°; the 4-amino analog of V, m. 83-5°, and its 3,5-bis(methoxycarbonyl)phenoxyacetyl derivative, m. 157-8° (HOAc); the p-nitro analog of IV, m. 136-9°; its p-amino analog, m. 134-6° (MeOH), and II derivative, m. 155-7° (EtOH); 2-benzoyl-5'-[2-(2,4-tert-amylphenoxy)butyrylamino]-2'-methoxyacetanilide, m. 135-7° (MeOH); 2-benzoyl-4'-(2-(2,4-di-tert-amylphenoxy)-5-[2,4-bis(methoxycarbonylmethoxy)benzamido]benzamido)-2'-methoxyacetanilide, m. 173-5° (MeOH); 2-benzoyl-4'-[2-(2,4-di-tert-amylphenoxy)-5-aminobenzamido]-2'-methoxyacetanilide, no m.p. given; its 5-[3,5-bis(methoxycarbonyl)phenylcarbamoylpentanoylamino] analog, no m.p. given; 2-(4-[2-(2,4-di-tert-amylphenoxy)-5-nitrobenzamido]benzoyl)-2'-methoxyacetanilide, m. 166-7° (acetonitrile); its 5-amino analog (V) m. 190-2°; the 3,5-bis(methoxycarbonyl)phenoxyacetyl derivative of V, m. 150-3° (EtOH); 2-(3-[2-(2,4-di-tert-amylphenoxy)butyrylamino]benzoyl)-2'-methoxyacetanilide (VI), m. 105° (ligroine); the n-amyl analog of VI m. 80°.
IT 20364-04-9, o-Acetanisidide, 2-p-[2-(2,4-di-tert-pentylphenoxy)acetamido]benzoyl]- 108846-21-5, Isophthalic acid, 5-[[[p-[2'-(octadecyloxy)malonanilo]phenyl]carbamoyl]methoxy]-, dimethyl ester (preparation of)

L9 ANSWER 229 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1959:43985 CAPLUS
DN 53:43985
OREF 53:7839d-i,7840a-e
TI 1-Alkyl-3-acylamino-5-pyrazolone couplers for color photography
IN Feniak, Geo.; Loria, Anthony; Reckhow, Warren A.
PA Eastman Kodak Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2865751		19581223	US 1956-610639	19560918 <--
GB 865720			GB	

GI For diagram(s), see printed CA Issue.
AB The pyrazolone couplers have the general structure A, in which R is an alkyl group of 1-12 C atoms, R' is a monocyclic aryl group, n is 1 or 2, n' is 1-3, R'' is H or a lower alkyl group, and m is 1 or 2. 1-Methyl-3-(2-(4-nitrophenoxy)acetamido)-5-pyrazolone (I), m. 213-15°, is prepared in 8 g. yield by refluxing 3.4 g. 1-methyl-3-amino-5-pyrazolone and 7.5 g. 2-(nitrophenoxy)acetyl chloride in 100 ml. dry MeCN until solid (1 hr.). MeCN 50 ml. is added to break up the solid, which is filtered and heated with 300 ml. water and 5 g. NaOAc to 50°, filtered, washed with cold water, and dried. 1-Methyl-3-(2-(4-aminophenoxy)acetamido)-5-pyrazolone (II), m. 100-2°, is prepared in 4.1 g. yield by adding 7 g. I to 250 ml. EtOH, 100 ml. water, and about 0.5 g. Ni catalyst, and shaking at 50 lb. H pressure for 1 hr. at 70-80°. The mixture is filtered and evaporated in vacuo. The residue is dissolved in hot water, filtered, and cooled to 0°, and the precipitate filtered, washed with 20 ml. ice water, and air dried. 1-Methyl-3-[α-(4-[α-(2,4-di-tert-amylphenoxy)butyrylamino]phenoxy)acetamido]-5-pyrazolone (III), m. 78-80° (from petr. ether), (λ maximum 520 mμ) is prepared in 2.5 g. yield by stirring together 2 g. II and 5 g. α-(2,4-di-tert-amylphenoxy)butyryl chloride in 50 ml. dry MeCN with 2 ml. pyridine, for 30 min., adding 2 g. KOH and 50 ml. EtOH, washing with water, and drying the precipitate formed upon addition of 50 ml. water. Similarly was prepared 1-methyl-3-[α-(4-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy)acetamido]-5-pyrazolone, m. 221-3° (from EtOH), λ maximum 520 mμ. 1-Methyl-3-[γ-(4-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy)butyrylamino]-5-pyrazolone (IV), m. 135-7° (from C6H6), (λ maximum 524 mμ) is prepared by refluxing for 65 hrs. a mixture of 322 g. p-O2NC6HONa, 207 g. γ-chlorobutyronitrile, 3 l. PrOH, and 1 l. water until 2 l. was distilled off, and 4 l. water added to the residue. The solid was filtered, washed with water, and recrystd. from EtOH, m. 53-4°. This was hydrolyzed to γ-(p-nitrophenoxy)butyric acid, m. 127-8°, by heating with a 3:1 mixture of glacial AcOH and concentrated HCl overnight on a steam bath. It crystallized upon cooling. It was converted with SOCl2 to the acid chloride, m. 56-7°, of which 4.1 g. was added to a refluxing solution of 2.5 g. 1-methyl-3-amino-5-pyrazolone in 100 ml. dry MeCN. Pyridine (2 ml.) was added after 5 min. and refluxing continued for 30 min. The mixture was drowned in water, precipitate filtered, and washed with water to give a product, m. 198-203° (from absolute EtOH). This material was reduced over Raney Ni in absolute EtOH with H at 20 lb./sq. in. This solution was evaporated to dryness, to yield 1-methyl-3-[γ-(p-

L9 ANSWER 229 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

aminophenoxy)butyramido]-5-pyrazolone, m. 140-2° (from water). This product was condensed with 2 equivs. 2,4-di-tert-amylphenoxyacetyl chloride in the presence of 2 equivs. of pyridine in dry MeCN at 30° for 30 min. The mixt. was drowned in water, hydrolyzed with 2 equivs. alc. KOH at room temp. for 30 min., the soln. acidified with AcOH, and the resulting oily material washed with water, warmed with Et2O, ether, and filtered to give IV. 1-Dodecyl-3-[α-(2,4-di-tert-amylphenoxy)acetamido]-5-pyrazolone. (V), m. 78-80° (from EtOH-C6H6) (λ max. 524 mμ) was prepd. by refluxing for 18 hrs. a mixt. of 400 g. 1-chlorododecane, 1840 ml. EtOH, and 340 g. aq. 95% H2NNH2. The EtOH was removed in vacuo, and the residue extd. with 3 l. EtOH. Distn. of the dried exts. gave dodecylhydrazine, b1 154-8°. A mixt. of 184 g. dodecylhydrazine, 160 g. Et β-ethoxy-β aminoacrylate, and 920 g. abs. EtOH was allowed to stand at room temp. for 5 hrs., then refluxed for 30 min. and cooled to 0°. The 1-dodecyl-3-amino-5-pyrazolone, m. 77.5-8.5 (from EtOH) was filtered off and treated with 2 equivs. 2,4-di-tert-amylphenoxyacetyl chloride and 2 equivs. PhNMe2 in refluxing MeCN for 3.5 hrs. Upon drowning the mixt. gave the diacylated compd., which was hydrolyzed with 2 equivs. NaOH in aq. EtOH at room temp. for 30 min. This mixt. was acidified with AcOH to give V. 1-Hexyl-3-[α-(2,4-diamylphenoxy)acetamido]-5-pyrazolone, m. 75-6.5° (from MeOH) (λ max. 523 mμ), is prepd. by converting hexylhydrazine to 1-hexyl-3-amino-5-pyrazolone, m. 59-62°, which was refluxed for 45 min. with 1 equiv. 2,4-diamylphenoxyacetyl chloride and the mixt. drowned in water. 1-Hexyl-3-{α-{p-[α-(2,4-di-tert-amylphenoxy)acetamido]phenoxy} acetamido]-5-pyralozone, m. 166-7° (λ max. 522 mμ), 1-dodecyl-3-{α-(2,4-diamylphenoxy)acetamido]-5-pyrazolone, m. 59-61° (λ max. 523 mμ), and 1-dodecyl-3-{m-[α-(2,4-diamylphenoxy)acetamido]benzamido}-5-pyrazolone, m. 116.5-18° (λ max. 523 mμ), are similarly prepd. m-[α-(2,4-Diamylphenoxy)acetamido]benzoyl chloride was prepd. by acylating 3-H2NC6H4CO2H with 2,4-di-m-amylphenoxyacetyl chloride in the presence of quinoline in dioxane, and converting the resulting acid to the acid chloride. The "λ max." values indicated are the wave lengths of max. absorption of dyes made by oxidative coupling of each coupler with 2-amino-5-diethyfaminotoluene-HCl.

IT 103277-39-0, p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- 103390-16-5, p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-hexyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- 105912-78-5, Acetanilide, 2-(2,4-di-tert-pentylphenoxy)-4'-[3-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]propoxy]-
(manufacture and use in color photography)

RN 103277-39-0 CAPLUS

CN p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- (6CI) (CA INDEX NAME)

L9 ANSWER 229 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 103390-16-5 CAPLUS

CN p-Acetanisidide, 2-(2,4-di-tert-pentylphenoxy)-α-[(1-hexyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]- (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 105912-78-5 CAPLUS

CN Acetanilide, 2-(2,4-di-tert-pentylphenoxy)-4'-[3-[(1-methyl-5-oxo-2-pyrazolin-3-yl)carbamoyl]propoxy]- (6CI) (CA INDEX NAME)



L9 ANSWER 229 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 230 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1959:33467 CAPLUS

DN 53:33467

OREF 53:5934a-i

TI 3-Acylamido-5-pyrazolone and 3-acylamido-5-acyloxypyrazole couplers for color photography

IN Feniak, Geo.; Loria, Anthony; Reckhow, Warren A.

PA Eastman Kodak Co.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2865748		19581223	US 1956-619151	19561030 <--
	GB 865721			GB	

AB The preparation of pyrazolone and pyrazole couplers for the production of color photographic images is described. Thus, 1-(2-hydroxyethyl)-3-amino-5-pyrazolone is reduced in glacial AcOH over 10% Pd on charcoal with H, and the catalyst filtered. The filtrate is concentrated and treated with 3 equivs. of palmitoyl chloride in refluxing MeCN in the presence of 3 equivs. PhNMe2 for 90 min. The triacylated material is separated when cool and 20 g. treated with 10 ml. of 30% aqueous NaOH in 400 ml. of EtOH. The reaction mixture is warmed to 65° for 15 min., filtered, the filtrate acidified with glacial AcOH and cooled. The solid is recrystd. from a mixture of HCONMe2-MeCN and washed with ether to yield 1-(2-hydroxyethyl)-3-[α-(palmitoylaminophenoxy)acetamido]-5-pyrazolone, m. 182-4°. 1-[2-(2,4-diamylphenoxyacetoxy)ethyl]-3-(2,4-diamylphenoxyacetamido)-5-(2,4-diamylphenoxyacetoxy)pyrazole (I), m. 61-3° (from EtOH) is obtained by refluxing a mixture of 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, MeCN, 2,4-diamylphenoxyacetyl chloride, and PhNMe2 for 3 hrs., drowning in water, and recrystg. from EtOH. 1-(2-Octanoyloxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(octanoyloxy)pyrazole (II), m. 50-2° (from MeOH), is obtained by the hydrolysis of I with NaOH and the acylation of the intermediate with octanoyl chloride in the presence of PhNMe2 in dry MeCN. Similarly, 1-(2-phenylacetoxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(phenylacetoxy)pyrazole (III), m. 72-3°, is prepared like II by using PhCH2COCl instead of octanoyl chloride, while 1-(2-phenoxyacetoxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-(phenoxyacetoxy)pyrazole, m. 89.5-91°, is prepared like III except that PhOCH2COCl is used as the acylating agent, and 1-[2-(2,4-di-tert-amylphenoxyacetoxy)ethyl]-3-(2,4-di-tert-amylphenoxyacetamido)-5-(2,4-di-tert-amylphenoxyacetoxy)pyrazole, m. 113-16°, is prepared like I except that 2,4-di-tert-amylphenoxyacetyl chloride is used. 1-(2-hydroxypropyl)-3-(p-nitrophenoxyacetamido)-5-pyrazolone, (IV), m. 255-6° (from BuOH), is prepared by the acylation of 1-(2-hydroxypropyl)-3-amino-5-pyrazolone with p-nitrophenoxyacetyl chloride; 1-(2-phenyl-2-hydroxyethyl)-3-(p-nitrophenoxyacetamido)-5-pyrazolone, m. 199-202° (from BuOH), is prepared by the method for IV by using 2-phenyl-2-hydroxyethylhydrazine; and 1-(2-hydroxypropyl)-3-[4-(2,4-di-tert-amylphenoxyacetamido)phenoxyacetamido]-5-pyrazolone is prepared from IV by the reduction of the nitro group and reaction with 2,4-di-tert-amylphenoxyacetyl chloride. 1-(2-Hydroxyethyl)-3-[α-(2,4-di-tert-amylphenoxy)acetamido]-5-pyrazolone (V), m. 105-6° (from toluene), is prepared from 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, α-(2,4-di-tert-amylphenoxy)acetyl chloride and PhNMe2 in dry MeCN; 1-(2-hydroxyethyl)-3-(2,4-diamylphenoxyacetamido)-5-pyrazolone, m. 143-4°, is prepared like V except that 2,4-diamylphenoxyacetyl chloride is used; and 1-(2-hydroxyethyl)-3-tetracosanoylamino-5-

L9 ANSWER 230 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyrazolone, m. 167-9° (from toluene) and 1-(2-hydroxyethyl)-3-lauroylamino-5-pyrazolone, m. 112-15°, (from EtOH), are prepd. like V with lauroyl chloride used in the prepn. of the latter compd. 1-(2-hydroxyethyl)-3-(p-[m-(2,4-di-tert-amylphenoxyacetamido)benzamido]phenoxyacetamido)-5-pyrazolone, m. 156-63° (from EtOH), is formed from the mixt. of 1-(2-hydroxyethyl-3-(p-nitrophenoxyacetamido)-5-pyrazolone, dry MeCN, BzCl, and PhNMe2; 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, m. 160-2°, (from EtOH), from 2-hydroxyethylhydrazine and Et β-ethoxy-β-iminopropionate with 1 ml. AcOH as a catalyst; and 1-(2-benzoyloxyethyl)-3-benzamido-5-pyrazolone, m. 204-5° (from EtOH), from the mixt. of 1-(2-hydroxyethyl)-3-amino-5-pyrazolone, dry MeCN, BzCl, and PhNMe2. The color couplers are useful for the development of multilayer color films in which some or all of the emulsion layers are devoid of coupler compds.
IT 105912-79-6, p-Acetanisidide, 2-(2,4-dipentylphenoxy)-α-[[1-(3-hydroxypropyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]-
(preparation of)
RN 105912-79-6 CAPLUS
CN p-Acetanisidide, 2-(2,4-dipentylphenoxy)-α-[[1-(3-hydroxypropyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]- (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 231 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetanilide, 4'-formyl-2-phenoxy-, thiosemicarbazone (6CI) (CA INDEX NAME)



RN 112745-14-9 CAPLUS
CN Acetanilide, 4'-formyl-2-thymyloxy-, thiosemicarbazone (6CI) (CA INDEX NAME)



L9 ANSWER 231 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1958:56230 CAPLUS
DN 52:56230
OREF 52:10181g-i,10182a-c
TI Thiosemicarbazones
IN Behnisch, Robert; Mietzsch, Fritz; Schmidt, Hans
PA Farbenfabriken Bayer A.-G.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 852086		19521013	DE	<--

AB Thiosemicarbazones, having antituberculosis properties, were prepared 4-O2NC6H4CH:Z (Z = NNHCSNH2) (100 g.) added to 1 l. 18% NaHS solution with stirring, heated 2 hrs. at 70-80° on a H2O bath, cooled, solid NH4Cl added until a test sample produced no further precipitation with NH4Cl, the precipitate filtered off, and recrystd. twice from 80% EtOH gave 4-H2NC6H4CH:Z (I), m. 204°, soluble in aqueous NaOH and HCl, forming a Cu salt and an Fe salt. 3-O2NC6H4CH:Z reduced with Fe filings in boiling dilute AcOH gave the 3-H2N compound, m. 158° (MeOH), forming a Cu salt. 2-H2NC6H4CHO (39 g.) in 39 cc. H2O and 156 cc. AcOH treated with 30 g. H2NNHCSNH2 and heated 1 hr. on a H2O bath gave 34 g. 2-H2NC6H4CH:Z, m. 202° (with foaming). I (19 g.) and 10 g. (CH2CO2)O in 100 cc. EtAc heated to boiling with stirring and boiled 30 min. more gave 4-HO2CCH2CH2CONHC6H4CH:Z, m. 206°. Other compds. prepared by the above procedures were (compound and m.p. given): 4-H2NC6H4C(Me):Z, 172°; 4-(2-HO2CC6H4CONH)C6H4CH:Z, 220° (decomposition); 3-(HO2CCH2CH2CONH)C6H4CH:Z, 230°; 3,4-H2N(HO)C6H3CH:Z, 206° (decomposition) (HCl salt, m. 210; sulfate, did not melt): 3,4-H2N(MeO)C6H3CH:Z, 172°; 4,3-MeO(AcHN)C6H3CH:Z, 267° (decomposition); 4,3-MeO(EtCOHN)C6H3CH:Z, 212°; 4,3-MeO(MeOCH2COHN)C6H3CH:Z, 220°; 4-(4-H2NCO2C6H4SO2HN)C6H4CH:Z, 221° (decomposition); 4-MeHNCSNHC6H4CH:Z, 229°; 4-PhNHCSHNC6H4CH:Z, 212°; 4-AcHNC6H4CH:Z, 230° (decomposition); 2,4-MeO(AcHN)C6H3CH:Z, 174° (with foaming); 4-(n-H23C11COHN) C6H4CH:Z, 193°; 4-EtCOHN C6H4CH:Z, 225° (decomposition); 4-Me2CHCOHNC6H4CH:Z, 220°; 4-(n-H35C17COHN)C6H4CH:Z, -; 4-MeOCH2COHNC6H4CH:Z, 218° (decomposition); 3-AcHNC6H4CH:Z, 202°; 4-H2NO2SC6H4NHCSNHNH2, 185; 4-H2NO2SC6H4NHCSNHN:CHC6H4NHAc-4, 220°; H2NCONHC6H4CH:Z, 240° (decomposition); 4-BzHNC6H4CH:Z, 285° (decomposition); 4-(4-MeC6H4COHN)C6H4CH:Z, 310° (decomposition); 4-(4-MeOC6H4COHN)C6H4CH:Z, 295° (decomposition); 4-(2-ClC6H4COHN)C6H4CH:Z, 198° (sintering previously); 4-(4-ClC6H3COHN)C6H4CH:Z, 305° (decomposition); 4-(4-O2NC6H4COHN)C6H4CH:Z, -; 4-PhOCH2COHNC6H4CH:Z, 230° (decomposition); 4-(2-FC6H4COHN)C6H4CH:Z, 220° (decomposition); 4-[1,4-Me(Me2CH)C6H3OCH2COHN]C6H4CH:Z, 208° (decomposition); 4-AcHNC6H4C(Me):Z, 226°; 4-EtCOHNC6H4CH:Z, 194° (with foaming); 2-AcHNC6H4CH:Z, 223° (with foaming); 4-Ac2NC6H4CH:NNHCSNHAc, 200; 4-AcHNC6H4CH:NNHCSNHCH2CH:CH2, 242°.
IT 101281-53-2, Acetanilide, 4'-formyl-2-phenoxy-, thiosemicarbazone
112745-14-9, Acetanilide, 4'-formyl-2-thymyloxy-, thiosemicarbazone
(preparation of)
RN 101281-53-2 CAPLUS

L9 ANSWER 232 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1956:15408 CAPLUS
DN 50:15408
OREF 50:3127d-i,3128a-b
TI Photographically useful compounds containing an isophthalate group
IN Loria, Anthony; Pesch, Edward T.
PA Eastman Kodak Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2721798		19551025	US 1953-378158	19530902 <--

AB The preparation of new compds. containing an isophthalate group is described. Thus, a mixture of 156 g. 3,5-dicarboxyphenol and 800 ml. distilled SOCl2 was refluxed about 36 hrs., and the excess SOCl2 carefully distilled off in 2 stages to produce 3,5-bis(chlorocarbonyl)phenol (I). To 1 l. absolute MeOH cooled to 10° 187 g. of warm I was carefully added, stirred, and the mixture cooled to 10°, filtered, dried, and crystallized from 2 l. dry xylene to yield 138 g. 3,5-dicarbomethoxyphenol (II), m. 163-5°, long white needles, yield 77%. Next, to NaOMe (precipitated from 13.8 g. Na and 300 ml. absolute MeOH) is added 63 g. II, followed by 41.7 g. (0.3 mol.) bromoacetic acid dissolved in 100 ml. absolute MeOH, stirred, refluxed for 18 hrs. on a steam bath, cooled, poured into 1 l. cold H2O, acidified with dilute HCl, filtered, and the solid washed free of acid, air dried, and recrystd. from hot, dry xylene to give 3,5-dicarbomethoxyphenoxyacetic acid (III), m. 164-5°, white crystalline solid. Similarly, 21 g. II and a solution of 16.7 g. of α-bromobutyric acid in 200 ml. dry xylene were treated with NaOMe solution to yield 16.7 g. of α-(3,5-dicarbomethoxyphenyl)butyric acid (IV), m. 149-52° (56%), white crystals. 3,5-Dicarbomethoxyphenoxyacetyl chloride (V) 2.86 g. (prepared by refluxing III with thionyl chloride) was treated with 5.8 g. of 1-hydroxy-N-(2-[2-(2,4-di-tert-amylphenoxy)-5-aminobenzamido]ethyl)-2-naphthamide (Weissberger and Edens, U.S. 2,589,004, C.A. 46, 4941f) in the presence of 150 ml. anhydrous AcOH to yield 1-hydroxy-N-(2-[2-[2,4-di-tert-amylphenoxy]-5-[α-(3,5-dicarbomethoxyphenoxy)acetamido]-benzamido)ethyl)-2-naphthamide (VI), m. 149-51° after recrystn. twice from MeOH. 1-Phenyl-3-(3-[2-[2,4-di-tert-amylphenoxy]-5-[α-(3,5-dicarbomethoxyphenoxy)acetamido]benzamido)benzamido)-5-pyrazolone, m. 149-50°, was prepared similarly by using KOAc instead of NaOAc as the condensing agent. The pyrazolone used was prepared by Salminen and Weissberger (U.S. 2,694,718, C.A. 49, 3704f). A mixture of 6-[5-amino-2-(2,4-di-tert-amylphenoxy)benzamido]-2,4-dichloro-3-methylphenol and the acid chloride of IV were reacted in dry acetonitrile to give 6-(2-[2,4-di-tert-amylphenoxy]-5-[α-(3,5-dicarbomethoxyphenoxy)butyramido]benzamido)-2,4-dichloro-3-methylphenol (VII), m. 194-6°. 6-(4-[2,4-Di-tert-amylphenoxy]-3-[α-(3,5-dicarbomethoxyphenoxy)acetamido]benzamido-2,4-dichloro-3-methylphenol (VIII), m. 208-10°, was prepared by using the same method as for VII. Similarly, V and 2-(4-aminobenzoyl)-2'-(2,4-di-tert-amylphenoxy)acetanilide were reacted to give 2-(4-[α-(3,5-dicarbomethoxyphenoxy)acetamido]benzoyl)-2'-(2,4-di-tert-amylphenoxy)acetanilide, m. 287-9°, while 1-(2,4,6-trichlorophenyl)-3-(3-[α-(3,5-dicarbomethoxyphenoxy)butyramido]benzamido)-5-pyrazolone, m. 187-9°, was made by the same method as used for VI. Finally, 6-(α-4-[α-(2,5-dicarbomethoxyphenoxy)butyramido]phenoxy)acetamido)-2,4-dichloro-3-methylphenol, m. 185-7°, slightly pink

L9 ANSWER 232 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
solid, was prepd. from 6-[α-(4-aminophenoxy)acetamido]-2,4-dichloro-3-methylphenol with α-(dicarbomethoxyphenoxy)butyryl chloride. These compds. can be incorporated into photographic emulsions as color couplers to combine with the oxidation products of the developer in producing color images.
IT 855643-45-7, Isophthalic acid, 5-[[[p-[[[o-[2,4-bis(1,1-dimethylpropyl)phenoxy]phenyl]carbamoyl]acetyl]phenyl]carbamoyl]methoxy]-, dimethyl ester
(preparation of)
RN 855643-45-7 CAPLUS
CN Isophthalic acid, 5-[[[p-[[[o-[2,4-bis(1,1-dimethylpropyl)phenoxy]phenyl]carbamoyl]acetyl]phenyl]carbamoyl]methoxy]-, dimethyl ester (5CI) (CA INDEX NAME)



L9 ANSWER 233 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1952:29242 CAPLUS
DN 46:29242
OREF 46:4941f-g,4942a-d
TI Couplers from bifunctional amines
IN Weissberger, Arnold; Edens, Charles O., Jr.
PA Eastman Kodak Co.
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2589004		19520311	US 1948-58352	19481104 <--

AB New couplers suitable for use in emulsion layers or color-forming developer solns. used in processes of subtractive color photography are obtained by acylating the aliphatic NH2 group of m- or p-H2NC6H4(CH2)nNH2, where n is an interger from 1 to 5, and then acylating the aromatic NH2 group. p-H2NC6H4CH2CN is hydrogenated in liquid NH3 and MeOH with Raney Ni at 105° and 1500 lb./sq. in. pressure to yield p-H2NC6H4(CH2)nNH2 (I), b2 117-19°, nD25 1.5915. Equimol. amts. of m-H2NC6H4(CH2)2NH2 and MeSO3Ph are rapidly heated 10 min. at reflux temperature, the mixture cooled, dissolved in 95% EtOH, the solution cooled to 0°, the resulting crystalline plates filtered off, washed with cold EtOH and Et2O, and dried at 50° to yield m-H2NC6H4(CH2)2NHO2SMe (II), m. 85-6°; II and BzCH2CO2Et (equimol. amts.) are heated in xylene at 150° in a still so devised that the EtOH formed is removed in the course of the reaction, and the resulting product is recrystd. from glacial AcOH, EtOH, or dioxane to give 3-(2-methylsulfonamidoethyl)-α-benzoylacetanilide, which gives a yellow dye in the color development process. Equimol. amts. of 1,2-HOC10H6CO2Ph and I are heated at 150°, the PhOH is distilled off, and the mixture refluxed 2 min. with AcOH, NaOAc, and AcCl to yield 94% 1-hydroxy-N-(p-acetamidophenethyl)-2-,naphthamide, m. 228-9°, giving a cyan dye in the color development process. Similarly are prepared the following couplers (color of dye in the color development given): 4-(2-(benzoylacetamido)ethyl]-α-(2,4-diamylphenoxy)acetanilide, yellow; 4-substituted α-benzoylacetanilides (4-substituent given): 2-methylsulfonamidoethyl; [p-(α-mercaptoacetamido)phenethylcarbamyl]thiolacetate (III); 2-[α-(2,4-diamylphenoxy)acetamido]ethyl; 2-(2-[2,4-diamylphenoxy]-5-[3,5-bis(chlorosulfonyl)benzamido]benzamido)-ethyl, all yellow; 3-substituted 1-phenyl-5-pyrazolones (3-substituent given): 2-(p-acetamidophenethylcarbamyl); 4 [α-(2,4-diamylphenoxy)acetamido]phenethylcarbamyl; III; 4-(2-[2,4-diamylphenoxy]-5-[3,5-bis(chlorosulfonyl)benzamido]benzamido)phenethylcarbamyl; all magenta; N-substituted 1-hydroxy-2-naphthamides (N-substituent given): 4-[α-(2,4-diamylphenoxy)acetamido]phenethyl; [p-(α-mercaptoacetamido)phenethyl] thiolacetate; 4-(2-[2,4-diamylphenoxy]-5-[3,5-bis(chlorosulfonyl)benzamido] benzamido) phenethyl; 4-[2-(p-tolylsulfonamido)ethyl]phenyl, all cyan; 3-[2-(α-benzoylacetamido)ethyl]-α-(2,4-diamylphenoxy)acetanilide, yellow; 1-phenyl-3-[3-(2-acetamidoethyl)phenylcarbamyl]-5-pyrazolone, magenta.
IT 856059-29-5, 2-Naphthamide, N-[p-[2-(2,4-dipentylphenoxy)acetamido]phenethyl]-1-hydroxy- 857182-37-7, 2-Pyrazoline-3-carboxamide, N-[p-[2-(2,4-dipentylphenoxy)acetamido]phenethyl]-5-oxo-1-phenyl- 861061-83-8, Acetanilide,

L9 ANSWER 233 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4'-[2-(2-benzoylacetamido)ethyl]-2-(2,4-dipentylphenoxy)-
(prepn. of)
RN 856059-29-5 CAPLUS
CN 2-Naphthamide, N-[p-[2-(2,4-dipentylphenoxy)acetamido]phenethyl]-1-hydroxy- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—(CH2)4—Me

RN 857182-37-7 CAPLUS
CN 2-Pyrazoline-3-carboxamide, N-[p-[2-(2,4-dipentylphenoxy)acetamido]phenethyl]-5-oxo-1-phenyl- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—(CH2)4—Me

RN 861061-83-8 CAPLUS
CN Acetanilide, 4'-[2-(2-benzoylacetamido)ethyl]-2-(2,4-dipentylphenoxy)- (5CI) (CA INDEX NAME)



L9 ANSWER 233 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 234 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1951:46513 CAPLUS
DN 45:46513
OREF 45:7899d-i,7900a-d
TI 1-Cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
IN Weissberger, Arnold; Vittum, Paul W.; Edens, Charles O.
PA Eastman Kodak Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2511231		19500613	US 1949-83762	19490326 <--

AB Couplers which produce magenta images in the presence of primary aromatic amino developing agents comprise 1-R-3-R'-5-pyrazolones where R is a mononuclear cyanoaryl radical and R' is a carboxyacyl radical. The compds. are prepared by condensing a p-cyanoarylhydrazine with ethyl β-ethoxy-β-iminopropionate (I) to form an ethyl β-[(p-cyanoaryl)hydrazino]-β-iminopropionate, followed by ring closure of the latter with NaOEt. The amino compound is acylated to give the acylaminopyrazolone. Thus p-nitrobenzonitrile was reduced with SnCl2 to give p-cyanoaniline (II) m. 84-6°, yield 85-8%. Diazotized II was added to cold Na2SO3 solution, warmed to 60° for 30 min., and acidified with concentrated HCl. After heating overnight on a steam bath, p-cyanophenylhydrazine-HCl was obtained by adding concentrated HCl to the hot solution; yield 85%. The free base (III) m. 92-9°. III was added to boiling C6H5Cl then I and a small amount of HOAc was added. After refluxing 5 min., the mixture was cooled overnight at 0-5° to give crystals of ethyl β-[(p-cyanophenyl)hydrazino]-β-iminopropionate (IV) m. 147-8°, yield 81%. IV was refluxed 15-20 min. with NaOEt, cooled to 50°, diluted with H2O, and acidified with HOAc to give 1-(p-cyanophenyl)-3-amino-5-pyrazolone (V), m. 222-4° (decomposition), yield 92%. PhCOCl was added to V in dry C6H5N and heated 10 min. on a steam bath, cooled to room temperature, and diluted with H2O to give the dibenzoyl derivative m. 185-8°, yield 82%. Treatment with alc. KOH and acidification with HOAc gave 1-(p-cyanophenyl)-3-benzamido-5-pyrazolone m. 256-7° (from dioxane), yield 61%. Similarly the following acylated derivs. of V were prepared by using the appropriate acid chloride: 3-acetamido, 3-(o-terphenyl-4-ylcarbonylamino), 3-(2,4-di-tert-amylphenoxyacetamido), 3-{ [4-(2,4-di-tert-amylphenoxy)phenyl]carbamylvalerylamino}, 3-[2-(2,4-di-tert-amylphenoxy)-5-(p-sec-amylbenzamido)benzamido], 3-[4-(2,4-diamylphenoxy)-3-(p-sec-amylbenzamido)benzamido], 3-(p-nitrobenzamido), 3-(m-nitrophenylacetamido), 3-(m-nitrobenzamido), 3-(o-chlorobenzamido), 3-(p-sec-amylbenzamido), 3-(p-amoxybenzamido), 3-(p-toluylamino), 3-(o-toluylamino), 3-(p-methoxybenzamido), 3-(o-methoxybenzamido), 3-(2,4-dichlorobenzamido), 3-(p-chlorobenzamido), 3-(3,4-dichlorobenzamido), 3-(m-methoxybenzamido), 3-(m-chlorobenzamido), 3-(o-nitrobenzamido), 3-phenylacetamido, 3-(p-cyanobenzamido), 3-nicotinamido, 3-(3-[α-(2,4-di-tert-amylphenoxy)butyrylamino]benzamido), 3-[4-(2,4-di-tert-amylphenoxyacetamido)phenylacetamido], 3-[3-(2,4-di-tert-amylphenoxyacetamido)phenylacetamido], 3-[4-(2,4-di-tert-amylphenoxyacetamido)benzamido], 3-[4-(2,4-di-tert-amylphenoxy)-3-(4-methylbenzamido)benzamido], 3-[4-(2,4-di-tert-amylphenoxy)-3-(4-

L9 ANSWER 234 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

chlorobenzamido)benzamido], 3-[4-(2,4-di-tert-amylphenoxy)-3-nitrobenzamido], 3-[2-(2,4-di-tert-amylphenoxy)-5-aminobenzamido], 3-[2-(2,4-di-tert-amylphenoxy)-5-nitrobenzamido], 3-[3-(4-tert-amylphenoxy)benzamido], 3-[β-(2,4-di-tert-amylphenoxy)propionylamino], 3-[3-(2,4-di-tert-amylphenoxyacetamido)benzamido], 3-(3-[2-(2,4-di-tert-amylphenoxy)-5-(3,5-bis(chlorosulfonyl)benzamido} benzamido]benzamido}, 3-(3-[2-(2,4-di-tert-amylphenoxy)-5-(3-carboxy-4-hydroxyphenylsulfonamido)benzamido]benzamido}, 3-(3-[2-(2,4-di-tert-amylphenoxy)-5-(3,4-dicarboxyphenylsulfonamido)benzamido]benzamido). Examples of other couplers are 1-(m-cyanophenyl)-3-benzamido-5-pyrazolone, 1-(2,6-dichloro-4-cyanophenyl)-3-benzamido-5-pyrazolone, 1-(2,6-dichloro-4-cyanophenyl)-3-[3-(2,4-di-tert-amylphenoxyacetamido)benzamido]-5-pyrazolone, 1-(2,6-dichloro-4-cyanophenyl)-3-[β-(2,4-di-tert-amylphenoxy)propionylamino]-5-pyrazolone, and 1-(p-cyanophenyl)-3-furoylamino-5-pyrazolone. Examples are given for the prepn. of the acid chlorides and phys. consts. were reported in the patent for the following intermediates: 2,4-di-tert-amylphenoxyacetic acid, m. 116-17°; 2,4-di-tert-amylphenoxyacetyl chloride, b2.0 143-6°; 2-(2,4-di-tert-amylphenoxy)-5-nitrobenzoic acid, m. 189-91°; 4-(2,4-diamylphenoxy)-3-nitrobenzoic acid, m. 168-70°; 1-(p-cyanophenyl)-3-(3-nitrobenzamido)-5-pyrazolone, m. 254-5°; 1-(p-cyanophenyl)-3-(3-aminobenzamido)-5-pyrazolone, m. 245-7°; α-(2,4-di-tert-amylphenoxy)butyric acid, b1.0 170-200°; α-(2,4-di-tert-amylphenoxy)butyryl chloride; b1.0 138-40°; 3-(4-tert-amylphenoxy)benzoic acid, m. 134-6°; β-(2,4-di-tert-amylphenoxy)propionitrile, b1.0 136-42°; 3-[2-(2,4-di-tert-amylphenoxy)-5-nitrobenzamido]benzoic acid, m. 215-16°; (2,6-dichloro-4-cyanophenyl)hydrazine, m. 131-3°; and 2,6-dichloro-4-cyanoaniline, m. 117-18°.

IT 857569-28-9, p-Acetotoluidide, 2-[2,4-bis(1,1-dimethylpropyl)-phenoxy]-α-[[1-(p-cyanophenyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]]- 857947-67-2, Acetanilide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-4'-[[1-(p-cyanophenyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]- (preparation of)

RN 857569-28-9 CAPLUS

CN p-Acetotoluidide, 2-[2,4-bis(1,1-dimethylpropyl)-phenoxy]-α-[[1-(p-cyanophenyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]]- (5CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 234 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 857947-67-2 CAPLUS

CN Acetanilide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-4'-[[1-(p-cyanophenyl)-5-oxo-2-pyrazolin-3-yl]carbamoyl]- (5CI) (CA INDEX NAME)

L9 ANSWER 235 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1920:1418 CAPLUS
DN 14:1418
OREF 14:283d-i,284a-b
TI Aromatic arsenic compounds. VIII. The amides of (4-arsonic acid)-phenoxyacetic acid and the isomeric phenoxyacetylarsanilic acids
AU Jacobs, Walter A.; Heidelberger, Michael
SO Journal of the American Chemical Society (1919), 41, 1834-40
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable

AB In the preparation of [4-arsonic acid]-phenoxyacetamides from p-HOC6H4AsO3H2 (C) and chloroacetylamino compds., the addition of an extra mol. of NaOH to form the Na phenolate is essential for success. With chloroacetyl compds. sufficiently stable in alkaline solution the yields are good, but where the halide is readily decomposed the yields suffer accordingly. In general, the arsonic acids of this type crystalline readily when pure, have high decomposition points and are sparingly soluble in the usual solvents; they are stronger than the amides of H2O3AsC6H4NHCH2CO2H, only mineral acids or a large excess of AcOH displacing them from their salts. In preparing phenoxyacetylarsanilic acids from A also, an extra mol. of alkali is required and as the resulting mixture is strongly alkaline the sensitive A suffers partial decomposition, so that the yields are smaller than in the synthesis of the glycylarsanilic acids. As a rule, these new acids crystalline readily and are sparingly soluble in the usual solvents but yield readily soluble Na salts. They are stronger acids than the glycylarsanilic acids and are displaced from their salts only by mineral acids or a large excess of AcOH. On reduction, both of the above groups of compds. yield arsenoxides and arseno compds. Methyl (p-arsonophenoxy)acetate (9.5 g. from 10 g. of the acid (Ger. pat. 216,270) boiled 2 hrs. with 30 g. MeOH and 3 g. concentrated H2SO4), plates, partially m. 192.5° (gas evolution), decomps. at higher temps. without melting completely. Amide (37.5 g. from 60 g. of the Me ester and 360 cc. concentrated NH4OH), rhombic microprisms, does not m. 280°; sodium salt, platelets. p-(Phenylcarbamylmethoxy)benzenearsonic acid [4-arsonic acid-phenoxyacetanilide] (from 5 g. p-HOC6H4AsO3NaH, 3.4 g. ClCH2CONHPh and 3 g. NaI boiled 3 hrs. in 20 cc. N NaOH and 20 cc. alc.), platelets, does not m. 280°. p-[(m-Hydroxyphenylcarbamyl)methoxy]benzenearsonic acid [(4-arsonic acid)phenoxyacetyl-3-aminophenol] (from 43.6 g. C in 400 cc. of N NaOH boiled 15 min. with 38 g. m-ClCH2CONHC6H4OH), microleaflets, m. 238-40° (decomposition), purified through the sodium salt, pink microneedles and long thin platelets. 4-Aminophenol, microcrystals, gradually darkens and decomps. 238-40°, gives with NaNO2 in AcOH yellow crystals, probably of the NO compound; sodium salt. 4-Aminophenylurea (7 g. from 8.8 g. C and 9.2 g. p-ClCH2CONHC6H4NHCONH2), microneedles, darkens and softens about 230-40°, does not melt completely 265°. Phenoxyacetylarsanilic acid (3.5 g. from 4.4 g. B in 50 cc. of 20% NaOAc and 4 g. PhOCH2COCl), microcrystals, does not decompose 280°, also obtained, but in poor yield, by boiling 3 g. A in 20 cc. N NaOH with 1 g. PhOH for 0.5 hr. p-[(p-Arsonophenylcarbamyl)methoxy]oxanilic acid [p-oxaminophenoxyacetylarsanilic acid], obtained (instead of the amide) by boiling equivalent amts. of A and p-HOC6H4NHCOCONH2, each in the calculated amount of NaOH, for 20 min., creamcolored microcrystals, does not m. 280°,

L9 ANSWER 235 OF 235 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
seps. with 1 H2O. (p-Carbamidophenoxyacetyl)arsanilic acid, microspindles, decomps. about 280-3°; sodium salt (3.5 g. from 11.8 g. A and 6.5 g. p-HOC6H4NHCONH2), minute needles with approx. 3 H2O. (o-Carbamylphenoxyacetyl)arsanilic acid (from o-HOC6H4CONH2), delicate needles, does not decomp. 280°; sodium salt, prismatic needles with approx. 5.5 H2O. p-Isomer, long needles, does not m. 280°, isolated through the sodium salt (3.7 g. from 2.8 g. p-HOC6H4CONH2), long, flat, delicate needles with approx. 7.5 H2O.

IT 861785-66-2, Benzenearsonic acid, p-[[(p-carbamidophenyl)carbamyl]-methoxy}-
(preparation of)

RN 861785-66-2 CAPLUS

CN Benzenearsonic acid, p-[[(p-carbamidophenyl)carbamyl]-methoxy]- (2CI) (CA INDEX NAME)



```
=> => d que l21 stat
L10           38 SEA FILE=CAPLUS ABB=ON  PLU=ON  "STENKAMP DIRK"/AU
L11           27 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("MUELLER STEPHAN G"/AU OR
                 "MUELLER STEPHAN GEORG"/AU)
L12           82 SEA FILE=CAPLUS ABB=ON  PLU=ON  "ROTH GERALD J"/AU OR "ROTH
                 GERALD JUERGEN"/AU
L13           35 SEA FILE=CAPLUS ABB=ON  PLU=ON  "LUSTENBERGER PHILIPP"/AU
L14           80 SEA FILE=CAPLUS ABB=ON  PLU=ON  "RUDOLF KLAUS"/AU
L15           28 SEA FILE=CAPLUS ABB=ON  PLU=ON  "LEHMANN LINTZ THORSTEN"/AU
L16           22 SEA FILE=CAPLUS ABB=ON  PLU=ON  "ARNDT KIRSTEN"/AU
L17           23 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("LOTZ RALF"/AU OR "LOTZ RALF
                 R H"/AU OR "LOTZ RALF RICHARD HERMANN"/AU)
L18           29 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("LENTER MARTIN"/AU OR "LENTER
                 MARTIN C"/AU)
L19           48 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("WIELAND HEIKE"/AU OR
                 "WIELAND HEIKE A"/AU OR "WIELAND HEIKE ANDREA"/AU)
L20          263 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 OR L11 OR L12 OR L13 OR
                 L14 OR L15 OR L16 OR L17 OR L18 OR L19
L21            9 SEA FILE=CAPLUS ABB=ON  PLU=ON  L20 AND MCH


=> d 1-9 bib abs
```

L21 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1176939 CAPLUS
DN 143:440274
TI Preparation of alkynyl quinoline derivatives as MCH receptor antagonists
IN Stenkamp, Dirk; Mueller, Stephan Georg; Lehmann-Lintz, Thorsten; Lustenberger, Philipp; Thomas, Leo; Schindler, Marcus; Roth, Gerald Juergen; Rudolf, Klaus; Lotz, Ralf R. H.
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005103029	A1	20051103	WO 2005-EP3684	20050408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004017932	A1	20051103	DE 2004-102004017932	20040414
	US 2005267115	A1	20051201	US 2005-104914	20050413
PRAI	DE 2004-102004017932	A	20040414		
	US 2004-563688P	P	20040420		

OS MARPAT 143:440274
GI

L21 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form a (un)substituted alkylene bridge in which one CH2 group not adjacent to NR1R2 may be replaced by O, S, SO, etc.; W and Z independently = single bond or (un)substituted alkylene bridge; Y = (un)substituted quinoline, indole, quinazoline, etc.; A = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; B = (un)substituted alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as MCH receptor antagonists. Thus, e.g., II was prepared by amidation of 4-bromoaniline with diketene and subsequent cyclization and iodination to give 6-iodo-4-methyl-1H-quinolin-2-one (III). Palladium catalyzed cross-coupling of III with 5-(4-chloro-phenyl)-2-ethynyl-pyridine (preparation given) followed by reduction/bromination/amination sequence using POCl3, tetrabutylammonium bromide and methylamine yielded II. The binding activity of I towards MCH-1 receptor was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 6.8 up to 246 nM. I as MCH receptor antagonist should prove useful in the treatment of diseases such as but not limited to bulimia, diabetes and obesity. Pharmaceutical compns. comprising I are disclosed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1176932 CAPLUS
DN 143:440271
TI Preparation of alkynyl pyridine derivatives as MCH receptor antagonists
IN Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Schindler, Marcus; Thomas, Leo; Lotz, Ralf R. H.; Rudolf, Klaus
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005103032	A2	20051103	WO 2005-EP3686	20050408
	WO 2005103032	A3	20060202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004017930	A1	20051103	DE 2004-102004017930	20040414
	US 2005245529	A1	20051103	US 2005-105010	20050413
PRAI	DE 2004-102004017930	A	20040414		
	US 2004-563631P	P	20040420		

OS MARPAT 143:440271
GI



I



II

L21 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form a (un)substituted alkylene bridge in which one CH2 group not adjacent to NR1R2 may be replaced by O, S, SO, etc.; X = (un)substituted alkylene bridge; W and Z independently = single bond or (un)substituted alkylene bridge in which two adjacent C-atoms may be connected to each other; Y and A independently = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; B = (un)substituted alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as MCH receptor antagonists. Thus, e.g., II was prepared by Sonogashira coupling of 3-(4-iodo-phenyl)cyclohexanol (preparation given) with 5-(4-chloro-phenyl)-2-ethynyl-pyridine followed by mesylation and subsequent coupling with 3,5-dimethylpiperidine. The binding activity of I towards MCH-1 receptor was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 3.7 up to 25 nM. I as MCH receptor antagonist should prove useful in the treatment of diseases such as but not limited to bulimia, diabetes and obesity. Pharmaceutical compns. comprising I are disclosed.

L21 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1154507 CAPLUS
DN 143:422252
TI Preparation of alkynyl benzopyran derivatives as MCH receptor antagonists
IN Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Rudolf, Klaus; Schindler, Marcus; Thomas, Leo; Lotz, Ralf R. H.
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG; et al.
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005100285	A2	20051027	WO 2005-EP3710	20050408
	WO 2005100285	A3	20051201		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004017933	A1	20051103	DE 2004-102004017933	20040414
	US 2005267120	A1	20051201	US 2005-104832	20050413
PRAI	DE 2004-102004017933	A	20040414		
	US 2004-563654P	P	20040420		

OS MARPAT 143:422252
GI

L21 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1 and R2 independently = H, alkyl, cycloalkyl, etc. or R1 and R2 together form a (un)substituted alkylene bridge in which one CH2 group not adjacent to NR1R2 may be replaced by O, S, SO, etc.; X = (un)substituted alkylene bridge; W and Z independently = single bond or (un)substituted alkylene bridge; Y = (un)substituted benzopyranone, benzopyran, benzopiperidine, etc.; A = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; B = (un)substituted alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as MCH receptor antagonists. Thus, e.g., II was prepared by halogenation of 1-benzopyran-2-yl-methanol using iodine and subsequent palladium catalyzed coupling with 5-(4-chloro-phenyl)-2-ethynyl-pyridine (preparation given) followed by a mesylation/coupling sequence using (S)-1-pyrrolidin-2-yl-methanol. The binding activity of I towards MCH-1 receptor was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 3 up to 6 nM. I as MCH receptor antagonist should prove useful in the treatment of diseases such as but not limited to bulimia, diabetes and obesity. Pharmaceutical compns. comprising I are disclosed.

L21 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1132924 CAPLUS
DN 143:405812
TI Preparation of substituted pyridine alkynes with MCH antagonistic activity for the treatment of metabolic disorders
IN Stenkamp, Dirk; Mueller, Stephan Georg; Lustenberger, Philipp; Lehmann-Lintz, Thorsten; Roth, Gerald Juergen; Rudolf, Klaus; Schindler, Marcus; Thomas, Leo; Lotz, Ralf
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005234101	A1	20051020	US 2005-104889	20050413
	DE 102004017934	A1	20051103	DE 2004-102004017934	20040414
	WO 2005103002	A2	20051103	WO 2005-EP3685	20050408
	WO 2005103002	A3	20060202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DE 2004-102004017934	A	20040414		
	US 2004-563590P	P	20040420		

GI



II

AB Various substituted pyridinyl alkynes are prepared For instance, 2-[[4-[[5-(4-chlorophenyl)pyridin-2-yl]ethynyl]-2-methylphenyl]oxy]ethyl methanesulfonate (I) is prepared in 6 steps from 4-iodophenol, 2-bromoethanol, trimethylsilylacetylene, 2,5-dibromopyridine and 4-chlorophenylboronic acid. This intermediate is reacted with a variety of amines to produce example compds. I is converted to II by displacement with the corresponding amine. II exhibits an IC50 = 6.2 nM for

L21 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
MCH-1. Example compds. are useful for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

L21 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1004726 CAPLUS
DN 143:305940
TI Preparation of β-ketoamide derivatives as antagonists of MCH receptor
IN Roth, Gerald-Juergen; Lustenberger, Philipp; Schindler, Marcus; Thomas, Leo; Stenkamp, Dirk; Mueller, Stephan Georg; Lehmann-Lintz, Thorsten; Santagostino, Marco; Lotz, Ralf Richard Hermann
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005085221	A1	20050915	WO 2005-EP2132	20050301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004010893	A1	20050922	DE 2004-102004010893	20040306
	US 2005245500	A1	20051103	US 2005-71797	20050303
PRAI	DE 2004-102004010893	A	20040306		
	US 2004-554229P	P	20040318		

OS MARPAT 143:305940
GI

L21 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1 and R2 independently = H, (un)substituted alkyl, cycloalkyl, etc. or R1 and R2 together form alkylene bridge in which one or two CH2 groups may be substituted by either O, S, CO, etc.; R3 = H, alkyl, phenylalkyl, etc.; X = alkylene bridge in which one or two non-neighboring CH2 groups may be substituted by either O, S, CO, etc.; Z = single bond or CR6R7CR8R9; A, B and Y independently = Ph, (un)saturated carbocycle, heterocycle, etc.; n = 0-1; R4 and R5 independently = H, CF3, F, etc.; R6 and R8 independently = H, Cl, alkyl, etc.; R7 and R9 independently = H, F, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of MCH receptors. Thus, e.g., II was prepared by subsequent couplings of 4-acetylbiphenyl with di-Et carbonate and 2-[4-(pyrrolidin-1-yl-methyl)-phenyl]-ethylamine. The antagonistic activity of II was evaluated in a MCH-1 receptor binding assay and it was revealed that this compound possesses an IC50 value of 63.7 nM. I as antagonist of MCH receptor should prove useful in the treatment of diseases such as but not limited to diabetes, obesity and bulimia. Pharmaceutical compns. comprising I are disclosed.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:612084 CAPLUS
DN 143:133281
TI Preparation of 3-(4-piperidin-1-ylmethylphenyl)propionic acid phenylamides and related compounds used as MCH-1R antagonists (MCH = melanin concentrating hormone) for treating eating disorders
IN Lehmann-Lintz, Thorsten; Lustenberger, Philipp; Roth, Gerald Juergen; Schindler, Marcus; Thomas, Leo; Mueller, Stephan Georg; Stenkamp, Dirk; Lotz, Ralf R. H.; Rudolf, Klaus
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 343 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063239	A1	20050714	WO 2004-EP14378	20041217
	WO 2005063239	C2	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10360745	A1	20050728	DE 2003-10360745	20031223
	CA 2550649	AA	20050714	CA 2004-2550649	20041217
	US 2005267093	A1	20051201	US 2004-21897	20041223
PRAI	DE 2003-10360745	A	20031223		
	US 2004-538593P	P	20040123		
	WO 2004-EP14378	W	20041217		

OS MARPAT 143:133281
GI



I

AB The invention relates to 3-substituted propanoic, propenoic, and propynoic acid phenylamides R1R2N-X-Y-Z-N(R3)-W-A-Bb (I representing a very large range of compds.; variables defined in the first claim; e.g. 3-[4-(pyrrolidin-1-ylmethyl)phenyl]propynoic acid N-(4'-chlorobiphenyl-4-yl)-N-methylamide (shown as II)) and to drugs contg. at least one I. Because of the antagonist activity towards an MCH-1 receptor, the drugs I are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes. IC50 values are reported for 3 examples of I, e.g. 7.5 nM for II. Although the methods of prepn. are not claimed, many example prepns. are included. For example, II was prepd. in 3 steps (29, 36, and 25 % yields) starting with amide formation between (4'-chlorobiphenyl-4-yl)amine and propynoic acid followed by N-methylation and then coupling between 1-(4-iodobenzyl)pyrrolidine and the propynoic acid N-(4'-chlorobiphenyl-4-yl)-N-methylamide intermediate.

L21 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:390227 CAPLUS
DN 140:406742
TI Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.
IN Mueller, Stephan-Georg; Stenkamp, Dirk; Arndt, Kirsten; Roth, Gerald Juergen; Lotz, Ralf Richard Hermann; Lehmann-Lintz, Thorsten; Lenter, Martin; Lustenberger, Philipp; Rudolf, Klaus
PA Boehringer Ingelheim, Germany
SO PCT Int. Appl., 361 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039780	A1	20040513	WO 2003-EP11887	20031025
	WO 2004039780	C1	20040715		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10250708	A1	20040519	DE 2002-10250708	20021031
	CA 2504160	AA	20040513	CA 2003-2504160	20031025
	AU 2003300507	A1	20040525	AU 2003-300507	20031025
	EP 1558578	A1	20050803	EP 2003-809734	20031025
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014839	A	20050830	BR 2003-14839	20031025
	CN 1732154	A	20060208	CN 2003-80102635	20031025
	JP 2006511492	T2	20060406	JP 2004-547566	20031025
	US 2004209865	A1	20041021	US 2003-697443	20031030
	NO 2005000749	A	20050523	NO 2005-749	20050211
PRAI	DE 2002-10250708	A	20021031		
	US 2003-456543P	P	20030321		
	WO 2003-EP11887	W	20031025		

OS MARPAT 140:406742
GI

L21 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

II

III

AB Title compds. I [R1, R2 = H, (un)substituted alkyl, cycloalkyl, etc; X = alkyl, alkenyl, alkynyl, etc.; W, Z = alkylene with provisos; Y = Cy with provisos; A = Cy; B = Cy, alkyl, alkenyl, etc.; Cy = (un)substituted carbocycle, heterocycle] and their pharmaceutically acceptable salts and formulations were prepared For example, palladium mediated coupling of bromopyridine II, e.g., prepared from 4-iodophenol in 2-steps, and 4-bromophenylboronic acid afforded claimed ethynylpyridine III in 11% yield. In melanin concentrating hormone receptor (MCH-1R) binding assays, 2-examples of compds. I exhibited IC50 values ranging from 8-74 nM, e.g., the IC50 of ethynylpyridine III was 8 nM. Compds. I are claimed useful for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

L21 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:390211 CAPLUS
DN 140:406638
TI Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists.
IN Stenkamp, Dirk; Mueller, Stephan Georg; Roth, Gerald Juergen; Lustenberger, Philipp; Rudolf, Klaus; Lehmann-Lintz, Thorsten; Arndt, Kirsten; Lotz, Ralf R. H.; Lenter, Martin; Wieland, Heike-Andrea
PA Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany; et al.
SO PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039764	A1	20040513	WO 2003-EP11933	20031028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10250743	A1	20040519	DE 2002-10250743	20021031
	CA 2504207	AA	20040513	CA 2003-2504207	20031028
	AU 2003285306	A1	20040525	AU 2003-285306	20031028
	EP 1558567	A1	20050803	EP 2003-778292	20031028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015797	A	20050913	BR 2003-15797	20031028
	CN 1708476	A	20051214	CN 2003-80102236	20031028
	JP 2006504761	T2	20060209	JP 2004-547576	20031028
	US 2004152742	A1	20040805	US 2003-699089	20031031
	NO 2005000745	A	20050523	NO 2005-745	20050211
PRAI	DE 2002-10250743	A	20021031		
	US 2003-456482P	P	20030321		
	WO 2003-EP11933	W	20031028		

OS MARPAT 140:406638
AB R1R2NXYZNR3COWABb [R1, R2 = H, (substituted) alkyl, cycloalkyl, heterocyclyl, Ph, pyridyl; R1R2 = alkylene optionally interrupted by CH:N, CH:CH, O, S, SO, SO2, CO, imino, etc.; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl; X = alkylene optionally interrupted by CH:CH, C.tplbond.C, O, S, SO, SO2, CO, imino; W = CR6aR6bO, CR7a:CR7c, etc.; Z = bond, (fused) (alkyl-substituted) alkylene; Y, A, B = Cy; b = 0, 1; Cy = (substituted) (unsatd.) carbocyclyl, Ph, (aromatic) heterocyclyl; R6a, R6b = H, alkyl, CF3; R7a, R7c = H, F, Cl, alkyl, CF3; with provisos and specific exceptions], were prepared for treatment of obesity, diabetes, heart failure, arteriosclerosis, hypertension, arthritis, mastocytosis, depression, anxiety, etc. Thus, Me aminoacetate hydrochloride, Et3N, and N-[3-chloro-4-(2-oxoethoxy)phenyl]-2-(2,4-dichlorophenoxy)acetamide in CH2Cl2/THF were treated with NaBH(OAc)3 followed by stirring for 3 h to give 78% Me [2-[2-chloro-4-[2-(2,4-dichlorophenoxy)acetylamino]phenoxy]ethylamino]acetate. Tested title compds. bound to MCH-1 receptors with IC50 = 17-41 nM.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

L21 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:198178 CAPLUS
DN 140:235748
TI Preparation of arylquinoazolinones and related compounds as melanin concentrating hormone (MCH) antagonists.
IN Stenkamp, Dirk; Lehmann-Lintz, Thorsten; Mueller, Stephan; Rudolf, Klaus; Lustenberger, Phillip; Arndt, Kirsten; Lotz, Ralf; Wieland, Heike; Lenter, Martin
PA Boehringer Ingelheim International G.m.b.H., Germany; Novo Nordisk A/S
SO Ger. Offen., 132 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10238865	A1	20040311	DE 2002-10238865	20020824
	CA 2496563	AA	20040325	CA 2003-2496563	20030816
	WO 2004024702	A1	20040325	WO 2003-EP9099	20030816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003258620	A1	20040430	AU 2003-258620	20030816
	EP 1534689	A1	20050601	EP 2003-794886	20030816
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013790	A	20050712	BR 2003-13790	20030816
	CN 1678591	A	20051005	CN 2003-820076	20030816
	JP 2006507246	T2	20060302	JP 2004-535098	20030816
	US 2004242572	A1	20041202	US 2003-647156	20030822
	NO 2005000068	A	20050304	NO 2005-68	20050106
PRAI	DE 2002-10238865	A	20020824		
	US 2002-408224P	P	20020904		
	WO 2003-EP9099	W	20030816		

OS MARPAT 140:235748
AB R1R2NXYZNR3COAWkB [R1, R2 = H, (substituted) alkyl, cycloalkyl, Ph; R1R2 = (heteroatom-interrupted) (substituted) alkylene; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, aminoalkyl; X = bond, (heteroatom-interrupted) (substituted) alkylene; Z = (heteroatom-interrupted) (substituted) alkylene; A, Y = (hetero)cyclylene; B = (hetero)cyclyl; W = bond, O, alkylene, alkenylene, alkynylene, alkyleneoxy, imino, etc.; k = 0, 1; R1Y, R32, AR3 = atoms to form rings], were prepared Thus, 4'-chloro-3-aminobiphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethylphenyl)ethyl]amide (preparation given) was stirred with HCO2H for 3 h at room temperature and for 2 h at 100° to give 64.6% 7-(4-chlorophenyl)-3-[2-(4-pyrrolidin-1-ylmethylphenyl)ethyl]-3H-quinazolin-4-one. Tested I showed MCH-1 binding activity with IC50 = 2.1-30.5 nM.

L21 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

```
=> d his full

     (FILE 'HOME' ENTERED AT 13:43:30 ON 20 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 13:43:42 ON 20 SEP 2006

     FILE 'CAPLUS' ENTERED AT 13:43:51 ON 20 SEP 2006
                ACT FIONA/A
               ---------
L1                STR
L2   (     12311)SEA SSS FUL L1
L3   (      1515)SEA ABB=ON  PLU=ON  L2
L4           1452 SEA ABB=ON  PLU=ON  L3 AND PY<2004
                 ---------

     FILE 'REGISTRY' ENTERED AT 13:44:09 ON 20 SEP 2006
L5                STRUCTURE UPLOADED
                  D
L6             41 SEA SSS SAM L5
L7           6183 SEA SSS FUL L5

     FILE 'CAPLUS' ENTERED AT 13:45:47 ON 20 SEP 2006
L8            273 SEA ABB=ON  PLU=ON  L7
L9            235 SEA ABB=ON  PLU=ON  L8 AND PY<2004
                  D QUE L9 STAT
                  D 1-235 BIB ABS HITSTR
                  E STENKAMP DIRK/AU
L10            38 SEA ABB=ON  PLU=ON  "STENKAMP DIRK"/AU
                  E MUELLER STEPHAN/AU
L11            27 SEA ABB=ON  PLU=ON  ("MUELLER STEPHAN G"/AU OR "MUELLER
                  STEPHAN GEORG"/AU)
                  E ROTH GERALD/AU
L12            82 SEA ABB=ON  PLU=ON  "ROTH GERALD J"/AU OR "ROTH GERALD
                  JUERGEN"/AU
                  E LUSTENBERGER PHILIPP/AU
L13            35 SEA ABB=ON  PLU=ON  "LUSTENBERGER PHILIPP"/AU
                  E RUDOLF KLAUS/AU
L14            80 SEA ABB=ON  PLU=ON  "RUDOLF KLAUS"/AU
                  E LEHMANN LINTZ THORSTEN/AU
L15            28 SEA ABB=ON  PLU=ON  "LEHMANN LINTZ THORSTEN"/AU
                  E ARNDT KIRSTEN/AU
L16            22 SEA ABB=ON  PLU=ON  "ARNDT KIRSTEN"/AU
                  E LOTZ RALF/AU
L17            23 SEA ABB=ON  PLU=ON  ("LOTZ RALF"/AU OR "LOTZ RALF R H"/AU OR
                  "LOTZ RALF RICHARD HERMANN"/AU)
                  E LENTER MARTIN/AU
L18            29 SEA ABB=ON  PLU=ON  ("LENTER MARTIN"/AU OR "LENTER MARTIN
                  C"/AU)
                  E WIELAND HEIKE/AU
L19            48 SEA ABB=ON  PLU=ON  ("WIELAND HEIKE"/AU OR "WIELAND HEIKE
                  A"/AU OR "WIELAND HEIKE ANDREA"/AU)
L20           263 SEA ABB=ON  PLU=ON  L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR
                  L16 OR L17 OR L18 OR L19
L21             9 SEA ABB=ON  PLU=ON  L20 AND MCH
                  D QUE L21 STAT
                  D 1-9 BIB ABS
```

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6
DICTIONARY FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE CAPLUS

FILE COVERS 1907 - 20 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 19 Sep 2006 (20060919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1271.76	1440.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-183.00	-183.00

STN INTERNATIONAL LOGOFF AT 13:57:38 ON 20 SEP 2006